RELATED APPLICATIONS This application is a continuation of U.S. application Ser. No. 11/409,535, filed Apr. 21, 2006, which is a continuation-in-part of U.S. application Ser. No. 11/060,135, filed Feb. 17, 2005 which claims the benefit of priority to U.S. Provisional Application Ser. No. 60/545,425 filed Feb. 18, 2004; U.S. Provisional Application Ser. No. 60/559,754, filed Apr. 5, 2004; U.S. Provisional Application Ser. No. 60/632,862, filed Dec. 3, 2004; U.S. Provisional Application Ser. No. 60/639,068, filed Dec. 22, 2004; and U.S. Provisional Application Ser. No. 60/648,188, filed Jan. 28, 2005. U.S. application Ser. No. 11/409,535 is a also continuation-in-part of U.S. application Ser. No. 10/728,486, filed Dec. 5, 2003 which claims the benefit of priority to U.S. Provisional Application Ser. No. 60/501,926, filed Sep. 11, 2003. U.S. application Ser. No. 11/409,535 also claims the benefit of priority to: U.S. Provisional Application Ser. No. 60/674,118, filed Apr. 21, 2005; U.S. Provisional Application Ser. No. 60/705,631, filed Aug. 3, 2005; U.S. Provisional Application Ser. No. 60/732,539, filed Nov. 1, 2005; and U.S. Provisional Application Ser. No. 60/773,124, filed Feb. 13, 2006. Each of the above-referenced U.S. applications is incorporated herein by reference in its entirety. Methods disclosed in U.S. application Ser. Nos. 09/891,793, 10/156,608, 10/405,756, 10/418,514, 10/660,122, 10,660,996, 10/660,997, 10/660,998, 10/728,486, 11/060,135, and 11/073,362, are commonly owned and incorporated herein by reference in their entirety for any purpose.
STATEMENT OF GOVERNMENT SUPPORT This invention was made with United States Government support under CDC contract RO1 CI000099-01. The United States Government has certain rights in the invention.
SEQUENCE LISTING The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled DIBIS0083USC13SEQ.txt, created on Mar. 13, 2007 which is 252 Kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION The present invention provides compositions, kits and methods for rapid identification and quantification of bacteria by molecular mass and base composition analysis.
BACKGROUND OF THE INVENTION A problem in determining the cause of a natural infectious outbreak or a bioterrorist attack is the sheer variety of organisms that can cause human disease. There are over 1400 organisms infectious to humans; many of these have the potential to emerge suddenly in a natural epidemic or to be used in a malicious attack by bioterrorists (Taylor et al. Philos. Trans. R. Soc. London B. Biol. Sci., 2001, 356, 983-989). This number does not include numerous strain variants, bioengineered versions, or pathogens that infect plants or animals.
Much of the new technology being developed for detection of biological weapons incorporates a polymerase chain reaction (PCR) step based upon the use of highly specific primers and probes designed to selectively detect certain pathogenic organisms. Although this approach is appropriate for the most obvious bioterrorist organisms, like smallpox and anthrax, experience has shown that it is very difficult to predict which of hundreds of possible pathogenic organisms might be employed in a terrorist attack. Likewise, naturally emerging human disease that has caused devastating consequence in public health has come from unexpected families of bacteria, viruses, fungi, or protozoa. Plants and animals also have their natural burden of infectious disease agents and there are equally important biosafety and security concerns for agriculture.
A major conundrum in public health protection, biodefense, and agricultural safety and security is that these disciplines need to be able to rapidly identify and characterize infectious agents, while there is no existing technology with the breadth of function to meet this need. Currently used methods for identification of bacteria rely upon culturing the bacterium to effect isolation from other organisms and to obtain sufficient quantities of nucleic acid followed by sequencing of the nucleic acid, both processes which are time and labor intensive.
Mass spectrometry provides detailed information about the molecules being analyzed, including high mass accuracy. It is also a process that can be easily automated. DNA chips with specific probes can only determine the presence or absence of specifically anticipated organisms. Because there are hundreds of thousands of species of benign bacteria, some very similar in sequence to threat organisms, even arrays with 10,000 probes lack the breadth needed to identify a particular organism.
The present invention provides oligonucleotide primers and compositions and kits containing the oligonucleotide primers, which define bacterial bioagent identifying amplicons and, upon amplification, produce corresponding amplification products whose molecular masses provide the means to identify bacteria, for example, at and below the species taxonomic level.
SUMMARY OF THE INVENTION The present invention provides compositions, kits and methods for rapid identification and quantification of bacteria by molecular mass and base composition analysis.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 456.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1261.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 456 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1261.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 288.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1269.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 288 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1269.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 698.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1420.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 698 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1420.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 217.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1167
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 217 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1167.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 399.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1041.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 399 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1041.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 430.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1321.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 430 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1321.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 174.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 853.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 174 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 853.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 172.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1360.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 172 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1360.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 456 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1261.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 456 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1261 and further comprising one or more primer pairs wherein each member of said one or more primer pairs is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by SEQ ID NOs: 288:1269, 698:1420, 217:1167, 399:1041, 430:1321, 174:853, and 172:1360.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 681.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1022.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 681 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1022.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 315.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1379.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 315 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1379.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 346.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 955.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 346 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 955.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 504.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1409.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 504 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1409.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 323.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1068.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 323 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1068.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 479.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 938.
Another embodiment is an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 479 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 938.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 681 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1022.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 681 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1022 and further comprising one or more primer pairs wherein each member of said one or more primer pairs is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by SEQ ID NOs: 315:1379, 346:955, 504:1409, 323:1068, 479:938.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 583.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 923.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 583 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 923.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 454.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1418.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 454 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1418.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 250.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 902.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 250 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 902.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 384.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 878.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 384 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 878.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 694.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1215.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 694 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1215.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 194.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1173.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 194 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1173.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 375.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 890.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 375 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 890.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 656.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1224.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 656 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1224.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 618.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1157.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 618 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1157.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 302.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 852.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 302 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 852.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 199.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 889.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 199 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 889.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 596.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1169.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 596 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1169.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 150.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1242.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 150 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1242.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 166.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1069.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 166 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1069.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 166.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1168.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 166 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1168.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 583 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 923 and further comprising one or more primer pairs wherein each member of said one or more primer pairs is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by SEQ ID NOs: 454:1418, 250:902, 384:878, 694:1215, 194:1173, 375:890, 656:1224, 618:1157, 302:852, 199:889, 596:1169, 150:1242, 166:1069 and 166:1168.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 437.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1137.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 437 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1137.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 530.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 891.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 530 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 891.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 474.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 869.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 474 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 869.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 268.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1284.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 268 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1284.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 418.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1301.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 418 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1301.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 318.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1300.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 318 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1300.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 440.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1076.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 440 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1076.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 219.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1013.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 219 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1013.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 437 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1137 and further comprising one or more primer pairs wherein each member of said one or more primer pairs is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by SEQ ID NOs: 530:891, 474:869, 268:1284, 418:1301, 318:1300, 440:1076 and 219:1013.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 325.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1163.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 325 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1163.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 278.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1039.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 278 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1039.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 465.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1037.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 465 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1037.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 148.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1172.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 148 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1172.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 190.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1254.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 190 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1254.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 266.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1094.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 266 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1094.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 508.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1297.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 508 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1297.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 259.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1060.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 259 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1060.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 325 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1163 and further comprising one or more primer pairs wherein each member of said one or more primer pairs is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by SEQ ID NOs: 278:1039: 465:1037, 148:1172, 190:1254, 266:1094, 508:1297 and 259:1060.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 376.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1265.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 376 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1265.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 267.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1341.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 267 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1341.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 705.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1056.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 705 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1056.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 710.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1259.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 710 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1259.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 374.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1111.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 374 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1111.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 545.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 978.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 545 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 978.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 249.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1095.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 249 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1095.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 195.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1376.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 195 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1376.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 311.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1014.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 311 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1014.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 365.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1052.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 365 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1052.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 527.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1071.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 527 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1071.
One embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 490.
Another embodiment is an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1182.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 490 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1182.
Another embodiment is a kit comprising an oligonucleotide primer pair including an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 376 and an oligonucleotide primer 14 to 35 nucleobases in length having at least 70% sequence identity with SEQ ID NO: 1265 and further comprising one or more primer pairs wherein each member of said one or more primer pairs is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by SEQ ID NOs: 267:1341, 705:1056, 710:1259, 374:1111, 545:978, 249:1095, 195:1376, 311:1014, 365:1052, 527:1071 and 490:1182.
In some embodiments, either or both of the primers of a primer pair composition contain at least one modified nucleobase such as 5-propynyluracil or 5-propynylcytosine for example.
In some embodiments, either or both of the primers of the primer pair comprises at least one universal nucleobase such as inosine for example.
In some embodiments, either or both of the primers of the primer pair comprises at least one non-templated T residue on the 5′-end.
In some embodiments, either or both of the primers of the primer pair comprises at least one non-template tag.
In some embodiments, either or both of the primers of the primer pair comprises at least one molecular mass modifying tag.
In some embodiments, the present invention provides primers and compositions comprising pairs of primers, and kits containing the same, and methods for use in identification of bacteria. The primers are designed to produce amplification products of DNA encoding genes that have conserved and variable regions across different subgroups and genotypes of bacteria.
Some embodiments are kits that contain one or more of the primer pair compositions. In some embodiments, each member of the one or more primer pairs of the kit is of a length of 14 to 35 nucleobases and has 70% to 100% sequence identity with the corresponding member from any of the primer pairs listed in Table 2.
Some embodiments of the kits contain at least one calibration polynucleotide for use in quantitation of bacteria in a given sample, and also for use as a positive control for amplification.
Some embodiments of the kits contain at least one anion exchange functional group linked to a magnetic bead.
In some embodiments, the present invention also provides methods for identification of bacteria. Nucleic acid from the bacterium is amplified using the primers described above to obtain an amplification product. The molecular mass of the amplification product is measured. Optionally, the base composition of the amplification product is determined from the molecular mass. The molecular mass or base composition is compared with a plurality of molecular masses or base compositions of known analogous bacterial identifying amplicons, wherein a match between the molecular mass or base composition and a member of the plurality of molecular masses or base compositions identifies the bacterium. In some embodiments, the molecular mass is measured by mass spectrometry in a modality such as electrospray ionization (ESI) time of flight (TOF) mass spectrometry or ESI Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, for example. Other mass spectrometry techniques can also be used to measure the molecular mass of bacterial bioagent identifying amplicons.
In some embodiments, the present invention is also directed to a method for determining the presence or absence of a bacterium in a sample. Nucleic acid from the sample is amplified using the composition described above to obtain an amplification product. The molecular mass of the amplification product is determined. Optionally, the base composition of the amplification product is determined from the molecular mass. The molecular mass or base composition of the amplification product is compared with the known molecular masses or base compositions of one or more known analogous bacterial bioagent identifying amplicons, wherein a match between the molecular mass or base composition of the amplification product and the molecular mass or base composition of one or more known bacterial bioagent identifying amplicons indicates the presence of the bacterium in the sample. In some embodiments, the molecular mass is measured by mass spectrometry.
In some embodiments, the present invention also provides methods for determination of the quantity of an unknown bacterium in a sample. The sample is contacted with the composition described above and a known quantity of a calibration polynucleotide comprising a calibration sequence. Nucleic acid from the unknown bacterium in the sample is concurrently amplified with the composition described above and nucleic acid from the calibration polynucleotide in the sample is concurrently amplified with the composition described above to obtain a first amplification product comprising a bacterial bioagent identifying amplicon and a second amplification product comprising a calibration amplicon. The molecular masses and abundances for the bacterial bioagent identifying amplicon and the calibration amplicon are determined. The bacterial bioagent identifying amplicon is distinguished from the calibration amplicon based on molecular mass and comparison of bacterial bioagent identifying amplicon abundance and calibration amplicon abundance indicates the quantity of bacterium in the sample. In some embodiments, the base composition of the bacterial bioagent identifying amplicon is determined.
In some embodiments, the present invention provides methods for detecting or quantifying bacteria by combining a nucleic acid amplification process with a mass determination process. In some embodiments, such methods identify or otherwise analyze the bacterium by comparing mass information from an amplification product with a calibration or control product. Such methods can be carried out in a highly multiplexed and/or parallel manner allowing for the analysis of as many as 300 samples per 24 hours on a single mass measurement platform. The accuracy of the mass determination methods in some embodiments of the present invention permits allows for the ability to discriminate between different bacteria such as, for example, various genotypes and drug resistant strains of Staphylococcus aureus.
BRIEF DESCRIPTION OF THE DRAWINGS The foregoing summary of the invention, as well as the following detailed description of the invention, is better understood when read in conjunction with the accompanying drawings which are included by way of example and not by way of limitation.
FIG. 1: process diagram illustrating a representative primer pair selection process.
FIG. 2: process diagram illustrating an embodiment of the calibration method.
FIG. 3: common pathogenic bacteria and primer pair coverage. The primer pair number in the upper right hand corner of each polygon indicates that the primer pair can produce a bioagent identifying amplicon for all species within that polygon.
FIG. 4: a representative 3D diagram of base composition (axes A, G and C) of bioagent identifying amplicons obtained with primer pair number 14 (a precursor of primer pair number 348 which targets 16S rRNA). The diagram indicates that the experimentally determined base compositions of the clinical samples (labeled NHRC samples) closely match the base compositions expected for Streptococcus pyogenes and are distinct from the expected base compositions of other organisms.
FIG. 5: a representative mass spectrum of amplification products indicating the presence of bioagent identifying amplicons of Streptococcus pyogenes, Neisseria meningitidis, and Haemophilus influenzae obtained from amplification of nucleic acid from a clinical sample with primer pair number 349 which targets 23S rRNA. Experimentally determined molecular masses and base compositions for the sense strand of each amplification product are shown.
FIG. 6: a representative mass spectrum of amplification products representing a bioagent identifying amplicon of Streptococcus pyogenes, and a calibration amplicon obtained from amplification of nucleic acid from a clinical sample with primer pair number 356 which targets rplB. The experimentally determined molecular mass and base composition for the sense strand of the Streptococcus pyogenes amplification product is shown.
FIG. 7: a representative mass spectrum of an amplified nucleic acid mixture which contained the Ames strain of Bacillus anthracis, a known quantity of combination calibration polynucleotide (SEQ ID NO: 1464), and primer pair number 350 which targets the capC gene on the virulence plasmid pX02 of Bacillus anthracis. Calibration amplicons produced in the amplification reaction are visible in the mass spectrum as indicated and abundance data (peak height) are used to calculate the quantity of the Ames strain of Bacillus anthracis.
DEFINITIONS As used herein, the term “abundance” refers to an amount. The amount may be described in terms of concentration which are common in molecular biology such as “copy number,” “pfu or plate-forming unit” which are well known to those with ordinary skill. Concentration may be relative to a known standard or may be absolute.
As used herein, the term “amplifiable nucleic acid” is used in reference to nucleic acids that may be amplified by any amplification method. It is contemplated that “amplifiable nucleic acid” also comprises “sample template.”
As used herein the term “amplification” refers to a special case of nucleic acid replication involving template specificity. It is to be contrasted with non-specific template replication (i.e., replication that is template-dependent but not dependent on a specific template). Template specificity is here distinguished from fidelity of replication (i.e., synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of “target” specificity. Target sequences are “targets” in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out. Template specificity is achieved in most amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under conditions they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. For example, in the case of Qβ replicase, MDV-1 RNA is the specific template for the replicase (D. L. Kacian et al., Proc. Natl. Acad. Sci. USA 69:3038 [1972]). Other nucleic acid will not be replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters (Chamberlin et al., Nature 228:227 [1970]). In the case of T4 DNA ligase, the enzyme will not ligate the two oligonucleotides or polynucleotides, where there is a mismatch between the oligonucleotide or polynucleotide substrate and the template at the ligation junction (D. Y. Wu and R. B. Wallace, Genomics 4:560 [1989]). Finally, Taq and Pfu polymerases, by virtue of their ability to function at high temperature, are found to display high specificity for the sequences bounded and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences (H. A. Erlich (ed.), PCR Technology, Stockton Press [1989]).
As used herein, the term “amplification reagents” refers to those reagents (deoxyribonucleotide triphosphates, buffer, etc.), needed for amplification, excluding primers, nucleic acid template, and the amplification enzyme. Typically, amplification reagents along with other reaction components are placed and contained in a reaction vessel (test tube, microwell, etc.).
As used herein, the term “analogous” when used in context of comparison of bioagent identifying amplicons indicates that the bioagent identifying amplicons being compared are produced with the same pair of primers. For example, bioagent identifying amplicon “A” and bioagent identifying amplicon “B”, produced with the same pair of primers are analogous with respect to each other. Bioagent identifying amplicon “C”, produced with a different pair of primers is not analogous to either bioagent identifying amplicon “A” or bioagent identifying amplicon “B”.
As used herein, the term “anion exchange functional group” refers to a positively charged functional group capable of binding an anion through an electrostatic interaction. The most well known anion exchange functional groups are the amines, including primary, secondary, tertiary and quaternary amines.
The term “bacteria” or “bacterium” refers to any member of the groups of eubacteria and archaebacteria.
As used herein, a “base composition” is the exact number of each nucleobase (for example, A, T, C and G) in a segment of nucleic acid. For example, amplification of nucleic acid of Staphylococcus aureus strain carrying the lukS-PV gene with primer pair number 2095 (SEQ ID NOs: 456:1261) produces an amplification product 117 nucleobases in length from nucleic acid of the lukS-PV gene that has a base composition of A35 G17 C19 T46 (by convention—with reference to the sense strand of the amplification product). Because the molecular masses of each of the four natural nucleotides and chemical modifications thereof are known (if applicable), a measured molecular mass can be deconvoluted to a list of possible base compositions. Identification of a base composition of a sense strand which is complementary to the corresponding antisense strand in terms of base composition provides a confirmation of the true base composition of an unknown amplification product. For example, the base composition of the antisense strand of the 139 nucleobase amplification product described above is A46 G19 C17 T35.
As used herein, a “base composition probability cloud” is a representation of the diversity in base composition resulting from a variation in sequence that occurs among different isolates of a given species. The “base composition probability cloud” represents the base composition constraints for each species and is typically visualized using a pseudo four-dimensional plot.
In the context of this invention, a “bioagent” is any organism, cell, or virus, living or dead, or a nucleic acid derived from such an organism, cell or virus. Examples of bioagents include, but are not limited, to cells, (including but not limited to human clinical samples, bacterial cells and other pathogens), viruses, fungi, protists, parasites, and pathogenicity markers (including but not limited to: pathogenicity islands, antibiotic resistance genes, virulence factors, toxin genes and other bioregulating compounds). Samples may be alive or dead or in a vegetative state (for example, vegetative bacteria or spores) and may be encapsulated or bioengineered. In the context of this invention, a “pathogen” is a bioagent which causes a disease or disorder.
As used herein, a “bioagent division” is defined as group of bioagents above the species level and includes but is not limited to, orders, families, classes, clades, genera or other such groupings of bioagents above the species level.
As used herein, the term “bioagent identifying amplicon” refers to a polynucleotide that is amplified from a bioagent in an amplification reaction and which 1) provides sufficient variability to distinguish among bioagents from whose nucleic acid the bioagent identifying amplicon is produced and 2) whose molecular mass is amenable to a rapid and convenient molecular mass determination modality such as mass spectrometry, for example.
As used herein, the term “biological product” refers to any product originating from an organism. Biological products are often products of processes of biotechnology. Examples of biological products include, but are not limited to: cultured cell lines, cellular components, antibodies, proteins and other cell-derived biomolecules, growth media, growth harvest fluids, natural products and bio-pharmaceutical products.
The terms “biowarfare agent” and “bioweapon” are synonymous and refer to a bacterium, virus, fungus or protozoan that could be deployed as a weapon to cause bodily harm to individuals. Military or terrorist groups may be implicated in deployment of biowarfare agents.
In context of this invention, the term “broad range survey primer pair” refers to a primer pair designed to produce bioagent identifying amplicons across different broad groupings of bioagents. For example, the ribosomal RNA-targeted primer pairs are broad range survey primer pairs which have the capability of producing bacterial bioagent identifying amplicons for essentially all known bacteria. With respect to broad range primer pairs employed for identification of bacteria, a broad range survey primer pair for bacteria such as 16S rRNA primer pair number 346 (SEQ ID NOs: 202:1110) for example, will produce an bacterial bioagent identifying amplicon for essentially all known bacteria.
The term “calibration amplicon” refers to a nucleic acid segment representing an amplification product obtained by amplification of a calibration sequence with a pair of primers designed to produce a bioagent identifying amplicon.
The term “calibration sequence” refers to a polynucleotide sequence to which a given pair of primers hybridizes for the purpose of producing an internal (i.e: included in the reaction) calibration standard amplification product for use in determining the quantity of a bioagent in a sample. The calibration sequence may be expressly added to an amplification reaction, or may already be present in the sample prior to analysis.
The term “clade primer pair” refers to a primer pair designed to produce bioagent identifying amplicons for species belonging to a clade group. A clade primer pair may also be considered as a “speciating” primer pair which is useful for distinguishing among closely related species.
The term “codon” refers to a set of three adjoined nucleotides (triplet) that codes for an amino acid or a termination signal.
In context of this invention, the term “codon base composition analysis,” refers to determination of the base composition of an individual codon by obtaining a bioagent identifying amplicon that includes the codon. The bioagent identifying amplicon will at least include regions of the target nucleic acid sequence to which the primers hybridize for generation of the bioagent identifying amplicon as well as the codon being analyzed, located between the two primer hybridization regions.
As used herein, the terms “complementary” or “complementarity” are used in reference to polynucleotides (i.e., a sequence of nucleotides such as an oligonucleotide or a target nucleic acid) related by the base-pairing rules. For example, for the sequence “5′-A-G-T-3′,” is complementary to the sequence “3′-T-C-A-5′.” Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods that depend upon binding between nucleic acids. Either term may also be used in reference to individual nucleotides, especially within the context of polynucleotides. For example, a particular nucleotide within an oligonucleotide may be noted for its complementarity, or lack thereof, to a nucleotide within another nucleic acid strand, in contrast or comparison to the complementarity between the rest of the oligonucleotide and the nucleic acid strand.
The term “complement of a nucleic acid sequence” as used herein refers to an oligonucleotide which, when aligned with the nucleic acid sequence such that the 5′ end of one sequence is paired with the 3′ end of the other, is in “antiparallel association.” Certain bases not commonly found in natural nucleic acids may be included in the nucleic acids of the present invention and include, for example, inosine and 7-deazaguanine. Complementarity need not be perfect; stable duplexes may contain mismatched base pairs or unmatched bases. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length of the oligonucleotide, base composition and sequence of the oligonucleotide, ionic strength and incidence of mismatched base pairs. Where a first oligonucleotide is complementary to a region of a target nucleic acid and a second oligonucleotide has complementary to the same region (or a portion of this region) a “region of overlap” exists along the target nucleic acid. The degree of overlap will vary depending upon the extent of the complementarity.
In context of this invention, the term “division-wide primer pair” refers to a primer pair designed to produce bioagent identifying amplicons within sections of a broader spectrum of bioagents For example, primer pair number 352 (SEQ ID NOs: 687:1411), a division-wide primer pair, is designed to produce bacterial bioagent identifying amplicons for members of the Bacillus group of bacteria which comprises, for example, members of the genera Streptococci, Enterococci, and Staphylococci. Other division-wide primer pairs may be used to produce bacterial bioagent identifying amplicons for other groups of bacterial bioagents.
As used herein, the term “concurrently amplifying” used with respect to more than one amplification reaction refers to the act of simultaneously amplifying more than one nucleic acid in a single reaction mixture.
As used herein, the term “drill-down primer pair” refers to a primer pair designed to produce bioagent identifying amplicons for identification of sub-species characteristics or confirmation of a species assignment. For example, primer pair number 2146 (SEQ ID NOs: 437:1137), a drill-down Staphylococcus aureus genotyping primer pair, is designed to produce Staphylococcus aureus genotyping amplicons. Other drill-down primer pairs may be used to produce bioagent identifying amplicons for Staphylococcus aureus and other bacterial species.
The term “duplex” refers to the state of nucleic acids in which the base portions of the nucleotides on one strand are bound through hydrogen bonding the their complementary bases arrayed on a second strand. The condition of being in a duplex form reflects on the state of the bases of a nucleic acid. By virtue of base pairing, the strands of nucleic acid also generally assume the tertiary structure of a double helix, having a major and a minor groove. The assumption of the helical form is implicit in the act of becoming duplexed.
As used herein, the term “etiology” refers to the causes or origins, of diseases or abnormal physiological conditions.
The term “gene” refers to a DNA sequence that comprises control and coding sequences necessary for the production of an RNA having a non-coding function (e.g., a ribosomal or transfer RNA), a polypeptide or a precursor. The RNA or polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or function is retained.
The terms “homology,” “homologous” and “sequence identity” refer to a degree of identity. There may be partial homology or complete homology. A partially homologous sequence is one that is less than 100% identical to another sequence. Determination of sequence identity is described in the following example: a primer 20 nucleobases in length which is otherwise identical to another 20 nucleobase primer but having two non-identical residues has 18 of 20 identical residues (18/20=0.9 or 90% sequence identity). In another example, a primer 15 nucleobases in length having all residues identical to a 15 nucleobase segment of a primer 20 nucleobases in length would have 15/20=0.75 or 75% sequence identity with the 20 nucleobase primer. In context of the present invention, sequence identity is meant to be properly determined when the query sequence and the subject sequence are both described and aligned in the 5′ to 3′ direction. Sequence alignment algorithms such as BLAST, will return results in two different alignment orientations. In the Plus/Plus orientation, both the query sequence and the subject sequence are aligned in the 5′ to 3′ direction. On the other hand, in the Plus/Minus orientation, the query sequence is in the 5′ to 3′ direction while the subject sequence is in the 3′ to 5′ direction. It should be understood that with respect to the primers of the present invention, sequence identity is properly determined when the alignment is designated as Plus/Plus. Sequence identity may also encompass alternate or modified nucleobases that perform in a functionally similar manner to the regular nucleobases adenine, thymine, guanine and cytosine with respect to hybridization and primer extension in amplification reactions. In a non-limiting example, if the 5-propynyl pyrimidines propyne C and/or propyne T replace one or more C or T residues in one primer which is otherwise identical to another primer in sequence and length, the two primers will have 100% sequence identity with each other. In another non-limiting example, Inosine (I) may be used as a replacement for G or T and effectively hybridize to C, A or U (uracil). Thus, if inosine replaces one or more C, A or U residues in one primer which is otherwise identical to another primer in sequence and length, the two primers will have 100% sequence identity with each other. Other such modified or universal bases may exist which would perform in a functionally similar manner for hybridization and amplification reactions and will be understood to fall within this definition of sequence identity.
As used herein, “housekeeping gene” refers to a gene encoding a protein or RNA involved in basic functions required for survival and reproduction of a bioagent. Housekeeping genes include, but are not limited to genes encoding RNA or proteins involved in translation, replication, recombination and repair, transcription, nucleotide metabolism, amino acid metabolism, lipid metabolism, energy generation, uptake, secretion and the like.
As used herein, the term “hybridization” is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is influenced by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, and the Tm of the formed hybrid. “Hybridization” methods involve the annealing of one nucleic acid to another, complementary nucleic acid, i.e., a nucleic acid having a complementary nucleotide sequence. The ability of two polymers of nucleic acid containing complementary sequences to find each other and anneal through base pairing interaction is a well-recognized phenomenon. The initial observations of the “hybridization” process by Marmur and Lane, Proc. Natl. Acad. Sci. USA 46:453 (1960) and Doty et al., Proc. Natl. Acad. Sci. USA 46:461 (1960) have been followed by the refinement of this process into an essential tool of modem biology.
The term “in silico” refers to processes taking place via computer calculations. For example, electronic PCR (ePCR) is a process analogous to ordinary PCR except that it is carried out using nucleic acid sequences and primer pair sequences stored on a computer formatted medium.
As used herein, “intelligent primers” are primers that are designed to bind to highly conserved sequence regions of a bioagent identifying amplicon that flank an intervening variable region and, upon amplification, yield amplification products which ideally provide enough variability to distinguish individual bioagents, and which are amenable to molecular mass analysis. By the term “highly conserved,” it is meant that the sequence regions exhibit between about 80-100%, or between about 90-100%, or between about 95-100% identity among all, or at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% of species or strains.
The “ligase chain reaction” (LCR; sometimes referred to as “Ligase Amplification Reaction” (LAR) described by Barany, Proc. Natl. Acad. Sci., 88:189 (1991); Barany, PCR Methods and Applic., 1:5 (1991); and Wu and Wallace, Genomics 4:560 (1989) has developed into a well-recognized alternative method for amplifying nucleic acids. In LCR, four oligonucleotides, two adjacent oligonucleotides which uniquely hybridize to one strand of target DNA, and a complementary set of adjacent oligonucleotides, that hybridize to the opposite strand are mixed and DNA ligase is added to the mixture. Provided that there is complete complementarity at the junction, ligase will covalently link each set of hybridized molecules. Importantly, in LCR, two probes are ligated together only when they base-pair with sequences in the target sample, without gaps or mismatches. Repeated cycles of denaturation, hybridization and ligation amplify a short segment of DNA. LCR has also been used in combination with PCR to achieve enhanced detection of single-base changes. However, because the four oligonucleotides used in this assay can pair to form two short ligatable fragments, there is the potential for the generation of target-independent background signal. The use of LCR for mutant screening is limited to the examination of specific nucleic acid positions.
The term “locked nucleic acid” or “LNA” refers to a nucleic acid analogue containing one or more 2′-O, 4′-C-methylene-β-D-ribofuranosyl nucleotide monomers in an RNA mimicking sugar conformation. LNA oligonucleotides display unprecedented hybridization affinity toward complementary single-stranded RNA and complementary single- or double-stranded DNA. LNA oligonucleotides induce A-type (RNA-like) duplex conformations. The primers of the present invention may contain LNA modifications.
As used herein, the term “mass-modifying tag” refers to any modification to a given nucleotide which results in an increase in mass relative to the analogous non-mass modified nucleotide. Mass-modifying tags can include heavy isotopes of one or more elements included in the nucleotide such as carbon-13 for example. Other possible modifications include addition of substituents such as iodine or bromine at the 5 position of the nucleobase for example.
The term “mass spectrometry” refers to measurement of the mass of atoms or molecules. The molecules are first converted to ions, which are separated using electric or magnetic fields according to the ratio of their mass to electric charge. The measured masses are used to identity the molecules.
The term “microorganism” as used herein means an organism too small to be observed with the unaided eye and includes, but is not limited to bacteria, virus, protozoans, fungi; and ciliates.
The term “multi-drug resistant” or multiple-drug resistant” refers to a microorganism which is resistant to more than one of the antibiotics or antimicrobial agents used in the treatment of said microorganism.
The term “multiplex PCR” refers to a PCR reaction where more than one primer set is included in the reaction pool allowing 2 or more different DNA targets to be amplified by PCR in a single reaction tube.
The term “non-template tag” refers to a stretch of at least three guanine or cytosine nucleobases of a primer used to produce a bioagent identifying amplicon which are not complementary to the template. A non-template tag is incorporated into a primer for the purpose of increasing the primer-duplex stability of later cycles of amplification by incorporation of extra G-C pairs which each have one additional hydrogen bond relative to an A-T pair.
The term “nucleic acid sequence” as used herein refers to the linear composition of the nucleic acid residues A, T, C or G or any modifications thereof, within an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single or double stranded, and represent the sense or antisense strand
As used herein, the term “nucleobase” is synonymous with other terms in use in the art including “nucleotide,” “deoxynucleotide,” “nucleotide residue,” “deoxynucleotide residue,” “nucleotide triphosphate (NTP),” or deoxynucleotide triphosphate (dNTP).
The term “nucleotide analog” as used herein refers to modified or non-naturally occurring nucleotides such as 5-propynyl pyrimidines (i.e., 5-propynyl-dTTP and 5-propynyl-dTCP), 7-deaza purines (i.e., 7-deaza-dATP and 7-deaza-dGTP). Nucleotide analogs include base analogs and comprise modified forms of deoxyribonucleotides as well as ribonucleotides.
The term “oligonucleotide” as used herein is defined as a molecule comprising two or more deoxyribonucleotides or ribonucleotides, preferably at least 5 nucleotides, more preferably at least about 13 to 35 nucleotides. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, PCR, or a combination thereof. Because mononucleotides are reacted to make oligonucleotides in a manner such that the 5′ phosphate of one mononucleotide pentose ring is attached to the 3′ oxygen of its neighbor in one direction via a phosphodiester linkage, an end of an oligonucleotide is referred to as the “5′-end” if its 5′ phosphate is not linked to the 3′ oxygen of a mononucleotide pentose ring and as the “3′-end” if its 3′ oxygen is not linked to a 5′ phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also may be said to have 5′ and 3′ ends. A first region along a nucleic acid strand is said to be upstream of another region if the 3′ end of the first region is before the 5′ end of the second region when moving along a strand of nucleic acid in a 5′ to 3′ direction. All oligonucleotide primers disclosed herein are understood to be presented in the 5′ to 3′ direction when reading left to right. When two different, non-overlapping oligonucleotides anneal to different regions of the same linear complementary nucleic acid sequence, and the 3′ end of one oligonucleotide points towards the 5′ end of the other, the former may be called the “upstream” oligonucleotide and the latter the “downstream” oligonucleotide. Similarly, when two overlapping oligonucleotides are hybridized to the same linear complementary nucleic acid sequence, with the first oligonucleotide positioned such that its 5′ end is upstream of the 5′ end of the second oligonucleotide, and the 3′ end of the first oligonucleotide is upstream of the 3′ end of the second oligonucleotide, the first oligonucleotide may be called the “upstream” oligonucleotide and the second oligonucleotide may be called the “downstream” oligonucleotide.
In the context of this invention, a “pathogen” is a bioagent which causes a disease or disorder.
As used herein, the terms “PCR product,” “PCR fragment,” and “amplification product” refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.
The term “peptide nucleic acid” (“PNA”) as used herein refers to a molecule comprising bases or base analogs such as would be found in natural nucleic acid, but attached to a peptide backbone rather than the sugar-phosphate backbone typical of nucleic acids. The attachment of the bases to the peptide is such as to allow the bases to base pair with complementary bases of nucleic acid in a manner similar to that of an oligonucleotide. These small molecules, also designated anti gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, et al. Anticancer Drug Des. 8:53 63). The primers of the present invention may comprise PNAs.
The term “polymerase” refers to an enzyme having the ability to synthesize a complementary strand of nucleic acid from a starting template nucleic acid strand and free dNTPs.
As used herein, the term “polymerase chain reaction” (“PCR”) refers to the method of K. B. Mullis U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188, hereby incorporated by reference, that describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one “cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the “polymerase chain reaction” (hereinafter “PCR”). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified.” With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of 32P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.
The term “polymerization means” or “polymerization agent” refers to any agent capable of facilitating the addition of nucleoside triphosphates to an oligonucleotide. Preferred polymerization means comprise DNA and RNA polymerases.
As used herein, the terms “pair of primers,” or “primer pair” are synonymous. A primer pair is used for amplification of a nucleic acid sequence. A pair of primers comprises a forward primer and a reverse primer. The forward primer hybridizes to a sense strand of a target gene sequence to be amplified and primes synthesis of an antisense strand (complementary to the sense strand) using the target sequence as a template. A reverse primer hybridizes to the antisense strand of a target gene sequence to be amplified and primes synthesis of a sense strand (complementary to the antisense strand) using the target sequence as a template.
The primers are designed to bind to highly conserved sequence regions of a bioagent identifying amplicon that flank an intervening variable region and yield amplification products which ideally provide enough variability to distinguish each individual bioagent, and which are amenable to molecular mass analysis. In some embodiments, the highly conserved sequence regions exhibit between about 80-100%, or between about 90-100%, or between about 95-100% identity, or between about 99-100% identity. The molecular mass of a given amplification product provides a means of identifying the bioagent from which it was obtained, due to the variability of the variable region. Thus design of the primers requires selection of a variable region with appropriate variability to resolve the identity of a given bioagent. Bioagent identifying amplicons are ideally specific to the identity of the bioagent.
Properties of the primers may include any number of properties related to structure including, but not limited to: nucleobase length which may be contiguous (linked together) or non-contiguous (for example, two or more contiguous segments which are joined by a linker or loop moiety), modified or universal nucleobases (used for specific purposes such as for example, increasing hybridization affinity, preventing non-templated adenylation and modifying molecular mass) percent complementarity to a given target sequences.
Properties of the primers also include functional features including, but not limited to, orientation of hybridization (forward or reverse) relative to a nucleic acid template. The coding or sense strand is the strand to which the forward priming primer hybridizes (forward priming orientation) while the reverse priming primer hybridizes to the non-coding or antisense strand (reverse priming orientation). The functional properties of a given primer pair also include the generic template nucleic acid to which the primer pair hybridizes. For example, identification of bioagents can be accomplished at different levels using primers suited to resolution of each individual level of identification. Broad range survey primers are designed with the objective of identifying a bioagent as a member of a particular division (e.g., an order, family, genus or other such grouping of bioagents above the species level of bioagents). In some embodiments, broad range survey intelligent primers are capable of identification of bioagents at the species or sub-species level. Other primers may have the functionality of producing bioagent identifying amplicons for members of a given taxonomic genus, clade, species, sub-species or genotype (including genetic variants which may include presence of virulence genes or antibiotic resistance genes or mutations). Additional functional properties of primer pairs include the functionality of performing amplification either singly (single primer pair per amplification reaction vessel) or in a multiplex fashion (multiple primer pairs and multiple amplification reactions within a single reaction vessel).
As used herein, the terms “purified” or “substantially purified” refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated. An “isolated polynucleotide” or “isolated oligonucleotide” is therefore a substantially purified polynucleotide.
The term “reverse transcriptase” refers to an enzyme having the ability to transcribe DNA from an RNA template. This enzymatic activity is known as reverse transcriptase activity. Reverse transcriptase activity is desirable in order to obtain DNA from RNA viruses which can then be amplified and analyzed by the methods of the present invention.
The term “ribosomal RNA” or “rRNA” refers to the primary ribonucleic acid constituent of ribosomes. Ribosomes are the protein-manufacturing organelles of cells and exist in the cytoplasm. Ribosomal RNAs are transcribed from the DNA genes encoding them.
The term “sample” in the present specification and claims is used in its broadest sense. On the one hand it is meant to include a specimen or culture (e.g., microbiological cultures). On the other hand, it is meant to include both biological and environmental samples. A sample may include a specimen of synthetic origin. Biological samples may be animal, including human, fluid, solid (e.g., stool) or tissue, as well as liquid and solid food and feed products and ingredients such as dairy items, vegetables, meat and meat by-products, and waste. Biological samples may be obtained from all of the various families of domestic animals, as well as feral or wild animals, including, but not limited to, such animals as ungulates, bear, fish, lagamorphs, rodents, etc. Environmental samples include environmental material such as surface matter, soil, water, air and industrial samples, as well as samples obtained from food and dairy processing instruments, apparatus, equipment, utensils, disposable and non-disposable items. These examples are not to be construed as limiting the sample types applicable to the present invention. The term “source of target nucleic acid” refers to any sample that contains nucleic acids (RNA or DNA). Particularly preferred sources of target nucleic acids are biological samples including, but not limited to blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum and semen.
As used herein, the term “sample template” refers to nucleic acid originating from a sample that is analyzed for the presence of “target” (defined below). In contrast, “background template” is used in reference to nucleic acid other than sample template that may or may not be present in a sample. Background template is often a contaminant. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified away from the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.
A “segment” is defined herein as a region of nucleic acid within a target sequence.
The “self-sustained sequence replication reaction” (3SR) (Guatelli et al., Proc. Natl. Acad. Sci., 87:1874-1878 [1990], with an erratum at Proc. Natl. Acad. Sci., 87:7797 [1990]) is a transcription-based in vitro amplification system (Kwok et al., Proc. Natl. Acad. Sci., 86:1173-1177 [1989]) that can exponentially amplify RNA sequences at a uniform temperature. The amplified RNA can then be utilized for mutation detection (Fahy et al., PCR Meth. Appl., 1:25-33 [1991]). In this method, an oligonucleotide primer is used to add a phage RNA polymerase promoter to the 5′ end of the sequence of interest. In a cocktail of enzymes and substrates that includes a second primer, reverse transcriptase, RNase H, RNA polymerase and ribo- and deoxyribonucleoside triphosphates, the target sequence undergoes repeated rounds of transcription, cDNA synthesis and second-strand synthesis to amplify the area of interest. The use of 3SR to detect mutations is kinetically limited to screening small segments of DNA (e.g., 200-300 base pairs).
As used herein, the term ““sequence alignment”” refers to a listing of multiple DNA or amino acid sequences and aligns them to highlight their similarities. The listings can be made using bioinformatics computer programs.
In context of this invention, the term “speciating primer pair” refers to a primer pair designed to produce a bioagent identifying amplicon with the diagnostic capability of identifying species members of a group of genera or a particular genus of bioagents. Primer pair number 2249 (SEQ ID NOs: 430:1321), for example, is a speciating primer pair used to distinguish Staphylococcus aureus from other species of the genus Staphylococcus.
As used herein, a “sub-species characteristic” is a genetic characteristic that provides the means to distinguish two members of the same bioagent species. For example, one viral strain could be distinguished from another viral strain of the same species by possessing a genetic change (e.g., for example, a nucleotide deletion, addition or substitution) in one of the viral genes, such as the RNA-dependent RNA polymerase. Sub-species characteristics such as virulence genes and drug-are responsible for the phenotypic differences among the different strains of bacteria.
As used herein, the term “target” is used in a broad sense to indicate the gene or genomic region being amplified by the primers. Because the present invention provides a plurality of amplification products from any given primer pair (depending on the bioagent being analyzed), multiple amplification products from different specific nucleic acid sequences may be obtained. Thus, the term “target” is not used to refer to a single specific nucleic acid sequence. The “target” is sought to be sorted out from other nucleic acid sequences and contains a sequence that has at least partial complementarity with an oligonucleotide primer. The target nucleic acid may comprise single- or double-stranded DNA or RNA. A “segment” is defined as a region of nucleic acid within the target sequence.
The term “template” refers to a strand of nucleic acid on which a complementary copy is built from nucleoside triphosphates through the activity of a template-dependent nucleic acid polymerase. Within a duplex the template strand is, by convention, depicted and described as the “bottom” strand. Similarly, the non-template strand is often depicted and described as the “top” strand.
As used herein, the term “Tm” is used in reference to the “melting temperature.” The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. Several equations for calculating the Tm of nucleic acids are well known in the art. As indicated by standard references, a simple estimate of the Tm value may be calculated by the equation: Tm=81.5+0.41(% G+C), when a nucleic acid is in aqueous solution at 1 M NaCl (see e.g., Anderson and Young, Quantitative Filter Hybridization, in Nucleic Acid Hybridization (1985). Other references (e.g., Allawi, H. T. & SantaLucia, J., Jr. Thermodynamics and NMR of internal G.T mismatches in DNA. Biochemistry 36, 10581-94 (1997) include more sophisticated computations which take structural and environmental, as well as sequence characteristics into account for the calculation of Tm.
The term “triangulation genotyping analysis” refers to a method of genotyping a bioagent by measurement of molecular masses or base compositions of amplification products, corresponding to bioagent identifying amplicons, obtained by amplification of regions of more than one gene. In this sense, the term “triangulation” refers to a method of establishing the accuracy of information by comparing three or more types of independent points of view bearing on the same findings. Triangulation genotyping analysis carried out with a plurality of triangulation genotyping analysis primers yields a plurality of base compositions that then provide a pattern or “barcode” from which a species type can be assigned. The species type may represent a previously known sub-species or strain, or may be a previously unknown strain having a specific and previously unobserved base composition barcode indicating the existence of a previously unknown genotype.
As used herein, the term “triangulation genotyping analysis primer pair” is a primer pair designed to produce bioagent identifying amplicons for determining species types in a triangulation genotyping analysis.
The employment of more than one bioagent identifying amplicon for identification of a bioagent is herein referred to as “triangulation identification.” Triangulation identification is pursued by analyzing a plurality of bioagent identifying amplicons produced with different primer pairs. This process is used to reduce false negative and false positive signals, and enable reconstruction of the origin of hybrid or otherwise engineered bioagents. For example, identification of the three part toxin genes typical of B. anthracis (Bowen et al., J. Appl. Microbiol., 1999, 87, 270-278) in the absence of the expected signatures from the B. anthracis genome would suggest a genetic engineering event.
In the context of this invention, the term “unknown bioagent” may mean either: (i) a bioagent whose existence is known (such as the well known bacterial species Staphylococcus aureus for example) but which is not known to be in a sample to be analyzed, or (ii) a bioagent whose existence is not known (for example, the SARS coronavirus was unknown prior to April 2003). For example, if the method for identification of coronaviruses disclosed in commonly owned U.S. patent Ser. No. 10/829,826 (incorporated herein by reference in its entirety) was to be employed prior to April 2003 to identify the SARS coronavirus in a clinical sample, both meanings of “unknown” bioagent are applicable since the SARS coronavirus was unknown to science prior to April, 2003 and since it was not known what bioagent (in this case a coronavirus) was present in the sample. On the other hand, if the method of U.S. patent Ser. No. 10/829,826 was to be employed subsequent to April 2003 to identify the SARS coronavirus in a clinical sample, only the first meaning (i) of “unknown” bioagent would apply since the SARS coronavirus became known to science subsequent to April 2003 and since it was not known what bioagent was present in the sample.
The term “variable sequence” as used herein refers to differences in nucleic acid sequence between two nucleic acids. For example, the genes of two different bacterial species may vary in sequence by the presence of single base substitutions and/or deletions or insertions of one or more nucleotides. These two forms of the structural gene are said to vary in sequence from one another. In the context of the present invention, “viral nucleic acid” includes, but is not limited to, DNA, RNA, or DNA that has been obtained from viral RNA, such as, for example, by performing a reverse transcription reaction. Viral RNA can either be single-stranded (of positive or negative polarity) or double-stranded.
The term “virus” refers to obligate, ultramicroscopic, parasites that are incapable of autonomous replication (i.e., replication requires the use of the host cell's machinery). Viruses can survive outside of a host cell but cannot replicate.
The term “wild-type” refers to a gene or a gene product that has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the “normal” or “wild-type” form of the gene. In contrast, the term “modified”, “mutant” or “polymorphic” refers to a gene or gene product that displays modifications in sequence and or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
As used herein, a “wobble base” is a variation in a codon found at the third nucleotide position of a DNA triplet. Variations in conserved regions of sequence are often found at the third nucleotide position due to redundancy in the amino acid code.
DETAILED DESCRIPTION OF EMBODIMENTS A. Bioagent Identifying Amplicons
The present invention provides methods for detection and identification of unknown bioagents using bioagent identifying amplicons. Primers are selected to hybridize to conserved sequence regions of nucleic acids derived from a bioagent, and which bracket variable sequence regions to yield a bioagent identifying amplicon, which can be amplified and which is amenable to molecular mass determination. The molecular mass then provides a means to uniquely identify the bioagent without a requirement for prior knowledge of the possible identity of the bioagent. The molecular mass or corresponding base composition signature of the amplification product is then matched against a database of molecular masses or base composition signatures. A match is obtained when an experimentally-determined molecular mass or base composition of an analyzed amplification product is compared with known molecular masses or base compositions of known bioagent identifying amplicons and the experimentally determined molecular mass or base composition is the same as the molecular mass or base composition of one of the known bioagent identifying amplicons. Alternatively, the experimentally-determined molecular mass or base composition may be within experimental error of the molecular mass or base composition of a known bioagent identifying amplicon and still be classified as a match. In some cases, the match may also be classified using a probability of match model such as the models described in U.S. Ser. No. 11/073,362, which is commonly owned and incorporated herein by reference in entirety. Furthermore, the method can be applied to rapid parallel multiplex analyses, the results of which can be employed in a triangulation identification strategy. The present method provides rapid throughput and does not require nucleic acid sequencing of the amplified target sequence for bioagent detection and identification.
Despite enormous biological diversity, all forms of life on earth share sets of essential, common features in their genomes. Since genetic data provide the underlying basis for identification of bioagents by the methods of the present invention, it is necessary to select segments of nucleic acids which ideally provide enough variability to distinguish each individual bioagent and whose molecular mass is amenable to molecular mass determination.
Unlike bacterial genomes, which exhibit conservation of numerous genes (i.e. housekeeping genes) across all organisms, viruses do not share a gene that is essential and conserved among all virus families. Therefore, viral identification is achieved within smaller groups of related viruses, such as members of a particular virus family or genus. For example, RNA-dependent RNA polymerase is present in all single-stranded RNA viruses and can be used for broad priming as well as resolution within the virus family.
In some embodiments of the present invention, at least one bacterial nucleic acid segment is amplified in the process of identifying the bacterial bioagent. Thus, the nucleic acid segments that can be amplified by the primers disclosed herein and that provide enough variability to distinguish each individual bioagent and whose molecular masses are amenable to molecular mass determination are herein described as bioagent identifying amplicons.
In some embodiments of the present invention, bioagent identifying amplicons comprise from about 45 to about 150 nucleobases (i.e. from about 45 to about 200 linked nucleosides), although both longer and short regions may be used. One of ordinary skill in the art will appreciate that the invention embodies compounds of 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, and 150 nucleobases in length, or any range therewithin.
It is the combination of the portions of the bioagent nucleic acid segment to which the primers hybridize (hybridization sites) and the variable region between the primer hybridization sites that comprises the bioagent identifying amplicon. Thus, it can be said that a given bioagent identifying amplicon is “defined by” a given pair of primers.
In some embodiments, bioagent identifying amplicons amenable to molecular mass determination which are produced by the primers described herein are either of a length, size or mass compatible with the particular mode of molecular mass determination or compatible with a means of providing a predictable fragmentation pattern in order to obtain predictable fragments of a length compatible with the particular mode of molecular mass determination. Such means of providing a predictable fragmentation pattern of an amplification product include, but are not limited to, cleavage with chemical reagents, restriction enzymes or cleavage primers, for example. Thus, in some embodiments, bioagent identifying amplicons are larger than 150 nucleobases and are amenable to molecular mass determination following restriction digestion. Methods of using restriction enzymes and cleavage primers are well known to those with ordinary skill in the art.
In some embodiments, amplification products corresponding to bioagent identifying amplicons are obtained using the polymerase chain reaction (PCR) that is a routine method to those with ordinary skill in the molecular biology arts. Other amplification methods may be used such as ligase chain reaction (LCR), low-stringency single primer PCR, and multiple strand displacement amplification (MDA). These methods are also known to those with ordinary skill.
B. Primers and Primer Pairs
In some embodiments, the primers are designed to bind to conserved sequence regions of a bioagent identifying amplicon that flank an intervening variable region and yield amplification products which provide variability sufficient to distinguish each individual bioagent, and which are amenable to molecular mass analysis. In some embodiments, the highly conserved sequence regions exhibit between about 80-100%, or between about 90-100%, or between about 95-100% identity, or between about 99-100% identity. The molecular mass of a given amplification product provides a means of identifying the bioagent from which it was obtained, due to the variability of the variable region. Thus, design of the primers involves selection of a variable region with sufficient variability to resolve the identity of a given bioagent. In some embodiments, bioagent identifying amplicons are specific to the identity of the bioagent.
In some embodiments, identification of bioagents is accomplished at different levels using primers suited to resolution of each individual level of identification. Broad range survey primers are designed with the objective of identifying a bioagent as a member of a particular division (e.g., an order, family, genus or other such grouping of bioagents above the species level of bioagents). In some embodiments, broad range survey intelligent primers are capable of identification of bioagents at the species or sub-species level. Examples of broad range survey primers include, but are not limited to: primer pair numbers: 346 (SEQ ID NOs: 202:1110), 347 (SEQ ID NOs: 560:1278), 348 SEQ ID NOs: 706:895), and 361 (SEQ ID NOs: 697:1398) which target DNA encoding 16S rRNA, and primer pair numbers 349 (SEQ ID NOs: 401:1156) and 360 (SEQ ID NOs: 409:1434) which target DNA encoding 23S rRNA.
In some embodiments, drill-down primers are designed with the objective of identifying a bioagent at the sub-species level (including strains, subtypes, variants and isolates) based on sub-species characteristics which may, for example, include single nucleotide polymorphisms (SNPs), variable number tandem repeats (VNTRs), deletions, drug resistance mutations or any other modification of a nucleic acid sequence of a bioagent relative to other members of a species having different sub-species characteristics. Drill-down intelligent primers are not always required for identification at the sub-species level because broad range survey intelligent primers may, in some cases provide sufficient identification resolution to accomplishing this identification objective. Examples of drill-down primers include, but are not limited to: confirmation primer pairs such as primer pair numbers 351 (SEQ ID NOs: 355:1423) and 353 (SEQ ID NOs: 220:1394), which target the pX01 virulence plasmid of Bacillus anthracis. Other examples of drill-down primer pairs are found in sets of triangulation genotyping primer pairs such as, for example, the primer pair number 2146 (SEQ ID NOs: 437:1137) which targets the arcC gene (encoding carmabate kinase) and is included in an 8 primer pair panel or kit for use in genotyping Staphylococcus aureus, or in other panels or kits of primer pairs used for determining drug-resistant bacterial strains, such as, for example, primer pair number 2095 (SEQ ID NOs: 456:1261) which targets the pv-luk gene (encoding Panton-Valentine leukocidin) and is included in an 8 primer pair panel or kit for use in identification of drug resistant strains of Staphylococcus aureus.
A representative process flow diagram used for primer selection and validation process is outlined in FIG. 1. For each group of organisms, candidate target sequences are identified (200) from which nucleotide alignments are created (210) and analyzed (220). Primers are then designed by selecting appropriate priming regions (230) to facilitate the selection of candidate primer pairs (240). The primer pairs are then subjected to in silico analysis by electronic PCR (ePCR) (300) wherein bioagent identifying amplicons are obtained from sequence databases such as GenBank or other sequence collections (310) and checked for specificity in silico (320). Bioagent identifying amplicons obtained from GenBank sequences (310) can also be analyzed by a probability model which predicts the capability of a given amplicon to identify unknown bioagents such that the base compositions of amplicons with favorable probability scores are then stored in a base composition database (325). Alternatively, base compositions of the bioagent identifying amplicons obtained from the primers and GenBank sequences can be directly entered into the base composition database (330). Candidate primer pairs (240) are validated by testing their ability to hybridize to target nucleic acid by an in vitro amplification by a method such as PCR analysis (400) of nucleic acid from a collection of organisms (410). Amplification products thus obtained are analyzed by gel electrophoresis or by mass spectrometry to confirm the sensitivity, specificity and reproducibility of the primers used to obtain the amplification products (420).
Many of the important pathogens, including the organisms of greatest concern as biowarfare agents, have been completely sequenced. This effort has greatly facilitated the design of primers for the detection of unknown bioagents. The combination of broad-range priming with division-wide and drill-down priming has been used very successfully in several applications of the technology, including environmental surveillance for biowarfare threat agents and clinical sample analysis for medically important pathogens.
Synthesis of primers is well known and routine in the art. The primers may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed.
In some embodiments primers are employed as compositions for use in methods for identification of bacterial bioagents as follows: a primer pair composition is contacted with nucleic acid (such as, for example, bacterial DNA or DNA reverse transcribed from the rRNA) of an unknown bacterial bioagent. The nucleic acid is then amplified by a nucleic acid amplification technique, such as PCR for example, to obtain an amplification product that represents a bioagent identifying amplicon. The molecular mass of each strand of the double-stranded amplification product is determined by a molecular mass measurement technique such as mass spectrometry for example, wherein the two strands of the double-stranded amplification product are separated during the ionization process. In some embodiments, the mass spectrometry is electrospray Fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR-MS) or electrospray time of flight mass spectrometry (ESI-TOF-MS). A list of possible base compositions can be generated for the molecular mass value obtained for each strand and the choice of the correct base composition from the list is facilitated by matching the base composition of one strand with a complementary base composition of the other strand. The molecular mass or base composition thus determined is then compared with a database of molecular masses or base compositions of analogous bioagent identifying amplicons for known viral bioagents. A match between the molecular mass or base composition of the amplification product and the molecular mass or base composition of an analogous bioagent identifying amplicon for a known viral bioagent indicates the identity of the unknown bioagent. In some embodiments, the primer pair used is one of the primer pairs of Table 2. In some embodiments, the method is repeated using one or more different primer pairs to resolve possible ambiguities in the identification process or to improve the confidence level for the identification assignment.
In some embodiments, a bioagent identifying amplicon may be produced using only a single primer (either the forward or reverse primer of any given primer pair), provided an appropriate amplification method is chosen, such as, for example, low stringency single primer PCR (LSSP-PCR). Adaptation of this amplification method in order to produce bioagent identifying amplicons can be accomplished by one with ordinary skill in the art without undue experimentation.
In some embodiments, the oligonucleotide primers are broad range survey primers which hybridize to conserved regions of nucleic acid encoding the hexon gene of all (or between 80% and 100%, between 85% and 100%, between 90% and 100% or between 95% and 100%) known bacteria and produce bacterial bioagent identifying amplicons.
In some cases, the molecular mass or base composition of a bacterial bioagent identifying amplicon defined by a broad range survey primer pair does not provide enough resolution to unambiguously identify a bacterial bioagent at or below the species level. These cases benefit from further analysis of one or more bacterial bioagent identifying amplicons generated from at least one additional broad range survey primer pair or from at least one additional division-wide primer pair. The employment of more than one bioagent identifying amplicon for identification of a bioagent is herein referred to as triangulation identification.
In other embodiments, the oligonucleotide primers are division-wide primers which hybridize to nucleic acid encoding genes of species within a genus of bacteria. In other embodiments, the oligonucleotide primers are drill-down primers which enable the identification of sub-species characteristics. Drill down primers provide the functionality of producing bioagent identifying amplicons for drill-down analyses such as strain typing when contacted with nucleic acid under amplification conditions. Identification of such sub-species characteristics is often critical for determining proper clinical treatment of viral infections. In some embodiments, sub-species characteristics are identified using only broad range survey primers and division-wide and drill-down primers are not used.
In some embodiments, the primers used for amplification hybridize to and amplify genomic DNA, and DNA of bacterial plasmids.
In some embodiments, various computer software programs may be used to aid in design of primers for amplification reactions such as Primer Premier 5 (Premier Biosoft, Palo Alto, Calif.) or OLIGO Primer Analysis Software (Molecular Biology Insights, Cascade, Colo.). These programs allow the user to input desired hybridization conditions such as melting temperature of a primer-template duplex for example. In some embodiments, an in silico PCR search algorithm, such as (ePCR) is used to analyze primer specificity across a plurality of template sequences which can be readily obtained from public sequence databases such as GenBank for example. An existing RNA structure search algorithm (Macke et al., Nucl. Acids Res., 2001, 29, 472-44735, which is incorporated herein by reference in its entirety) has been modified to include PCR parameters such as hybridization conditions, mismatches, and thermodynamic calculations (SantaLucia, Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 1460-1465, which is incorporated herein by reference in its entirety). This also provides information on primer specificity of the selected primer pairs. In some embodiments, the hybridization conditions applied to the algorithm can limit the results of primer specificity obtained from the algorithm. In some embodiments, the melting temperature threshold for the primer template duplex is specified to be 35° C. or a higher temperature. In some embodiments the number of acceptable mismatches is specified to be seven mismatches or less. In some embodiments, the buffer components and concentrations and primer concentrations may be specified and incorporated into the algorithm, for example, an appropriate primer concentration is about 250 nM and appropriate buffer components are 50 mM sodium or potassium and 1.5 mM Mg2+.
One with ordinary skill in the art of design of amplification primers will recognize that a given primer need not hybridize with 100% complementarity in order to effectively prime the synthesis of a complementary nucleic acid strand in an amplification reaction. Moreover, a primer may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event. (e.g., for example, a loop structure or a hairpin structure). The primers of the present invention may comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity with any of the primers listed in Table 2. Thus, in some embodiments of the present invention, an extent of variation of 70% to 100%, or any range therewithin, of the sequence identity is possible relative to the specific primer sequences disclosed herein. Determination of sequence identity is described in the following example: a primer 20 nucleobases in length which is identical to another 20 nucleobase primer having two non-identical residues has 18 of 20 identical residues (18/20=0.9 or 90% sequence identity). In another example, a primer 15 nucleobases in length having all residues identical to a 15 nucleobase segment of primer 20 nucleobases in length would have 15/20=0.75 or 75% sequence identity with the 20 nucleobase primer.
Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for UNIX, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489). In some embodiments, complementarity of primers with respect to the conserved priming regions of viral nucleic acid is between about 70% and about 75% 80%. In other embodiments, homology, sequence identity or complementarity, is between about 75% and about 80%. In yet other embodiments, homology, sequence identity or complementarity, is at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or is 100%.
In some embodiments, the primers described herein comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 98%, or at least 99%, or 100% (or any range therewithin) sequence identity with the primer sequences specifically disclosed herein.
One with ordinary skill is able to calculate percent sequence identity or percent sequence homology and able to determine, without undue experimentation, the effects of variation of primer sequence identity on the function of the primer in its role in priming synthesis of a complementary strand of nucleic acid for production of an amplification product of a corresponding bioagent identifying amplicon.
In one embodiment, the primers are at least 13 nucleobases in length. In another embodiment, the primers are less than 36 nucleobases in length.
In some embodiments of the present invention, the oligonucleotide primers are 13 to 35 nucleobases in length (13 to 35 linked nucleotide residues). These embodiments comprise oligonucleotide primers 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleobases in length, or any range therewithin. The present invention contemplates using both longer and shorter primers. Furthermore, the primers may also be linked to one or more other desired moieties, including, but not limited to, affinity groups, ligands, regions of nucleic acid that are not complementary to the nucleic acid to be amplified, labels, etc. Primers may also form hairpin structures. For example, hairpin primers may be used to amplify short target nucleic acid molecules. The presence of the hairpin may stabilize the amplification complex (see e.g., TAQMAN MicroRNA Assays, Applied Biosystems, Foster City, Calif.).
In some embodiments, any oligonucleotide primer pair may have one or both primers with less then 70% sequence homology with a corresponding member of any of the primer pairs of Table 2 if the primer pair has the capability of producing an amplification product corresponding to a bioagent identifying amplicon. In other embodiments, any oligonucleotide primer pair may have one or both primers with a length greater than 35 nucleobases if the primer pair has the capability of producing an amplification product corresponding to a bioagent identifying amplicon.
In some embodiments, the function of a given primer may be substituted by a combination of two or more primers segments that hybridize adjacent to each other or that are linked by a nucleic acid loop structure or linker which allows a polymerase to extend the two or more primers in an amplification reaction.
In some embodiments, the primer pairs used for obtaining bioagent identifying amplicons are the primer pairs of Table 2. In other embodiments, other combinations of primer pairs are possible by combining certain members of the forward primers with certain members of the reverse primers. An example can be seen in Table 2 for two primer pair combinations of forward primer 16S_EC—789—810_F (SEQ ID NO: 206), with the reverse primers 16S_EC—880—894_R (SEQ ID NO: 796), or 16S_EC—882—899_R or (SEQ ID NO: 818). Arriving at a favorable alternate combination of primers in a primer pair depends upon the properties of the primer pair, most notably the size of the bioagent identifying amplicon that would be produced by the primer pair, which preferably is between about 45 to about 150 nucleobases in length. Alternatively, a bioagent identifying amplicon longer than 150 nucleobases in length could be cleaved into smaller segments by cleavage reagents such as chemical reagents, or restriction enzymes, for example.
In some embodiments, the primers are configured to amplify nucleic acid of a bioagent to produce amplification products that can be measured by mass spectrometry and from whose molecular masses candidate base compositions can be readily calculated.
In some embodiments, any given primer comprises a modification comprising the addition of a non-templated T residue to the 5′ end of the primer (i.e., the added T residue does not necessarily hybridize to the nucleic acid being amplified). The addition of a non-templated T residue has an effect of minimizing the addition of non-templated adenosine residues as a result of the non-specific enzyme activity of Taq polymerase (Magnuson et al., Biotechniques, 1996, 21, 700-709), an occurrence which may lead to ambiguous results arising from molecular mass analysis.
In some embodiments of the present invention, primers may contain one or more universal bases. Because any variation (due to codon wobble in the 3rd position) in the conserved regions among species is likely to occur in the third position of a DNA (or RNA) triplet, oligonucleotide primers can be designed such that the nucleotide corresponding to this position is a base which can bind to more than one nucleotide, referred to herein as a “universal nucleobase.” For example, under this “wobble” pairing, inosine (I) binds to U, C or A; guanine (G) binds to U or C, and uridine (U) binds to U or C. Other examples of universal nucleobases include nitroindoles such as 5-nitroindole or 3-nitropyrrole (Loakes et al., Nucleosides and Nucleotides, 1995, 14, 1001-1003), the degenerate nucleotides dP or dK (Hill et al.), an acyclic nucleoside analog containing 5-nitroindazole (Van Aerschot et al., Nucleosides and Nucleotides, 1995, 14, 1053-1056) or the purine analog 1-(2-deoxy-β-D-ribofuranosyl)-imidazole-4-carboxamide (Sala et al., Nucl. Acids Res., 1996, 24, 3302-3306).
In some embodiments, to compensate for the somewhat weaker binding by the wobble base, the oligonucleotide primers are designed such that the first and second positions of each triplet are occupied by nucleotide analogs that bind with greater affinity than the unmodified nucleotide. Examples of these analogs include, but are not limited to, 2,6-diaminopurine which binds to thymine, 5-propynyluracil (also known as propynylated thymine) which binds to adenine and 5-propynylcytosine and phenoxazines, including G-clamp, which binds to G. Propynylated pyrimidines are described in U.S. Pat. Nos. 5,645,985, 5,830,653 and 5,484,908, each of which is commonly owned and incorporated herein by reference in its entirety. Propynylated primers are described in U.S Pre-Grant Publication No. 2003-0170682, which is also commonly owned and incorporated herein by reference in its entirety. Phenoxazines are described in U.S. Pat. Nos. 5,502,177, 5,763,588, and 6,005,096, each of which is incorporated herein by reference in its entirety. G-clamps are described in U.S. Pat. Nos. 6,007,992 and 6,028,183, each of which is incorporated herein by reference in its entirety.
In some embodiments, primer hybridization is enhanced using primers containing 5-propynyl deoxy-cytidine and deoxy-thymidine nucleotides. These modified primers offer increased affinity and base pairing selectivity.
In some embodiments, non-template primer tags are used to increase the melting temperature (Tm) of a primer-template duplex in order to improve amplification efficiency. A non-template tag is at least three consecutive A or T nucleotide residues on a primer which are not complementary to the template. In any given non-template tag, A can be replaced by C or G and T can also be replaced by C or G. Although Watson-Crick hybridization is not expected to occur for a non-template tag relative to the template, the extra hydrogen bond in a G-C pair relative to an A-T pair confers increased stability of the primer-template duplex and improves amplification efficiency for subsequent cycles of amplification when the primers hybridize to strands synthesized in previous cycles.
In other embodiments, propynylated tags may be used in a manner similar to that of the non-template tag, wherein two or more 5-propynylcytidine or 5-propynyluridine residues replace template matching residues on a primer. In other embodiments, a primer contains a modified internucleoside linkage such as a phosphorothioate linkage, for example.
In some embodiments, the primers contain mass-modifying tags. Reducing the total number of possible base compositions of a nucleic acid of specific molecular weight provides a means of avoiding a persistent source of ambiguity in determination of base composition of amplification products. Addition of mass-modifying tags to certain nucleobases of a given primer will result in simplification of de novo determination of base composition of a given bioagent identifying amplicon from its molecular mass.
In some embodiments of the present invention, the mass modified nucleobase comprises one or more of the following: for example, 7-deaza-2′-deoxyadenosine-5-triphosphate, 5-iodo-2′-deoxyuridine-5′-triphosphate, 5-bromo-2′-deoxyuridine-5′-triphosphate, 5-bromo-2′-deoxycytidine-5′-triphosphate, 5-iodo-2′-deoxycytidine-5′-triphosphate, 5-hydroxy-2′-deoxyuridine-5′-triphosphate, 4-thiothymidine-5′-triphosphate, 5-aza-2′-deoxyuridine-5′-triphosphate, 5-fluoro-2′-deoxyuridine-5′-triphosphate, O6-methyl-2′-deoxyguanosine-5′-triphosphate, N2-methyl-2′-deoxyguanosine-5′-triphosphate, 8-oxo-2′-deoxyguanosine-5′-triphosphate or thiothymidine-5′-triphosphate. In some embodiments, the mass-modified nucleobase comprises 15N or 13C or both 15N and 13C.
In some embodiments, multiplex amplification is performed where multiple bioagent identifying amplicons are amplified with a plurality of primer pairs. The advantages of multiplexing are that fewer reaction containers (for example, wells of a 96- or 384-well plate) are needed for each molecular mass measurement, providing time, resource and cost savings because additional bioagent identification data can be obtained within a single analysis. Multiplex amplification methods are well known to those with ordinary skill and can be developed without undue experimentation. However, in some embodiments, one useful and non-obvious step in selecting a plurality candidate bioagent identifying amplicons for multiplex amplification is to ensure that each strand of each amplification product will be sufficiently different in molecular mass that mass spectral signals will not overlap and lead to ambiguous analysis results. In some embodiments, a 10 Da difference in mass of two strands of one or more amplification products is sufficient to avoid overlap of mass spectral peaks.
In some embodiments, as an alternative to multiplex amplification, single amplification reactions can be pooled before analysis by mass spectrometry. In these embodiments, as for multiplex amplification embodiments, it is useful to select a plurality of candidate bioagent identifying amplicons to ensure that each strand of each amplification product will be sufficiently different in molecular mass that mass spectral signals will not overlap and lead to ambiguous analysis results.
C Determination of Molecular Mass of Bioagent Identifying Amplicons
In some embodiments, the molecular mass of a given bioagent identifying amplicon is determined by mass spectrometry. Mass spectrometry has several advantages, not the least of which is high bandwidth characterized by the ability to separate (and isolate) many molecular peaks across a broad range of mass to charge ratio (m/z). Thus mass spectrometry is intrinsically a parallel detection scheme without the need for radioactive or fluorescent labels, since every amplification product is identified by its molecular mass. The current state of the art in mass spectrometry is such that less than femtomole quantities of material can be readily analyzed to afford information about the molecular contents of the sample. An accurate assessment of the molecular mass of the material can be quickly obtained, irrespective of whether the molecular weight of the sample is several hundred, or in excess of one hundred thousand atomic mass units (amu) or Daltons.
In some embodiments, intact molecular ions are generated from amplification products using one of a variety of ionization techniques to convert the sample to gas phase. These ionization methods include, but are not limited to, electrospray ionization (ES), matrix-assisted laser desorption ionization (MALDI) and fast atom bombardment (FAB). Upon ionization, several peaks are observed from one sample due to the formation of ions with different charges. Averaging the multiple readings of molecular mass obtained from a single mass spectrum affords an estimate of molecular mass of the bioagent identifying amplicon. Electrospray ionization mass spectrometry (ESI-MS) is particularly useful for very high molecular weight polymers such as proteins and nucleic acids having molecular weights greater than 10 kDa, since it yields a distribution of multiply-charged molecules of the sample without causing a significant amount of fragmentation.
The mass detectors used in the methods of the present invention include, but are not limited to, Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS), time of flight (TOF), ion trap, quadrupole, magnetic sector, Q-TOF, and triple quadrupole.
D. Base Compositions of Bioagent Identifying Amplicons
Although the molecular mass of amplification products obtained using intelligent primers provides a means for identification of bioagents, conversion of molecular mass data to a base composition signature is useful for certain analyses. As used herein, “base composition” is the exact number of each nucleobase (A, T, C and G) determined from the molecular mass of a bioagent identifying amplicon. In some embodiments, a base composition provides an index of a specific organism. Base compositions can be calculated from known sequences of known bioagent identifying amplicons and can be experimentally determined by measuring the molecular mass of a given bioagent identifying amplicon, followed by determination of all possible base compositions which are consistent with the measured molecular mass within acceptable experimental error. The following example illustrates determination of base composition from an experimentally obtained molecular mass of a 46-mer amplification product originating at position 1337 of the 16S rRNA of Bacillus anthracis. The forward and reverse strands of the amplification product have measured molecular masses of 14208 and 14079 Da, respectively. The possible base compositions derived from the molecular masses of the forward and reverse strands for the B. anthracis products are listed in Table 1. TABLE 1
Possible Base Compositions for B. anthracis 46mer Amplification Product
Calc. Mass Mass Error Base Calc. Mass Mass Error Base
Forward Forward Composition of Reverse Reverse Composition of
Strand Strand Forward Strand Strand Strand Reverse Strand
14208.2935 0.079520 A1 G17 C10 T18 14079.2624 0.080600 A0 G14 C13 T19
14208.3160 0.056980 A1 G20 C15 T10 14079.2849 0.058060 A0 G17 C18 T11
14208.3386 0.034440 A1 G23 C20 T2 14079.3075 0.035520 A0 G20 C23 T3
14208.3074 0.065560 A6 G11 C3 T26 14079.2538 0.089180 A5 G5 C1 T35
14208.3300 0.043020 A6 G14 C8 T18 14079.2764 0.066640 A5 G8 C6 T27
14208.3525 0.020480 A6 G17 C13 T10 14079.2989 0.044100 A5 G11 C11 T19
14208.3751 0.002060 A6 G20 C18 T2 14079.3214 0.021560 A5 G14 C16 T11
14208.3439 0.029060 A11 G8 C1 T26 14079.3440 0.000980 A5 G17 C21 T3
14208.3665 0.006520 A11 G11 C6 T18 14079.3129 0.030140 A10 G5 C4 T27
14208.3890 0.016020 A11 G14 C11 T10 14079.3354 0.007600 A10 G8 C9 T19
14208.4116 0.038560 A11 G17 C16 T2 14079.3579 0.014940 A10 G11 C14 T11
14208.4030 0.029980 A16 G8 C4 T18 14079.3805 0.037480 A10 G14 C19 T3
14208.4255 0.052520 A16 G11 C9 T10 14079.3494 0.006360 A15 G2 C2 T27
14208.4481 0.075060 A16 G14 C14 T2 14079.3719 0.028900 A15 G5 C7 T19
14208.4395 0.066480 A21 G5 C2 T18 14079.3944 0.051440 A15 G8 C12 T11
14208.4620 0.089020 A21 G8 C7 T10 14079.4170 0.073980 A15 G11 C17 T3
— — — 14079.4084 0.065400 A20 G2 C5 T19
— — — 14079.4309 0.087940 A20 G5 C10 T13
Among the 16 possible base compositions for the forward strand and the 18 possible base compositions for the reverse strand that were calculated, only one pair (shown in bold) are complementary base compositions, which indicates the true base composition of the amplification product. It should be recognized that this logic is applicable for determination of base compositions of any bioagent identifying amplicon, regardless of the class of bioagent from which the corresponding amplification product was obtained.
In some embodiments, assignment of previously unobserved base compositions (also known as “true unknown base compositions”) to a given phylogeny can be accomplished via the use of pattern classifier model algorithms. Base compositions, like sequences, vary slightly from strain to strain within species, for example. In some embodiments, the pattern classifier model is the mutational probability model. On other embodiments, the pattern classifier is the polytope model. The mutational probability model and polytope model are both commonly owned and described in U.S. patent application Ser. No. 11/073,362 which is incorporated herein by reference in entirety.
In one embodiment, it is possible to manage this diversity by building “base composition probability clouds” around the composition constraints for each species. This permits identification of organisms in a fashion similar to sequence analysis. A “pseudo four-dimensional plot” can be used to visualize the concept of base composition probability clouds. Optimal primer design requires optimal choice of bioagent identifying amplicons and maximizes the separation between the base composition signatures of individual bioagents. Areas where clouds overlap indicate regions that may result in a misclassification, a problem which is overcome by a triangulation identification process using bioagent identifying amplicons not affected by overlap of base composition probability clouds.
In some embodiments, base composition probability clouds provide the means for screening potential primer pairs in order to avoid potential misclassifications of base compositions. In other embodiments, base composition probability clouds provide the means for predicting the identity of a bioagent whose assigned base composition was not previously observed and/or indexed in a bioagent identifying amplicon base composition database due to evolutionary transitions in its nucleic acid sequence. Thus, in contrast to probe-based techniques, mass spectrometry determination of base composition does not require prior knowledge of the composition or sequence in order to make the measurement.
The present invention provides bioagent classifying information similar to DNA sequencing and phylogenetic analysis at a level sufficient to identify a given bioagent. Furthermore, the process of determination of a previously unknown base composition for a given bioagent (for example, in a case where sequence information is unavailable) has downstream utility by providing additional bioagent indexing information with which to populate base composition databases. The process of future bioagent identification is thus greatly improved as more BCS indexes become available in base composition databases.
E. Triangulation Identification
In some cases, a molecular mass of a single bioagent identifying amplicon alone does not provide enough resolution to unambiguously identify a given bioagent. The employment of more than one bioagent identifying amplicon for identification of a bioagent is herein referred to as “triangulation identification.” Triangulation identification is pursued by determining the molecular masses of a plurality of bioagent identifying amplicons selected within a plurality of housekeeping genes. This process is used to reduce false negative and false positive signals, and enable reconstruction of the origin of hybrid or otherwise engineered bioagents. For example, identification of the three part toxin genes typical of B. anthracis (Bowen et al., J. Appl. Microbiol., 1999, 87, 270-278) in the absence of the expected signatures from the B. anthracis genome would suggest a genetic engineering event.
In some embodiments, the triangulation identification process can be pursued by characterization of bioagent identifying amplicons in a massively parallel fashion using the polymerase chain reaction (PCR), such as multiplex PCR where multiple primers are employed in the same amplification reaction mixture, or PCR in multi-well plate format wherein a different and unique pair of primers is used in multiple wells containing otherwise identical reaction mixtures. Such multiplex and multi-well PCR methods are well known to those with ordinary skill in the arts of rapid throughput amplification of nucleic acids. In other related embodiments, one PCR reaction per well or container may be carried out, followed by an amplicon pooling step wherein the amplification products of different wells are combined in a single well or container which is then subjected to molecular mass analysis. The combination of pooled amplicons can be chosen such that the expected ranges of molecular masses of individual amplicons are not overlapping and thus will not complicate identification of signals.
F. Codon Base Composition Analysis
In some embodiments of the present invention, one or more nucleotide substitutions within a codon of a gene of an infectious organism confer drug resistance upon an organism which can be determined by codon base composition analysis. The organism can be a bacterium, virus, fungus or protozoan.
In some embodiments, the amplification product containing the codon being analyzed is of a length of about 35 to about 200 nucleobases. The primers employed in obtaining the amplification product can hybridize to upstream and downstream sequences directly adjacent to the codon, or can hybridize to upstream and downstream sequences one or more sequence positions away from the codon. The primers may have between about 70% to 100% sequence complementarity with the sequence of the gene containing the codon being analyzed.
In some embodiments, the codon base composition analysis is undertaken
In some embodiments, the codon analysis is undertaken for the purpose of investigating genetic disease in an individual. In other embodiments, the codon analysis is undertaken for the purpose of investigating a drug resistance mutation or any other deleterious mutation in an infectious organism such as a bacterium, virus, fungus or protozoan. In some embodiments, the bioagent is a bacterium identified in a biological product.
In some embodiments, the molecular mass of an amplification product containing the codon being analyzed is measured by mass spectrometry. The mass spectrometry can be either electrospray (ESI) mass spectrometry or matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Time-of-flight (TOF) is an example of one mode of mass spectrometry compatible with the analyses of the present invention.
The methods of the present invention can also be employed to determine the relative abundance of drug resistant strains of the organism being analyzed. Relative abundances can be calculated from amplitudes of mass spectral signals with relation to internal calibrants. In some embodiments, known quantities of internal amplification calibrants can be included in the amplification reactions and abundances of analyte amplification product estimated in relation to the known quantities of the calibrants.
In some embodiments, upon identification of one or more drug-resistant strains of an infectious organism infecting an individual, one or more alternative treatments can be devised to treat the individual.
G. Determination of the Quantity of a Bioagent
In some embodiments, the identity and quantity of an unknown bioagent can be determined using the process illustrated in FIG. 2. Primers (500) and a known quantity of a calibration polynucleotide (505) are added to a sample containing nucleic acid of an unknown bioagent. The total nucleic acid in the sample is then subjected to an amplification reaction (510) to obtain amplification products. The molecular masses of amplification products are determined (515) from which are obtained molecular mass and abundance data. The molecular mass of the bioagent identifying amplicon (520) provides the means for its identification (525) and the molecular mass of the calibration amplicon obtained from the calibration polynucleotide (530) provides the means for its identification (535). The abundance data of the bioagent identifying amplicon is recorded (540) and the abundance data for the calibration data is recorded (545), both of which are used in a calculation (550) which determines the quantity of unknown bioagent in the sample.
A sample comprising an unknown bioagent is contacted with a pair of primers that provide the means for amplification of nucleic acid from the bioagent, and a known quantity of a polynucleotide that comprises a calibration sequence. The nucleic acids of the bioagent and of the calibration sequence are amplified and the rate of amplification is reasonably assumed to be similar for the nucleic acid of the bioagent and of the calibration sequence. The amplification reaction then produces two amplification products: a bioagent identifying amplicon and a calibration amplicon. The bioagent identifying amplicon and the calibration amplicon should be distinguishable by molecular mass while being amplified at essentially the same rate. Effecting differential molecular masses can be accomplished by choosing as a calibration sequence, a representative bioagent identifying amplicon (from a specific species of bioagent) and performing, for example, a 2-8 nucleobase deletion or insertion within the variable region between the two priming sites. The amplified sample containing the bioagent identifying amplicon and the calibration amplicon is then subjected to molecular mass analysis by mass spectrometry, for example. The resulting molecular mass analysis of the nucleic acid of the bioagent and of the calibration sequence provides molecular mass data and abundance data for the nucleic acid of the bioagent and of the calibration sequence. The molecular mass data obtained for the nucleic acid of the bioagent enables identification of the unknown bioagent and the abundance data enables calculation of the quantity of the bioagent, based on the knowledge of the quantity of calibration polynucleotide contacted with the sample.
In some embodiments, construction of a standard curve where the amount of calibration polynucleotide spiked into the sample is varied provides additional resolution and improved confidence for the determination of the quantity of bioagent in the sample. The use of standard curves for analytical determination of molecular quantities is well known to one with ordinary skill and can be performed without undue experimentation.
In some embodiments, multiplex amplification is performed where multiple bioagent identifying amplicons are amplified with multiple primer pairs which also amplify the corresponding standard calibration sequences. In this or other embodiments, the standard calibration sequences are optionally included within a single vector which functions as the calibration polynucleotide. Multiplex amplification methods are well known to those with ordinary skill and can be performed without undue experimentation.
In some embodiments, the calibrant polynucleotide is used as an internal positive control to confirm that amplification conditions and subsequent analysis steps are successful in producing a measurable amplicon. Even in the absence of copies of the genome of a bioagent, the calibration polynucleotide should give rise to a calibration amplicon. Failure to produce a measurable calibration amplicon indicates a failure of amplification or subsequent analysis step such as amplicon purification or molecular mass determination. Reaching a conclusion that such failures have occurred is in itself, a useful event.
In some embodiments, the calibration sequence is comprised of DNA. In some embodiments, the calibration sequence is comprised of RNA.
In some embodiments, the calibration sequence is inserted into a vector that itself functions as the calibration polynucleotide. In some embodiments, more than one calibration sequence is inserted into the vector that functions as the calibration polynucleotide. Such a calibration polynucleotide is herein termed a “combination calibration polynucleotide.” The process of inserting polynucleotides into vectors is routine to those skilled in the art and can be accomplished without undue experimentation. Thus, it should be recognized that the calibration method should not be limited to the embodiments described herein. The calibration method can be applied for determination of the quantity of any bioagent identifying amplicon when an appropriate standard calibrant polynucleotide sequence is designed and used. The process of choosing an appropriate vector for insertion of a calibrant is also a routine operation that can be accomplished by one with ordinary skill without undue experimentation.
H. Identification of Bacteria
In other embodiments of the present invention, the primer pairs produce bioagent identifying amplicons within stable and highly conserved regions of bacteria. The advantage to characterization of an amplicon defined by priming regions that fall within a highly conserved region is that there is a low probability that the region will evolve past the point of primer recognition, in which case, the primer hybridization of the amplification step would fail. Such a primer set is thus useful as a broad range survey-type primer. In another embodiment of the present invention, the intelligent primers produce bioagent identifying amplicons including a region which evolves more quickly than the stable region described above. The advantage of characterization bioagent identifying amplicon corresponding to an evolving genomic region is that it is useful for distinguishing emerging strain variants or the presence of virulence genes, drug resistance genes, or codon mutations that induce drug resistance.
The present invention also has significant advantages as a platform for identification of diseases caused by emerging bacterial strains such as, for example, drug-resistant strains of Staphylococcus aureus. The present invention eliminates the need for prior knowledge of bioagent sequence to generate hybridization probes. This is possible because the methods are not confounded by naturally occurring evolutionary variations occurring in the sequence acting as the template for production of the bioagent identifying amplicon. Measurement of molecular mass and determination of base composition is accomplished in an unbiased manner without sequence prejudice.
Another embodiment of the present invention also provides a means of tracking the spread of a bacterium, such as a particular drug-resistant strain when a plurality of samples obtained from different locations are analyzed by the methods described above in an epidemiological setting. In one embodiment, a plurality of samples from a plurality of different locations is analyzed with primer pairs which produce bioagent identifying amplicons, a subset of which contains a specific drug-resistant bacterial strain. The corresponding locations of the members of the drug-resistant strain subset indicate the spread of the specific drug-resistant strain to the corresponding locations.
I. Kits
The present invention also provides kits for carrying out the methods described herein. In some embodiments, the kit may comprise a sufficient quantity of one or more primer pairs to perform an amplification reaction on a target polynucleotide from a bioagent to form a bioagent identifying amplicon. In some embodiments, the kit may comprise from one to fifty primer pairs, from one to twenty primer pairs, from one to ten primer pairs, or from two to five primer pairs. In some embodiments, the kit may comprise one or more primer pairs recited in Table 2.
In some embodiments, the kit comprises one or more broad range survey primer(s), division wide primer(s), or drill-down primer(s), or any combination thereof. If a given problem involves identification of a specific bioagent, the solution to the problem may require the selection of a particular combination of primers to provide the solution to the problem. A kit may be designed so as to comprise particular primer pairs for identification of a particular bioagent. A drill-down kit may be used, for example, to distinguish different genotypes or strains, drug-resistant, or otherwise. In some embodiments, the primer pair components of any of these kits may be additionally combined to comprise additional combinations of broad range survey primers and division-wide primers so as to be able to identify a bacterium.
In some embodiments, the kit contains standardized calibration polynucleotides for use as internal amplification calibrants. Internal calibrants are described in commonly owned U.S. Patent Application Ser. No. 60/545,425 which is incorporated herein by reference in its entirety.
In some embodiments, the kit comprises a sufficient quantity of reverse transcriptase (if RNA is to be analyzed for example), a DNA polymerase, suitable nucleoside triphosphates (including alternative dNTPs such as inosine or modified dNTPs such as the 5-propynyl pyrimidines or any dNTP containing molecular mass-modifying tags such as those described above), a DNA ligase, and/or reaction buffer, or any combination thereof, for the amplification processes described above. A kit may further include instructions pertinent for the particular embodiment of the kit, such instructions describing the primer pairs and amplification conditions for operation of the method. A kit may also comprise amplification reaction containers such as microcentrifuge tubes and the like. A kit may also comprise reagents or other materials for isolating bioagent nucleic acid or bioagent identifying amplicons from amplification, including, for example, detergents, solvents, or ion exchange resins which may be linked to magnetic beads. A kit may also comprise a table of measured or calculated molecular masses and/or base compositions of bioagents using the primer pairs of the kit.
Some embodiments are kits that contain one or more survey bacterial primer pairs represented by primer pair compositions wherein each member of each pair of primers has 70% to 100% sequence identity with the corresponding member from the group of primer pairs represented by any of the primer pairs of Table 5. The survey primer pairs may include broad range primer pairs which hybridize to ribosomal RNA, and may also include division-wide primer pairs which hybridize to housekeeping genes such as rplB, tufB, rpoB, rpoC, valS, and infB, for example.
In some embodiments, a kit may contain one or more survey bacterial primer pairs and one or more triangulation genotyping analysis primer pairs such as the primer pairs of Tables 8, 12, 14, 19, 21, 23, or 24. In some embodiments, the kit may represent a less expansive genotyping analysis but include triangulation genotyping analysis primer pairs for more than one genus or species of bacteria. For example, a kit for surveying nosocomial infections at a health care facility may include, for example, one or more broad range survey primer pairs, one or more division wide primer pairs, one or more Acinetobacter baumannii triangulation genotyping analysis primer pairs and one or more Staphylococcus aureus triangulation genotyping analysis primer pairs. One with ordinary skill will be capable of analyzing in silico amplification data to determine which primer pairs will be able to provide optimal identification resolution for the bacterial bioagents of interest.
In some embodiments, a kit may be assembled for identification of strains of bacteria involved in contamination of food. An example of such a kit embodiment is a kit comprising one or more bacterial survey primer pairs of Table 5 with one or more triangulation genotyping analysis primer pairs of Table 12 which provide strain resolving capabilities for identification of specific strains of Campylobacter jejuni.
Some embodiments of the kits are 96-well or 384-well plates with a plurality of wells containing any or all of the following components: dNTPs, buffer salts, Mg2+, betaine, and primer pairs. In some embodiments, a polymerase is also included in the plurality of wells of the 96-well or 384-well plates.
Some embodiments of the kit contain instructions for PCR and mass spectrometry analysis of amplification products obtained using the primer pairs of the kits.
Some embodiments of the kit include a barcode which uniquely identifies the kit and the components contained therein according to production lots and may also include any other information relative to the components such as concentrations, storage temperatures, etc. The barcode may also include analysis information to be read by optical barcode readers and sent to a computer controlling amplification, purification and mass spectrometric measurements. In some embodiments, the barcode provides access to a subset of base compositions in a base composition database which is in digital communication with base composition analysis software such that a base composition measured with primer pairs from a given kit can be compared with known base compositions of bioagent identifying amplicons defined by the primer pairs of that kit.
In some embodiments, the kit contains a database of base compositions of bioagent identifying amplicons defined by the primer pairs of the kit. The database is stored on a convenient computer readable medium such as a compact disk or USB drive, for example.
In some embodiments, the kit includes a computer program stored on a computer formatted medium (such as a compact disk or portable USB disk drive, for example) comprising instructions which direct a processor to analyze data obtained from the use of the primer pairs of the present invention. The instructions of the software transform data related to amplification products into a molecular mass or base composition which is a useful concrete and tangible result used in identification and/or classification of bioagents. In some embodiments, the kits of the present invention contain all of the reagents sufficient to carry out one or more of the methods described herein.
While the present invention has been described with specificity in accordance with certain of its embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same. In order that the invention disclosed herein may be more efficiently understood, examples are provided below. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting the invention in any manner.
EXAMPLES Example 1 Design and Validation of Primers that Define Bioagent Identifying Amplicons for Identification of Bacteria For design of primers that define bacterial bioagent identifying amplicons, a series of bacterial genome segment sequences were obtained, aligned and scanned for regions where pairs of PCR primers would amplify products of about 45 to about 150 nucleotides in length and distinguish subgroups and/or individual strains from each other by their molecular masses or base compositions. A typical process shown in FIG. 1 is employed for this type of analysis.
A database of expected base compositions for each primer region was generated using an in silico PCR search algorithm, such as (ePCR). An existing RNA structure search algorithm (Macke et al., Nucl. Acids Res., 2001, 29, 4724-4735, which is incorporated herein by reference in its entirety) has been modified to include PCR parameters such as hybridization conditions, mismatches, and thermodynamic calculations (SantaLucia, Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 1460-1465, which is incorporated herein by reference in its entirety). This also provides information on primer specificity of the selected primer pairs.
Table 2 represents a collection of primers (sorted by primer pair number) designed to identify bacteria using the methods described herein. The primer pair number is an in-house database index number. Primer sites were identified on segments of genes, such as, for example, the 16S rRNA gene. The forward or reverse primer name shown in Table 2 indicates the gene region of the bacterial genome to which the primer hybridizes relative to a reference sequence. In Table 2, for example, the forward primer name 16S_EC—1077—1106_F indicates that the forward primer (_F) hybridizes to residues 1077-1106 of the reference sequence represented by a sequence extraction of coordinates 4033120 . . . 4034661 from GenBank gi number 16127994 (as indicated in Table 3). As an additional example: the forward primer name BONTA_X52066—450—473 indicates that the primer hybridizes to residues 450-437 of the gene encoding Clostridium botulinum neurotoxin type A (BoNT/A) represented by GenBank Accession No. X52066 (primer pair name codes appearing in Table 2 are defined in Table 3. One with ordinary skill knows how to obtain individual gene sequences or portions thereof from genomic sequences present in GenBank. In Table 2, Tp=5-propynyluracil; Cp=5-propynylcytosine; *=phosphorothioate linkage; I=inosine. T. GenBank Accession Numbers for reference sequences of bacteria are shown in Table 3 (below). In some cases, the reference sequences are extractions from bacterial genomic sequences or complements thereof. TABLE 2
Primer Pairs for Identification of Bacteria
Primer +HC,86
Pair Forward SEQ Reverse SEQ
Number Forward Primer Name Forward Sequence ID NO: Reverse Primer Name Reverse Sequence ID NO:
1 16S_EC_1077_1106_F GTGAGATGTTGGGTTAAGTCCCGTAA 134 16S_EC_1175_1195_R GACGTCATCCCCACCTTCCTC 809
CGAG
2 16S_EC_1082_1106_F ATGTTGGGTTAAGTCCCGCAACGAG 38 16S_EC_1175_1197_R TTGACGTCATCCCCACCTTCCTC 1398
3 16S_EC_1090_1111_F TTAAGTCCCGCAACGATCGCAA 651 16S_EC_1175_1196_R TGACGTCATCCCCACCTTCCTC 1159
4 16S_EC_1222_1241_F GCTACACACGTGCTACAATG 114 16S_EC_1303_1323_R CGAGTTGCAGACTGCGATCCG 787
5 16S_EC_1332_1353_F AAGTCGGAATCGCTAGTAATCG 10 16S_EC_1389_1407_R GACGGGCGGTGTGTACAAG 806
6 16S_EC_30_54_F TGAACGCTGGTGGCATGCTTAACAC 429 16S_EC_105_126_R TACGCATTACTCACCCGTCCGC 897
7 16S_EC_38_64_F GTGGCATGCCTAATACATGCAAGTCG 136 16S_EC_101_120_R TTACTCACCCGTCCGCCGCT 1365
8 16S_EC_49_68_F TAACACATGCAAGTCGAACG 152 16S_EC_104_120_R TTACTCACCCGTCCGCC 1364
9 16S_EC_683_700_F GTGTAGCGGTGAAATGCG 137 16S_EC_774_795_R GTATCTAATCCTGTTTGCTCCC 839
10 16S_EC_713_732_F AGAACACCGATGGCGAAGGC 21 16S_EC_789_809_R CGTGGACTACCAGGGTATCTA 798
11 16S_EC_785_806_F GGATTAGAGACCCTGGTAGTCC 118 16S_EC_880_897_R GGCCGTACTCCCCAGGCG 830
12 16S_EC_785_810_F GGATTAGATACCCTGGTAGTCCACGC 119 16S_EC_80_897_2_R GGCCGTACTCCCCAGGCG 830
13 16S_EC_789_810_F TAGATACCCTGGTAGTCCACGC 206 16S_EC_880_894_R CGTACTCCCCAGGCG 796
14 16S_EC_960_981_F TTCGATGCAACGCGAAGAACCT 672 16S_EC_1054_1073_R ACGAGCTGACGACAGCCATG 735
15 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078_R ACGACACGAGCTGACGAC 734
16 23S_EC_1826_1843_F CTGACACCTGCCCGGTGC 80 23S_EC_1906_1924_R GACCGTTATAGTTACGGCC 805
17 23S_EC_2645_2669_F TCTGTCCCTAGTACGAGAGGACCGG 408 235_EC_2744_2761_R TGCTTAGATGCTTTCAGC 1252
18 23S_EC_2645_2669_2_F CTGTCCCTAGTACGAGAGGACCGG 83 23S_EC_2751_2767_R GTTTCATGCTTAGATGCTTTCAGC 846
19 23S_EC_493_518_F GGGGAGTGAAAGAGATCCTGAAACCG 125 23S_EC_551_571_R ACAAAAGGTACGCCGTCACCC 717
20 23S_EC_493_518_2_F GGGCAGTGAAAGAGATCCTGAAACCG 125 23S_EC_551_571_2_R ACAAAAGGCACGCCATCACCC 716
21 23S_EC_971_992_F CGAGAGGGAAACAACCCAGACC 66 23S_EC_1059_1077_R TGGCTGCTTCTAAGCCAAC 1282
22 CAPC_BA_104_131_F GTTATTTAGCACTCGTTTTTAATCAG 139 CAPC_BA_180_205_R TGAATCTTGAAACACCATACGTAACG 1150
CC
23 CAPC_BA_114_133_F ACTCGTTTTTAATCAGCCCG 20 CAPC_BA_185_205_R TGAATCTTGAAACACCATACG 1149
24 CAPC_BA_274_303_F GATTATTGTTATCCTGTTATGCCATT 109 CAPC_BA_349_376_R GTAACCCTTGTCTTTGAATTGTATTTGC 837
TGAG
25 CAPC_BA_276_296_F TTATTGTTATCCTGTTATGCC 663 CAPC_BA_358_377_R GGTAACCCTTGTCTTTGAAT 834
26 CAPC_BA_281_301_F GTTATCCTGTTATGCCATTTG 138 CAPC_BA_361_378_R TGGTAACCCTTGTCTTTG 1298
27 CAPC_BA_315_334_F CCGTGGTATTGGAGTTATTG 59 CAPC_BA_361_378_R TGGTAACCCTTGTCTTTG 1298
28 CYA_BA_1055_1072_F GAAAGAGTTCGGATTGGG 92 CYA_BA_1112_1130_R TGTTGACCATGCTTCTTAG 1352
29 CYA_BA_1349_1370_F ACAACGAGTACAATACAAGAC 12 CYA_BA_1447_1426_R CTTCTACATTTTTAGCCATCAC 800
30 CYA_BA_1353_1379_F CGAAGTACAATACAAGACAAAAGAAG 64 CYA_BA_1448_1467_R TGTTAACGGCTTCAAGACCC 1342
G
31 CYA_BA_1359_1379_F ACAATACAAGACAAAAGAAGG 13 CYA_BA_1447_1461_R CGGCTTCAAGACCCC 794
32 CYA_BA_914_937_F CAGGTTTAGTACCAGAACATGCAG 53 CYA_BA_999_1026_R ACCACTTTTAATAAGGTTTGTAGCTAAC 728
33 CYA_BA_916_935_F GGTTTAGTACCAGAACATGC 131 CYA_BA_1003_1025_R CCACTTTTAATAAGGTTTGTAGC 768
34 INFB_EC_1365_1393_F TGCTCGTGGTGCACAAGTAACGGATA 524 INFB_EC_1439_1467_R TGCTGCTTTCGCATGGTTAATTGCTTCA 1248
TTA A
35 LEF_BA_1033_1052_F TCAAGAAGAAAAAGAGC 254 LEG_BA_1119_1135_R GAATATCAATTTGTAGC 803
36 LEF_BA_1036_1066_F CAAGAAGAAAAAGAGCTTCTAAAAAG 44 LEF_BA_1119_1149_R AGATAAAGAATCACGAATATCAATTTGT 745
AATAC AGC
37 LEF_BA_756_781_F AGCTTTTGCATATTATATCGAGCCAC 26 LEF_BA_843_872_R TCTTCCAAGGATAGATI2TATTTCTTGTT 1135
CG
38 LEF_BA_758_778_F CTTTTGCATATTATATCGAGC 90 LEF_BA_843_865_R AGGATAGATTTATTTCTTGTTCG 748
39 LEF_BA_795_813_F TTTACAGCTTTATGCACCG 700 LEF_BA_883_900_R TCTTGACAGCATCCGTTG 1140
40 LEG_BA_883_899_F CAACGGATGCTGGCAAG 43 LEF_BA_939_958_R CAGATAAAGAATCGCTCCAG 762
41 PAG_BA_122_142_F CAGAATCAAGTTCCCAGGGG 49 PAG_BA_190_209_R CCTGTAGTAGAAGAGGTAAC 781
42 PAG_BA_123_145_F AGAATCAAGTTCCCAGGGGTTAC 22 PAG_BA_187_210 R CCCTGTAGTAGAAGAGGTAACCAC 774
43 PAG_BA_269_287_F AATCTGCTATTTGGTCAGG 11 PAG_BA_326_344_R TGATTATCAGCGGAAGTAG 1186
44 PAG_BA_655_675_F GAAGGATATACGGTTGATGTC 93 PAG_BA_755_772_R CCGTGCTCCATTTTTCAG 778
45 PAG_BA_753_772_F TCCTGAAAAATGGAGCACGG 341 PAG_BA_849_868_R TCGGATAAGCTGCCACAAGG 1089
46 PAG_BA_763_761_F TGGAGCACGGCTTCTGATC 552 PAG_BA_849_868_R TCGGATAAGCTGCCACAAGG 1089
47 RPOC_EC_1018_1045_F CAAAACTTATTAGGTAAGCGTGTTGA 39 RPOC_EC_1095_1124_R TCAAGCGCCATTTCTTTTGGTAAACCAC 959
CT AT
48 RPOC_EC_1018_1045_2_F CAAAACTTATTAGGTAAGCGTGTTGA 39 PROC_EC_1095_1124_2_R TCAAGCGCCATCTCTTTCGGTAATCCAC 958
CT AT
49 RPOC_EC_114_140_F TAAGAAGCCGGAAACCATCAACTACC 158 RFOC_EC_213_232_R GGCGCTTGTACTTACCGCAC 831
G
50 RFOC_EC_2178_2196_F TGATTCTGGTGCCCGTGGT 478 RFOC_EC_2225_2246_R TTGGCCATCAGGCCACGCATAC 1414
51 RFOC_EC_2178_2196_2_F TGATTCCGGTGCCCGTGGT 477 RFOC_EC_2225_2246_2_R TTGGCCATCAGACCACGCATAC 1413
52 RFOC_EC_2218_2241_F CTGGCAGGTATGCGTGGTCTGATG 81 RFOC_EC_2313_2337_R CGCACCGTGGGTTGAGATGAAGTAC 790
53 RFOC_EC_2218_2241_2_F CTTGCTGGTATGCGTGGTCTGATG 86 EFOC_EC_2313_2337_2_R CGCACCATGCGTAGAGATGAAGTAC 789
54 EPOC_EC_808_833_F CGTCGGGTGATTAACCGTAACAACCG 75 RPOC_EC_865_889_R GTTTTTCGTTGCGTACGATGATGTC 847
55 RFOC_EC_808_833_2_F CGTCGTGTAATTAACCGTAACAACCG 76 RFOC_EC_865_891_R ACGTTTTTCGTTTTGAACGATAATGCT 741
56 RFOC_EC_993_1019_F CAAAGGTAAGCAAGGTCGTTTCCGTC 41 RFOC_EC_1036_1059_R CGAACGGCCTGAGTAGTCAACACG 785
A
57 RPOC_EC_993_1019_2_F CAAAGGTAAGCAAGGACGTTTCCGTC 40 RPOC_EC_1036_1059_2_R CGAACGGCCAGAGTAGTCAACACG 784
A
58 SSPE_BA_115_137_F CAAGCAAACGCACAATCAGAAGC 45 SSPE_BA_197_222_R TGCACGTCTGTTTCAGTTGCAAATTC 1201
59 TUFB_EC_239_259_F TAGACTGCCCAGGACACGCTG 204 TUFB_EC_283_303_R GCCGTCCATCTGAGCAGCACC 815
60 TUFB_EC_239_259_2_F TTGACTGCCCAGGTCACGCTG 678 TUFB_EC_283_303_2_R GCCGTCCATTTGAGCAGCACC 816
61 TUFB_EC_976_1000_F AACTACCGTCCCCAGTTCTACTTCC 4 TUFB_EC_1045_1068_R GTTGTCCCCAGGCATAACCATTTC 845
62 TUFB_EC_976_1000_2_F AACTACCGTCCTCAGTTCTACTTCC 5 TUFB_EC_1045_1068_2_R GTTGTCACCAGCCATTACCATTTC 844
63 TUFB_EC_985_1012_F CCACAGTTCTACTTCCGTACTACTGA 56 TUFB_EC_1033_1062_R TCCAGGCATTACCATTTCTACTCCTTCT 1006
CG CG
66 RPLB_EC_650_679_F GACCTACAGTAAGAGGTTCTGTAATG 98 RPLB_EC_739_762_R TCCAACTGCTCCTTTACCCCATGG 999
AACC
67 RPLB_EC_688_710_F CATCCACACGGTGGTGGTGAAGG 54 RPLB_EC_736_757_R GTGCTGGTTTACCCCATGGAGT 842
68 RPOC_EC_1036_1060_F CGTGTTGACTATTCGGGGCGTTCAG 78 RPOC_EC_1097_1126_R ATTCAACAGCCATTTCTTTTGGTAAACC 754
AC
69 RFOB_EC_3762_3790_F TCAACAACCTCTTCGAGGTAAAGCTC 248 RPOB_EC_3836_3865_R TTTCTTGAAGAGTATGAGCTGCTCCGTA 1435
AGT AG
70 RPLB_EC_688_710_F CATCCACACGGTGGTGGTGAAGG 54 RPLB_EC_743_771_R TGTTTTGTATCCAAGTCCTGGTTTACCC 1356
C
71 VALS_EC_1105_1124_F CGTGGCGGCGTGGTTATCGA 77 VALS_EC_1195_1218_R CGGTACGAACTGGATGTCGCCGTT 795
72 RFOB_EC_1845_1866_F TATCGCTCAGGCGAACTCCAAC 233 RPOB_EC_1909_1929_R GCTGGATTCGCCTTTGCTACG 825
73 RPLB_EC_669_698_F TGTAATGAACCCTAATGACCATCCAC 623 RPLB_EC_735_761_R CCAAGTGCTGGTTTACCCCATGGAGTA 767
ACGG
74 RPLB_EC_671_700_F TAATGAACCCTAATGACCATCCACAC 169 RPLB_EC_737_762_R TCCAAGTGCTGGTTTACCCCATGGAG 1000
GGTG
75 SP101_SPET11_1_29_F AACCTTAATTGGAAAGAAACCCAAGA 2 SP101_SPET11_92_116_R CCTACCCAACGTTCACCAAGGGCAG 779
AGT
76 SP101_SPET11_118_14 GCTGGTGAAAATAACCCAGATGTCGT 115 SP101_SPET11_213_238_R TGTGGCCGATTTCACCACCTGCTCCT 1340
7_F CCTC
77 SP101_SPET11_216_24 AGCAGGTGGTGAAATCGGCCACATGA 24 SP101_SPET11_308_333_R TGCCACTTTGACAACTCCTGTTGCTG 1209
3_F TT
78 SP101_SPET11_226_29 CTTGTACTTGTGGCTCACACGGCTGT 89 SP101_SPET11_355_380_R GCTGCTTTGATGGCTGAATCCCCTTC 824
5_F TTGG
79 SP101_SPET11_322_34 GTCAAAGTGGCACGTTTACTGGC 132 SP101_SPET11_423_441_R ATCCCCTGCTTCTGCTGCC 753
4_F
80 SP101_SPET11_358_38 GGGGATTCAGCCATCAAAGCAGCTAT 126 SP101_SPET11_448_473_R CCAACCTTTTCCACAACAGAATCAGC 766
7_F
81 SP101_SPET11_600_62 CCTTACTTCGAACTATGAATCTTTTG 62 SP101_SPET11_686_714_R CCCATTTTTTCACGCATGCTGAAAATAT 772
9_F GAAG C
82 SP101_SPET11_658_68 GGGGATTGATATCACCGATAAGAAGA 127 SP101_SPET11_756_784_R GATTGGCGATAAAGTGATATTTTCTAAA 813
4_F A A
83 SP101_SPET11_776_80 TCGCCAATCAAAACTAAGGGAATGGC 364 SP101_SPET11_871_896_R GCCCACCAGAAAGACTAGCAGGATAA 814
1_F
84 SP101_SPET11_893_92_ GGGCAACAGCAGCGGATTGCGATTGC 123 SP101_SPET11_988_1012_R CATGACAGCCAAGACCTCACCCACC 763
1_F GCG
85 SP1010_SPET11_1154_1 CAATACCGCAACAGCGGTGGCTTGGG 47 SP101_SPET11_1251_1277_R GACCCCAACCTGGCCTTTTGTCGTTGA 804
179_F
86 SP101_SPET11_1314_1 CGCAAAAAAATCCAGCTATTAGC 68 SP101_SPET11_1403_1431_R AAACTATTTTTTTAGCTATACTCGAACA 711
336_F C
87 SP101_SPET11_1408_1 CGAGTATAGCTAAAAAAATAGTTTAT 67 SP101SPET11_486_1515_R GGATAATTGGTCGTAACAGGGATAGTG 828
437_F GACA AG
88 SP101_SPET11_1688_1 CCTATATTAATCGTTTACAGAAACTG 60 SP101_SPET11_1783_1808_R ATATGATTATCATTGAACTGCGGCCG 752
716_F GCT
89 SP101_SPET11_1711_1 CTGGCTAAAACTTTGGCAACGGT 82 SP101_SPET11_1808_1835_R GCGTGACGACCTTCTTGAATTGTAATCA 821
733_F
90 SP101_SPET11_1807_1 ATGATTACAATTCAAGAAGGTCGTCA 33 SP101_SPET11_1901_1927_R TTGGACCTGTAATCAGCTGAATACTGG 1412
835_F CGC
91 SP101_SPET11_1967_1 TAACGGTTATCATGGCCCAGATGGG 155 SP101_SPET11_2062_2083_R ATTGCCCAGAAATCAAATCATC 755
991_F
92 SP101_SPET11_2260_2 CAGAGACCGTTTTATCCTATCAGC 50 SP101_SPET11_2375_2397_R TCTGGGTGACCTGGTGTTTTAGA 1131
283_F
93 SP101_SPET11_2375_2 TCTAAAACACCAGGTCACCCAGAAG 390 SP101_SPET11_2470_2497_R AGCTGCTAGATGAGCTTCTGCCATGGCC 747
399_F
94 SP101_SPET11_2468_2 ATGGCCATGGCAGAAGCTCA 35 SP101_SPET11_2543_2570_R CCATAAGGTCACCGTCACCATTCAAAGC 770
487_F
95 SP101_SPET11_2961_2 ACCATGACACAAGGCATTTTGACA 15 SP101_SPET11_3023_3045_R GGAATTTACCAGCGATAGACACC 827
984_F
96 SP101_SPET11_3075_3 GATGACTTTTTAGCTAATGGTCAGGC 108 SP101_SPET11_3168_3196_R AATCGACGACCATCTTGGAAAGATTTCT 715
103_F AGC C
97 SP101_SPET11_3386_3 AGCGTAAAGGTGAACCTT 25 SP101_SPET11_3480_3506_R CCAGCAGTTACTGTCCCCTCATCTTTG 769
403_F
98 SP101_SPET11_3511_3 GCTTCAGGAATCAATGATGGAGCAG 116 SP101_SPET11_3605_3629_R GGGTCTACACCTGCACTTGCATAAC 832
535_F
111 RPOB_EC_3775_3803_F CTTGGAGGTAAGTCTCATTTTGGTGG 87 RPOB_EC_3829_3858_R CGTATAAGCTGCACCATAAGCTTGTAAT 797
GCA GC
112 VALS_EC_1833_1850_F CGACGCGCTGCGCTTCAC 65 VALS_EC_1920_1943_R GCGTTCCACAGCTTGTTGCAGAAG 822
113 RPOB_SC_1336_1353_F GACCACCTCGGCAACCGT 97 RPOB_EC_1438_1455_R TTCGCTCTCGGCCTGGCC 1386
114 TUFB_EC_225_251_F GCACTATGCACACGTAGATTGTCCTG 111 TUFB_EC_284_309_R TATAGCACCATCCATCTGAGCGGCAC 930
G
115 DNAK_EC_428_449_F CGGCGTACTTCAACGACAGCCA 72 DNAK_EC_503_522_R CGCGGTCGGCTCCTTGATGA 792
116 VALS_EC_1920_1943_F CTTCTGCAACAAGCTGTGGAACGC 85 VALS_EC_1948_1970_R TCGCAGTTCATCACCACGAAGCG 1075
117 TUFB_EC_757_774_F AAGACGACCTGCACGGGC 6 TUFB_EC_849_867_R GCGCTCCACCTCTTCACGC 819
118 23S_EC_2646_2667_F CTGTTCTTAGTACGAGAGGACC 84 23S_EC_2745_2765_R TTCCTGCTTACATCCTTTCAC 1389
119 16S_EC_969_985_1P_F ACGCGAAGAACCTTACpC 19 16S_EC_1061_1078_2P_R ACGACACGAGCpTpGACGAC 733
120 16S_EC_972_985_2P_F CGAAGAACpCpTTACC 63 16S_SC_1064_1075_2P_R ACACGAGCpTpGAC 727
121 16S_EC_972_985_F CGAAGAACCTTACC 63 16S_EC_1064_1075_R ACACGAGCTGAC 727
122 TRNA_ILE- CCTGATAAGGGTGAGGTCG 61 23S_EC_40_59_R ACGTCCTTCATCGCCTCTGA 740
RRNG_EC_32_50.2_F
123 23S_EC_−7_15_F GTTGTGAGGTTAAGCGACTAAG 140 23S_EC_430_450_R CTATCGGTCAGTCAGGAGTAT 799
124 23S_EC_−7_15_F GTTGTGAGGTTAAGCGACTAAG 141 23S_EC_891_910_R TTGCATCGGGTTGGTAAGTC 1403
125 23S_EC_430_450_F ATACTCCTGACTGACCGATAG 30 23S_EC_1424_1442_R AACATAGCCTTCTCCGTCC 712
126 23S_EC_891_910_F GACTTACCAACCCGATGCAA 100 23S_EC_1908_1931_R TACCTTAGGACCGTTATAGTTACG 893
127 23S_EC_1424_1442_F GGACGGAGAAGGCTATGTT 117 23S_EC_2475_2494_R CCAAACACCGCCGTCGATAT 765
128 23S_EC_1908_1931_F CGTAACTATAACGGTCCTAAGGTA 73 23S_EC_2833_2852_R GCTTACACACCCGGCCTATC 826
129 23S_EC_2475_2494_F ATATCGACGGCGGTGTTTGG 31 TRNA_ASP- GCGTGACAGGCAGGTATTC 820
RRNh_EC_23_41.2_R
131 16S_EC_−60_−39_F AGTCTCAAGAGTGAACACGTAA 28 16S_EC_508_525_R GCTGCTGGCACGGAGTTA 823
132 16S_EC_326_345_F GACACGGTCCAGACTCCTAC 95 16S_EC_1041_1058_R CCATGCAGCACCTGTCTC 771
133 16S_EC_705_724_F GATCTGGAGGAATACCGGTG 107 16S_EC_1493_1512_R ACGGTTACCTTGTTACGACT 739
134 16S_EC_1268_1287_F GAGAGCAAGCGGACCTCATA 101 TRNA_ALA- CCTCCTGCGTGCAAAGC 780
RENH_EC_30_46.2_R
135 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078.2_R ACAACACGAGCTGACGAC 719
137 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078.2_I14_R ACAACACGAGCTGICGAC 721
138 16S_EC_969_985_F ACGCOAAGAACCTTACC 19 16S_EC_1061_1078.2_I12_R ACAACACGAGCTGACGAC 718
139 16S_EC_969_985_F ACGCGAACAACCTTACC 19 16S_EC_1061_1078.2_I11_R ACAACACGAGITGACGAC 722
140 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078.2_I16_R ACAACACGAGCTGACIAC 720
141 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078.2_2I_R ACAACACGAICTIACGAC 723
142 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078.2_3I_R ACAACACIAICTIACGAC 724
143 16S_EC_969_985_F ACGCGAAGAACCTTACC 19 16S_EC_1061_1078.2_4I_R ACAACACIAICTIACIAC 725
147 23S_EC_2652_2669_F CTAGTACGACAGGACCGG 79 23S_EC_2741_2760_R ACTTAGATGCTTTCAGCGGT 743
158 16S_EC_683_700_F GTGTAGCGGTGAAATGCG 137 16S_EC_880_894_R CGTACTCCCCAGGCG 796
159 16S_EC_1100_1116_F CAACGACCGCAACCCTT 42 16S_EC_1174_1188_R TCCCCACCTTCCTCC 1019
21S SSPE_BA_121_137_F AACGCACAATCAGAAGC 3 SSPE_BA_197_216_R TCTGTTTCASTTGCAAATTC 1132
220 GROL_EC_941_959_F TGGAAGATCTGGGTCAGGC 544 GROL_EC_1039_1060_R CAATCTGCTGACGGATCTGAGC 759
221 INFB_EC_1103_1124_F GTCGTGAAAACGAGCTGGAAGA 133 INFB_EC_1174_1191_R CATGATGGTCACAACCGG 764
222 HFLB_EC_1082_1102_F TGGCGAACCTGGTGAACGAAGC 569 HFLB_EC_1144_1168_R CTTTCGCTTTCTCGAACTCAACCAT 802
223 INFB_EC_1969_1994_F CGTCAGGGTAAATTCCGTGAAGTTAA 74 INFB_EC_2038_2058_R AACTTCGCCTTCGGTCATGTT 713
224 GROL_EC_219_242_F GGTGAAAGAAGTTGCCTCTAAAGC 128 GROL_EC_328_350_R TTCAGGTCCATCGGGTTCATGCC 1377
225 VALS_EC_1105_1124_F CGTGGCGGCGTGGTTATCGA 77 VALS_EC_1195_1214_R ACGAACTGGATGTCGCCGTT 732
226 16S_EC_556_575_F CGGAATTACTGGGCGTAAAG 70 16S_EC_683_700_R CGCATTTCACCGCTACAC 791
227 RPOC_EC_1256_1277_F ACCCAGTGCTGCTGAACCGTGC 16 RPOC_EC_1295_1315_R GTTCAAATGCCTGGATACCCA 843
228 16S_EC_774_795_F GGGAGCAAACAGGATTAGATAC 122 16S_EC_880_894_R CGTACTCCCCAGGCG 796
229 RPOC_EC_1584_1604_F TGGCCCGAAAGAAGCTGAGCG 567 RPOC_EC_1623_1643_R ACGCGGGCATGCAGAGATGCC 737
230 16S_EC_1082_1100_F ATGTTGGGTTAAGTCCCGC 37 16S_EC_1177_1196_R TGACGTCATCCCCACCTTCC 1158
231 16S_EC_1389_1407_F CTTGTACACACCGCCCGTC 88 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC 714
232 16S_EC_1303_1323_F CGGATTGGAGTCTGCAACTCG 71 16S_EC_1389_1407_R GACGGGCGGTGTGTACAAG 808
233 23S_EC_23_37_F GGTGGATGCCTTGGC 129 23S_EC_115_130_R GGGTTTCCCCATTCGG 833
234 23S_EC_187_207_F GGGAACTGAAACATCTAAGTA 121 23S_EC_242_256_R TTCGCTCGCCGCTAC 1385
23S 23S_EC_1602_1620_F TACCCCAAACCGACACAGG 184 23S_EC_1686_1703_R CCTTCTCCCGAAGTTACG 782
236 23S_EC_1685_1703_F CCGTAACTTCGGGAGAAGG 58 23S_EC_1828_1842_R CACCGGGCAGGCGTC 760
237 23S_EC_1827_1843_F GACGCCTGCCCCGTGC 99 23S_EC_1929_1949_R CCGACAAGGAATTTCGCTACC 775
238 23S_EC_2434_2456_F AAGGTACTCCGGGGATAACAGGC 9 23S_EC_2490_2511_R AGCCGACATCGAGGTGCCAAAC 746
239 23S_EC_2599_2616_F GACAGTTCCGTCCCTATC 96 23S_EC_2653_2669_R CCGGTCCTCTCGTACTA 777
240 23S_EC_2653_2669_F TAGTACGAGAGGACCGG 227 23S_EC_2737_2758_R TTAGATGCTTTCACCACTTATC 1369
241 23S_BS_−68_−44_F AAACTAGATAACAGTAGACATCAC 1 23S_EC_5_21_R GTGCGCCCTTTCTAACTT 841
242 16S_EC_8_27_F ACAGTTTGATCATGGCTCAG 23 16S_EC_342_358_R ACTGCTGCCTCCCGTAG 742
243 16S_EC_314_332_F CACTGGAACTGAGACACGG 48 16S_EC_556_575_R CTTTACGCCCAGTAATTCCG 801
244 16S_EC_518_536_F CCAGCAGCCCCGGTAATAC 57 16S_EC_774_795_R GTATCTAATCCTGTTTGCTCCC 839
245 16S_EC_683_700_F GTGTAGCGGTGAAATGCG 137 16S_EC_967_985_R CGTAAGGTTCTTCGCGTTG 835
246 16S_EC_937_954_F AAGCGGTGGAGCACGTGG 7 16S_EC_1220_1240_R ATTGTAGCACGTGTGTAGCCC 757
247 16S_EC_1195_1213_F CAAGTCATCATGGCCCTTA 46 16S_EC_1525_1541_5 AAGGAGGTGATCCAGCC 714
248 16S_EC_8_27_F AGAGTTTGATCATGGCTCAG 23 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC 714
249 23S_EC_1831_1849_F ACCTGCCCAGTGCTGGAAG 18 23S_EC_1919_1936_R TCGCTACCTTAGGACCGT 1080
250 16S_EC_1387_1407_F GCCTTGTACACACCTCCCGTC 112 16S_EC_1494_1513_R CACGGCTACCTTGTTACGAC 761
251 16S_EC_1390_1411_F TTGTACACACCGCCCGTCATAC 693 A6S_EC_1486_1505_R CCTTGTTACGACTTCACCCC 783
252 16S_EC_1367_1387_F TACGGTGAATACGTTCCCGGG 191 16S_EC_1485_1506_R ACCTTGTTACGACTTCACCCCA 731
253 16S_EC_804_822_F ACCACGCCGTAAACGATGA 14 16S_EC_909_929_R CCCCCGTCAATTCCTTTGAGT 773
254 16S_EC_791_812_F GATACCCTGGTAGTCCACACCG 106 16S_EC_886_904_R GCCTTGCGACCGTACTCCC 817
255 16S_EC_789_810_F TAGATACCCTGCTAGTCCACGC 206 16S_EC_882_899_R GCGACCGTACTCCCCAGG 818
256 16S_EC_1092_1109_F TAGTCCCGCAACGAGCGC 228 16S_EC_1174_1198_R CACGTCATCCCCACCTTCCTCC 810
257 23S_EC_2586_2607_F TAGAACGTCGCCAGACAGTTCG 203 23S_EC_2658_2677_R AGTCCATCCCGGTCCTCTCG 749
258 RNASEP_SA_31_49_F GAGGAAACTCCATGCTCAC 103 RNASEP_SA_358_379_R ATAAGCCATGTTCTGTTCCATC 750
258 RNASEP_SA_31_49_F GAGGAAAGTCCATGCTCAC 103 RNASEP_EC_345_362_R ATAAGCCGGGTTCTGTCG 751
258 RNASEP_SA_31_49_F GAGGAAAGTCCATGCTCAC 103 RNASEP_ES_363_384_R GTAAOCCATGTTTTGTTCCATC 838
258 RNASEP_ES_43_61_F GACGAAAGTCCATGCTCCC 104 RNASEP_SA_358_379_R ATAAGCCATGTTCTGTTCCATC 750
258 RNASEP_ES_43_61_F CAGGAAAGTCCATGCTCGC 104 RNASEP_EC_345_362_R ATAAGCCGGGTTCTGTCG 751
258 RNASEP_ES_43_61_F GAGGAAAGTCCATGCTCGC 104 RNASEP_ES_363_384_R GTAAGCCATGTTTTGTTCCATC 838
258 RNASEP_EC_61_277_F GAGGAAAGTCCGGGCTC 105 RNASEP_SA_358_379_R ATAAGCCATGTTCTCTTCCATC 750
258 RNASEP_EC_61_77_F GAGGAAAGTCCGGCCTC 105 RNASEP_EC_345_362_R ATAAGCCGGGTTCTGTCG 751
258 RNASEP_EC_61_277_F GAGGAAAGTCCGGGCTC 105 RNASEP_ES_363_384_R GTAAGCCATGTTTTGTTCCATC 838
259 RNASEP_ES_43_61_F GAGCAAAGTCCATGCTCGC 104 RNASEP_ES_363_384_R GTAAGCCATGTTTTGTTCCATC 838
260 RNASEP_EC_61_77_F GAGGAAAGTCCGGGCTC 105 RNASEP_EC_345_362_R ATAAGCCGGGTTCTGTCG 751
262 RNASEP_SA_31_49_F GAGGAAACTCCATGCTCAC 103 RNASEP_SA_358_379_R ATAAGCCATGTTCTGTTCCATC 750
263 16S_EC_1082_1100_F ATGTTGGGTTAAGTCCCGC 37 16S_EC_1525_1541_R AAGGAGGTGATCCAGCC 714
264 16S_EC_556_575_F CGGAATTACTGCGCGTAAAG 70 16S_EC_774_795_R GTATCTAATCCTGTTTGCTCCC 839
265 16S_EC_1082_1100_F ATGTTGGGTTAAGTCCCGC 37 16S_EC_1177_1196_10G_R TGACGTCATGCCCACCTTCC 1160
266 16S_EC_1082_1100_F ATGTTGCCTTAACTCCCGC 37 16S_EC_1177_1196_10G_115_R TGACGTCATGGCCACCTTCC 1161
268 YAED_EC_513_532_F_M GGTGTTAAATAGCCTGGCAG 130 TRNA_ALA- AGACCTCCTGCGTGCAAAGC 744
OD RRNH_EC_30_49_F_MOD
269 16S_EC_1082_1100_F_ ATGTTCGGTTAAGTCCCGC 37 16S_EC_1177_1196_R_MOD TGACGTCATCCCCACCTTCC 1158
MOD
270 23S_EC_2586_2607_F TAGAACGTCGCGAGACAGTTCG 203 23S_EC_2658_2677_R_MOD AGTCCATCCCGGTCCTCTCG 749
MOD
272 16S_EC_969_985_F ACCCGAAGAACCTTACC 19 16S_EC_1389_1407_R GACGGGCCGTGTGTACAAG 807
273 16S_EC_683_700_F GTGTAGCGGTGAAATGCG 137 16S_EC_1303_1323_R CGAGTTGCAGACTGCGATCCG 788
274 16S_EC_49_68_F TAACACATGCAAGTCGAACG 152 16S_EC_880_894_R CGTACTCCCCAGGCG 796
275 16S_EC_49_68_F TAACACATGCAAGTCGAACG 152 16S_EC_1061_1078_R ACGACACGAGCTGACGAC 734
277 CYA_BA_1349_1370_F ACAACGAAGTACAATACAAGAC 12 CYA_BA_1426_1447_R CTTCTACATTTTAGCCATCAC 800
278 16S_EC_1090_1111_2_F TTAAGTCCCGCAACGAGCGCAA 650 16S_EC_1175_1196_R TGACGTCATCCCCACCTTCCTC 1159
279 16S_EC_405_432_F TGAGTGATGAAGGCCTTAGGGTTGTA 464 16S_EC_507_527_R CGGCTGCTGGCACGAAGTTAG 793
AA
280 GROL_EC_496_518_F ATGGACAAGGTTGGCAAGGAAGG 34 GROL_EC_577_596_R TAGCCGCGGTCGAATTGCAT 914
281 GROL_EC_511_536_F AAGGAAGGCGTGATCACCGTTGAAGA 8 GROL_EC_571_593_R CCGCGGTCGAATTGCATGCCTTC 776
288 RPOB_EC_3802_3821_F CAGCGTTTCGGCGAAATGGA 51 RPOB_EC_3862_3885_R CGACTTGACGGTTAACATTTCCTG 786
289 RPOB_EC_3799_3821_F GGGCAGCGTTTCGGCGAAATGGA 124 RPOB_EC_3862_3888_R GTCCGACTTGACGGTCAACATTTCCTG 840
290 RPOC_EC_2146_2174_F CAGGAGTCGTTCAACTCGATCTACAT 52 RPOC_EC_2227_2245_R ACGCCATCAGGCCACGCAT 736
GAT
291 ASPS_EC_405_422_F GCACAACCTGCGGCTGCG 110 ASPS_EC_521_538_R ACGGCACGAGGTAGTCGC 738
292 RPOC_EC_1374_1393_F CGCCGACTTCGACGGTGACC 69 RPOC_EC_1437_1455_R GAGCATCAGCGTGCGTGCT 811
293 TUFB_EC_957_979_F CCACACGCCGTTCTTCAACAACT 55 TUFB_EC_1034_1058_R GGCATCACCATTTCCTTGTCCTTCG 829
294 16S_EC_733_F GAGAGTTTGATCCTGGCTCAGAACGA 102 16S_EC_101_122_R TGTTACTCACCCGTCTGCCACT 1345
A
295 VALS_EC_610_649_F ACCGAGCAAGGAGACCAGC 17 VALS_EC_705_727_R TATAACGCACATCGTCAGGGTGA 929
344 16S_EC_971_990_F GCGAAGAACCTTACCAGGTC 113 16S_EC_1043_1062_R ACAACCATGCACCACCTGTC 726
346 16S_EC_713_732_TMOD_F TAGAACACCGATGGCGAAGGC 202 16S_EC_789_809_TMOD_R TCGTGGACTACCAGGGTATCTA 1110
347 16S_EC_785_806_TMOD_F TGGATTAGAGACCCTGGTAGTCC 560 16S_EC_880_897_TMOD_R TGGCCGTACTCCCCAGGCG 1278
348 16S_EC_960_981_TMOD_F TTTCGATGCAACGCGAAGAACCT 706 16S_EC_1054_1073_TMOD_R TACGAGCTGACGACAGCCATG 895
349 23S_BC_1826_1843_TM TCTGACACCTGCCCGGTGC 401 23S_EC_1906_1924_TMOD_R TGACCGTTATAGTTACGGCC 1156
OD_F
350 CAPC_BA_274_303_TMO TGATTATTGTTATCCTGTTATGCCAT 476 CAPC_BA_349_376_TMOD_R TGTAACCCTTGTCTTTGAATTGTATTTG 1314
D_F TTGAG C
351 CYA_BA_1353_1379_TM TCGAAGTACAATACAAGACAAAAGAA 355 CYA_BA_1448_1467_TMOD_R TTGTTAACGGCTTCAAGACCC 1423
OD_F GG
352 INFB_EC_1365_1393_T TTGCTCGTGGTGCACAAGTAACGGAT 687 INFB_EC_1439_1467_TMOD_R TTGCTGCTTTCGCATGGTTAATTGCTTC 1411
MOD_F AA
353 LEF_BA_756_781_TMOD_F TAGCTTTTGCATATTATATCGAGCCA 220 LEF_BA_843_872_TMOD_R TTCTTCCAAGGATAGATTTATTTCTTGT 1394
C TCG
354 RPOC_EC_2218_2241_T TCTGGCAGGTATGCGTGGTCTGATG 405 RPOC_EC_2313_2337_TMOD_R TCOCACCGTGGGTTGAGATGAAGTAC 1072
MOD_F
355 SSPE_BA_115_137_TMO TCAAGCAAACGCACAATCAGAAGC 255 SSPE_BA_197_222_TMOD_R TTGCACGTCTGTTTCAGTTGCAAATTC 1402
D_F
356 RPLB_EC_650_679_TMO TGACCTACAGTAAGAGGTTCTGTAAT 449 RFLB_EC_739_762_TMOD_R TTCCAAGTGCTGGTTTACCCCATGG 1380
D_F GAACC
357 RPLB_EC_688_710_TMO TCATCCACACGGTGGTGGTGAAGG 296 RFLB_EC_736_757_TMOD_R TGTGCTGGTTTACCCCATGGAGT 1337
D_F
358 VALS_EC_1105_1124_T TCGTGGCGGCGTGGTTATCGA 385 VALS_EC_1195_1218_TMOD_R TCGGTACGAACTGGATGTCGCCGTT 1093
MOD_F
359 RPOB_EC_1845_1866_T TTATCGCTCAGGCGAACTCCAAC 659 RPOB_EC_1909_1929_TMOD_R TGCTGGATTCGCCTTTGCTACG 1250
MOD_F
360 23S_EC_2646_2667_TM TCTGTTCTTAGTACGACAGGACC 409 23S_EC_2745_2765_TMOD_R TTTCGTGCTTAGATCCTTTCAG 1434
OD_F
361 16S_EC_1090_1111_2_ TTTAAGTCCCGCAACGAGCGCAA 697 16S_EC_1175_1196_TMOD_R TTGACCTCATCCCCACCTTCCTC 1398
TMOD_F
362 RFOB_EC_3799_3821_T TGGCCAGCGTTTCGGCGAAATGGA 581 RPOB_EC_3862_3888_TMOD_R TGTCCGACTTGACGGTCAACATTTCCTG 1325
MOD_F
363 RPOC_EC_2146_2174_T TCAGGAGTCGTTCAACTCGATCTACA 284 EFOC_EC_2227_2245_TMOD_R TACCCCATCAGGCCACCCAT 898
MOD_F
364 RPOC_EC_1374_1393_T TCGCCGACTTCGACGGTGACC 367 RPOC_EC_1437_1455_TMOD_R TGAGCATCAGCGTGCGTGCT 1166
MOD_F
367 TUFB_EC_957_979_TMO TCCACACGCCGTTCTTCAACAACT 308 TUFB_EC_1034_1058_TMOD_R TGGCATCACCATTTCCTTGTCCTTCG 1276
D_F
423 SP101_SPET11_893_92 TGGGCAACAGCAGCGGATTGCGATTG 580 SP101_SPET11_988_1012_TMO TCATGACAGCCAAGACCTCACCCACC 990
1_TMOD_F CGCG D_R
424 SP101_SPET11_1154_1 TCAATACCGCAACAGCGGTGGCTTGG 258 SP101_SPET11_1251_1277_TM TGACCCCAACCTGGCCTTTTGTCGTTCA 1155
179_TMOD_F G OD_R
425 SP101_SPET11_118_14 TGCTGGTGAAAATAACCCAGATGTCG 528 SP101_SPET11_213_238_TMOD_ TTGTGGCCGATTTCACCACCTGCTCCT 1422
7_TMOD_F TCTTC R
426 SP101_SPET11_1314_1 TCGCAAAAAAATCCAGCTATTAGC 363 SP101_SPET11_1403_1431_TM TAAACTATTTTTTTAGCTATACTCGAAC 849
336_TMOD_F OD_R AC
427 SP101_SPET11_1408_1 TCGAGTATAGCTAAAAAAATAGTTTA 359 SP101_SPET11_1486_1515_TM TGGATAATTGGTCGTAACAAGGGATAGT 1268
437_TMOD_F TGACA OD_R GAG
428 SP101_SPET11_1688_1 TCCTATATTAATCGTTTACAGAAACT 334 SP101_SPET11_1783_1808_TM TATATGATTATCATTGAACTGCGGCCG 932
716_TMOD_F GGCT OD_R
429 SP101_SPET11_1711_1 TCTGGCTAAAACTTTGGCAACGGT 406 SP101_SPET11_1808_1835_TM TGCGTGACGACCTTCTTGAATTGTAATC 1239
733_TMOD_F OD_R A
430 SP101_SPET11_1807_1 TATGATTACAATTCAAGAAGGTCGTC 235 SP101_SPET11_1901_1927_TM TTTGGACCTGTAATCAGCTGAATACTGG 1439
835_TMOD_F ACGC OD_R
431 SP101_SPET11_1967_1 TTAACGGTTATCATGGCCCAGATGGG 649 SP101_SPET11_2062_2083_TM TATTGCCCAGAAATCAAATCATC 940
991_TMOD_F OD_R
432 SP101_SPET11_216_24 TAGCAGGTGGTGAAATCGGCCACATG 210 SP101_SPET11_308_333_TMOD_ TTGCCACTTTGACAACTCCTGTTGCTG 1404
3_TMOD_F ATT R
433 SP101_SPET11_2260_2 TCAGAGACCGTTTTATCCTATCAGC 272 SP101_SPET11_2375_2397_TM TTCTGGGTGACCTGGTGTTTTAGA 1393
283_TMOD_F OD_R
434 SP101_SPET11_2375_2 TTCTAAAACACCAGGTCACCCAGAAG 675 SP101_SPET11_2470_2497_TM TAGCTGCTAGATGAGCTTCTGCCATGGC 918
399_TMOD_F OD_R C
435 SP101_SPET11_2468_2 TATGGCCATGGCAGAAGCTCA 238 SP101_SPET11_2543_2570_TM TCCATAAGGTCACCGTCACCATTCAAAG 1007
487_TMOD_F OD_R C
436 SP101_SPET11_266_29 TCTTGTACTTGTGGCTCACACGGCTG 417 SP101_SPET11_355_380_TMOD_ TGCTGCTTTGATGGCTGAATCCCCTTC 1249
5_TMOD_F TTTGG R
437 SP101_SPET11_2961_2 TACCATGACAGAAGGCATTTTGACA 183 SP101_SPET11_3023_3045_TM TGGAATTTACCAGCGATAGACACC 1264
984_TMOD_F OD_R
438 SP101_SPET11_3075_3 TGATGACTTTTTAGCTAATGGTCAGG 473 SP101_SPET11_3168_3196_TM TAATCGACGACCATCTTGGAAAGATTTC 875
103_TMOD_F CAGC OD_R TC
439 SP101_SPET11_322_34 TGTCAAAGTGGCACCTTTACTGGC 631 SP101_SPET11_423_441_TMOD_ TATCCCCTGCTTCTGCTGCC 934
4_TMOD_F R
440 SP101_SPET11_3368_3 TAGCGTAAAGGTGAACCTT 215 SP101_SPET11_3480_3506_TM TCCACCAGTTACTCTCCCCTCATCTTTC 1005
403_TMOD_F OD_R
441 SP101_SPET11_3511_3 TGCTTCAGCAATCAATGATGGAGCAG 531 SP101_SPET11_3605_3629_TM TGGGTCTACACCTGCACTTCCATAAC 1294
535_TMOD_F OD_R
442 SP101_SPET11_358_38 TGGGGATTCAGCCATCAAAGCAGCTA 588 SP101_SPET11_448_473_TMOD_ TCCAACCTTTTCCACAACACAATCACC 998
7_TMOD_F TTGAC R
443 SF101_SPET11_600_62 TCCTTACTTCCAACTATCAATCTTTT 348 SP101_SPET11_686_714_TMOD_ TCCCATTTTTTCACGCATCCTGAAAATA 1018
9_TMOD_F GGAAC R TC
444 SP101_SPET11_658_68 TGGGGATTCATATCACCGATAAGAAG 589 SP101_SPET11_756_784_TMOD TGATTGGCGATAAAGTGATATTTTCTAA 1189
4_TMOD_F AA R AA
445 SP101_SPET11_776_80 TTCGCCAATCAAAACTAAGGGAATGG 673 SP101_SPET11_871_896_TMOD_ TGCCCACCAGAAACACTAGCAGGATAA 1217
1_TMOD_F C R
446 SP101_SPET11_1_29_T TAACCTTAATTGGAAAGAAACCCAAG 154 SP101_SPET11_92_116_TMOD_ TCCTACCCAACGTTCACCAAGGGCAG 1044
MOD_F AAGT R
447 SP101_SPET11_364_38 TCACCCATCAAACCAGCTATTG 276 SP101_SPET11_448_471_R TACCTTTTCCACAACAGAATCAGC 894
5_F
448 SP101_SPET11_3085_3 TAGCTAATGGTCAGGCAGCC 216 SF101_SPET11_3170_3194_R TCCACGACCATCTTCCAAAGATTTC 1066
104_F
449 RPLB_EC_690_710_F TCCACACGCTCCTGGTGAACG 309 RPLB_EC_737_758_R TCTGCTCCTTTACCCCATGGAC 1336
481 BONTA_X52066_538_55 TATCGCTCTACTCAA 239 BONTA_X52066_647_660_R TGTTACTGCTGGAT 1346
2_F
482 BONTA_X52066_538_55 TA*TpGGC*Tp*Cp*TpA*Cp*Tp*C 143 BONTA_X52066_647_660P_R TG*Tp*TpA*Cp*TpG*Cp*TpGGAT 1146
2P_F pAA
483 BONTA_X52066_701_72 GAATAGCAATTAATCCAAAT 94 BONTA_X52066_759_775_R TTACTTCTAACCCACTC 1367
0_F
484 BONTA_X52066_701_72 GAA*TpAG*CpAA*Tp*TpAA*Tp*C 91 BONTA_X52066_759_775P_R TTA*Cp*Tp*Tp*Cp*TpAA*Cp*Cp*C 1359
p*CpAAAT pA*Cp*TpC
485 BONTA_X52066_450_47 TCTAGTAATAATAGGACCCTCAGC 393 BONTA_X52066_517_539_R TAACCATTTCGCGTAAGATTCAA 859
3_F
486 BONTA_X52066_450_47 T*Cp*TpAGTAATAATAGGA*Cp*Cp 142 BONTA_X52066_517_539P_R TAACCA*Tp*Tp*Tp*CpGCGTAAGA*T 857
3P_F *Cp*Tp*CpAGC p*Tp*CpAA
487 BONTA_X52066_591_62 TGAGTCACTTGAAGTTGATACAAATC 463 BONTA_X52066_644_671_R TCATGTGCTAATGTTACTGCTGGATCTG 992
0_F CTCT
608 SSPE_BA_156_168P_F TGCTpGCpTpAGCpATT 616 SSPE_BA_243_255P_R TGCpACCpTGATpTpGT 1241
609 SSPE_BA_75_89P_F TACpAGACTpTpTpGCpGAC 192 SSPE_BA_163_177P_R TGTGCTpTpTpGAATpGCpT 1338
610 SSPE_BA_150_168P_F TCCTTCTGGTpCCpTpAGCpATT 533 SSPE_BA_243_2642_R TGATTGTTTTCCpAGCPTGATpTpGT 1191
611 SSPE_BA_72_89P_F TCGTACpAGAGTpTPTpGCpGAC 602 SSPE_BA_163_182P_R TCATTTGTGCTpTpTpGAATpGCpT 995
612 SSPE_BA_114_1372_F TCAACCAAACGCACAATpCpAGAAGC 255 SSPE_BA_196_222P_R TTGCACGTCpTpCTTTCAGTTGCAAATT 1401
C
699 SSPE_BA_123_153_F TGCACAATCAGAAGCTAAGAAAGCGC 488 SSPE_BA_202_231_R TTTCACAGCATGCACGTCTGTTTCAGTT 1431
AAGCT GC
700 SSPE_BA_156_168_F TCGTGCTAGCATT 612 SSPE_BA_243_255_R TCCAGCTGATTCT 1202
701 SSPE_BA_75_89_F TACAGACTTTGCGAC 179 SSPE_BA_163_177_R TGTGCTTTGAATGCT 1338
702 SSPE_BA_150_168_F TGCTTCTCCTGCTAGCATT 533 SSPE_BA_243_264_R TGATTGTTTTGCAGCTGATTGT 1190
703 SSPE_BA_72_89_F TGGTACAGAGTTTGCGAC 600 SSPE_BA_163_182_R TCATTTGTGCTTTGAATGCT 995
704 SSPE_BA_146_168_F TGCAAGCTTCTGGTGCTAGCATT 484 SSPE_BA_242_267_R TTGTGATTGTTTTGCAGCTGATTGTG 1421
705 SSPE_BA_63_89_F TGCTAGTTATCCTACAGAGTTTGCGA 518 SSPE_BA_163_191_R TGATAACTAGCATTTGTGCTTTGAATGC 986
C T
706 SSPE_BA_114_137_F TCAAGCAAACGCACAATCAGAAGC 255 SSPE_BA_196_222_R TTGCACGTCTGTTTCAGTTGCAAATTC 1402
770 PLA_AF053945_7377_7 TGACATCCGGCTCACGTTATTATGGT 442 PLA_AF053945_7434_7462_R TGTAAATTCCGCAAAGACTTTCGCATTA 1313
402_F G
771 PLA_AF053945_7382_7 TCCGGCTCACGTTATTATGGTAC 327 PLA_AF053945_7482_7502_R TGGTCTGAGTACCTCCTTTGC 1304
404_F
772 PLA_AF053945_7481_7 TGCAAAGGAGGTACTCAGACCAT 481 PLA_AF053945_7539_7562_R TATTGGAAATACCGGCAGCATCTC 943
503_F
773 PLA_AF053945_7186_7 TTATACCGGAAACTTCCCGAAAGGAG 657 PLA_AF053945_7257_7280_R TAATGCCATACTGGCCTGCAAGTC 879
211_F
774 CAF1_AF053947_33407_ TCAGTTCCGTTATCGCCATTGCAT 292 CAF1_AF053947_33494_33514_ TGCGGGCTGGTTCAACAAGAG 1235
33430_F R
775 CAF1_AF053947_33515_ TCACTCTTACATATAAGGAAGGCGCT 270 CAF1_AF053947_33595_33621_ TCCTGTTTTATAGCCGCCAAGAGTAAG 1053
33541_F C R
776 CAF1_AF053947_33435 TGGAACTATTGCAACTGCTAATG 542 CAF1_AF053947_33499_33517_ TGATGCGGGCTGGTTCAAC 1183
33457_F R
777 CAF1_AF053947_33687_ TCAGGATGGAAATAACCACCAATTCA 286 CAF1_AF053947_33755_33782_ TCAAGGTTCTCACCGTTTACCTTAGGAG 962
33716_F CTAC R
778 INV_U22457_515_539_ TGGCTCCTTGGTATGACTCTGCTTC 573 INV_U22457_571_598_R TGTTAAGTGTGTTGCGGCTGTCTTTATT 1343
F
779 INV_U22457_699_724_ TGCTCAGGCCTGGACCGATTATTTAC 525 INV_U22457_753_776_R TCACGCGACGAGTGCCATCCATTG 976
F
780 INV_U22457_834_858_ TTATTTACCTGCACTCCCACAACTG 664 INV_U22457_942_966_R TGACCCAAAGCTGAAAGCTTTACTG 1154
F
781 INV_U22457_1558_158 TGGTAACAGAGCCTTATAGGCGCA 597 INV_U22457_1619_1643_R TTGCGTTGCAGATTATCTTTACCAA 1408
1_F
782 LL_NC003143_2366996_ TGTAGCCGCTAACCACTACCATCC 627 LL_NC003143_2367073_23670 TCTCATCCCGATATTACCGCCATGA 1123
2367019_F 97_R
783 LL_NC003143_2367172_ TGGACCGCATCACGATTCTCTAC 550 LL_NC003143_2367249_23672 TGGCAACAGCTCAACACCTTTGG 1272
2367194_F 71_R
874 RPLB_EC_649_679_F TGICCIACIGTIIGIGGTTCTGTAAT 620 RPLB_EC_739_762_TMOD_R TTCCAAGTGCTGGTTTACCCCATGG 1380
GAACC
875 RPLB_EC_642_679P_F TpCpCpTpTpGITpGTCCIACIGTII 646 RPLB_EC_739_762_TMOD_R TTCCAAGTGCTGGTTTACCCCATGG 1380
GIGGTTCTGTAATGAACC
876 MECIA_Y14051_3315_3 TTACACATATCGTGAGCAATGAACTG 653 MECIA_Y14051_3367_3393_R TGTGATATGGAGGTGTAGAACGTGTTA 1333
341_F A
877 MECA_Y14051_3774_38 TAAAACAAACTACGGTAACATTGATC 144 MECA_Y14051_3828_3854_R TCCCAATCTAACTTCCACATACCATCT 1015
02_F GCA
878 MECA_Y14051_3645_36 TGAAGTAGAAATGACTGAACGTCCGA 434 MECA_Y14051_3690_3719_R TGATCCTGAATGTTTATATCTTTAACGC 1181
70_F CT
879 MECA_Y14051_4507_45 TCAGGTACTGCTATCCACCCTCAA 288 MECA_Y14051_4555_4581_R TGGATAGACGTCATATGAAGGTGTGCT 1269
30_F
880 MECA_Y14051_4507_45 TGTACTGCTATCCACCCTCAA 626 MECA_Y14051_4586_4610_R TATTCTTCGTTACTCATGCCATACA 939
30_F
881 MECA_Y14051_4669_46 TCACCAGGTTCAACTCAAAAAATATT 262 MECA_Y14051_4765_4793_R TAACCACCCCAAGATTTATCTTTTTGCC 858
98_F AACA A
882 MECA_Y14051_4520_45 TCpCpACpCpCpTpCpAA 389 MECA_Y14051_4590_4600P_R TpACpTpCpATpGCpCpA 1357
30P_F
883 MECA_Y14051_4520_45 TCpCpACpCpCpTpCpAA 389 MECA_Y14051_4600_4610P_R TpATpTpCpTpTpCpGTpT 1358
30P_F
902 TRPE_AY094355_1467_ ATGTCGATTGCAATCCGTACTTGTG 36 TRPE_AY094355_1569_1592_R TGCGCGAGCTTTTATTTGGGTTTC 1231
1491_F
903 TRPE_AY094355_1445_ TGGATGCCATGGTGAAATGGATATGT 557 TRPE_AY094355_1551_1580_R TATTTGGGTTTCATTCCACTCAGATTCT 944
1471_F C GG
904 TRPE_AY094355_1278_ TCAAATGTACAAGGTGAAGTGCGTCA 247 TRPE_AY094355_1392_1418_R TCCTCTTTTCACAGGCTCTACTTCATC 1048
1303_F
905 TRPE_AY094355_1064_ TCGACCTTTGGCAGGAACTAGAC 357 TRPE_AY094355_1171_1196_R TACATCGTTTCGCCCAAGATCAATCA 885
1086_F
906 TRPE_AY094355_666_6 GTGCATGCGGATACAGAGCAGAG 135 TRPE_AY094355_769_791_R TTCAAAATGCGGAGGCGTATGTG 1372
88_F
907 TRPE_AY094355_757_7 TGCAAGCGCGACCACATACG 483 TRPE_AY094355_864_883_R TGCCCAGGTACAACCTGCAT 1218
76_F
908 RECA_AF251469_43_68_ TGGTACATGTGCCTTCATTGATGCTG 601 RECA_AF251469_140_163_R TTCAAGTGCTTGCTCACCATTGTC 1375
F
909 RECA_AF251469_169_1 TGACATGCTTGTCCGTTTCAGGC 446 RECA_AF251469_277_300_R TGGCTCATAAGACGCGCTTGTAGA 1280
90_F
910 PARC_X95819_87_110_ TGGTGACTCGGCATGTTATGAAGC 609 PARC_X95819_201_2229_R TTCGGTATAACGCATCGCAGCA 1387
F
911 PARC_X95819_87_110_ TGGTGACTCGGCATGTTATGAAGC 609 PARC_X95819_192_219_R GGTATAACGCATCGCAGCAAAAGATTTA 836
F
912 PARC_X95819_123_147_ GGCTCAGCCATTTAGTTACCGCTAT 120 PARC_X95819_232_260_R TCGCTCAGCAATAATTCACTATAAGCCG 1081
F A
913 PARC_X95819_43_63_F TCAGCGCGTACAGTGGGTGAT 277 PARC_X95819_143_170_R TTCCCCTGACCTTCGATTAAAGGATAGC 1383
914 OMPA_AY485227_272_3 TTACTCCATTATTGCTTGGTTACACT 655 OMPA_AY485227_364_388_R GAGCTGCGCCAACGAATAAATCGTC 812
01_F TTCC
915 OMPA_AY485227_379_4 TGCGCAGCTCTTGGTATCGAGTT 509 OMPA_AY485227_492_519_R TGCCGTAACATAGAAGTTACCGTTGATT 1223
01_F
916 OMPA_AY485227_313_3 TACACAACAATGGCGGTAAAGATGG 178 OMPA_AY485227_424_453_R TACGTCGCCTTTAACTTGGTTATATTCA 901
35_F GC
917 OMPA_AY485227_415_4 TGCCTCGAAGCTGAATATAACCAAGT 506 OMPA_AY485227_514_546_R TCGGGCGTAGTTTTTAGTAATTAAATCA 1092
41_F T GAAGT
918 OMPA_AY485227_494_5 TCAACGGTAACTTCTATGTTACTTCT 252 OMPA_AY485227_569_596_R TCGTCGTATTTATAGTGACCAGCACCTA 1108
20_F G
919 OMPAAY4_8522_75_515 TCAAGCCGTACGTATTATTAGGTGCT 257 OMPA_AY485227_658_680_R TTTAAGCGCCAGAAAGCACCAAC 1425
77_F G
920 OMPA_AY485227_555_5 TCCGTACGTATTATTAGGTGCTGGTC 328 OMPA_AY485227_635_662_R TCAACACCAGCGTTACCTAAAGTACCTT 954
81_F A
921 OMPA_AY485227_556_5 TCGTACGTATTATTAGGTGCTGGTCA 379 OMPA_AY485227_659_683_R TCGTTTAAGCGCCAGAAAGCACCAA 1114
83_F CT
922 OMPA_AY485227_657_6 TGTTGGTGCTTTCTGGCGCTTAA 645 OMPA_AY485227_739_765_R TAAGCCAGCAAGAGCTGTATAGTTCCA 871
79_F
923 OMPA_AY485227_660_6 TGGTGCTTTCTGGCGCTTAAACGA 613 OMPA_AY485227_786_807_R TACAGGAGCAGCAGGCTTCAAG 884
83_F
924 GYRA_AF100557_4_23_ TCTGCCCGTGTCGTTGGTGA 402 GYRA_AF100557_119_142_R TCGAACCGAAGTTACCCTGACCAT 1063
F
925 GYRA_AF100557_70_94_ TCCATTGTTCGTATGGCTCAAGACT 316 GYRA_AF100557_178_201_R TGCCAGCTTAGTCATACGGACTTC 1211
F
926 GYRB_AB008700_19_40_ TCAGGTGGCTTACACGGCGTAG 289 GYRB_AB008700_111_140_R TATTGCGGATCACCATGATGATATTCTT 941
F GC
927 GYRB_AB008700_265_2 TCTTTCTTGAATGCTGGTGTACGTAT 420 GYRB_AB008700_369_395_R TCGTTGAGATGGTTTTTACCTTCGTTG 1113
92_F CG
928 GYRB_AB008700_368_3 TCAACGAAGGTAAAAACCATCTCAAC 641 GYRB_AB008700_466_494_R TTTGTGAAACAGCGAACATTTTCTTGGT 1440
94_F G A
929 GYRB_AB008700_477_5 TGTTCGCTGTTTCACAAACAACATTC 641 GYRB_AB008700_611_632_R TCACGCGCATCATCACCAGTCA 977
04_F CA
930 GYRB_AB008700_760_7 TACTTACTTGAGAATCCACAAGCTGC 198 GYRB_AB008700_862_888_R ACCTGCAATATCTAATGCACTCTTACG 729
87_F AA
931 WAAA_Z96925_2_29_F TCTTGCTCTTTCGTGAGTTCAGTAAA 416 WAAA_Z96925_115_138_R CAAGCGGTTTGCCTCAAATAGTCA 758
TG
932 WAAA_Z96925_286_311_ TCGATCTGGTTTCATGCTGTTTCAGT 360 WAAA_Z96925_394_412_R TGGCACGAGCCTGACCTGT 1274
F
939 RPOB_EC_3798_3821_F TGGGCAGCGTTTCGGCGAAATGGA 581 RPOB_EC_3862_3889_R TGTCCGACTTGACGGTCAGCATTTCCTG 1326
940 RPOB_EC_3798_3821_F TGGGCAGCGTTTCGGCGAAATGGA 581 RPOB_EC_3862_3889_2_R TGTCCGACTTGACGGTTAGCATTTCCTG 1327
941 TUFB_EC_272_299_F TGATCACTGGTGCTGCTCAGATGGA 468 TUFB_EC_337_362_R TGGATGTGCTCACGAGTCTGTGGCAT 1271
942 TUFB_EC_251_278_F TGCACGCCGACTATGTTAAGAACATG 493 TUFB_EC_337_360_R TATGTGCTCACGAGTTTGCGGCAT 937
AT
949 GYRB_AB008700_760_7 TACTTACTTGAGAATCCACAAGCTGC 198 GYRB_AB008700_862_888_2_R TCCTGCAATATCTAATGCACTCTTACG 1050
87_F AA
958 RPOC_EC_2223_2243_F TGGTATGCGTGGTCTGATGGC 605 RPOC_EC_2329_2352_R TGCTAGACCTTTACGTGCACCGTG 1243
959 RPOC_EC_918_938_F TCTGGATAACGGTCGTCGCGG 404 RPOC_EC_1009_1031_R TCCAGCAGGTTCTGACGGAAACG 1004
960 RPOC_EC_2334_2357_F TGCTCGTAAGGGTCTGGCGGATAC 523 RPOC_EC_2380_2403_R TACTAGACGACGGGTCAGGTAACC 905
961 RPOC_EC_917_938_F TATTGGACAACCGTCGTCGCGG 242 RPOC_EC_1009_1034_R TTACCGAGCACGTTCTGACGGAAACG 1362
962 RPOB_EC_2005_2027_F TCGTTCCTGCAACACGATGACGC 387 RPOB_EC_2041_2064_R TTGACGTTGCATGTTCGAGCCCAT 1399
963 RPOB_EC_1527_1549_F TCAGCTGTCGCAGTTCATGGACC 282 RPOB_EC_1630_1649_R TCGTCGCGGACTTCGAAGCC 1104
964 INFB_EC_1347_1367_F TGCGTTTACCOCAATGCGTGC 515 INFB_EC_1414_1432_R TCGGCATCACGCCGTCGTC 1090
965 VALS_EC_1128_1151_F TATCCTGACCGACCAGTGCTACGT 237 VALS_EC_1231_1257_R TTCGCGCATCCAGGAGAACTACATGTT 1384
978 RPOC_EC_2145_2175_F TCAGGAGTCGTTCAACTCGATCTACA 285 RPOC_EC_2228_2247_R TTACGCCATCACGCCACGCA 1363
TGATG
1045 CJST_CJ_1668_1700_F TGCTCGAGTGATTGACTTTGCTAAAT 522 CJST_CJ_1774_1799_R TGACCGTGTGGAAAAGGACTTCGATG 1170
TTAGAGA
1046 CJST_CJ_2171_2197_F TCCTTTGGTGGTCGTAGATGAAAAAG 388 CJST_CJ_2283_2313_R TCTCTTTCAAAGCACCATTGCTCATTAT 1126
G AGT
1047 CJST_CJ_584_616_F TCCAGGACAAATGTATGAAAAATGTC 315 CJST_CJ_663_692_R TTCATTTTCTGGTCCAAAGTAAGCAGTA 1379
CAAGAAG TC
1048 CJST_CJ_360_394_F TCCTGTTATCCCTGAAGTAGTTAATC 346 CJST_CJ_442_476_R TCAACTGGTTCAAAAACATTAAGTTGTA 955
AAGTTTGTT ATTGTCC
1049 CJST_CJ_2636_2668_F TGCCTAGAACATCTTAAAAATTTCCG 504 CJST_CJ_2753_2777_R TTGCTGCCATAGCAAAGCCTACACC 1409
CCAACTT
1050 CJST_CJ_1290_1320_F TGGCTTATCCAAATTTAGATCGTGGT 575 CJST_CJ_1406_1433_R TTTCCTCATGATCTGCATGAAGCATAAA 1437
TTTAC
1051 CJST_CJ_3267_3293_F TTTCATTTTACGCCCTCCTCCAGGTC 707 CJST_CJ_3356_3385_R TCAAAGAACCCGCACCTAATTCATCATT 951
G TA
1052 CJST_CJ_5_39_F TAGGCGAAGATATACAAAGAGTATTA 222 CJST_CJ_104_137_R TCCCTTATTTTTCTTTCTACTACCTTCG 1029
GAAGCTAGA GATAAT
1053 CJST_CJ_1080_1110_F TTGAGGGTATGCACCGTCTTTTTGAT 681 CJST_CJ_1166_1198_R TCCCCTCATGTTTAAATGATCAGGATAA 1022
TCTTT AAAGC
1054 CJST_CJ_2060_2090_F TCCCGGACTTAATATCAATGAAAATT 323 CJST_CJ_2148_2174_R TCGATCCGCATCACCATCAAAAGCAAA 1068
GTGGA
1055 CJST_CJ_2869_2895_F TGAAGCTTGTTCTTTAGCAGGACTTC 432 CJST_CJ_2979_3007_R TCCTCCTTGTGCCTCAAAACGCATTTTT 1045
A A
1056 CJST_CJ_1880_1910_F TCCCAATTAATTCTGCCATTTTTCCA 317 CJST_CJ_1981_2011_R TGGTTCTTACTTGCTTTGCATAAACTTT 1309
GGTAT CCA
1057 CJST_CJ_2185_2212_F TAGATGAAAAGGGCGAAGTGGCTAAT 208 CJST_CJ_2283_2316_R TGAATTCTTTCAAAGCACCATTGCTCAT 1152
GG TATAGT
1058 CJST_CJ_1643_1670_F TTATCGTTTGTGGAGCTAGTGCTTAT 660 CJST_CJ_1724_1752_R TGCAATGTGTGCTATGTCAGCAAAAAGA 1198
GC T
1059 CJST_CJ_2165_2194_F TGCGGATCGTTTGGTGGTTGTAGATG 511 CJST_CJ_2247_2278_R TCCACACTGGATTGTAATTTACCTTGTT 1002
AAAA CTTT
1060 CJST_CJ_599_632_F TGAAAAATGTCCAAGAAGCATAGCAA 424 CJST_CJ_711_743_R TCCCGAACAATGAGTTGTATCAACTATT 1024
AAAAAGCA TTTAC
1061 CJST_CJ_360_393_F TCCTGTTATCCCTGAAGTAGTTAATC 345 CJST_CJ_443_477_R TACAACTGGTTCAAAAACATTAAGCTGT 882
AAGTTTGT AATTGTC
1062 CJST_CJ_2678_2703_F TCCCCAGGACACCCTGAAATTTCAAC 321 CJST_CJ_2760_2787_R TGTGCTTTTTTTGCTGCCATAGCAAAGC 1339
1063 CJST_CJ_1268_1299_F AGTTATAAACACGGCTTTCCTATGGC 29 CJST_CJ_1349_1379_R TCGGTTTAAGCTCTACATGATCGTAAGG 1096
TTATCC ATA
1064 CJST_CJ_1650_1713_F TGATTTTGCTAAATTTAGACAAATTG 479 CJST_CJ_1795_1822_R TATGTGTAGTTGAGCTTACTACATGAGC 938
CGGATGAA
1065 CJST_CJ_2857_2887_F TGGCATTTCTTATGAAGCTTGTTCTT 565 CJST_CJ_2965_2998_R TGCTTCAAAACGCATTTTTACATTTTCG 1253
TAGCA TTAAAG
1070 RNASEP_BKM_580_599_ TGCGGGTAGGGAGCTTGAGC 512 RNASEP_BKM_665_686_R TCCGATAAGCCGGATTCTGTGC 1034
F
1071 RNASEP_BKM_616_637_ TCCTAGAGGAATGGCTGCCACG 333 RNASEP_BKM_665_687_R TGCCGATAAGCCGGATTCTGTGC 1222
F
1072 RNASEP_BKM_574_592_ TGGCACGGCCATCTCCGTG 561 RNASEP_BKM_616_635_R TCGTTTCACCCTGTCATGCCG 1115
F
1073 23S_BRM_1110_1129_F TGCGCGGAAGATGTAACGGG 510 23S_BRM_1176_1201_R TCGCAGGCTTACAGAACGCTCTCCTA 1074
1074 23S_BRM_515_536_F TGCATACAAACAGTCGGAGCCT 496 23S_BRM_616_635_R TCGGACTCGCTTTCGCTACG 1088
1075 RNASEP_CLB_459_487_ TAAGGATAGTGCAACAGAGATATACC 162 RNASEP_CLB_498_526_R TGCTCTAACCTCACCGTTCCACCCTTAC 1247
F GCC C
1076 RNASEP_CLB_459_487_ TAAGGATAGTGCAACAGAGATATACC 162 RNASEP_CLB_498_522_R TTTACCTCGCCTTACCACCCTTACC 1426
F GCC
1077 ICD_CXB_93_120_F TCCTGACCGACCCATTATTCCCTTTA 343 ICD_CXB_172_194_R TAGGATTTTTCCACGGCGGCATC 921
TC
1078 ICD_CXB_92_120_F TTCCTGACCGACCCATTATTCCCTTT 671 ICD CXB_172_194_R TAGGATTTTTCCACGGCGGCATC 921
ATC
1079 ICD_CXB_176_198_F TCGCCGTGGAAAAATCCTACGCT 369 ICD_CXB_224_247_R TAGCCTTTTCTCCGGCGTAGATCT 916
1080 IS1111A_NC002971_74 TCAGTATGTATCCACCGTAGCCAGTC 290 IS1111A_NC002971_6928_695 TAAACGTCCGATACCAATGGTTCGCTC 848
66_6891_F 4_R
1081 IS1111A_NC002971_74 TGGGTGACATTCATCAATTTCATCGT 594 IS1111A_NC002971_7529_755 TCAACAACACCTCCTTATTCCCACTC 952
56_7483_F 4_R
1082 RNASEP_RKP_419_448_ TGGTAAGAGCGCACCGGTAAGTTGGT 599 RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957
F AACA
1083 RNASEP_RKP_422_443_ TAAGAGCGCACCGGTAAGTTSG 159 RNSASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957
F
1084 RNASEP_RKP_466_491_ TCCACCAAGAGCAAGATCAAATAGGC 310 RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957
F
1085 RNASEP_RKP_264_287_ TCTAAATGGTCGTGCAGTTGCGTG 391 RNASEP_RKP_295_321_R TCTATAGAGTCCGGACTTTCCTCGTGA 1119
F
1086 RNASEP_RKP_426_448_ TGCATACCGGTAAGTTGGCAACA 497 RNASEP_RKP_542_565_R TCAAGCGATCTACCCGCATTACAA 957
F
1087 OMPB_RKP_860_890_F TTACAGGAAGTTTAGGTGGTAATCTA 654 OMPB_RKP_972_996_R TCCTGCAGCTCTACCTGCTCCATTA 1051
AAAGG
1088 OMPB_RKP_1192_1221_ TCTACTGATTTTGGTAATCTTGCAGC 392 OMPH_RKP_1288_1315_R TAGCAgCAAAAGTTATCACACCTGCAGT 910
F ACAG
1089 OMPB_RKP_3417_3440_ TGCAAGTGGTACTTCAACATGGGG 485 OMPH_RKP_3520_3550_R TGGTTGTAGTTCCTGTAOTTGTTGCATT 1310
F AAC
1090 GLTA_RKP_1043_1072_ TGGGACTTGAAGCTATCGCTCTTAAA 576 GLTA_RKP_1138_1162_R TGAACATTTGCGACGGTATACCCAT 1147
G GATG
1091 GLTA_RKP_400_428_F TCTTCTCATCCTATGGCTATTATGCT 413 GLTA_RKP_499_529_R TGGTGGGTATCTTAGCAATCATTCTAAT 1305
TGC AGC
1092 GLTA_RKP_1023_1055_ TCCGTTCTTACAAATAGCAATAGAAC 330 GLTA_RKP_1129_1156_R TTGGCGACGGTATACCCATAGCTTTATA 1415
F TTGAAGC
1093 GLTA_RKP_1043_1072_ TGGAGCTTGAAGCTATCGCTCTTAAA 553 GLTA_RKP_1138_1162_R TGAACATTTGCGACGGTATACCCAT 1147
2_F GATG
1094 GLTA_RKP_1043_1072_ TGGAACTTGAAGCTCTCGCTCTTAAA 543 GLTA_RKP_1138_1164_R TGTGAACATTTGCGACGGTATACCCAT 1330
3_F GATG
1095 GLTA_RKP_400_428_F TCTTCTCATCCTATGGCTATTATGCT 413 GLTA_RKP_505_534_R TGCGATGGTAGGTATCTTAGCAATCATT 1230
TGC CT
1096 CTXA_VBC_117_142_F TCTTATGCCAAGAGGACAGAGTGAGT 410 CTXA_VBC_194_218_R TGCCTAACAAATCCCGTCTGAGTTC 1226
1097 CTXA_VBC_351_377_F TGTATTAGGGGCATACAGTCCTCATC 630 CTXA_VBC_441_466_R TGTCATCAAGCACCCCAAAATGAACT 1324
C
1098 RNASEP_VBC_331_349_ TCCGCGGAGTTGACTGGGT 325 RNASEP_VBC_388_414_R TGACTTTCCTCCCCCTTATCAGTCTCC 1163
F
1099 TOXR_VBC_135_158_F TCGATTAGGCAGCAACGAAAGCCG 362 TOXR_VBC_221_246_R TTCAAAACCTTGCTCTCGCCAAACAA 1370
1100 ASD_FRT_1_29_F TTGCTTAAAGTTGGTTTTATTGGTTG 690 ASD_FRT_86_116_R TGAGATGTCGAAAAAAACGTTGGCAAAA 1164
GCG TAC
1101 ASD_FRT_43_76_F TCAGTTTTAATGTCTCGTATGATCGA 295 ASD_FRT_129_156_R TCCATATTGTTGCATAAAACCTGTTGGC 1009
ATCAAAAG
1102 GALE_FRT_165_199_F TTATCAGCTAGACCTTTTAGGTAAAG 658 GALE_FRT_241_269_R TCACCTACAGCTTTAAAGCCAGCAAAAT 973
CTAAGC G
1103 GALE_FRT_834_865_F TCAAAAAGCCCTAGGTAAAGAGATTC 245 GALE_FRT_901_925_R TAGCCTTGGCAACATCAGCAAAACT 915
CATATC
1104 GALE_FRT_308_339_F TCCAAGGTACACTAAACTTACTTGAG 306 GALE_FRT_390_422_R TCTTCTGTAAAGGGTGGTTTATTATTCA 1136
CTAATG TCCCA
1105 IPAH_SGF_258_277_F TGAGGACCGTGTCGCGCTCA 458 IPAH_SGF_301_327_R TCCTTCTGATGCCTGATGGACCAGGAG 1055
1106 IPAH_SGF_113_134_F TCCTTGACCGCCTTTCCGATAC 350 IPAH_SGF_172_191_R TTTTCCAGCCATGCAGCGAC 1441
1107 IPAH_SGF_462_486_F TCAGACCATGCTCGCAGAGAAACTT 271 IPAH_SGF_522_540_R TGTCACTCCCGACACGCCA 1322
1111 RNASEP_BRM_461_488_ TAAACCCCATCGGGAGCAAGACCGAA 147 RNASEP_BRM_542_561_R TGCCTCGCGCAACCTACCCG 1227
F TA
1112 RNASEP_BRM_325_347_ TACCCCAGGGAAAGTGCCACAGA 185 RNASEP_BRM_402_428_R TCTCTTACCCCACCCTTTCACCCTTAC 1125
F
1128 HUPB_CJ_113_134_F TAGTTGCTCAAACAGCTGGGCT 230 HUPB_CJ_157_188_R TCCCTAATAGTAGAAATAACTGCATCAG 1028
TAGC
1129 HUPB_CJ_76_102_F TCCCGGAGCTTTTATGACTAAAGCAG 324 HUPB_CJ_157_188_R TCCCTAATAGTAGAAATAACTGCATCAG 1028
AT TAGC
1130 HUPB_CJ_76_102_F TCCCGGAGCTTTTATGACTAAAGCAG 324 HUPB_CJ_114_135_R TAGCCCAGCTGTTTGAGCAACT 913
AT
1151 AB_MLST-11- TGAGATTGCTGAACATTTAATGCTGA 454 AB_MLST-11- TTGTACATTTGAAACAATATGCATGACA 1418
OIF007_62_91_F TTGA OIF007_169_203_R TGTGAAT
1152 AB_MLST-11- TATTGTTTCAAATGTACAAGGTGAAG 243 AB_MLST-11- TCACAGGTTCTACTTCATCAATAATTTC 969
OIF007_185_214_F TGCG OIF007_291_324_R CATTGC
1153 AB_MLST-11- TGGAACGTTATCAGGTGCCCCAAAAA 541 AB_MLST-11- TTGCAATCGACATATCCATTTCACCATG 1400
OIF007_260_289_F TTCG OIF007_364_393_R CC
1154 AB_MLST-11- TGAAGTGCGTGATGATATCGATGCAC 436 AB_MLST-11- TCCGCCAAAAACTCCCCTTTTCACAGG 1036
OIF007_206_239_F TTGATGTA OIF007_318_344_R
1155 AB_MLST-11- TCGGTTTAGTAAAAGAACGTATTGCT 378 AB_MLST-11- TTCTGCTTGAGGAATAGTGCGTGG 1392
OIF007_522_552_F CAACC OIF007_587_610_R
1156 AB_MLST-11- CCAACCTGACTGCGTGAATGGTTGT 250 AB_MLST-11- TACGTTCTACGATTTCTTCATCAGGTAC 902
OIF007_547_571_F OIF007_656_68_R ATC
1157 AB_MLST-11- TCAAGCAGAAGCTTTGGAAGAAGAAG 256 AB_MLST-11- TACAACGTGATAAACACGACCAGAAGC 881
OIF007_601_627_F G OIF007_710_736_R
1158 AB_MLST-11- TCGTGCCCGCAATTTGCATAAAGC 384 AB_MLST-11- TAATGCCGGGTAGTGCAATCCATTCTTC 878
OIF007_1202_1225_F OIF007_1266_1296_R TAG
1159 AB_MLST-11- TCGTGCCCGCAATTTGCATAAAGC 384 AB_MLST-11- TGCACCTGCGGTCGAGCG 1199
OIF007_1202_1225_F OIF007_1299_1316_R
1160 AB_MLST-11- TTGTAGCACAGCAAGGCAAATTTCCT 694 AB_MLST-11- TGCCATCCATAATCACGCCATACTGACG 1215
OIF007_1234_1264_F OIF007_1335_1362_R
1161 AB_MLST-11- TAGGTTTACGTCAGTATGGCGTGATT 225 AB_MLST-11- TGCCAGTTTCCACATTTCACGTTCGTG 1212
OIF007_1327_1356_F OIF007_1422_1448_R
1162 AB_MLST-11- TCGTGATTATGGATGGCAACGTGAA 383 AB_MLST-11- TCGCTTGAGTGTAGTCATGATTGCG 1083
OIF007_1345_1369_F OIF007_1470_1494_R
1163 AB_MLST-11- TTATGGATGGCAACGTGAAACGCGT 662 AB_MLST-11- TCGCTTGAGTGTAGTCATGATTGCG 1083
OIF007 1351_1375_F OIF007_1470_1494_R
1164 AB_MLST-11- TCTTTGCCATTGAAGATGACTTAAGC 422 AB_MLST-11- TCGCTTGAGTGTAGTCATGATTGCG 1083
OIF007_1387_1412_F OIF007_1470_1494_R
1165 AB_MLST-11- TACTAGCGGTAAGCTTAAACAAGATT 194 AB_MLST-11- TGAGTCGGGTTCACTTTACCTGGCA 1173
OIF007_1542_1569_F GC OIF007_1656_1680_R
1166 AB_MLST-11- TTGCCAATGATATTCGTTGGTTAGCA 684 AB_MLST-11- TGAGTCGGGTTCACTTTACCTGGCA 1173
OIF007_1566_1593_F AG OIF007_1656_1650_R
1167 AB_MLST-11- TCGGCGAAATCCGTATTCCTGAAAAT 375 AB_MLST-11- TACCGGAAGCACCAGCGACATTAATAG 890
OIF007_1611_1638_F GA OIF007_1731_1757_R
1168 AB_MLST-11- TACCACTATTAATGTCGCTGGTGCTT 182 AB_MLST-11-T GCAACTGAATAGATTGCAGTAAGTTAT 1195
OIF007_1726_1752_F C OIF007_1790_1821_R AAGC
1169 AB_MLST-11- TTATAACTTACTGCAATCTATTCAGT 656 AB_MLST-11- TGAATTATGCAAGAAGTGATCAATTTTC 1151
OIF007_1792_1826_F TGCTTGGTG OIF007_1876_1909_R TCACGA
1170 AB_MLST-11- TTATAACTTACTGCAATCTATTCAGT 656 AB_MLST-11- TGCCGTAACTAACATAAGAGAATTATGC 1224
OIF007_1792_1826_F TGCTTGGTG OIF007_1895_1927_R AAGAA
1171 AB_MLST-11- TGGTTATGTACCAAATACTTTGTCTG 618 AB_MLST-11- TGACGGCATCGATACCACCGTC 1157
OIF007_1970_2002_F AAGATGG OIF007_2097_2118_R
1172 RNASEP_BRM_461_488_ TAAACCCCATCGGGAGCAAGACCGAA 147 RNASEP_BRM_542_561_2_R TGCCTCGTGCAACCCACCCG 1228
F TA
2000 CTXB_NC002505_46_70_ TCAGCGTATGCACATGGAACTCCTC 278 CTXB_NC002505_132_162_R TCCGGCTAGAGATTCTGTATACGACAAT 1039
F ATC
2001 FUR_NC002505_87_113_ TGAGTGCCAACATATCAGTGCTGAAG 465 FUR_NC002505_205_228_R TCCGCCTTCAAAATGGTGGCGAGT 1037
F A
2002 FUR_NC002505_87_113_ TGAGTGCCAACATATCAGTGCTGAAG 465 FUR_NC002505_178_205_R TCACGATACCTGCATCATCAAATTGGTT 974
F A
2003 GAPA_NC002505_533_5 TCGACAACACCATTATCTATGGTGTG 356 GAPA_NC002505_646_671_R TCAGAATCGATGCCAAATGCGTCATC 980
60_F AA
2004 GAPA_NC002505_694_7 TCAATGAACGACCAACAAGTGATTGA 259 GAPA_NC002505_769_798_R TCCTCTATGCAACTTAGTATCARCAGGA 1046
21_F TG AT
2005 GAPA_NC002505_753_7 TGCTAGTCAATCTATCATTCCGGTTG 517 GAPA_NC002505_856_881_R TCCATCGCAGTCACGTTTACTGTTGG 1011
82_F ATAC
2006 GYRB_NC002505_2_32_ TGCCGGACAATTACGATTCATCGAGT 501 GYRB_NC002505_109_134_R TCCACCACCTCAAAGACCATGTGGTG 1003
F ATTAA
2007 GYRB_NC002505_123_1 TGAGGTGGTGGATAACTCAATTGATG 460 GYRB_NC002505_199_225_R TCCGTCATCGCTGACAGAAACTGAGTT 1042
52_F AAGC
2008 GYRB_NC002505_768_7 TATGCAGTGGAACGATGGTTTCCAAG 236 GYRB_NC002505_832_860_R TGGAAACCGGCTAAGTGAGTACCACCAT 1262
94_F A C
2009 GYRB_NC002505_837_8 TGGTACTCACTTAGCGGGTTTCCG 603 GYRS_NC002505_937_957_R TCCTTCACGCGCATCATCACC 1054
60_F
2010 GYRB_NC002505_934_9 TCGGGTGATGATGCGCGTGAAGG 377 GYRB_NC002505_982_1007_R TGGCTTGAGAATTTAGGATCCGGCAC 1283
56_F
2011 GYRB_NC002505_1161_ TAAAGCCCGTGAAATGACTCGTCGTA 148 GYRB_NC002505_1255_1284_R TGAGTCACCCTCCACAATGTATAGTTCA 1172
1190_F AAGG GA
2012 OMPU_NC002505_85_11 TACGCTGACGGAATCAACCAAAGCGG 190 OMPU_NC002505_154_180_R TGCTTCAGCACGGCCACCAACTTCTAG 1254
0_F
2013 OMPU_NC002505_258_2 TGACGGCCTATACGGTGTTGGTTTCT 451 OMPU_NC002505_346_369_R TCCGAGACCAGCGTAGGTGTAACG 1033
83_F
2014 OMPU_NC002505_431_4 TCACCGATATCATGGCTAACCACGG 266 OMFU_NC002505_544_567_R TCGGTCAGCAAAACGGTAGCTTGC 1094
55_F
2015 OMPU_NC002505_533_5 TAGGCGTGAAAGCAAGCTACCGTTT 223 OMPU_NC002505_625_651_R TAGAGAGTAGCCATCTTCACCGTTGTC 908
57_F
2016 OMPU_NC002505_689_7 TAGGTGCTGGTTACGCAGATCAAGA 224 OMPU_NC002505_725_751_R TGGGGTAAGACGCGGCTAGCATGTATT 1291
13_F
2017 OMPU_NC002505_727_7 TACATGCTAGCCGCGTCTTAC 181 OMPU_NC002505_811_835_R TAGCAGCTAGCTCGTAACCAGTGTA 911
47_F
2018 OMPU_NC002505_931_9 TACTACTTCAAGCCGAACTTCCG 193 OMPU_NC002505_1033_1053_R TTAGAAGTCGTAACGTGGACC 1368
53_F
2019 OMPU_NC002505_927_9 TACTTACTACTTCAAGCCGAACTTCC 197 OMPU_NC002505_1033_1054_R TGGTTAGAAGTCGTAACGTGGACC 1307
53_F
2020 TCPA_NC002505_48_73_ TCACGATAAGAAAACCGGTCAAGAGG 269 TCPA_NC002505_148_170_R TTCTGCGAATCAATCGCACGCTG 1391
F
2021 TDH_NC004605_265_28 TGGCTGACATCCTACATGACTGTGA 574 TDH_NC004605_357_386_R TGTTGAAGCTGTACTTGACCTGATTTTA 1351
9_F CG
2022 VVHA_NC004460_772_8 TCTTATTCCAACTTCAAACCGAACTA 412 VVHA_NC00446O_862_886_R TACCAAAGCGTGCACGATAGTTGAG 887
02_F TGACG
2023 23S_EC_2643_2667_F TGCCTGTTCTTAGTACGAGAGGACC 508 23S_EC_2746_2770_R TGGGTTTCGCGCTTAGATGCTTTCA 1297
2024 16S_EC_713_732_TMOD_ TAGAACACCGATGGCGAAGGC 202 16S_EC_789_811_R TGCGTGGACTACCAGGGTATCTA 1240
F
2025 16S_EC_784_806_F TGGATTAGAGACCCTGGTAGTCC 560 16S_EC_880_897_TMOD_R TGGCCGTACTCCCCAGGCG 1278
2026 16S_EC_959_981_F TGTCGATGCAACGCGAAGAACCT 634 16S_EC_1052_1074_R TACGAGCTGACGACAGCCATGCA 896
2027 TUFB_EC_956_979_F TGCACACGCCGTTCTTCAACAACT 489 TUFB_EC_1034_1058_2_R TGCATCACCATTTCCTTGTCCTTCG 1204
2028 RPOC_EC_2146_2174_T TCAGGAGTCGTTCAACTCGATCTACA 284 RPOCEC_2227_2249_R TGCTAGGCCATCAGGCCACGCAT 1244
MOD_F TGAT
2029 RPOB_EC_1841_1866_F TGGTTATCGCTCAGGCGAACTCCAAC 617 RPOB_EC_1909_1929_TMOD_R TGCTGGATTCGCCTTTGCTACG 1250
2030 RPLB_EC_650_679_TMO TGACCTACAGTAAGAGGTTCTGTAAT 449 RPLB_EC_739_763_R TGCCAAGTGCTGGTTTACCCCATGG 1208
D_F GAACC
2031 RFLB_EC_690_710_F TCCACACGGTGGTGGTGAAGG 309 RPLB_BC_737_760_R TGGGTGCTGGTTTACCCCATGGAG 1295
2032 INFB_EC_1366_1393_F TCTCGTGGTGCACAAGTAACGGATAT 397 INFB_BC_1439_1469_R TGTGCTGCTTTCGCATGGTTAATTGCTT 1335
TA CAA
2033 VALS_EC_1105_1124_T TCGTCCCGGCGTGGTTATCGA 385 VALS_EC_1195_1219_R TGGGTACGAACTGGATGTCGCCGTT 1292
MOD_F
2034 SSPE_BA_113_137_F TGCAACCAAACGCACAATCAGAAGC 482 SSPE_BA_197_222_TMOD_R TTGCACGTCTGTTTCAGTTGCAAATTC 1402
2035 RPOC_EC_2218_2241_T TCTGGCAGGTATGCGTCGTCTGATG 405 RPOC_EC_2313_2338_R TGGCACCGTGGGTTGAGATGAAGTAC 1273
MOD_F
2056 MECI-R_NC003923- TTTACACATATCGTGACCAATGAACT 698 MECI-R_NC003923-41798- TTGTGATATGGAGGTGTAGAAGGTGTTA 1420
41798-41609_33_60_F GA 41609_86_113_R
2057 AGR-III_NC003923- TCACCAGTTTGCCACGTATCTTCAA 263 AGT-III_NC003923-2108074- ACCTGCATCCCTAAACGTACTTGC 730
2108074 2109507_56_79_R
2109507_1_23_F
2058 AGR-III_NC003923- TGAGCTTTTAGTTGACTTTTTCAACA 457 AGR-III_NC003923-2108074- TACTTCAGCTTCGTCCAATAAAAAATCA 906
2108074- GC 2109507_622_653_R CAAT
2109507569_596_F
2059 AGR-III_NC003923- TTTCACACAGCGTGTTTATAGTTCTA 701 AGR-III_NC003923-2108074- TGTAGGCAAGTGCATAAGAAATTGATAC 1319
2108074- CCA 2109507_1070_1098_R A
21095071024_1052_F
2060 AGR- TGGTCACTTCATAATGGATGAAGTTG 610 AGR-I_AJ617706_694_726_R TCCCCATTTAATAATTCCACCTACTATC 1021
I_AJ617706_622_651_ AAGT ACACT
F
2061 AGR- TGGGATTTTAAAAAACATTGGTAACA 579 AGR-I_AJ617706_626_655_R TGGTACTTCAACTTCATCCATTATGAAG 1302
L_AJ617706_580_611- TCGCAG TC
F
2062 AGR-II_NC002745- TCTTGCAGCAGTTTATTTGATGAACC 415 AGR-II_NC002745-2079448- TTGTTTATTGTTTCCATATGCTACACAC 1424
2079448- TAAAGT 2080879_700_731_R TTTC
2080879_620_651_F
2063 AGR-II_NC002745- TGTACCCGCTGAATTAACGAATTTAT 624 AGR-II_NC002745-2079448- TCGCCATAGCTAAGTTGTTTATTGTTTC 1077
2079448- ACGAC 2080879_715_745_R CAT
2080879_649_679_F
2064 AGR- TGGTATTCTATTTTGCTGATAATGAC 606 AGR- TGCCCTATCAACGATTTTGACAATATAT 1233
IV_AJ617711_931_961_ CTCGC IV_AJ617711_1004_1035_R GTGA
F
2065 AGR- TGGCACTCTTGCCTTTAATATTAGTA 562 AGR-IV_AJ617711_309_335_R TCCCATACCTATGGCGATAACTGTCAT 1017
IV_AJ617711_250_283_ AACTATCA
F
2066 BLAZ_NC002952(191382 TCCACTTATCGCAAATGGAAAATTAA 312 BLAZ_18C002952(1913827 . . . TGGCCACTTTTATCAGCAACCTTACAGT 1277
7 . . . 1914672)_68_68_ GCAA 1914672)_68_68_R C
F
2067 BLAZ_NC002952(191382 TGCACTTATCOCAAATGGAAAATTAA 494 BLAZ_NC002952(1913827 . . . TAGTCTTTTGGAACACCGTCTTTAATTA 926
7 . . . 1914672)_68_68_ GCAA 1914672)68_68_2_R AAGT
2_F
2068 BLAZ_NC002952(191382 TGATACTTCAACGCCTGCTGCTTTC 467 BLAZ_NC002952(1913827 . . . TGGAACACCGTCTTTAATTAAAGTATCT 1263
7 . . . 1914672)_68_68_ 1914672)_68_68_3_R CC
3_F
2069 BLAZ_NC002952(191382 TATACTTCAACGCCTGCTGCTTTC 232 BLAZ_NC002952(1913827 . . . TCTTTTCTTTGCTTAATTTTCCATTTGC 1145
7 . . . 1914672)6868 1914672)_68_68_4_R GAT
4_F
2070 BLAZ_NC002952(191382 TGCAATTGCTTTAGTTTTAAGTGCAT 487 BLAZ_NC002952(1913827 . . . TTACTTCCTTACCACTTTTAGTATCTAA 1366
7 . . . 1914672)_1_33_F GTAATTC 1914672)_34_67_R ACCATA
2071 BLAZ_NC002952(191382 TCCTTGCTTTAGTTTTAAGTGCATGT 351 BLAZ_NC002952(1913827 . . . TGGGGACTTCCTTACCACTTTTAGTATC 1289
7 . . . 1914672)_3_34_F AATTCAA 1914672)_40_68_R TAA
2072 BSA-A_NC003923- TAGCGAATGTGGCTTTACTTCACAAT 214 BSA-A_NC003923-1304065- TGCAAGGGAAACCTAGAATTACAAACCC 1197
1304065- T 1303589_165_193_R T
1303589_99_125_F
2073 BSA-A_NC003923- ATCAATTTGGTGGCCAAGAACCTGG 32 BSA-A_NC003923-1304065- TGCATAGGGAAGGTAACACCATAGTT 1203
1304065- 1303589_253_278_R
1303589_194_218_F
2074 BSA-A_NC003923- TTGACTGCGGCACAACACGGAT 679 BSA-A_NC003923-1304065- TAACAACGTTACCTTCGCGATCCACTAA 856
1304065- 130358_388_415_R
1303589_328_349_F
2075 BSA-ANC003923- TGCTATGGTGTTACCTTCCCTATGCA 519 BSA-A_NC003923-1304065- TGTTGTGCCGCAGTCAAATATCTAAATA 1353
1304065- 1303589_317_344_R
1303589_253_278_F
2076 BSA-B_NC003923- TAGCAACAAATATATCTGAAGCAGCG 209 BSA-B_NC003923-1917149- TGTGAAGAACTTTCAAATCTGTGAATCC 1331
1917149- TACT 1914156_1011_1039_R A
1914156_953_982_F
2077 BSA-B_NC003923- TGAAAAGTATGGATTTGAACAACTCG 426 NSA-B_NC003923-1917149- TCTTCTTGAAAAATTGTTGTCCCGAAAC 1138
1917149- TGAATA 1914156_1109_1136_R
1914156_1050_1081_F
2078 NSA-B_NC003923- TCATTATCATGCGCCAATGAGTGCAG 300 NSA-B_NC003923-1917149- TGGACTAATAACAATGAGCTCATTGTAC 1267
1917149- A 1914156_1323_1353_R TGA
1914156_1260_1286_F
2079 NSA-BNC003923- TTTCATCTTATCGAGGACCCGAAATC 703 NSA-B_NC003923-1917149- TGAATATGTAATGCAAACCAGTCTTTGT 1148
1917149- GA 1914156_2186_2216_R CAT
1914156_2126_2153_F
2080 ERMA_NC002952- TCGCTATCTTATCGTTGAGAAGGGAT 372 ERMA_NC002952-55890- TGAGTCTACACTTGGCTTAGGATGAAA 1174
55890- T 56621_487_513_R
56621_366_392_F
2081 ERMA_NC002952- TAGCTATCTTATCGTTGAGAAGGGAT 217 ERMA_NC002952-55890- TGAGCATTTTTATATCCATCTCCACCAT 1167
55890- TTGC 56621_438_465_R
56621_366_395_F
2082 ERMA_NC002952- TGATCGTTGAGAAGGGATTTGCGAAA 470 ERMA_NC002952-55890- TCTTGGCTTAGGATGAAAATATAGTGGT 1143
55890- AGA 56621_473_504_R GGTA
56621_374_402_F
2083 ERMA_NC002952- TGCAAAATCTGCAACGAGCTTTGG 480 ERMA_NC002952-55890- TCAATACAGAGTCTACACTTGGCTTAGG 964
55890- 56621_491_520_R AT
56621_404_427_F
2084 ERMA_NC002952- TCATCCTAAGCCAAGTGTAGACTCTG 297 ERMA_NC002952-55890- TGGACGATATTCACGGTTTACCCACTTA 1266
55890- TA 56621_986_615_R TA
56621_489_516_F
2085 ERMA_NC002952- TATAAGTGGGTAAACCGTGAATATCG 231 ERMA_NC002952-55890- TTGACATTTGCATGCTTCAAAGCCTG 1397
55890- TGT 56621_640_665_R
56621_586_614_F
2086 ERMC_NC0059_08-2004- TCTGAACATGATAATATCTTTGAAAT 399 ERMC_NC005908-2004- TCCGTAGTTTTGCATAATTTATGGTCTA 1041
2738_85_116_F CGGCTC 2738_173_206_R TTTCAA
2087 ERMC_NC005908-2004- TCATGATAATATCTTTGAAATCGGCT 298 ERMC_NC005908-2004- TTTATGGTCTATTTCAATGGCAGTTACG 1429
2738_90_120_F CAGGA 2738_160_189_R AA
2088 ERMC_NC005908-2004- TCAGGAAAAGGGCATTTTACCCTTG 283 ERMC_NC005908-2004- TATGGTCTATTTCAATGGCAGTTACGA 936
2738_115_139_F 2738_61_187_R
2089 ERMC_NC005908-2004- TAATCGTGGAATACGGGTTTGCTA 165 ERMC_NC005908-2004- TCAACTTCTGCCATTAAAAGTAATGCCA 956
2738_374_397_F 2738_425_452_R
2090 ERMC_NC005908-2004- TCTTTGAAATCGGCTCAGGAAAAGG 421 ERMC_NC005908-2004- TGATGGTCTATTTCAATGGCAGTTACGA 1185
2738_101_125_F 2738_159_188_R
2091 ERMB_Y13600-625- TGTTGGGAGTATTCCTTACCATTTAA 644 ERME_Y13_600-625- TCAACAATCAGATAGATGTCAGACGCAT 953
1362_291_321_F GCACA 1362_352_980_R G
2092 ERMB_Y13600-625- TGGAAAGCCATGCGTCTGACATCT 536 ERMB_Y13600-625- TGCAAGAGCAACCCTAGTGTTCG 1196
1362_344_67_F 1362_415_437_R
2093 ERMB_Y13600-625- TGGATATTCACCGAACACTAGGGTTG 556 ERMB_Y13600-625- TAGGATGAAAGCATTCCGCTGGC 919
1362_404_429_F 1362_471_393_R
2094 ERMB_Y13600-625- TAAGCTGCCAGCGGAATGCTTTC 161 ERMB_Y13600-625- TCATCTGTGGTATGCCGGGTAAGTT 989
1362_465_487_F 1362_521_545_R
2095 PVLUK_NC003923- TGAGCTGCATCAACTGTATTGGATAG 456 PVLUK_NC003923-1529595- TGGAAAACTCATGAAATTAAAGTGAAAG 1261
1529595- 1531285_775_804_R GA
1531285_688_713_F
2096 PVLUK_NC003923- TGGAACAAAATAGTCTCTCGGATTTT 539 PVLUK_NC003923-1529595- TCATTAGGTAAAATGTCTGGACATGATC 993
1529595- GACT 1531285_1095_1125_R CAA
1531285_1039_1068_F
2097 PVLUK_NC003923- TGAGTAACATCCATATTTCTGCCATA 461 PVLUK_NC003923-1529595- TCTCATGAAAAAGGCTCAGGAGATACAA 1124
1529595- CGT 1531285_950_978_R G
1531285_908_936_F
2098 PVLUK_NC003923- TCGGAATCTGATGTTGCAGTTGTT 373 PVLUK_NC003923-1529595- TCACACCTGTAAGTGAGAAAAAGGTTGA 968
1529595- 1531285_654_682_R T
1531285_610_633_F
2099 SA442_NC003923- TGTCGGTACACGATATTCTTCACGA 635 SA442_NC003923-2538576- TTTCCGATGCAACGTAATGAGATTTCA 1433
2538576- 2538831_98_124_R
2538831_11_35_F
2100 SA442_NC003923- TGAAATCTCATTACGTTCCATCGGAA 427 SA4423_NC003923-2538576- TCGTATGACCAGCTTCGGTACTACTA 1098
2538576- A 2538831_163_188_R
2538831_98_124_F
2101 SA442_NC003923- TCTCATTACGTTGCATCGGAAACA 395 SA442_NC003923-2538576- TTTATGACCAGCTTCGGTACTACTAAA 1428
2538576- 2538831_161_187_R
2538831_103_126_F
2102 SA442_NC003923- TAGTACCGAAGCTGGTCATACGA 226 SA442_NC003923-2538576- TGATAATGAAGGGAAACCTTTTTCACG 1179
2538376- 2538831_231_257_R
2538831_166_188_F
2103 SEA_NC003923_ TGCAGGGAACAGCTTTAGGCA 495 SEA_NC003923-2052219- TCGATCGTGACTCTCTTTATTTTCAGTT 1070
2052219- 2051456_173_200_R
2051456_115_135_F
2104 SEA_NC003923- TAACTCTCATGTTTTTCATGGGAAGG 156 SEA_NC003923-2052219- TCTAATTAACCGAAGCTTCTCTACAAGT 1315
2052219- T 2051456_621_651_R ATG
2051456_572_598_F
2105 SEA_NC003923- TGTATGGTGGTGTAACGTTACATGAT 629 SEA_NC003923-2052219- TAACCGTTTCCAAAGGTACTGTATTTTG 861
2052219- AATAATC 2051456_464_492_R T
2051456_382_414_F
2106 SEA_NC003923- TTGTATCTATGGTCCTGTAACCTTAC 695 SEA_NC003923-2052219- TAACCCTTTCCAAAGGTACTCTATTTTG 862
2052219- ATGA 2051456_459_492_R TTTACC
2051456_377_406_F
2107 SEB_NC002758- TTTCACATGTAATTTTGATATTCGCA 702 SEB_NC002758-2135540- TCATCTGGTTTACGATCTCCTTGACT 988
2135540- CTGA 2135140_273_298_R
2135140_208_237_F
2108 SEB_NC002758- TATTTCACATCTAATTTTCATATTCC 244 SEB_NC002758-2135540- TGCAACTCATCTGGTTTAGGATCT 1194
2135540- CACT 2135140_281_304_R
2135140_206_235_F
2109 SEB_NC002758- TAACAACTCCCCTTATGAAACGGGAT 151 SEE NC002758-2135540- TGTGCAGGCATCATGTCATACCAA 1334
2135540- ATA 2135140_402_402_R
2135140_402_402_F
2110 SEB_NC002758- TTGTATGTATGGTGGTGTAACTGACC 696 SEB_NC002758-2135540- TTACCATCTTCAAATACCCGAACACTAA 1361
2135540- A 2135140_402_402_2_R
2135140_402_402_2_F
2111 SEC_NC003923- TTAACATGAACGAAACCACTTTGATA 648 SEC_NC003923-851678- TCAGTTTGCACTTCAAAAGAAATTGTGT 1177
851678- ATGG 852768_620_647_R
852768546_575_F
2112 SEC_NC003923- TGCAATAACAAAACATGAACCAAACC 546 SEC_NC003923-851678- TCAGTTTOCACTTCAAAAGAAATTGTGT 985
851678- ACTT 852768_619_647_R T
852768537_566_F
2113 SEC_NC003923- TGACTTTAACAGTTCACCATATGAAA 466 SEC_NC003923-851678- TCGCCTGGTCCAGGCATCATAT 1078
851678- CAGG 852768_794_815_R
852768_720_749_F
2114 SEC_NC003923- TCGTATGATATGATGCCTGCACCA 604 SEC_NC003923-851678- TCTTCACACTTTTAGAATCAACCGTTTT 1133
851678- 852768_853_886_R ATTGTC
852768_787_810_F
2115 SED_M28521_657_682_ TGGTGGTGAAATAGATAGGACTCCTT 615 SED_M28521_741_770_R TCTACACCATTTATCCACAAATTGATTG 1318
F GT
2116 SED_M28521_690_711_ TCCACCTCTCACTCCACACCAA 554 SED_M28521_739_770_R TCCCCACCATTTATCCACAAATTCATTC 1288
F CTAT
2117 SED_M28521_833_854_ TTCCACAACCAACCCCCTATTT 683 SED_M28521_888_911_R TCCCCCTCTATTTTTCCTCCCACA 1079
F
2118 SED_M28521_962_987_ TCCATCTTAACCCTCATTTTCCCCAA 559 SED_M28521_1022_1048_R TCTCAATATCAACCTCCTCTCTCCATA 1320
F
2119 SEA-SEE_NC002952- TTTACACTACTTTTATTCATTCCCCT 699 SEA-SEE_NC002952-2131289- TCATTTATTTCTTCCCTTTTCTCCCTAC 994
2131289- AACC 2130703_71_98_R
2130703_16_45_F
2120 SEA-SEE_NC002_952- TCATCATCCCTCCTATAACCATTTAT 469 SEA-SEE_NC002952-2131289- TAACCACCATATAACTCTACTTTTTTCC 870
2131289- TACT 2130703_314_344_R CTT
2130703_249_278_F
2121 SEE_NC002952- TGACATGATAATAACCGATTGACCGA 445 SEE_NC002952-2131289- TCTATAGGTACTGTAGTTTGTTTTCCGT 1120
2131289- AGA 2130703_465_494_R CT
2130703_409_437_F
2122 SEE_NC002952- TGTTCAAGAGCTAGATCTTCAGGCAA 640 SEE_NC002952-2131289- TTTGCACCTTACCGCCAAAGCT 1436
2131289- 2130703_586_586_R
2130703_525_550_F
2123 SEE_N4C002952- TGTTCAAGAGCTAGATCTTCAGGCA 639 SEE_NC002952-2131289- TACCTTACCGCCAAAGCTGTCT 892
2131289- 2130703_586_586_2_R
2130703_525_549_F
2124 SEE_NC002952- TCTGGAGGCACACCAAATAAAACA 403 SEE_NC002952-2131289- TCCGTCTATCCACAAGTTAATTGGTACT 1043
2131289- 2130703_444_471_R
2130703_361_384_F
2125 SEG_NC002758- TGCTCAACCCGATCCTAAATTAGACG 520 SEG_NC002758-1955100- TAACTCCTCTTCCTTCAACAGGTGGA 863
1955100- A 1954171_321_346_R
1954171_225_251_F
2126 SEG_NC002758- TGGACAATAGACAATCACTTGGATT 548 SEG_NC002758-1955100- TGCTTTGTAATCTAGTTCCTGAATAGTA 1260
1955100- ACA 1954171_671_702_R ACCA
1954171_623_651_F
2127 SEG_NC002758- TGGAGGTTGTTGTATGTATGGTGGT 555 SEG_NC0002758-1955100- TGTCTATTGTCGATTGTTACCTGTACAG 1329
1955100- 1954171_607_635_R T
1954171_540_564_F
2128 SEG_NC002758- TACAAAGCAAGACACTGGCTCACTA 173 SEG_NC002758-1955100- TGATTCAAATGCAGAACCATCAAACTCG 1187
1955100- 1954171_735_762_R
1954171_694_718_F
2129 SEH_NC002953-60024- TTGCAACTGCTGATTTAGCTCAGA 682 SEH_NC002953-60024- TAGTGTTGTACCTCCATATAGACATTCA 927
60977_449_472_F 60977_547_576_R GA
2130 SEH_NC002953-60024- TAGAAATCAAGGTGATAGTGGCAATG 201 SEH_EC002953-60024- TTCTGAGCTAAATCAGCAGTTGCA 1390
60977_408_434_F A 60977_450_473_R
2131 SEH_NC0029S3-60024- TCTGAATGTCTATATGGAGGTACAAC 400 SEH_NC002953-60024- TACCATCTACCCAAACATTAGCACCAA 888
60977_547_576_F ACTA 60977_608_634_R
2132 SEH_NC002953-60024- TTCTGAATGTCTATATGGAGGTACAA 677 SEH_NC002953-60024- TAGCACCAATCACCCTTTCCTGT 909
60977_546_575_F CACT 60977_594_616_R
2133 SEH_NC002758- TCAACTCGAATTTTCAACAGGTACCA 253 SEH_NC002758-1957830- TCACAAGGACCATTATAATCAATGCCAA 966
1957830- 1956949_419_446_R
1956949_324_349_F
2134 SEI_NC002758- TTCAACAGGTACCAATGATTTGATCT 666 SEI_NC002758-1957830- TGTACAAGGACCATTATAATCAATGCCA 1316
1957830- CA 1956949_420_447_R
1956949_336_363_F
2135 SEI_NC002758- TGATCTCAGAATCTAATAATTGGGAC 471 SEI_NC002758-1957830- TCTGGCCCCTCCATACATGTATTTAG 1129
1957830- GAA 1956949_449_474_R
1956949_356_384_F
2136 SEI_NC002758- TCTCAAGGTGATATTGGTGTAGGTAA 394 SEI_NC002758-1957830- TGGGTAGGTTTTTATCTGTGACGCCTT 1293
1957830- CTTAA 1956949_290_316_R
1956949_223_253_F
2137 SEJ_AF053140_1307_1 TGTGGAGTAACACTGCATGAAAACAA 637 SEJ_AF053140_1381_1404_R TCTAGCGGAACAACAGTTCTGATG 1118
332_F
2138 SEJ_AF053140_1378_1 TAGCATCAGAACTGTTGTTCCGCTAG 211 SEJ_AF053140_1429_1458_R TCCTGAAGATCTAGTTCTTGAATGGTTA 1049
403_F CT
2139 SEJ_AF053140_1431_1 TAACCATTCAAGAACTAGATCTTCAG 153 SEJ_AF053140_1500_1531_R TAGTCCTTTCTGAATTTTACCATCAAAG 925
459_F GCA GTAC
2140 SEJ_AF053140_1434_1 TCATTCAAGAACTAGATCTTCAGGCA 301 SEJ_AF053140_1521_1549_R TCAGGTATGAAACACGATTAGTCCTTTC 984
461_F AG T
2141 TSST_NC002758- TGGTTTAGATAATTCCTTAGGATCTA 619 TSST_NC002758-2137564- TGTAAAAGCAGGGCTATAATAAGGACTC 1312
2137564- TGCGT 2138293_278_305_R
2138293_206_236_F
2142 TSST_NC002758- TGCGTATAAAAAACACAGATGGCAGC 514 TSST_NC002758-2137564- TGCCCTTTTGTAAAAGCAGGGCTAT 1221
2137564- A 2138293_289_313_R
2138293_232_258_F
2143 TSST_NC002758- TCCAAATAAGTGGCGTTACAAATACT 304 TSST_NC002758-2137564- TACTTTAAGGGGCTATCTTTACCATGAA 907
2137564- GAA 2138293_448_478_R CCT
2138293_382_410_F
2144 TSST_NC002758- TCTTTTACAAAAGGGGAAAAAGTTGA 423 TSST_NC002758-2137564- TAAGTTCCTTCGCTAGTATGTTGGCTT 874
2137564- CTT 2138293_347_373_R
2138293_297_325_F
2145 ARCC_NC003923- TCGCCGGCAATGCCATTGGATA 368 ARCC_NC003923- TGAGTTAAAATGCGATTGATTTCAGTTT 1175
2725050- 2724595_97_128_R CCAA
2724595_37_58_F
2146 ARCC_NC003923- TGAATAGTGATAGAACTGTAGGCACA 437 ARCC_NC003923-2725050- TCTTCTTCTTTCGTATAAAAAGGACCAA 1137
2725050- ATCGT 2724595_214_245_R TTGG
2724595_131_161_F
2147 ARCC_NC003923- TTGGTCCTTTTTATACGAAAGAAGAA 691 ARCC_NC003923-2725050- TGGTGTTCTAGTATAGATTGAGGTAGTG 1306
2725050- GTTGAA 2724595_322_353_R GTGA
2724595_218_249_F
2148 AROE_NC003923- TTGCGAATAGAACGATGGCTCGT 686 AROE_NC003923-1674726- TCGAATTCAGCTAAATACTTTTCAGCAT 1064
1674726- 1674277_435_464_R CT
1674277_371_393_F
2149 AROE_NC003923- TGGGGCTTTAAATATTCCAATTGAAG 590 AROE_NC003923-1674726- TACCTGCATTAATCGCTTGTTCATCAA 891
1674726- ATTTTCA 1674277_155_181_R
1674277_30_62_F
2150 AROE_NC003923- TGATGGCAAGTGGATAGGGTATAATA 474 ARCE_NC003923-1674726- TAAGCAATACCTTTACTTGCACCACCTG 869
1674726- CAG 1674277_308_335_R
1674277_204_232_F
2151 GLPF_NC003923- TGCACCGGCTATTAAGAATTACTTTG 491 GLPF_NC003923-1296927- TGCAACAATTAATGCTCCGACAATTAAA 1193
1296927- CCAACT 1297391_382_414_R GGATT
1297391_270_301_F
2152 GLPF_NC003923- TGGATGGGGATTAGCGGTTACAATG 558 GLPF_NC003923-1296927- TAAAGACACCGCTGGGTTTAAATGTGCA 850
1296927- 1297391_81 _108_R
1297391_27_51_F
2153 GLPF_NC003923- TAGCTGGCGCGAAATTAGGTGT 218 GLPF_NC003923-1296927- TCACCGATAAATAAAATACCTAAAGTTA 972
1296927- 1297391_323_359_R ATGCCATTG
1297391_239_260_F
2154 GMK_NC003923- TACTTTTTTAAAACTAOGGATGCGTT 200 GMK_NC003923-1190906- TGATATTGAACTGGTGTACCATAATAGT 1180
1190906- TGAAGC 1191334_166_197_R TGCC
1191334_91_122_F
2155 GMK_NC003923- TGAAGTAGAAGGTGCAAAGCAAGTTA 435 GMK_14C003923-1190906- TCGCTCTCTCAAGTGATCTAAACTTGGA 1082
1190906- GA 1191334_305_333_R G
1191334_240_267_F
2156 GMK_NC003923- TCACCTCCAAGTTTAGATCACTTGAG 288 GMK_NC003923-1190908- TGGGACGTAATCGTATAAATTCATCATT 1284
1190906- AGA 1191334_403_432_R TC
1191334_301_329_F
2157 PTA_NC003923- TCTTGTTTATGCTGGTAAAGCAGATG 418 PTA_NC003923-628885- TGGTACACCTGGTTTCGTTTTGATGATT 1301
628885- G 629355_314_345_R TGTA
629355_237_263_F
2158 PTA_NC003923- TGAATTAGTTCAATCATTTGTTGAAC 439 PTA_NC003923-628885- TGCATTGTACCGAAGTAGTTCACATTGT 1207
628885- GACGT 629355_211_239_R T
629355_141_171_F
2159 PTA_NC003923- TCCAAACCAGGTGTATCAAGAACATC 303 PTA_NC003923-628885- TGTTCTGGATTGATTGCACAATCACCAA 1349
628885- AGG 629355_393_422_R AG
629355_328_356_F
2160 TPI_NC003923- TGCAAGTTAAGAAAGCTGTTGCAGGT 486 TPI_NC003923-830671- TGAGATGTTGATGATTTACCAGTTCCGA 1165
830671- TTAT 831072_209_239_R TTG
831072_131_160_F
2161 TPI_NC003923- TCCCACGAAACAGATGAAGAAATTAA 318 TPI_NC003923-830671- TGGTACAACATCGTTAGCTTTACCACTT 1300
830671- CAAAAAAG 831072_97_129_R TCACG
831072_1_34_F
2162 TPI_NC003923- TCAAACTGGGCAATCGGAACTGGTAA 246 TPI_NC003923-830671- TGGCAGCAATAGTTTGACGTACAAATGC 1275
830671- ATC 831072_253_286_R ACACAT
831072_199_227_F
2163 YQI_NC003923- TGAATTGCTGCTATGAAAGGTGGCTT 440 YQI_NC003923-378916- TCGCCAGCTAGCACGATGTCATTTTC 1076
378916- 379431_259_284_R
379431_142_167_F
2164 YQI_NC003923- TACAACATATTATTAAAGAGACGGGT 175 YQI_NC003923-378916- TTCGTGCTGGATTTTGTCCTTGTCCT 1388
378916- TTGAATCC 379431_120_145_R
379431_44_77_F
2165 YQI_NC003923- TCCAGCACGAATTGCTGCTATGAAAG 314 YQI_NC003923-378916- TCCAACCCAGAACCACATACTTTATTCA 997
378916- 379431_193_221_R C
379431_135_160_F
2166 YQI_NC003923- TAGCTGGCGGTATGGAGAATATGTCT 219 YQI_NC003923-378916- TCCATCTGTTAAACCATCATATACCATG 1013
378916- 379431_364_396_R CTATC
379431_275_300_F
2167 BLAZ_(1913827 . . . 19 TCCACTTATCGCAAATGGAAAATTAA 312 BLAZ_(1913827 . . . 1914672)— TGGCCACTTTTATCAGCAACCTTACAGT 1277
14672)_546_575_F GCAA 655_683_R C
2168 BLAZ_(1913827 . . . 19 TGCACTTATCGCAAATGGAAAATTAA 494 BLAZ_(1913827 . . . 1914672)— TAGTCTTTTGGAACACCGTCTTTAATTA 926
14672)_546_575_2_F GCAA 628_659_R AAGT
2169 BLAZ_(1913827 . . . 19 TGATACTTCAACGCCTGCTGCTTTC 467 BLAZ_(1913827 . . . 1914672)— TGGAACACCGTCTTTAATTAAAGTATCT 1263
14672)_507_531_F 622_651_R CC
2170 BLAZ_(1913827 . . . 19 TATACTTCAACGCCTGCTGCTTTC 232 BLAZ_(1913827 . . . 1914672)— TCTTTTCTTTGCTTAATTTTCCATTTGC 1145
14672)_508_531_F 553_583_R GAT
2171 BLAZ_(1913827 . . . 19 TGCAATTGCTTTAGTTTTAAGTGCAT 487 BLAZ_(1913827 . . . 1914672)— TTACTTCCTTACCACTTTTAGTATCTAA 1366
14672)_24_56_F GTAATTC 121_154_R AGCATA
2172 BLAZ_(1913827 . . . 19 TCCTTGCTTTAGTTTTAAGTGCATGT 351 BLAZ_(1913827 . . . 1914672)— TGGGGACTTCCTTACCACTTTTAGTATC 1289
14672)_26_58_F AATTCAA 127_157_R TAA
2173 BLAZ_NC002952- TCCACTTATCGCAAATGGAAAATTAA 312 BLAZ_NC002952-1913827- TGGCCACTTTTATCAGCAACCTTACAGT 1277
1913827- GCAA 1914672_655_683_R C
1914672_546_575_F
2174 BLAZ_NC002952- TGCACTTATCGCAAATGGAAAATTAA 494 BLAZ_NC002952-1913827- TAGTCTTTTGGAACACCGTCTTTAATTA 926
1913827- GCAA 1914672_628_659_R AAGT
1914672_546_575_2_F
2175 BLAZ_NC002952- TGATACTTCAACGCCTGCTGCTTTC 467 BLAZ_NC002952-1913827- TGGAACACCGTCTTTAATTAAAGTATCT 1263
1913827- 1914672_622_651_R CC
1914672_507_531_F
2176 BLAZ_NC002952- TATACTTCAACGCCTGCTGCTTTC 232 BLAZ_NC002952-1913827- TCTTTTCTTTGCTTAATTTTCCATTTGC 1145
1913827- 1914672_553_583_R GAT
1914672_08_531_F
2177 BLAZ_NC002952- TGCAATTGCTTTAGTTTTAAGTGCAT 487 BLAZ_NC002952-1913827- TTACTTCCTTACCACTTTTAGTATCTAA 1366
1913827- GTAATTC 1914672_121_154_R AGCATA
1914672_24_56_F
2178 BLAZ_NC002952- TCCTTGCTTTAOTTTTAAGTGCATGT 351 BLAZ_NC002952-1913827- TGGGGACTTCCTTACCACTTTTACTATC 1289
1913827- AATTCAA 1914672_127_157_R TAA
1914672_26_58_F
2247 TUFB_NC002758- TGTTGAACGTGGTCAAATCAAACTTC 643 TUFBNC002758-615038- TGTCACCAGCTTCAGCGTAGTCTAATAA 1321
615038- GTG 616222_793_820_R
616222_693_721_F
2248 TUFB_NC002758- TCGTGTTGAACGTGGTCAAATCAAAG 386 TUFB_NC002758-615038- TGTCACCAGCTTCAGCGTAGTCTAATAA 1321
615038- T 616222_793_820_R
616222_690_716_F
2249 TUFB_NC002758- TGAACGTGGTCAAATCAAAGTTGGTG 430 TUFB_NC002758-615038- TGTCACCAGCTTCAGCGTAGTCTAATAA 1321
615038- AAGA 616222_793_820_R
616222_696_725_F
2250 TUFB_NC002758- TCCCAGGTGACGATGTACCTGTAATC 320 TUFB_NC-02758-615038- TGGTTTGTCAGAATCACGTTCTGGAGTT 1311
615038- 616222_601_630_R GG
616222_488_513_F
2251 TUFB_NC002758- TGAAGGTGGACGTCACACTCCATTCT 433 TUFB_NC002758-615038- TAGGCATAACCATTTCAGTACCTTCTGG 922
615038- TC 616222_1030_1060_R TAA
616222_945_972_F
2252 TUFB_NC002758- TCCAATGCCACAAACTCGTGAACA 307 TUFB_NC002758-615038- TTCCATTTCAACTAATTCTAATAATTCT 1382
615038- 616222_424_459_R TCATCGTC
616222_333_356_F
2253 NUC_NC002758- TCCTGAAGCAAGTGCATTTACGA 342 NUC_NC002758-894288- TACGCTAAGCCACGTCCATATTTATCA 899
894288- 894974_483_509_R
894974_402_424_F
2254 NUC_NC002758- TCCTTATAGGGATGGCTATCAGTAAT 349 NUC_NC002758-894288- TGTTTGTGATGCATTTGCTGAGCTA 1354
894288- GTT 894974_165_189_R
894974_53_81_F
2255 NUC_NC002758- TCAGCAAATGCATCACAAACAGATAA 273 NUC_NC002758-894288- TAGTTGAAGTTGCACTATATACTGTTGG 928
894288- 894974_222_250_R A
894974_169_194_F
2256 NUC_NC002758- TACAAACCTCAACCAATCACATTCAC 174 NUC_NC002758-894288- TAAATCCACTTCCTTCACCCCCATAT 853
894288- ACTA 894974_396_421_R
894974_316_345_F
2270 RPOB_EC_3798_3821_1_ TCCCCACCCCTTCCCTCAAATCCA 566 RPOB_EC_3868_3895_R TCACCTCCTCCCACTTCACCCTCACCAT 979
F
2271 RPOB_EC_3789_3812_F TCACTTCCCCCCTCACCCCTTCCC 294 RPOB_EC_3860_3890_R TCGTCCCACTTAACCCTCACCATTTCCT 1107
CCA
2272 RPOB_EC_3789_3812_F TCACTTCCCCCCTCACCCCTTCCC 294 RPOB_EC_3860_3890_2_R TCCTCCCACTTAACCCTCACCATTTCCT 1102
CCA
2273 RPOB_EC_3789_3812_F TCACTTCCCCCCTCACCCCTTCCC 294 RPOB_EC_3862_3890_R TCCTCCCACTTAACCCTCACCATTTCCT 1106
G
2274 RPOB_EC_3789_3812_F TCACTTCCCCCCTCACCCCTTCGC 294 RPOB_EC_3862_3890_2_R TCCTCCCACTTAACCCTCACCATTTCCT 1101
C
2275 RPOB_EC_3793_3812_F TTCCCCCCTCACCCCTTCCC 674 RPOB_EC_3865_3890_R TCCTCCCACTTAACCCTCACCATTTC 1105
2276 RPCB_EC_3793_3812_F TTCCCCCCTCACCCCTTCCC 674 RPOB_EC_3865_3890_2_R TCCTCCCACTTAACCCTCACCATTTC 1100
2309 MUPR_X75439_1658_16 TCCTTTCATATATTATCCCATCCAAC 352 MUFR_X75439_1744_1773_R TCCCTTCCTTAATATCACAACCAAACCA 1030
89_F CTTCCT CT
2310 MUPR_X75439_1330_13 TTCCTCCTTTTCAAACCCACCCTT 669 MUPR_X75439_1413_1441_R TCACCTCCTCCTATATCAACAATACCAC 1171
53_F T
2312 MUPR_X75439_1314_13 TTTCCTCCTTTTCAAACCCACCCTT 704 MUPR_X75439_1381_1409_R TATATCAACAATACCACTTCCTTCTCAC 931
38_F T
2313 MUPR_X75439_2486_25 TAATTCCCCTCTTTCTCCCTTAAACA 172 MUPR_X75439_2548_2574_R TTAATCTCCCTCCCCAACTCAAATCCT 1360
16_F CCTTA
2314 MUPR_X75439_2547_25 TACCATTTCACTTCCCCACCCACATT 188 MUPR_X75439_2605_2630_R TCCTCCTCTCCAATCTCCCATATACC 1103
72_F
2315 MUPR_X75439_2666_26 TCCCTACAATACCCTTTATCAAATTT 513 MUPR_X75439_2711_2740_R TCACATATAAATCCAACAAATCCACCCA 981
96_F TAACA CT
2316 MUPR_X75439_2813_28 TAATCAACCATTCCAACATCAAATCC 165 MUPR_X75439_2867_2890_R TCTCCATTTTTCCCACCCTCTCTA 1127
43_F ATACC
2317 MUPR_X75439_884_914_ TCACATCCACTCCCCCTATATAACTC 447 MUPR_X75439_977_1007_R TCTACAATAACCACTCACCTTATCTCCC 1317
F TTCAC TTA
2318 CTXA_NC002505- TCCTCTTATCCCAACACCACACACTC 608 CTXA_NC002505-1568114- TCCTCCCTAACAAATCCCCTCTCACTTC 1109
1568114- ACT 1567341_194_221_R
1567341_114_142_F
2319 CTXA_NC002505- TCTTATCCCAACACCACACACTCACT 411 CTXA_NC002505-1568114- TCCTCCCTAACAAATCCCCTCTCACTTC 1109
1568114- ACT 1567341_194_221_R
1567341_117_145_F
2320 CTXA_NC002505- TCCTCTTATCCCAACACCACACACTC 608 CTXA_NC002505-1568114- TAACAAATCCCCTCTCACTTCCTCTTCC 855
1568114- ACT 1567341_186_214_R A
1567341_114_142_F
2321 CTXA_NC002505- TCTTATCCCAACACCACACACTCACT 411 CTXA_NC002505-1568114- TAACAAATCCCCTCTCACTTCCTCTTCC 855
1568114- ACT 1567341_186_214_R A
1567341_117_145_F
2322 CTXA_NC002505- ACCACACACTCACTACTTTCACCCAC 27 CTXA_NC002505-1568114- TCCCCTCTCACTTCCTCTTCCATCATCA 1027
1568114- CT 1567341_180_207_R
1567341_129_156_F
2323 CTXA_NC002505- TGCCAAGAGGACAGAGTGAGTACTTT 500 CTXA_NC002505-1568114- TAACAAATCCCGTCTGAGTTCCTCTTGC 855
1568114- GA 1567341_186_214_R A
1567341_122_49_F
2324 INV_U22457-74- TGCTTATTTACCTGCACTCCCACAAC 530 INV_U22457-74- TGACCCAAAGCTGAAAGCTTTACTG 1154
3772_831_858_F TG 3772_942_966_R
2325 INV_U22457-74- TGAATGCTTATTTACCTGCACTCCCA 438 INV_U22457-74- TAACTGACCCAAAGCTGAAAGCTTTACT 864
3772_827_857_F CAACT 3772_942_970_R G
2326 INV_U22457-74- TGCTGGTAACAGAGCCTTATAGGCGC 526 INV_U22457-74- TGGGTTGCGTTGCAGATTATCTTTACCA 1296
3772_1555_1581_F A 3772_619_1647_R A
2327 INV_U22457-74- TGGTAACAGAGCCTTATAGGCGCATA 598 INV_U22457-74- TCATAAGGGTTGCGTTGCAGATTATCTT 987
3772_1558_1585_F TG 3772_1622_1652_R TAC
2328 ASD_NC006570- TGAGGGTTTTATGCTTAAAGTTGGTT 459 ASD_NC006570-439714- TGATTCGATCATACGAGACATTAAAACT 1188
439714- TTATTGGTT 438608_54_84_R GAG
438608_937_F
2329 ASD_NC006570- TAAAGTTGGTTTTATTGGTTGGCGCG 149 ASD_EC006570-439714- TCAAAATCTTTTGATTCGATCATACGAG 948
439714- GA 438608_66_95_R AC
438608_18_45_F
2330 ASD_NC006570- TTAAAGTTGGTTTTATTGGTTGGCGC 647 ASD_NC006570-439714- TCCCAATCTTTTGATTCGATCATACGAG 1016
439714- GGA 438608_67_95_R A
438608_17_45_F
2331 ASD_NC006570- TTTTATGCTTAAAGTTGGTTTTATTG 709 ASD_NC006570-439714- TCTGCCTGAGATGTCGAAAAAAACGTTG 1128
439714- GTTGGG 438608_07_134_R
438608_9_40_F
2332 GALE_AF513299_171_2 TCAGCTAGACCTTTTAGGTAAAGCTA 280 GALE_AF513299_241_271_R TCTCACCTACAGCTTTAAAGCCAGCAAA 1122
00_F AGCT ATG
2333 GALE_AF513299_168_1 TTATCAGCTAGACCTTTTAGGTAAAG 658 GALE_AF513299_245_271_R TCTCACCTACAGCTTTAAAGCCAGCAA 1121
99_F CTAAGC
2334 GALE_AF513299_168_1 TTATCAGCTAGACCTTTTAGGTAAAG 658 GALE_AF513299_233_264_R TACAGCTTTAAAGCCAGCAAAATGAATT 883
99_F CTAAGC ACAG
2335 GALE_AF513299_169_1 TCCCAGCTAGACCTTTTAGGTAAAGC 319 GALE_AF513299_252_279_R TTCAACACTCTCACCTACAGCTTTAAAG 1374
98_F TAAG
2336 PLA_AF053945_7371_7 TTGAGAAGACATCCGGCTCACGTTAT 680 PLA_AF053945_7434_7468_R TACGTATGTAAATTCCGCAAAGACTTTG 900
403_F TATGGTA GCATTAG
2337 PLA_AF053945_7377_7 TGACATCCGGCTCACGTTATTATGGT 443 PLA_AF053945_7428_7455_R TCCGCAAAGACTTTGGCATTAGGTGTGA 1035
403_F A
2338 PLA_AF053945_7377_7 TGACATCCGGCTCACGTTATTATGGT 444 PLA_AF05394S_7430_7460_R TAAATTCCGCAAAGACTTTGGCATTAGG 854
404_F AC TGT
2339 CAF_AF053947_33412_ TCCGTTATCGCCATTGCATTATTTGG 329 CAF_AF053947_33498_33523_ TAAGAGTGATGCGGGCTGGTTCAACA 866
33441_F AACT R
2340 CAF_AF053947_33426_ TGCATTATTTGGAACTATTGCAACTG 499 CAF_AF053947_33483_33507_ TGGTTCAACAAGAGTTGCCGTTGCA 1308
33458_F CTAATGC R
2341 CAF_AF053947_33407 TCAGTTCCGTTATCGCCATTGCA 291 CAF_AF053947_33483_33504_ TTCAACAAGAGTTGCCGTTGCA 1373
33429_F R
2342 CAF_AF053947_33407 TCAGTTCCGTTATCGCCATTGCATT 293 CAF_AF053947_33494_33517_ TGATGCGGGCTGGTTCAACAAGAG 1184
33431_F R
2344 GAPA_NC_002505_1_28_ TCAATGAACGATCAACAAGTGATTGA 260 GAPA_NC_002505_29_58_R_1 TCCTTTATGCAACTTGGTATCALCAGGA 1060
F_1 TG AT
2472 OMPA_NC000117_68_89_ TGCCTGTAGGGAATCCTGCTGA 507 OMPA_NC000117_145_167_R TCACACCAAGTAGTGCAAGGATC 967
F
2473 OMPA_NC000117_798_8 TGATTACCATGAGTGGCAAGCAAG 475 OMPA_NC000117_865_893_R TCAAAACTTGCTCTAGACCATTTAACTC 947
21_F C
2474 OMPA_NC000117_645_6 TGCTCAATCTAAACCTAAAGTCGAAG 521 OMPA_NC000117_757_777_R TGTCGCAGCATCTGTTCCTGC 1328
71_F A
2475 OMPA_NC000117_947_9 TAACTGCATGGAACCCTTCTTTACTA 157 OMPA_NC000117_1011_1040_R TGACAGGACACAATCTGCATGAAGTCTG 1153
73_F C AG
2476 OMPA_NC000117_774_7 TACTGGAACAAAGTCTGCGACC 196 OMPA_NC000117_871_894_R TTCAAAAGTTGCTCGAGACCATTG 1371
95_F
2477 OMPA_NC000117_457_4 TTCTATCTCGTTGGTTTATTCGGAGT 676 OMPA_NC000117_511_534_R TAAAGAGACGTTTGGTAGTTCATTTGC 851
83_F T
2478 OMPA_NC000117_687_7 TAGCCCAGCACAATTTGTGATTCA 212 OMPA_NC000117_787_816_R TTGCCATTCATGGTATTTAAGTGTAGCA 1406
10_F GA
2479 OMPA_NC000117_540_5 TGGCGTAGTAGAGCTATTTACAGACA 571 OMPA_NC000117_649_672_R TTCTTGAACGCGAGGTTTCGATTG 1395
66_F C
2480 OMPA_NC000117_338_3 TGCACGATGCGGAACGGTTCACA 492 OMPA_NC000117_417_444_R TCCTTTAAAATAACCGCTAGTAGCTCCT 1058
60_F
2481 OMP2_NC000117_1840_ TATGACCAAACTCATCAGACGAG 234 OMP2_NC000117_71_91_R TCCCGCTGGCAAATAAACTCG 1025
F
2482 OMP2_NC000117_354_3 TGCTACGGTAGGATCTCCTTATCCTA 516 OMP2_NC000117_445_471_ TGGATCACTGCTTACGAACTCAGCTTC 1270
82_F TTG
2483 OMP2_NC000117_1297 TGGAAAGGTGTTGCAGCTACTCA 537 OMP2_NC000117_1396_1419_R TACGTTTGTATCTTCTCCAGAACC 903
1319_F
2484 OMP2_NC00011714_65 TCTGGTCCAACAAAAGGAACGATTAC 407 OMP2_NC000117_1541_1569_R TCCTTTCAATGTTACAGAAAACTCTACA 1062
1493_F AGG G
2485 OMP2_NC000117_44_66 TGACGATCTTCGCGGTGACTAGT 450 OMP2_NC000117_120_148_R TGTCAGCTAAGCTAATAACGTTTGTAGA 1323
F G
2486 OMP2_NC000117_166_1 TGACAGCGAAGAAGGTTAGACTTGTC 441 OMP2_NC000117_240_261_R TTGACATCGTCCCTCTTCACAG 1396
90_F C
2487 GYRA_NC000117_514_5 TCAGGCATTGCGCTTGGGATGGC 287 GYRA_NC000117_640_660_R TGCTGTAGGGAAATCAGGGCC 1251
36_F
2488 GYRA_NC000117_801_8 TGTGAATAAATCACGATTGATTGAGC 636 GYRA_NC000117_871_893_R TTGTCAGACTCATCGCGAACATC 1419
27_F A
2489 GYRA_NC002952_219_2 TGTCATGGGTAAATATCACCCTCA 632 GYRA_NC002952_319_345_R TCCATCCATAGAACCAAAGTTACCTTG 1010
42_F
2490 GYRA_NC002952_964_9 TACAAGCACTCCCAGCTGCA 176 GYRA_NC002952_1024_1041_R TCGCAGCGTGCGTGGCAC 1073
83_F
2491 GYRA_NC002952_1505_ TCGCCCGCGAGGACGT 366 GYRA_NC002952_1546_1562_R TTGGTGCGCTTGGCGTA 1416
1520_F
2492 GYRA_NC002952_59_81_ TCAGCTACATCGACTATGCGATG 279 GYRA_NC002952_124_143_R TGGCGATGCACTGGCTTGAG 1279
F
2493 GYRA_NC002952_216_2 TGACGTCATCGGTAAGTACCACCC 452 GYRA_NC002952_313_333_R TCCGAAGTTGCCCTGGCCGTC 1032
39_F
2494 GYRA_NC002952_219_2 TGTACTCGGTAAGTATCACCCGCA 625 GYRA_NC002952_308_330_R TAAGTTACCTTGCCCGTCAACCA 873
422_F
2495 GYRA_NC002952_115_1 TGAGATGGATTTAAACCTGTTCACCG 453 GYRA_NC002952_220_242_R TGCGGGTGATACTTACCGAGTAC 1236
41_F C
2496 GYRA_NC002952_517_5 TCAGGCATTGCGGTTGGGATGGC 287 GYRA_NC002952_643_663_R TGCTGTAGGGAAATCAGGGCC 1251
39_F
2497 GYRA_NC002952_273_2 TCGTATGGCTCAATGGTGGAG 380 GYRA_NC002952_338_360_R TGCGGCAGCACTATCACCATCCA 1234
93_F
2498 GYRA_NC000912_257_2 TGAGTAACTTCCACCCGCACGG 462 GYRA_NC000912_346_370_R TCGAGCCGAAGTTACCCTGTCCGTC 1067
78_F
2504 ARCC_NC003923- TAGTpGATpAGAACpTpGTAGGCpAC 229 ARCC_NC003923-2725050- TCpTpTpTpCpGTATAAAAAGGACpCpA 1116
2725050- pAATpCpCT 2724595_214_239P_R ATpTpGG
2724595_135_161P_F
2505 PTA_NC003923- TCTTGTpThTpATGCpTpGGTmGC 417 PTA_NC003923-628885- TACpACpCpTGGTpTpTpCpGTpTpTpT 904
628885- AGATGC 629355_314_342P_R pGATGATpTpTpGTA
629355_237_263P_F
2517 CJMLST_ST1_1852_188 TTTGCGGATGAAGTAGGTGCCTATCT 708 CJMLST_ST1_1945_1977_R TGTTTTATGTGTAGTTGAGCTTACTACA 1355
3_F TTTTCC TGAGC
2518 CJMLST_ST1_2963_299 TGAAATTGCTACAGGCCCTTTAGGAC 428 CJMLST_ST1_3073_3097_R TCCCCATCTCCGCAAAGACAATAAA 1020
2_F AAGG
2519 CJMLST_ST1_2350_237 TGCTTTTGATGGTGATGCAGATCGTT 535 CJMLST_ST1_2447_2481_R TCTACAACACTTGATTGTAATTTGCCTT 1117
8_F TGG GTTCTTT
2520 CJMLST_ST1_654_684_ TATGTCCAAGAAGCATAGCAAAAAAA 240 CJMLST_ST1_725_756_R TCGGAAACAAAGAATTCATTTTCTGGTC 1084
F CCAAT CAAA
2521 CJMLST_ST1_360_395_ TCCTGTTATTCCTGAAGTAGTTAATC 347 CJMLST_ST1_454_487_R TGCTATATGCTACAACTGGTTCAAAAAC 1245
F AAGTTTGTTA ATTAAG
2522 CJMLST_ST1_1231_125 TGGCAGTTTTACAAGGTGCTGTTTCA 564 CJMLST_ST1_1312_1340_R TTTAGCTACTATTCTAGCTGCCATTTCC 1427
8_F TC A
2523 CJMLST_ST1_3543_357 TGCTGTAGCTTATCGCGAAATGTCTT 529 CJMLST_ST1_3656_3685_R TCAAAGAACCAGCACCTAATTCATCATT 950
4_F TGATTT TA
2524 CJMLST_ST1_1_17_F TAAAACTTTTGCCGTAATGATGGGTG 145 CJMLST_ST1_55_84_R TGTTCCAATAGCAGTTCCGCCCAAATTG 1348
AAGATAT AT
2525 CJMLST_ST1_1312_134 TGGAAATGGCAGCTAGAATAGTAGCT 538 CJMLST_ST1_1383_1417_R TTTCCCCGATCTAAATTTGGATAAGCCA 1432
2_F AAAAT TAGGAAA
2526 CJMLST_ST1_2254_228 TGGGCCTAATGGGCTTAATATCAATG 582 CJMLST_ST1_2352_2379_R TCCAAACGATCTGCATCACCATCAAAAG 996
6_F AAAATTG
2527 CJMLST_ST1_1380_141 TGCTTTCCTATGGCTTATCCAAATTT 534 CJMLST_ST1_1486_1520_R TGCATGAAGCATAAAAACTCTATCAAGT 1205
1_F AGATCG GCTTTTA
2528 CJMLST_ST1_3413_343 TTGTAAATGCCGCTGCTTCAGATCC 692 CJMLST_ST1_3511_3542_R TGCTTGCTCAAATCATCATAAACAATTA 1257
7_F AACC
2529 CJMLST_ST1_1130_115 TACGCGTCTTGAAGCGTTTCGTTATG 189 CJMLST_ST1_1203_1230_R TAGGATGAGCATTATCAGGGAAAGAATC 920
6_F A
2530 CJMLST_ST1_2840_287 TGGGGCTTTGCTTTATAGTTTTTTAC 591 CJMLST_ST1_2940_2973_R TAGCGATTTCTACTCCTAGAGTTGAAAT 917
2_F ATTTAAG TTCAGG
2531 CJMLST_ST1_2058_208 TATTCAAGGTGGTCCTTTGATGCATG 241 CJMLST_ST1_2131_2162_R TTGGTTCTTACTTSTTTTGCATAAACTT 1417
4_F T TCCA
2532 CJMLST_ST1_553_585_ TCCTGATGCTCAAAGTGCTTTTTTAG 344 CJMLST_ST1_655_685_R TATTGCTTTTTTTGCTATGCTTCTTGGA 642
F ATCCTTT CAT
2564 GLTA_NC002163- TCATGTTGAGCTTAAACCTATAGAAG 299 GLTA_NC002163-1604930- TTTTGCTCATGATCTGCATGAAGCATAA 1443
1604930- TAAAAGC 1604529_352_380_R A
1604529_306_338_F
2565 UNCA_NC002163- TCCCCCACGCTTTAATTGTTTATGAT 322 UNCA_NC002163-112166- TCGACCTGGAGGACGACGTAAAATCA 1065
112166- GATTTGAG 112647_146_171_R
112647_80_113_F
2566 UNCA_NC002163- TAATGATGAATTAGGTGCGGGTTCTT 170 UNCA_NC002163-112166- TGGGATAACATTGGTTGGAATATAAGCA 1285
112166- T 112647_294_329_R GAAACATC
112647_233_259_F
2567 PGM_NC002163- TCTTGATACTTGTAATGTGGGCGATA 414 PGM_NC002163-327773- TCCATCGCCAGTTTTTGCATAATCGCTA 1012
327773- AATATGT 328270_365_396_R AAAA
328270_273_305_F
2568 TKT_NC002163- TTATGAAGCGTGTTCTTTAGCAGGAC 661 TKT_NC002163-1569415- TCAAAACGCATTTTTACATCTTCGTTAA 946
1569415- TTCA 1569873_350_383_R AGGCTA
1569873_255_284_F
2570 GLTA_NC002163- TCGTCTTTTTGATTCTTTCCCTGATA 381 GLTANC002_163-1604930- TGTTCATGTTTAAATGATCAGGATAAAA 1347
1604930- ATGC 1604529_109_142_R AGCACT
1604529_39_68_F
2571 TKT_NC002163- TGATCTTAAAAATTTCCGCCAACTTC 472 TKT_NC002163-1569415- TGCCATAGCAAAGCCTACAGCATT 1214
1569415- ATTC 1569903_139_162_R
1569903_33_62_F
2572 TKT_NC002163- TAAGGTTTATTGTCTTTGTGGAGATG 164 TKT_NC002163-1569415- TACATCTCCTTCGATAGAAATTTCATTG 886
1569415- GGGATTT 1569903_313_345_R CTATC
1569903_207_239_F
2573 TKT_NC002163- TAGCCTTTAACGAAAATGTAAAAATG 213 TKT_NC002163-1569415- TAAGACAAGGTTTTGTGGATTTTTTAGC 865
1569415- CGTTTTGA 1569903_449_481_R TTGTT
1569903_350_383_F
2574 TKT_NC002163- TTCAAAAACTCCAGGCCATCCTGAAA 665 TKT_NC002163-1569415- TTGCCATAGCAAAGCCTACAGCATT 1405
1569415- TTTCAAC 1569903_139_163_R
1569903_60_92_F
2575 GLTA_NC002163- TCGTCTTTTTGATTCTTTCCCTGATA 382 GLTA_NC002163-1604930- TGCCATTTCCATGTACTCTTCTCTAACA 1216
1604930- ATGCTC 1604529_139_168_R TT
1604529_39_70_F
2576 GLYA_NC002163- TCAGCTATTTTTCCAGGTATCCAAGG 281 GLYA_NC002_163-367572- ATTGCTTCTTACTTGCTTAGCATAAATT 756
367572- TGG 368079_476_508_R TTCCA
368079_386_414_F
2577 GLYA_NC002163- TGGTGCGAGTGCTTATGCTCGTATTA 611 GLYA_NC002163-367572- TGCTCACCTGCTACAACAAGTCCAGCAA 1246
367572- T 368079_242_270_R T
368079_148_174_F
2578 GLYA_NC002163- TGTAAGCTCTACAACCCACAAAACCT 622 GLYA_NC002163-367572 - TTCCACCTTGGATACCTGGAAAAATAGC 1381
367572- TACG 368079_384_416_R TGAAT
368079_298_327_F
2579 GLYA_NC002163- TGGTGGACATTTAACACATGGTGCAA 614 GLYA_NC002163-367572- TCAAGCTCTACACCATAAAAAAGCTCT 961
367572- A 368079_52_91_R CA
368079_1_27_F
2580 PGM_NC002163- TGAGCAATGGGGCTTTGAAAGAATTT 455 PGM_NC002163-327746- TTTGCTCTCCGCCAAAGTTTCCAC 1438
327746- TTAAAT 328270_356_379_R
328270_254_285_F
2581 PGM_NC002163- TGAAAAGGGTGAAGTAGCAAATGGAG 425 PGK_NC002163-327746- TGCCCCATTGCTCATGATAGTAGCTAC 1219
327746- ATAG 328270_241_267_R
328270_153_182_F
2582 PGM_NC002163- TGGCCTAATGGGCTTAATATCAATGA 568 PGM_NC002163-327746- TGCACGCAAACGCTTTACTTCAGC 1200
327746- AAATTG 328270_79_102_R
328270_19_50_F
2583 UNCA_NC002163- TAAGCATGCTGTGGCTTATCGTGAAA 160 UNCA_NC002163-112166- TGCCCTTTCTAAAAGTCTTGAGTGAAGA 1220
112186- TG 112647_196_225_R TA
112647_114_141_F
2584 UNCA_NC002163- TGCTTCGGATCCAGCAGCACTTCAAT 532 UNCA_NC0O2163-112166- TGCATGCTTACTCAAATCATCATAAACA 1206
112166- A 112647_88_123_R ATTAAAGC
112647_3_29_F
2585 ASPA_NC002163- TTAATTTGCCAAAAATGCAACCAGGT 652 ASPA_NC002163-96692- TGCAAAAGTAACGGTTACATCTGCTCCA 1192
96692- AG 97166_403_432_R AT
97166_308_335_F
2586 ASPA_NC002163- TCGCGTTGCAACAAAACTTTCTAAAG 370 ASPA_NC002163-96692- TCATGATAGAACTACCTGGTTGCATTTT 991
96692- TATGT 97166_916_346_R TGG
97166_228_258_F
2587 GLNA_NC002163- TGGAATGATGATAAAGATTTCGCAGA 547 GLNA_NC002163-658085- TGAGTTTGAACCATTTCAGAGCGAATAT 1176
658085- TAGCTA 657609_340_371_R CTAC
657609_244_275_F
2588 TKT_NC002163- TCGCTACAGGCCCTTTAGGACAAG 371 TKTNC002163-1569415- TCCCCATCTCCGCAAAGACAATAAA 1020
1569415- 1569903_212_236_R
1569903_107_130_F
2589 TKT_NC002163- TGTTCTTTAGCAGGACTTCACAAACT 642 TKT_NC002163-1569415- TCCTTGTGCTTCAAAACGCATTTTTACA 1057
1569415- TGATAA 1569903_361_393_R TTTTC
1569903_265_296_F
2590 GLYA_NC002163- TGCCTATCTTTTTGCTGATATAGCAC 505 GLYA_NC002163-367572- TCCTCTTGGGCCACGCAAAGTTTT 1047
367572- ATATTGC 368095_917_340_R
368095_214_246_F
2591 GLYA_NC002163- TCCTTTGATGCATGTAATTGCTGCAA 353 GLYA_NC002163-367572- TCTTGAGCATTGGTTCTTACTTGTTTTG 1141
367572- AAGC 368095_485_516_R CATA
368095_415_444_F
2592 PGM_NC002163_21_54_ TCCTAATGGACTTAATATCAATGAAA 332 PGM_NC002163_116_142_R TCAAACGATCCGCATCACCATCAAAAG 949
F ATTGTGGA
2593 PGM_NC002163_149_17 TAGATGAAAAAGGCGAAGTGGCTAAT 207 PGM_NC002163_247_277R TCCCCTTTAAAGCACCATTACTCATTAT 1023
6_F CC ACT
2594 GLNA_NC002163- TCTCCAACAAGCATACCAAAAAACC 633 GLNA_NC002163-658085- TCAAAAACAAACAATTCATTTTCTGGTC 945
658085- AA 657609_148_179_R CAAA
657609_79_106_F
2595 ASPA_NC002163- TCCTCTTATTCCTGAACTACTTTTTC 347 ASPA_NC002163-96685- TCAAGCTATATGCTACAACTCGTTC~ 960
96685- AACTTTCTTA 97196_467_497_R AAC
97196_367_402_F
ASPA_NC002163- TGCCCTAATCATACCTCAACATATAC 502 ASPA_NC002163-96685- TACAACCTTCCGATAATCAGGATCACAA 880
96685-97196_133_F AAAGACT 97196_95_127_R TTAAT
2597 ASPA_NC002163- TGGAACACGAATTAATTCTCATCCTC 540 ASPA_NC002163-96685- TAAGCTCCCGTATCTTGAGTCGCCTC 872
96685- ATTATCC 97196_185_210_R
97196_85_117_F
2598 PGM_NC002163- TGGCAGCTAGAATAGTAGCTAAAATC 563 PGM_NC0021_63-327746- TCACGATCTAAATTTGGATAAGCCATAG 975
327746- CCTAC 328270_930_261_R GAAA
328270_165_195_F
2599 PGM_NC002163- TGGGTCGTGGTTTTACAGAAAATTTC 593 PGM_NC002163-327746- TTTTGCTCATGATCTGCATGAAGCATAA 1443
327746- TTATATATG 328270_953_381_R A
328270_952_286_F
2600 PGM_NC002163- TGGGATGAAAAAGCGTTCTTTTATCC 577 PGM_NC002163-327746- TGATAAAAAGCACTAAGCGATGAAACAG 1178
327746- ATGA 328270_95_123_R C
328270_1_30_F
2601 PGM_NC002163- TAAACACGGCTTTCCTATGGCTTATC 146 PGM_NC002163-327746- TCAAGTGCTTTTACTTCTATAGGTTTAA 963
327746- CAAAT 328270_314_345_R GGTG
328270_220_250_F
2602 UNCA_NC002163- TGTAGCTTATCGCGAAATGTCTTTGA 628 UNCA_NC002163-112166 - TGCTTGCTCTTTCAAGCAGTCTTGAATG 1258
112166- TTTT 112647_199_229_R AAG
112647_123_152_F
2603 UNCA_NC002163- TCCAGATGGACAAATTTTCTTAGAAA 313 UNCA_NC002163-112166- TCCGAAACTTGTTTTGTAGCTTTAATTT 1031
112166- CTGATTT 112647_430_461_R GAGO
112647_333_965_F
2734 GYRA_AY291534_237_2 TCACCCTCATGGTGATTCAGCTGTTT 265 GYRA_AY291534_268_288_R TTGCGCCATACGTACCATCGT 1407
64_F AT
2735 GYRA_AY291534_224_2 TAATCGGTAAGTATCACCCTCATGGT 167 GYRA_AY291534_256_285_R TGCCATACGTACCATCGTTTCATAAACA 1213
52_F PAT PC
2736 GYRA_AY291534_170_1 TAGGAATTACGGCTGATAAAGCGTAT 221 GYRA_AY291534_268_288_R TTGCGCCATACGTACCATCGT 1407
98_F AAA
2737 GYRA_AY291534_224_2 TAATCGGTAAGTATCACCCTCATGT 167 GYRA_AY291534_319_346_R TATCGACAGATCCAAAGTTACCATGCCC 935
52_F PAT
2738 GYRA_NC002953-7005- TAAGGTATGACACCGGATAAATCATA 163 GYRA_NC002953-7005- TCTTGAGCCATACGTACCATTGC 1142
9668_166_195_F TAAA 9668965_287_R
2739 GYRA_NC002953-7005- TAATGGGTAAATATCACCCTCATGGT 171 GYRA_NC002953-7005- TATCCATTGAACCAAAGGTACCTTGGCC 933
9668_221_249_F GAC 9668916_343_R
2740 GYRA_NC002953-7005- TAATGGGTAAATATCACCCTCATGGT 171 GYRA_NC0029_53-7005- TAGCCATACGTACCATTGCTTCATAAAT 912
9668_221_249_F GAG 9668_253_283_R APA
GYRA_NC002953-7005- TCACCCTCATGGTGACTCATCTATTT 264 GYRA_NC002953-7005- TCTTGAGCCATACGTACCATTGC 1142
9668_234_261_F AT 9668_265_287_R
2842 CAPC_AF188935- TGGGATTATTGTTATCCTGTTATGCC 578 CAPC_AF188935-56074- TGGTAACCCTTGTCTTTGAATTGTATTT 1299
56074- ATTTPAPA 55628_348_378_R PCA
55628_271_304_F
2843 CAPC_AF188935- TGATTATTGTTATCCTGTTATGCpCp 476 CAPC_AF188935-56074- TGTAACCCTTGTCTTTGAATpTpGTATp 1314
56074- ATpTpTpPAG 55628_349_377F_R TpTpGC
55628_273_303P_F
2844 CAPC_AF188935- TCCGTTGATTATTGTTATCCTGTTAT 331 CAPC_AF188935-56074- TGTTAATGGTAACCCTTGTGTTTGAATT 1344
56074- GCCATTTGAG 55628_349_384_R GTATTTGC
55628_268_303_F
2845 CAPC_AF188935- TCCGTTGATTATTGTTATCCTGTTAT 331 CAPC_AF188935-56074- TAACCCTTGTCTTTGAATTGTATTTGCA 860
56074- GCCATTTGAG 55628_937_375_R ATTAATCCTGG 860
55628_268_303_F
2846 PARC_X95819_33_58_F TCCAAAAAAATCAGCGCGTACAGTGG 302 PARC_X95819_121_153_R TAAAGGATAGCGGTAACTAAATGGCTGA 852
GCCAT
2847 PARC_X95819_65_92_F TACTTGGTAAATACCACCCACATGGT 199 PARC_X95819_157_178_R TACCCCAGTTCCCCTGACCTTC 889
GA
2848 PARC_X95819_69_93_F TGGTAAATACCACCCACATGGTGAC 596 PARC_X95819_97_128_R TGAGCCATGAGTACCATGGCTTCATAAC 1169
ATGC
2849 PARC_NC003997- TTCCGTAAGTCGGCTAAAACAGTCG 668 PARC_NC003997-3362578- TCCAAGTTTGACTTAAACGTACCATCGC 1001
3362578- 3365001_256_283_R
3365001_181_205_F
2850 PARC_NC003997- TGTAACTATCACCCGCACGGTGAT 621 PARC_NC003997-3362578- TCGTCAACACTACCATTATTACCATGCA 1099
3362578- 3365001_304_335_R TCTC
3365001_217_240_F
2851 PARC_NC003997- TGTAACTATCACCCGCACGGTGAT 621 PARC_NC003997-3362578- TGACTTAAACGTACCATCGCTTCATATA 1162
3362578- 3365001_244_275_R CAGA
3365001_217_240_F
2852 GYRA_AYE42140_- TAAATCTGCCCGTGTCGTTGGTGAC 150 OYRA_AY642140_71_100_R TGCTAAAGTCTTGAGCCATACGAACAAT 1242
1_24_F GG
2853 GYRA_AY642140_26_54_ TAATCGGTAAATATCACCCGCATGGT 166 GYRA_AY642140_121_146_R TCGATCGAACCGAAGTTACCCTGACC 1069
_F GAC
2854 GYRA_AY642140_26_54_ TARTCGGTAAATATCACCCGCATGGT 166 GYRA_AY642140_58_89_R TGAGCCATACGAACAATGGTTTCATAAA 1168
F GAC CAGC
2860 CYA_AF065404_348_1 TCCAACGAAGTACAATACARGACARA 305 CYA_AF065404_1448_1472_R TCAGCTGTTAACGGCTTCAAGACCC 983
379_F AGAAGG
2861 LEF_BA_AF065404_751_ TCGAAAGCTTTTGCATATTATATCGA 354 LEF_BA_AF065404_843_881_R TCTTTAAGTTCTTCCAAGGATAGATTTA 1144
781_F GCCAC TTTCTTGTTCG
2862 LEF_BA_AF065404_762_ TGCATATTATATCGAGCCACAGCATC 498 LEF_BA_AF065404_843_881_R TCTTTAAGTTCTTCCAAGGATAGATTTA 1144
788_F G TTTCTTGTTCG
2917 MUTS_AY698802_106_1 TCCGCTGAATCTGTCGCCGC 326 MUTS_AY698802_172_193_R TGCGGTCTGGCGCATATAGGTA 1237
25_F
2918 MUTS_AY698802_172_1 TACCTATATGCGCCAGACCGC 187 MUTS_AY698802_228_252_R TCAATCTCGACTTTTTGTGCCGGTA 965
92_F
2919 MUTS_AY698802_228_2 TACCGGCGCAAAAAGTCGAGATTGG 186 MUTS_AY698802_314_342_R TCGGTTTCAGTCATCTCCACCATAAAGG 1097
52_F T
2920 NUTS_AY698802_315_3 TCTTTATGGTGGAGATGACTGAAACC 419 NUTS_AY698802_413_433_R TGCCAGCGACAGACCATCGTA 1210
42_F GA
2921 MUTS_AY698802_394_4 TGGGCGTGGAACGTCCAC 585 MUTS_AY698802_497_519_R TCCGGTAACTGGGTCAGCTCGAA 1040
11_F
2922 AB_MLST-11- TGGGCGATGCTGCgAAATGGTTAAAA 583 AB_MLST-11- TAGTATCACCACGTACACCCGGATCAGT 923
OIF007_991_1018_F GA OIF007_1110_1137_R
2927 GAPA_NC002505_694_9 TCAATGAACGACCAACAAGTGATTGA 259 GAPA_NC002505_29_58_R_1 TCCTTTATGCAACTTGGTATCARCAGGA 1060
21_F TG AT
2928 GAPA_NC002505_694_7 TCGATGAACGACCAACAAGTGATTGA 361 GAPA_NC002505_769_798_2_R TCCTTTATGCAACTTGGTATCAACCGGA 1061
21_2_F TG AT
2929 GAPA_NC002505_694_7 TCGATGAACGACCAACAAGTGATTGA 361 GAPA_NC002505_769_798_3_R TCCTTTATGCAACTTAGTATCAACCGGA 1059
21_2_F TG AT
2932 INFB_EC_1364_1394_F TTGCTCGTGGTGCACAAGTAACGGAT 688 INFB_EC_1439_1468_R TTGCTGCTTTCGCATGGTTAATCGCTTC 1410
ATTAC AA
2933 INFB_EC_1364_1394_2_ TTGCTCGTGGTGCAIAAGTAACGGAT 689 INFB_EC_1439_1468_R TTGCTGCTTTCGCATGGTTAATCGCTTC 1410
F ATTAC AA
2934 INFB_EC_80_110_F TTGCCCGCGGTGCGGAAGTAACCGAT 685 INFB_EC_1439_1468_R TTGCTGCTTTCGCATGGTTAATCGCTTC 1410
ATTAC AA
2949 ACS_NC002516- TCGGCGCCTGCCTGATGA 376 ACS_NC002516-970624- TGGACCACGCCGAAGAACGG 1265
970624- 971013_364_383_R
971013_299_316_F
2950 ARO_NC002516-26883- TCACCGTGCCGTTCAAGGAAGAG 267 ARO_NC002516-26883- TGTGTTGTCGCCGCGCAG 1341
27380_4_26_F 27380_111_128_R
2951 ARO_NC002516-26883- TTTCGAAGGGCCTTTCGACCTG 705 ARO_NC002516-26883- TCCTTGGCATACATCATGTCGTAGCA 1056
27380_356_377_F 27380_459_484_R
2952 GUA_NC002516- TGGACTCCTCGGTGGTCGC 551 GUA_NC002516-4226546- TCGGCGAACATGGCCATCAC 1091
4226546- 4226174_127_146_R
4226174_23_41_F
2953 GUA_NC002516- TGACCAGGTGATGGCCATGTTCG 448 GUA_NC002516-4226546- TGCTTCTCTTCCGGGTCGGC 1256
4226546- 4226174_214_233_R
4226174_120_142_F
2954 GUA_NC002516- TTTTGAAGGTGATCCGTGCCAACG 710 GUA_NC002516-4226546- TGCTTGGTGGCTTCTTCGTCGAA 1259
4226546- 4226174_265_287_R
4226174_155_178_F
2955 GUA_NC002516- TTCCTCGGCCGCCTGGC 670 GUA_NC0102516-4226546- TGCGAGGAACTTCACGTCCTGC 1229
4226546- 4226174_288_309_R
4226174_190_206_F
2956 GUA_NC002516- TCGGCCGCACCTTCATCGAAGT 374 GUA_NC002516-4226546- TCGTGGGCCTTGCCGGT 1111
4226546- 4226174_355_371_R
4226174_242_263_F
2957 MUT_NC002516- TGGAAGTCATCAAGCGCCTGGC 545 MUT_NC002516-5551158- TCACGGGCCAGCTCGTCT 978
5551158- 5550717_99_116_R
5550717_5_26_F
2958 MUT_NC002516- TCGAGCAGCCGCTGCCG 358 MUT_NC002516-5551158- TCACCATGCGCCCGTTCACATA 971
5551158- 5550717_256_277_R
5550717_152_168_F
2959 NUO_NC002516- TCAACCTCGGCCCGAACCA 249 NUO_NC002516-2984589- TCGGTGGTGGTAGCCGATCTC 1095
2984589- 2984954_97_117_R
2984954_8_26_F
2960 NUO_NC002516- TACTCTCGGTGGAGAAGCTCGC 195 NUO_NC002516-2984589- TTCAGGTACAGCAGGTGGTTCAGGAT 1376
2984589- 2984954_301_326_R
2984954_218_239_F
3961 PPS_NC002516- TCCACGGTCATGGAGCGCTA 311 PPS_NC002516-1915014- TCCATTTCCGACACGTCGTTGATCAC 1014
1915014- 1915383_140_165_R
1915383_44_63_F
2962 PPS_NC002516- TCGCCATCGTCACCAACCG 365 PPS_NC002516-1915014- TCCTGGCCATCCTGCAGGAT 1052
1915014- 1915383_341_360_R
1915383_240_258_F
2963 TRP_NC002516- TGCTGGTACGGGTCGAGGA 527 TRP_NC002516-671831- TCGATCTCCTTGGCGTCCGA 1071
671831- 672273_131 150_R
672273_24_42_F
2964 TRF_NC002516- TGCACATCGTGTCCAACGTCAC 490 TRP_NC002516-671831- TGATCTCCATGGCGCGGATCTT 1182
671831- 672273_362_383_R
672273_261_282_F
2972 ABD_MLST-11- TGGGIGATGCTGCIAAATGGTTAAAA 592 AB_MLST-11- TAGTATCACCACGTACICCIGGATCAGT 924
OIF007_1007_1034_F GA OIF007_126_1153_R
2993 OMPU_NC002505- TTCCCACCGATATCATGGCTTACCAC 667 OMPU_NC002505_544_567_R TCGGTCAGCAAAACGGTAGCTTGC 1094
674828- GG
675880_428_455_F
2994 GAPA_NC002505- TCCTCAATGAACGAICAACAAGTGAT 335 GAPA_NC002505-506780- TTTTCCCTTTAAGCAACTTAGTATCAAC 1442
506780- TGATG 507937_769_802_R IGGAAT
507937_691_721_F
2995 GAPA_NC002505- TCCTCIATGAACGAICAACAAGTGAT 339 GAPA_NC002_505-506780- TCCATACCTTTATGCAACTTIGTATCAA 1008
506780- TGATG 507937_769_803_R CIGGAAT
507937_691_721_2_F
2996 GAPA_NC002505- TCTCGATGAACGACCAACAAGTGATT 396 GAPA_NC002505-506780- TCGGAAATATTCTTTCAATACCTTTATG 1085
506780- GATG 507937_785_817_R CAACT
507937_692_721_F
2997 GAPA_NC002505- TCCTCGATGAACGAICAACAAGTIAT 337 GAPA_NC002505-506780- TCGGAAATATTCTTTCAATACCTTTATG 1085
506780- TGATG 507937_785_817_R CAACT
507937_691_721_3_F
2998 GAPA_50002505- TCCTCAATGAATGATCAACAAGTGAT 336 GAPA_NC002505-506780- TCGGAAATATTCTTTCAATICCTTTITG 1087
506780- TGATG 507937_784_817_R CAACTT
507937_691_721_4_F
2999 GAPA_NC002505- TCCTCIATGAAIGAICAACAAGTIAT 340 GAPA_NC002505-506780- TCGGAAATATTCTTTCAATACCTTTATG 1086
506780- TGATG 507937_784_817_2_R CAACTT
507937_691_721_5_F
3000 GAPA_NC002505- TCCTCGATGAATGAICAACAAGTIAT 338 PAPA_NC002505-506780- TTTGAATACCTTTATGCAACTTIGTATG 1430
506780- TGATG 507937_769_805_R AACIGGAAT
507937_691_721_6_F
3001 CTXB_NC002505- TCAGCATATGCACATGGAACACCTCA 275 CTXB_NC002505-1566967- TCCCGGCTAGAGATTCTGTATACGA 1026
1566967- 1567341_139_163_R
1567341_46_71_F
3002 CTXB_NC002505- TCAGCATATGCACATGGAACACCTC 274 CTXB_NC002505-1566967- TCCGGCTAGAGATTCTGTATAAAAT 1038
1566967- 1567341_132_162_R ATG
1567341_46_70_F
3003 CTXB_NC002505- TCAGCATATGCACATGGAACACCTC 274 CTXB_NC002_505-1566967- TGCCGTATACGAAAATATCTTATCATTT 1225
1566967- 1567341_118_150_R AGGCT
1567341_46_70_F
3004 TUFB_NC002758- TACAGGCCGTGTTGAACGTGG 180 TUFB_NC002758-615038- TCAGCGTAGTCTAATAATTTACGGAACA 982
615038- 616222_778_809_R TTTC
616222_684_704_F
3005 TUFB_50002758- TGCCGTGTTGAACGTGGTCAAAT 503 TUFB_NC002758-615038- TGCTTCAGCGTAGTCTAATAATTTACGG 1255
615038- 616222_783_813_R AAC
616222_688_710_F
3006 TUFB_NC002758- TGTGGTCAAATCAAAGTTGGTGAAGA 638 TUFB_NC002758-615038- TGCGTAGTCTAATAATTTACGGAACATT 1238
615038- A 616222_778_807_R TC
616222_700_726_F
3007 TUFB_NC002758- TGGTCAAATCAAAGTTGGTGAAGAA 607 TUFB_NC002758-615038- TGCGTAGTCTAATAATTTACGGAACATT 1238
615038- 616222_778_807_R TC
616222_702_726_F
3008 TUFB_NCC002758- TGAACGTGGTCAAATCAAAGTTGGTG 431 TUFB_NC002758-615038- TCACCAGCTTCAGCGTAGTCTAATAATT 970
615038- AAGAA 616222_785_818_R TACGGA
616222_696_726_F
3009 TUFB_NC002758- TCGTGTTGAACGTGGTCAAATCAAAG 386 TUFB_NC002758-615038- TCTTCAGCGTAGTCTAATAATTTACGGA 1134
615038- T 616222_778_812_R ACATTTC
616222_690_716_F
3010 MECI-R_NC003923- TCACATATCGTGAGCAATGAACTC 261 MECI-R_NC003923-41798- TGTGATATGGAGGTGTAGAAGGTG 1332
41798-41609_36_59_F 41609_89_112_R
3011 MECI-R_NC003923- TGGGCGTGAGCAATGAACTGATTATA 584 MECI-R_NC003923-41798- TGGCATGGAGGTGTAGAAGGTGTTATCA 1287
41798-41609_40_66_F C 41609_81_110_R TG
3012 MECI-R_140003923- TGGACACATATCGTGAGCAATGAACT 549 MECI-R_NC003923-41798- TGGGATGGAGGTGTAGAAGGTGTTATCA 1286
41798- GA 41609_81_110_R TG
41609_33_60_2_F
3013 MECI-R_NC003923- TCGGTTTACAGATATCGTGAGCAATG 595 MECI-R_NC003923-41798- TGGGGATATGGAGGTGTAGAAGGTGTTA 1290
41798-41609_29_60_F AACTGA 41609_81_113_R TGATG
3014 MUPR_X75439_2490_25 TGGGCTCTTTCTCGCTTAAACACCT 587 MUPR_X75439_2548_2570_R TCTGCCTGCGGAAGTGAAATCGT 1130
14_F
3015 MUPR_X75439_2490_25 TGGGCTCTTTCTCGCTTAAACACC 586 MUPR_X75439_2547_2568_R TGGCTGCGGAAGTGAAATCGTA 1281
13_F
3016 MUPR_X75439_2482_25 TAGATAATTGGGCTCTTTCTCGCTTA 205 MUPR_X75439_2551_2573_R TAATCTGGCTGCGGAAGTGAAAT 876
10_F AAC
3017 MUPR_X75439_2490_25 TGGGCTCTTTCTCGCTTAAACACCT 587 MUPR_X75439_2549_2573_R TAATCTGGCTGCGGAAGTGAAATCG 877
14_F
3018 MUPR_X75439_2482_25 TAGATAATTGGGCTCTTTCTCGGTTA 205 MUPR_X75439_2559_2589_ TGGTATATTCGTTAATTAATGTGGCTGC 1303
10_F AAC GGA
3019 MUPR_X75439_2490_25 TGGGCTCTTTCTCGCTTAAAGACCT 587 MUPR_X75439_2554_2581_R TCGTTAATTAATCTGGCTGCGGAAAGTGA 1112
14_F
3020 AROE_NC003923- TGATGGCAAGTGGATAGGGTATAATA 474 AROE_NC003923-1674726- TAAGCAATACCTTTACTTGCACCACCT 868
1674726- CAG 1674277_309_335_R
1674277_204_232_F
3021 AROE_NC003923- TGGCGAGTGGATAGGGTATAATACAG 570 AROE_NC003923-1674726- TTCATAAGCAATACCTTTACTTGCAGCA 1378
1674726- 1674277_311_339_R C
1674277_207_232_F
3022 AROE_NC003923- TGGCpAAGTpGGATpAGGGTpATpAA 572 AROE_NC003923-1674726- TAAGCAATACCpTpTpTpACTpTpGCpA 867
1674726- TpACpAG 1674277_311_335P_R CpCpAC
1674277_207_232P_F
3023 ARCC_NC003923- TCTGAAATGAATAGTGATAGAACTGT 398 AROC_140003923-2725050- TCTTCTTCTTTCGTATAAAAAGGACCAA 1137
2725050- AGGCAC 2724595_214_245_R TTGG
2724595_124_155_F
3024 ARCC_NC003923- TGAATAGTGATAGAACTGTAGGCACA 437 ARCC_NC003923-2725050- TCTTCTTTCGTATAAAAAGGACCAATTG 1139
2725050- ATCGT 2724595_212_242_R GTT
2724595_131_161_F
3025 ARCC_NC003923- TGAATAGTGATAGAACTGTAGGCACA 437 ARCC_NC003923-2725050- TGCGCTAATTCTTCAACTTCTTCTTTCG 1232
2725050- ATCGT 2724595_232_260_R T
2724595_131_161_F
3026 PTA_NC003923- TACAATGCTTGTTTATGCTGGTAAAG 177 PTA_NC003923-628885- TGTTCTTGATACACCTGGTTTCGTTTTG 1350
628885- CAG 629355_322_351_R AT
629355_231_259_F
3027 PTA_NC003923- TACAATGCTTGTTTATGCTGGTAAAG 177 PTA_NC003923-628885- TGGTACACCTGGTTTCGTTTTGATGATT 1301
628885- CAG 629355_314_345_R TGTA
629355_231_259_F
3028 PTA_NC003923- TCTTGTTTATGCTGGTAAAGCAGATG 418 PTA_NC003923-628885- TCTTCTTGATACACCTGGTTTCGTTTTG 1350
628885- G 629355_322_351_R AT
629355_237_263_F
Primer pair name codes and reference sequences are shown in Table 3. The primer name code typically represents the gene to which the given primer pair is targeted. The primer pair name may include specific coordinates with respect to a reference sequence defined by an extraction of a section of sequence or defined by a GenBank gi number, or the corresponding complementary sequence of the extraction, or the entire GenBank gi number as indicated by the label “no extraction.” Where “no extraction” is indicated for a reference sequence, the coordinates of a primer pair named to the reference sequence are with respect to the GenBank gi listing. Gene abbreviations are shown in bold type in the “Gene Name” column.
To determine the exact primer hybridization coordinates of a given pair of primers on a given bioagent nucleic acid sequence and to determine the sequences, molecular masses and base compositions of an amplification product to be obtained upon amplification of nucleic acid of a known bioagent with known sequence information in the region of interest with a given pair of primers, one with ordinary skill in bioinformatics is capable of obtaining alignments of the primers of the present invention with the GenBank gi number of the relevant nucleic acid sequence of the known bioagent. For example, the reference sequence GenBank gi numbers (Table 3) provide the identities of the sequences which can be obtained from GenBank. Alignments can be done using a bioinformatics tool such as BLASTn provided to the public by NCBI (Bethesda, Md.). Alternatively, a relevant GenBank sequence may be downloaded and imported into custom programmed or commercially available bioinformatics programs wherein the alignment can be carried out to determine the primer hybridization coordinates and the sequences, molecular masses and base compositions of the amplification product. For example, to obtain the hybridization coordinates of primer pair number 2095 (SEQ ID NOs: 456:1261), First the forward primer (SEQ ID NO: 456) is subjected to a BLASTn search on the publicly available NCBI BLAST website. “RefSeq_Genomic” is chosen as the BLAST database since the gi numbers refer to genomic sequences. The BLAST query is then performed. Among the top results returned is a match to GenBank gi number 21281729 (Accession Number NC—003923). The result shown below, indicates that the forward primer hybridizes to positions 1530282 . . . 1530307 of the genomic sequence of Staphylococcus aureus subsp. aureus MW2 (represented by gi number 21281729).
Staphylococcus aureus subsp. aureus MW2, complete
genome
Length = 2820462
Features in this part of subject sequence:
Panton-Valentine leukocidin chain F precursor
Score = 52.0 bits (26), Expect = 2e−05
Identities = 26/26 (100%), Gaps = 0/26 (0%)
Strand = Plus/Plus
Query 1 TGAGCTGCATCAACTGTATTGGATAG 26
||||||||||||||||||||||||||
Sbjct 1530282 TGAGCTGCATCAACTGTATTGGATAG 1530307
The hybridization coordinates of the reverse primer (SEQ ID NO: 1261) can be determined in a similar manner and thus, the bioagent identifying amplicon can be defined in terms of genomic coordinates. The query/subject arrangement of the result would be presented in Strand=Plus/Minus format because the reverse strand hybridizes to the reverse complement of the genomic sequence. HThe preceding sequence analyses are well known to one with ordinary skill in bioinformatics and thus, Table 3 contains sufficient information to determine the primer hybridization coordinates of any of the primers of Table 2 to the applicable reference sequences described therein. TABLE 3
Primer Name Codes and Reference Sequence
Reference
GenBank gi
Primer name code Gene Name Organism number
16S_EC 16S rRNA (16S ribosomal RNA gene) Escherichia coli 16127994
23S_EC 23S rRNA (23S ribosomal RNA gene) Escherichia coli 16127994
CAPC_BA capC (capsule biosynthesis gene) Bacillus anthracis 6470151
CYA_BA cya (cyclic AMP gene) Bacillus anthracis 4894216
DNAK_EC dnaK (chaperone dnaK gene) Escherichia coli 16127994
GROL_EC groL (chaperonin groL) Escherichia coli 16127994
HFLB_EC hflb (cell division protein peptidase Escherichia coli 16127994
ftsH)
INFB_EC infB (protein chain initiation factor Escherichia coli 16127994
infB gene)
LEF_BA lef (lethal factor) Bacillus anthracis 21392688
PAG_BA pag (protective antigen) Bacillus anthracis 21392688
RPLB_EC rplB (50S ribosomal protein L2) Escherichia coli 16127994
RPOB_EC rpoB (DNA-directed RNA polymerase beta Escherichia coli 6127994
chain)
RPOC_EC rpoC (DNA-directed RNA polymerase Escherichia coli 16127994
beta′ chain)
SP101ET_SPET_11 Artificial Sequence Concatenation Artificial 15674250
comprising: Sequence* -
gki (glucose kinase) partial gene
gtr (glutamine transporter protein) sequences of
murI (glutamate racemase) Streptococcus
mutS (DNA mismatch repair protein) pyogenes
xpt (xanthine phosphoribosyl
transferase)
yqiL (acetyl-CoA-acetyl transferase)
tkt (transketolase)
SSPE_BA sspE (small acid-soluble spore Bacillus anthracis 30253828
protein)
TUFB_EC tufB (Elongation factor Tu) Escherichia coli 16127994
VALS_EC valS (Valyl-tRNA synthetase) Escherichia coli 16127994
ASPS_EC aspS (Aspartyl-tRNA synthetase) Escherichia coli 16127994
CAF1_AF053947 caf1 (capsular protein caf1) Yersinia pestis 2996286
INV_U22457 inv (invasin) Yersinia pestis 1256565
LL_NC003143 Y. pestis specific chromosomal genes - Yersinia pestis 16120353
difference region
BONTA_X52066 BoNT/A (neurotoxin type A) Clostridium 40381
botulinum
MECA_Y14051 mecA methicillin resistance gene Staphylococcus 2791983
aureus
TRPE_AY094355 trpE (anthranilate synthase (large Acinetobacter 20853695
component)) baumanii
RECA_AF251469 recA (recombinase A) Acinetobacter 9965210
baumanii
GYRA_AF100557 gyrA (DNA gyrase subunit A) Acinetobacter 4240540
baumanii
GYRB_AB008700 gyrB (DNA gyrase subunit B) Acinetobacter 4514436
baumanii
WAAA_Z96925 waaA (3-deoxy-D-manno-octulosonic-acid Acinetobacter 2765828
transferase) baumanii
CJST_CJ Artificial Sequence Concatenation Artificial 15791399
comprising: Sequence* -
tkt (transketolase) partial gene
glyA (serine hydroxymethyltransferase) sequences of
gltA (citrate synthase) Campylobacter
aspA (aspartate ammonia lyase) jejuni
glnA (glutamine synthase)
pgm (phosphoglycerate mutase)
uncA (ATP synthetase alpha chain)
RNASEP_BDP RNase P (ribonuclease P) Bordetella 33591275
pertussis
RNASEP_BKM RNase P (ribonuclease P) Burkholderia 53723370
mallei
RNASEP_BS RNase P (ribonuclease P) Bacillus subtilis 16077068
RNASEP_CLB RNase P (ribonuclease P) Clostridium 18308982
perfringens
RNASEP_EC RNase P (ribonuclease P) Escherichia coli 16127994
RNASEP_RKP RNase P (ribonuclease P) Rickettsia 15603881
prowazekii
RNASEP_SA RNase P (ribonuclease P) Staphylococcus 15922990
aureus
RNASEP_VBC RNase P (ribonuclease P) Vibrio cholerae 15640032
ICD_CXB icd (isocitrate dehydrogenase) Coxiella burnetii 29732244
IS1111A multi-locus IS1111A insertion element Acinetobacter 29732244
baumannii
OMPA_AY485227 ompA (outer membrane protein A) Rickettsia 40287451
prowazekii
OMPB_RKP ompB (outer membrane protein B) Rickettsia 15603881
prowazekii
GLTA_RKP gltA (citrate synthase) Vibrio cholerae 15603881
TOXR_VBC toxR (transcription regulator toxR) Francisella 15640032
tularensis
ASD_FRT asd (Aspartate semialdehyde Francisella 56707187
dehydrogenase) tularensis
GALE_FRT galE (UDP-glucose 4-epimerase) Shigella flexneri 56707187
IPAH_SGF ipaH (invasion plasmid antigen) Campylobacter 30061571
jejuni
HUPB_CJ hupB (DNA-binding protein Hu-beta) Coxiella burnetii 15791399
AB_MLST Artificial Sequence Concatenation Artificial Sequenced
comprising: Sequence* - in-house
trpE (anthranilate synthase component partial gene (SEQ ID
I)) sequences of NO: 1444)
adk (adenylate kinase) Acinetobacter
mutY (adenine glycosylase) baumannii
fumC (fumarate hydratase)
efp (elongation factor p)
ppa (pyrophosphate phospho-
hydratase
MUPR_X75439 mupR (mupriocin resistance gene) Staphylococcus 438226
aureus
PARC_X95819 parC (topoisomerase IV) Acinetobacter 1212748
baumannii
SED_M28521 sed (enterotoxin D) Staphylococcus 1492109
aureus
PLA_AF053945 pla (plasminogen activator) Yersinia pestis 2996216
SEJ_AF053140 sej (enterotoxin J) Staphylococcus 3372540
aureus
GYRA_NC000912 gyrA (DNA gyrase subunit A) Mycoplasma 13507739
pneumoniae
ACS_NC002516 acsA (Acetyl CoA Synthase) Pseudomonas 15595198
aeruginosa
ARO_NC002516 aroE (shikimate 5-dehydrogenase Pseudomonas 15595198
aeruginosa
GUA_NC002516 guaA (GMP synthase) Pseudomonas 15595198
aeruginosa
MUT_NC002516 mutL (DNA mismatch repair protein) Pseudomonas 15595198
aeruginosa
NUO_NC002516 nuoD (NADH dehydrogenase I chain C, D) Pseudomonas 15595198
aeruginosa
PPS_NC002516 ppsA (Phosphoenolpyruvate synthase) Pseudomonas 15595198
aeruginosa
TRP_NC002516 trpE (Anthranilate synthetase Pseudomonas 15595198
component I) aeruginosa
OMP2_NC000117 ompB (outer membrane protein B) Chlamydia 15604717
trachomatis
OMPA_NC000117 ompA (outer membrane protein B) Chlamydia 15604717
trachomatis
GYRA_NC000117 gyrA (DNA gyrase subunit A) Chlamydia 15604717
trachomatis
CTXA_NC002505 ctxA (Cholera toxin A subunit) Vibrio cholerae 15640032
CTXB_NC002505 ctxB (Cholera toxin B subunit) Vibrio cholerae 15640032
FUR_NC002505 fur (ferric uptake regulator protein) Vibrio cholerae 15640032
GAPA_NC_002505 gapA (glyceraldehyde-3-phosphate Vibrio cholerae 15640032
dehydrogenase)
GYRB_NC002505 gyrB (DNA gyrase subunit B) Vibrio cholerae 15640032
OMPU_NC002505 ompU (outer membrane protein) Vibrio cholerae 15640032
TCPA_NC002505 tcpA (toxin-coregulated pilus) Vibrio cholerae 15640032
ASPA_NC002163 aspA (aspartate ammonia lyase) Campylobacter 15791399
jejuni
GLNA_NC002163 glnA (glutamine synthetase) Campylobacter 15791399
jejuni
GLTA_NC002163 gltA (glutamate synthase) Campylobacter 15791399
jejuni
GLYA_NC002163 glyA (serine hydroxymethyltransferase) Campylobacter 15791399
jejuni
PGM_NC002163 pgm (phosphoglyceromutase) Campylobacter 15791399
jejuni
TKT_NC002163 tkt (transketolase) Campylobacter 15791399
jejuni
UNCA_NC002163 uncA (ATP synthetase alpha chain) Campylobacter 15791399
jejuni
AGR-III_NC003923 agr-III (accessory gene regulator-III) Staphylococcus 21281729
aureus
ARCC_NC003923 arcC (carbamate kinase) Staphylococcus 21281729
aureus
AROE_NC003923 aroE (shikimate 5-dehydrogenase Staphylococcus 21281729
aureus
BSA-A_NC003923 bsa-a (glutathione peroxidase) Staphylococcus 21281729
aureus
BSA-B_NC003923 bsa-b (epidermin biosynthesis protein Staphylococcus 21281729
EpiB) aureus
GLPF_NC003923 glpF (glycerol transporter) Staphylococcus 21281729
aureus
GMK_NC003923 gmk (guanylate kinase) Staphylococcus 21281729
aureus
MECI-R_NC003923 mecR1 (truncated methicillin Staphylococcus 21281729
resistance protein) aureus
PTA_NC003923 pta (phosphate acetyltransferase) Staphylococcus 21281729
aureus
PVLUK_NC003923 pvluk (Panton-Valentine leukocidin Staphylococcus 21281729
chain F precursor) aureus
SA442_NC003923 sa442 gene Staphylococcus 21281729
aureus
SEA_NC003923 sea (staphylococcal enterotoxin A Staphylococcus 21281729
precursor) aureus
SEC_NC003923 sec4 (enterotoxin type C precursor) Staphylococcus 21281729
aureus
TPI_NC003923 tpi (triosephosphate isomerase) Staphylococcus 21281729
aureus
YQI_NC003923 yqi (acetyl-CoA C-acetyltransferase Staphylococcus 21281729
homologue) aureus
GALE_AF513299 galE (galactose epimerase) Francisella 23506418
tularensis
VVHA_NC004460 vVhA (cytotoxin, cytolysin precursor) Vibrio vulnificus 27366463
TDH_NC004605 tdh (thermostable direct hemolysin A) Vibrio 28899855
parahaemolyticus
AGR-II_NC002745 agr-II (accessory gene regulator-II) Staphylococcus 29165615
aureus
PARC_NC003997 parC (topoisomerase IV) Bacillus anthracis 30260195
GYRA_AY291534 gyrA (DNA gyrase subunit A) Bacillus anthracis 31323274
AGR-I_AJ617706 agr-I (accessory gene regulator-I) Staphylococcus 46019543
aureus
AGR-IV_AJ617711 agr-IV (accessory gene regulator-III) Staphylococcus 46019563
aureus
BLAZ_NC002952 blaZ (beta lactamase III) Staphylococcus 49482253
aureus
ERMA_NC002952 ermA (rRNA methyltransferase A) Staphylococcus 49482253
aureus
ERMB_Y13600 ermB (rRNA methyltransferase B) Staphylococcus 49482253
aureus
SEA-SEE_NC002952 sea (staphylococcal enterotoxin A Staphylococcus 49482253
precursor) aureus
SEA-SEE_NC002952 sea (staphylococcal enterotoxin A Staphylococcus 49482253
precursor) aureus
SEE_NC002952 sea (staphylococcal enterotoxin A Staphylococcus 49482253
precursor) aureus
SEH_NC002953 seh (staphylococcal enterotoxin H) Staphylococcus 49484912
aureus
ERMC_NC005908 ermC (rRNA methyltransferase C) Staphylococcus 49489772
aureus
MUTS_AY698802 mutS (DNA mismatch repair protein) Shigella boydii 52698233
NUC_NC002758 nuc (staphylococcal nuclease) Staphylococcus 57634611
aureus
SEB_NC002758 seb (enterotoxin type B precursor) Staphylococcus 57634611
aureus
SEG_NC002758 seg (staphylococcal enterotoxin G) Staphylococcus 57634611
aureus
SEI_NC002758 sei (staphylococcal enterotoxin I) Staphylococcus 57634611
aureus
TSST_NC002758 tsst (toxic shock syndrome toxin-1) Staphylococcus 57634611
aureus
TUFB_NC002758 tufB (Elongation factor Tu) Staphylococcus 57634611
aureus
Note: artificial reference sequences represent concatenations of partial gene extractions from the indicated reference gi number. Partial sequences were used to create the concatenated sequence because complete gene sequences were not necessary for primer design.
Example 2 Sample Preparation and PCR Genomic DNA was prepared from samples using the DNeasy Tissue Kit (Qiagen, Valencia, Calif.) according to the manufacturer's protocols.
All PCR reactions were assembled in 50 μL reaction volumes in a 96-well microtiter plate format using a Packard MPII liquid handling robotic platform and M. J. Dyad thermocyclers (MJ research, Waltham, Mass.) or Eppendorf Mastercycler thermocyclers (Eppendorf, Westbury, N.Y.). The PCR reaction mixture consisted of 4 units of Amplitaq Gold, 1× buffer II (Applied Biosystems, Foster City, Calif.), 1.5 mM MgCl2, 0.4 M betaine, 800 μM dNTP mixture and 250 nM of each primer. The following typical PCR conditions were used: 95° C. for 10 min followed by 8 cycles of 95° C. for 30 seconds, 48° C. for 30 seconds, and 72° C. 30 seconds with the 48° C. annealing temperature increasing 0.9° C. with each of the eight cycles. The PCR was then continued for 37 additional cycles of 95° C. for 15 seconds, 56° C. for 20 seconds, and 72° C. 20 seconds.
Example 3 Purification of PCR Products for Mass Spectrometry with Ion Exchange Resin-Magnetic Beads For solution capture of nucleic acids with ion exchange resin linked to magnetic beads, 25 μl of a 2.5 mg/mL suspension of BioClone amine terminated superparamagnetic beads were added to 25 to 50 μl of a PCR (or RT-PCR) reaction containing approximately 10 pM of a typical PCR amplification product. The above suspension was mixed for approximately 5 minutes by vortexing or pipetting, after which the liquid was removed after using a magnetic separator. The beads containing bound PCR amplification product were then washed three times with 50 mM ammonium bicarbonate/50% MeOH or 100 mM ammonium bicarbonate/50% MeOH, followed by three more washes with 50% MeOH. The bound PCR amplicon was eluted with a solution of 25 mM piperidine, 25 mM imidazole, 35% MeOH which included peptide calibration standards.
Example 4 Mass Spectrometry and Base Composition Analysis The ESI-FTICR mass spectrometer is based on a Bruker Daltonics (Billerica, Mass.) Apex II 70e electrospray ionization Fourier transform ion cyclotron resonance mass spectrometer that employs an actively shielded 7 Tesla superconducting magnet. The active shielding constrains the majority of the fringing magnetic field from the superconducting magnet to a relatively small volume. Thus, components that might be adversely affected by stray magnetic fields, such as CRT monitors, robotic components, and other electronics, can operate in close proximity to the FTICR spectrometer. All aspects of pulse sequence control and data acquisition were performed on a 600 MHz Pentium II data station running Bruker's Xmass software under Windows NT 4.0 operating system. Sample aliquots, typically 15 μl, were extracted directly from 96-well microtiter plates using a CTC HTS PAL autosampler (LEAP Technologies, Carrboro, N.C.) triggered by the FTICR data station. Samples were injected directly into a 10 μl sample loop integrated with a fluidics handling system that supplies the 100 μl/hr flow rate to the ESI source. Ions were formed via electrospray ionization in a modified Analytica (Branford, Conn.) source employing an off axis, grounded electrospray probe positioned approximately 1.5 cm from the metalized terminus of a glass desolvation capillary. The atmospheric pressure end of the glass capillary was biased at 6000 V relative to the ESI needle during data acquisition. A counter-current flow of dry N2 was employed to assist in the desolvation process. Ions were accumulated in an external ion reservoir comprised of an rf-only hexapole, a skimmer cone, and an auxiliary gate electrode, prior to injection into the trapped ion cell where they were mass analyzed. Ionization duty cycles greater than 99% were achieved by simultaneously accumulating ions in the external ion reservoir during ion detection. Each detection event consisted of 1M data points digitized over 2.3 s. To improve the signal-to-noise ratio (S/N), 32 scans were co-added for a total data acquisition time of 74 s.
The ESI-TOF mass spectrometer is based on a Bruker Daltonics MicroTOF™. Ions from the ESI source undergo orthogonal ion extraction and are focused in a reflectron prior to detection. The TOF and FTICR are equipped with the same automated sample handling and fluidics described above. Ions are formed in the standard MicroTOF™ ESI source that is equipped with the same off-axis sprayer and glass capillary as the FTICR ESI source. Consequently, source conditions were the same as those described above. External ion accumulation was also employed to improve ionization duty cycle during data acquisition. Each detection event on the TOF was comprised of 75,000 data points digitized over 75 μs.
The sample delivery scheme allows sample aliquots to be rapidly injected into the electrospray source at high flow rate and subsequently be electrosprayed at a much lower flow rate for improved ESI sensitivity. Prior to injecting a sample, a bolus of buffer was injected at a high flow rate to rinse the transfer line and spray needle to avoid sample contamination/carryover. Following the rinse step, the autosampler injected the next sample and the flow rate was switched to low flow. Following a brief equilibration delay, data acquisition commenced. As spectra were co-added, the autosampler continued rinsing the syringe and picking up buffer to rinse the injector and sample transfer line. In general, two syringe rinses and one injector rinse were required to minimize sample carryover. During a routine screening protocol a new sample mixture was injected every 106 seconds. More recently a fast wash station for the syringe needle has been implemented which, when combined with shorter acquisition times, facilitates the acquisition of mass spectra at a rate of just under one spectrum/minute.
Raw mass spectra were post-calibrated with an internal mass standard and deconvoluted to monoisotopic molecular masses. Unambiguous base compositions were derived from the exact mass measurements of the complementary single-stranded oligonucleotides. Quantitative results are obtained by comparing the peak heights with an internal PCR calibration standard present in every PCR well at 500 molecules per well. Calibration methods are commonly owned and disclosed in U.S. Provisional Patent Application Ser. No. 60/545,425 which is incorporated herein by reference in entirety.
Example 5 De Novo Determination of Base Composition of Amplification Products Using Molecular Mass Modified Deoxynucleotide Triphosphates Because the molecular masses of the four natural nucleobases have a relatively narrow molecular mass range (A=313.058, G=329.052, C=289.046, T=304.046—See Table 4), a persistent source of ambiguity in assignment of base composition can occur as follows: two nucleic acid strands having different base composition may have a difference of about 1 Da when the base composition difference between the two strands is GA (−15.994) combined with CT (+15.000). For example, one 99-mer nucleic acid strand having a base composition of A27G30C21T21 has a theoretical molecular mass of 30779.058 while another 99-mer nucleic acid strand having a base composition of A26G31C22T20 has a theoretical molecular mass of 30780.052. A 1 Da difference in molecular mass may be within the experimental error of a molecular mass measurement and thus, the relatively narrow molecular mass range of the four natural nucleobases imposes an uncertainty factor.
The present invention provides for a means for removing this theoretical 1 Da uncertainty factor through amplification of a nucleic acid with one mass-tagged nucleobase and three natural nucleobases. The term “nucleobase” as used herein is synonymous with other terms in use in the art including “nucleotide,” “deoxynucleotide,” “nucleotide residue,” “deoxynucleotide residue,” “nucleotide triphosphate (NTP),” or deoxynucleotide triphosphate (dNTP).
Addition of significant mass to one of the 4 nucleobases (dNTPs) in an amplification reaction, or in the primers themselves, will result in a significant difference in mass of the resulting amplification product (significantly greater than 1 Da) arising from ambiguities arising from the GA combined with CT event (Table 4). Thus, the same the GA (−15.994) event combined with 5-Iodo-CT (−110.900) event would result in a molecular mass difference of 126.894. If the molecular mass of the base composition A27G30 5-Iodo-C21T21 (33422.958) is compared with A26G3,5-Iodo-C22T20, (33549.852) the theoretical molecular mass difference is +126.894. The experimental error of a molecular mass measurement is not significant with regard to this molecular mass difference. Furthermore, the only base composition consistent with a measured molecular mass of the 99-mer nucleic acid is A27G305-Iodo-C21T21. In contrast, the analogous amplification without the mass tag has 18 possible base compositions. TABLE 4
Molecular Masses of Natural Nucleobases and the Mass-Modified
Nucleobase 5-Iodo-C and Molecular Mass Differences Resulting
from Transitions
Nucleobase Molecular Mass Transition Molecular Mass
A 313.058 A-->T −9.012
A 313.058 A-->C −24.012
A 313.058 A-->5-Iodo-C 101.888
A 313.058 A-->G 15.994
T 304.046 T-->A 9.012
T 304.046 T-->C −15.000
T 304.046 T-->5-Iodo-C 110.900
T 304.046 T-->G 25.006
C 289.046 C-->A 24.012
C 289.046 C-->T 15.000
C 289.046 C-->G 40.006
5-Iodo-C 414.946 5-Iodo-C-->A −101.888
5-Iodo-C 414.946 5-Iodo-C-->T −110.900
5-Iodo-C 414.946 5-Iodo-C-->G −85.894
G 329.052 G-->A −15.994
G 329.052 G-->T −25.006
G 329.052 G-->C −40.006
G 329.052 G-->5-Iodo-C 85.894
Mass spectra of bioagent-identifying amplicons were analyzed independently using a maximum-likelihood processor, such as is widely used in radar signal processing. This processor, referred to as GenX, first makes maximum likelihood estimates of the input to the mass spectrometer for each primer by running matched filters for each base composition aggregate on the input data. This includes the GenX response to a calibrant for each primer.
The algorithm emphasizes performance predictions culminating in probability-of-detection versus probability-of-false-alarm plots for conditions involving complex backgrounds of naturally occurring organisms and environmental contaminants. Matched filters consist of a priori expectations of signal values given the set of primers used for each of the bioagents. A genomic sequence database is used to define the mass base count matched filters. The database contains the sequences of known bacterial bioagents and includes threat organisms as well as benign background organisms. The latter is used to estimate and subtract the spectral signature produced by the background organisms. A maximum likelihood detection of known background organisms is implemented using matched filters and a running-sum estimate of the noise covariance. Background signal strengths are estimated and used along with the matched filters to form signatures which are then subtracted. The maximum likelihood process is applied to this “cleaned up” data in a similar manner employing matched filters for the organisms and a running-sum estimate of the noise-covariance for the cleaned up data.
The amplitudes of all base compositions of bioagent-identifying amplicons for each primer are calibrated and a final maximum likelihood amplitude estimate per organism is made based upon the multiple single primer estimates. Models of all system noise are factored into this two-stage maximum likelihood calculation. The processor reports the number of molecules of each base composition contained in the spectra. The quantity of amplification product corresponding to the appropriate primer set is reported as well as the quantities of primers remaining upon completion of the amplification reaction.
Base count blurring can be carried out as follows. “Electronic PCR” can be conducted on nucleotide sequences of the desired bioagents to obtain the different expected base counts that could be obtained for each primer pair. See for example, ncbi.nlm.nih.gov/sutils/e-pcr/; Schuler, Genome Res. 7:541-50, 1997. In one illustrative embodiment, one or more spreadsheets, such as Microsoft Excel workbooks contain a plurality of worksheets. First in this example, there is a worksheet with a name similar to the workbook name; this worksheet contains the raw electronic PCR data. Second, there is a worksheet named “filtered bioagents base count” that contains bioagent name and base count; there is a separate record for each strain after removing sequences that are not identified with a genus and species and removing all sequences for bioagents with less than 10 strains. Third, there is a worksheet, “Sheet1” that contains the frequency of substitutions, insertions, or deletions for this primer pair. This data is generated by first creating a pivot table from the data in the “filtered bioagents base count” worksheet and then executing an Excel VBA macro. The macro creates a table of differences in base counts for bioagents of the same species, but different strains. One of ordinary skill in the art may understand additional pathways for obtaining similar table differences without undo experimentation.
Application of an exemplary script, involves the user defining a threshold that specifies the fraction of the strains that are represented by the reference set of base counts for each bioagent. The reference set of base counts for each bioagent may contain as many different base counts as are needed to meet or exceed the threshold. The set of reference base counts is defined by taking the most abundant strain's base type composition and adding it to the reference set and then the next most abundant strain's base type composition is added until the threshold is met or exceeded. The current set of data was obtained using a threshold of 55%, which was obtained empirically.
For each base count not included in the reference base count set for that bioagent, the script then proceeds to determine the manner in which the current base count differs from each of the base counts in the reference set. This difference may be represented as a combination of substitutions, Si=Xi, and insertions, Ii=Yi, or deletions, Di=Zi. If there is more than one reference base count, then the reported difference is chosen using rules that aim to minimize the number of changes and, in instances with the same number of changes, minimize the number of insertions or deletions. Therefore, the primary rule is to identify the difference with the minimum sum (Xi+Yi) or (Xi+Zi), e.g., one insertion rather than two substitutions. If there are two or more differences with the minimum sum, then the one that will be reported is the one that contains the most substitutions.
Differences between a base count and a reference composition are categorized as one, two, or more substitutions, one, two, or more insertions, one, two, or more deletions, and combinations of substitutions and insertions or deletions. The different classes of nucleobase changes and their probabilities of occurrence have been delineated in U.S. Patent Application Publication No. 2004209260 (U.S. application Ser. No. 10/418,514) which is incorporated herein by reference in entirety.
Example 6 Use of Broad Range Survey and Division Wide Primer Pairs for Identification of Bacteria in an Epidemic Surveillance Investigation This investigation employed a set of 16 primer pairs which is herein designated the “surveillance primer set” and comprises broad range survey primer pairs, division wide primer pairs and a single Bacillus clade primer pair. The surveillance primer set is shown in Table 5 and consists of primer pairs originally listed in Table 2. This surveillance set comprises primers with T modifications (note TMOD designation in primer names) which constitutes a functional improvement with regard to prevention of non-templated adenylation (vide supra) relative to originally selected primers which are displayed below in the same row. Primer pair 449 (non-T modified) has been modified twice. Its predecessors are primer pairs 70 and 357, displayed below in the same row. Primer pair 360 has also been modified twice and its predecessors are primer pairs 17 and 118. TABLE 5
Bacterial Primer Pairs of the Surveillance Primer Set
Forward Reverse
Primer Primer Primer
Pair (SEQ ID (SEQ ID
No. Forward Primer Name NO:) Reverse Primer Name NO:) Target Gene
346 16S_EC_713_732_TMOD_F 202 16S_EC_789_809_TMOD_R 1110 16S rRNA
10 16S_EC_713_732_F 21 16S_EC_789_809 798 16S rRNA
347 16S_EC_785_806_TMOD_F 560 16S_EC_880_897_TMOD_R 1278 16S rRNA
11 16S_EC_785_806_F 118 16S_EC_880_897_R 830 16S rRNA
348 16S_EC_960_981_TMOD_F 706 16S_EC_1054_1073_TMOD_R 895 16S rRNA
14 16S_EC_960_981_F 672 16S_EC_1054_1073_R 735 16S rRNA
349 23S_EC_1826_1843_TMOD_F 401 23S_EC_1906_1924_TMOD_R 1156 23S rRNA
16 23S_EC_1826_1843_F 80 23S_EC_1906_1924_R 805 23S rRNA
352 INFB_EC_1365_1393_TMOD_F 687 INFB_EC_1439_1467_TMOD_R 1411 infB
34 INFB_EC_1365_1393_F 524 INFB_EC_1439_1467_R 1248 infB
354 RPOC_EC_2218_2241_TMOD_F 405 RPOC_EC_2313_2337_TMOD_R 1072 rpoC
52 RPOC_EC_2218_2241_F 81 RPOC_EC_2313_2337_R 790 rpoC
355 SSPE_BA_115_137_TMOD_F 255 SSPE_BA_197_222_TMOD_R 1402 sspE
58 SSPE_BA_115_137_F 45 SSPE_BA_197_222_R 1201 sspE
356 RPLB_EC_650_679_TMOD_F 232 RPLB_EC_739_762_TMOD_R 592 rplB
66 RPLB_EC_650_679_F 98 RPLB_EC_739_762_R 999 rplB
358 VALS_EC_1105_1124_TMOD_F 385 VALS_EC_1195_1218_TMOD_R 1093 valS
71 VALS_EC_1105_1124_F 77 VALS_EC_1195_1218_R 795 valS
359 RPOB_EC_1845_1866_TMOD_F 659 RPOB_EC_1909_1929_TMOD_R 1250 rpoB
72 RPOB_EC_1845_1866_F 233 RPOB_EC_1909_1929_R 825 rpoB
360 23S_EC_2646_2667_TMOD_F 409 23S_EC_2745_2765_TMOD_R 1434 23S rRNA
118 23S_EC_2646_2667_F 84 23S_EC_2745_2765_R 1389 23S rRNA
17 23S_EC_2645_2669_F 408 23S_EC_2744_2761_R 1252 23S rRNA
361 16S_EC_1090_1111_2_TMOD_F 697 16S_EC_1175_1196_TMOD_R 1398 16S rRNA
3 16S_EC_1090_1111_2_F 651 16S_EC_1175_1196_R 1159 16S rRNA
362 RPOB_EC_3799_3821_TMOD_F 581 RPOB_EC_3862_3888_TMOD_R 1325 rpoB
289 RPOB_EC_3799_3821_F 124 RPOB_EC_3862_3888_R 840 rpoB
363 RPOC_EC_2146_2174_TMOD_F 284 RPOC_EC_2227_2245_TMOD_R 898 rpoC
290 RPOC_EC_2146_2174_F 52 RPOC_EC_2227_2245_R 736 rpoC
367 TUFB_EC_957_979_TMOD_F 308 TUFB_EC_1034_1058_TMOD_R 1276 tufB
293 TUFB_EC_957_979_F 55 TUFB_EC_1034_1058_R 829 tufB
449 RPLB_EC_690_710_F 309 RPLB_EC_737_758_R 1336 rplB
357 RPLB_EC_688_710_TMOD_F 296 RPLB_EC_736_757_TMOD_R 1337 rplB
67 RPLB_EC_688_710_F 54 RPLB_EC_736_757_R 842 rplB
The 16 primer pairs of the surveillance set are used to produce bioagent identifying amplicons whose base compositions are sufficiently different amongst all known bacteria at the species level to identify, at a reasonable confidence level, any given bacterium at the species level. As shown in Tables 6A-E, common respiratory bacterial pathogens can be distinguished by the base compositions of bioagent identifying amplicons obtained using the 16 primer pairs of the surveillance set. In some cases, triangulation identification improves the confidence level for species assignment. For example, nucleic acid from Streptococcus pyogenes can be amplified by nine of the sixteen surveillance primer pairs and Streptococcus pneumoniae can be amplified by ten of the sixteen surveillance primer pairs. The base compositions of the bioagent identifying amplicons are identical for only one of the analogous bioagent identifying amplicons and differ in all of the remaining analogous bioagent identifying amplicons by up to four bases per bioagent identifying amplicon. The resolving power of the surveillance set was confirmed by determination of base compositions for 120 isolates of respiratory pathogens representing 70 different bacterial species and the results indicated that natural variations (usually only one or two base substitutions per bioagent identifying amplicon) amongst multiple isolates of the same species did not prevent correct identification of major pathogenic organisms at the species level.
Bacillus anthracis is a well known biological warfare agent which has emerged in domestic terrorism in recent years. Since it was envisioned to produce bioagent identifying amplicons for identification of Bacillus anthracis, additional drill-down analysis primers were designed to target genes present on virulence plasmids of Bacillus anthracis so that additional confidence could be reached in positive identification of this pathogenic organism. Three drill-down analysis primers were designed and are listed in Tables 2 and 6. In Table 6, the drill-down set comprises primers with T modifications (note TMOD designation in primer names) which constitutes a functional improvement with regard to prevention of non-templated adenylation (vide supra) relative to originally selected primers which are displayed below in the same row. TABLE 6
Drill-Down Primer Pairs for Confirmation of Identification of Bacillus anthracis
Forward Reverse
Primer Primer Primer
Pair (SEQ ID (SEQ ID
No. Forward Primer Name NO:) Reverse Primer Name NO:) Target Gene
350 CAPC_BA_274_303_TMOD_F 476 CAPC_BA_349_376_TMOD_R 1314 capC
24 CAPC_BA_274_303_F 109 CAPC_BA_349_376_R 837 capC
351 CYA_BA_1353_1379_TMOD_F 355 CYA_BA_1448_1467_TMOD_R 1423 cyA
30 CYA_BA_1353_1379_F 64 CYA_BA_1448_1467_R 1342 cyA
353 LEF_BA_756_781_TMOD_F 220 LEF_BA_843_872_TMOD_R 1394 lef
37 LEF_BA_756_781_F 26 LEF_BA_843_872_R 1135 lef
Phylogenetic coverage of bacterial space of the sixteen surveillance primers of Table 5 and the three Bacillus anthracis drill-down primers of Table 6 is shown in FIG. 3 which lists common pathogenic bacteria. FIG. 3 is not meant to be comprehensive in illustrating all species identified by the primers. Only pathogenic bacteria are listed as representative examples of the bacterial species that can be identified by the primers and methods of the present invention. Nucleic acid of groups of bacteria enclosed within the polygons of FIG. 3 can be amplified to obtain bioagent identifying amplicons using the primer pair numbers listed in the upper right hand corner of each polygon. Primer coverage for polygons within polygons is additive. As an illustrative example, bioagent identifying amplicons can be obtained for Chlamydia trachomatis by amplification with, for example, primer pairs 346-349, 360 and 361, but not with any of the remaining primers of the surveillance primer set. On the other hand, bioagent identifying amplicons can be obtained from nucleic acid originating from Bacillus anthracis (located within 5 successive polygons) using, for example, any of the following primer pairs: 346-349, 360, 361 (base polygon), 356, 449 (second polygon), 352 (third polygon), 355 (fourth polygon), 350, 351 and 353 (fifth polygon). Multiple coverage of a given organism with multiple primers provides for increased confidence level in identification of the organism as a result of enabling broad triangulation identification.
In Tables 7A-E, base compositions of respiratory pathogens for primer target regions are shown. Two entries in a cell, represent variation in ribosomal DNA operons. The most predominant base composition is shown first and the minor (frequently a single operon) is indicated by an asterisk (*). Entries with NO DATA mean that the primer would not be expected to prime this species due to mismatches between the primer and target region, as determined by theoretical PCR. TABLE 7A
Base Compositions of Common Respiratory Pathogens for Bioagent Identifying
Amplicons Corresponding to Primer Pair Nos: 346, 347 and 348
Primer 346 Primer 347 Primer 348
Organism Strain [A G C T] [A G C T] [A G C T]
Klebsiella MGH78578 [29 32 25 13] [23 38 28 26] [26 32 28 30]
pneumoniae [29 31 25 13]* [23 37 28 26]* [26 31 28 30]*
Yersinia pestis CO-92 Biovar [29 32 25 13] [22 39 28 26] [29 30 28 29]
Orientalis [30 30 27 29]*
Yersinia pestis KIM5 P12 (Biovar [29 32 25 13] [22 39 28 26] [29 30 28 29]
Mediaevalis)
Yersinia pestis 91001 [29 32 25 13] [22 39 28 26] [29 30 28 29]
[30 30 27 29]*
Haemophilus KW20 [28 31 23 17] [24 37 25 27] [29 30 28 29]
influenzae
Pseudomonas PAO1 [30 31 23 15] [26 36 29 24] [26 32 29 29]
aeruginosa [27 36 29 23]*
Pseudomonas Pf0-1 [30 31 23 15] [26 35 29 25] [28 31 28 29]
fluorescens
Pseudomonas KT2440 [30 31 23 15] [28 33 27 27] [27 32 29 28]
putida
Legionella Philadelphia-1 [30 30 24 15] [33 33 23 27] [29 28 28 31]
pneumophila
Francisella schu 4 [32 29 22 16] [28 38 26 26] [25 32 28 31]
tularensis
Bordetella Tohama I [30 29 24 16] [23 37 30 24] [30 32 30 26]
pertussis
Burkholderia J2315 [29 29 27 14] [27 32 26 29] [27 36 31 24]
cepacia [20 42 35 19]*
Burkholderia K96243 [29 29 27 14] [27 32 26 29] [27 36 31 24]
pseudomallei
Neisseria FA 1090, ATCC [29 28 24 18] [27 34 26 28] [24 36 29 27]
gonorrhoeae 700825
Neisseria MC58 (serogroup B) [29 28 26 16] [27 34 27 27] [25 35 30 26]
meningitidis
Neisseria serogroup C, FAM18 [29 28 26 16] [27 34 27 27] [25 35 30 26]
meningitidis
Neisseria Z2491 (serogroup A) [29 28 26 16] [27 34 27 27] [25 35 30 26]
meningitidis
Chlamydophila TW-183 [31 27 22 19] NO DATA [32 27 27 29]
pneumoniae
Chlamydophila AR39 [31 27 22 19] NO DATA [32 27 27 29]
pneumoniae
Chlamydophila CWL029 [31 27 22 19] NO DATA [32 27 27 29]
pneumoniae
Chlamydophila J138 [31 27 22 19] NO DATA [32 27 27 29]
pneumoniae
Corynebacterium NCTC13129 [29 34 21 15] [22 38 31 25] [22 33 25 34]
diphtheriae
Mycobacterium k10 [27 36 21 15] [22 37 30 28] [21 36 27 30]
avium
Mycobacterium 104 [27 36 21 15] [22 37 30 28] [21 36 27 30]
avium
Mycobacterium CSU#93 [27 36 21 15] [22 37 30 28] [21 36 27 30]
tuberculosis
Mycobacterium CDC 1551 [27 36 21 15] [22 37 30 28] [21 36 27 30]
tuberculosis
Mycobacterium H37Rv (lab strain) [27 36 21 15] [22 37 30 28] [21 36 27 30]
tuberculosis
Mycoplasma M129 [31 29 19 20] NO DATA NO DATA
pneumoniae
Staphylococcus MRSA252 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [29 31 30 29]*
Staphylococcus MSSA476 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [30 29 29 30]*
Staphylococcus COL [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [30 29 29 30]*
Staphylococcus Mu50 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [30 29 29 30]*
Staphylococcus MW2 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [30 29 29 30]*
Staphylococcus N315 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [30 29 29 30]*
Staphylococcus NCTC 8325 [27 30 21 21] [25 35 30 26] [30 29 30 29]
aureus [25 35 31 26]* [30 29 29 30]
Streptococcus NEM316 [26 32 23 18] [24 36 31 25] [25 32 29 30]
agalactiae [24 36 30 26]*
Streptococcus NC_002955 [26 32 23 18] [23 37 31 25] [29 30 25 32]
equi
Streptococcus MGAS8232 [26 32 23 18] [24 37 30 25] [25 31 29 31]
pyogenes
Streptococcus MGAS315 [26 32 23 18] [24 37 30 25] [25 31 29 31]
pyogenes
Streptococcus SSI-1 [26 32 23 18] [24 37 30 25] [25 31 29 31]
pyogenes
Streptococcus MGAS10394 [26 32 23 18] [24 37 30 25] [25 31 29 31]
pyogenes
Streptococcus Manfredo (M5) [26 32 23 18] [24 37 30 25] [25 31 29 31]
pyogenes
Streptococcus SF370 (M1) [26 32 23 18] [24 37 30 25] [25 31 29 31]
pyogenes
Streptococcus 670 [26 32 23 18] [25 35 28 28] [25 32 29 30]
pneumoniae
Streptococcus R6 [26 32 23 18] [25 35 28 28] [25 32 29 30]
pneumoniae
Streptococcus TIGR4 [26 32 23 18] [25 35 28 28] [25 32 30 29]
pneumoniae
Streptococcus NCTC7868 [25 33 23 18] [24 36 31 25] [25 31 29 31]
gordonii
Streptococcus NCTC 12261 [26 32 23 18] [25 35 30 26] [25 32 29 30]
mitis [24 31 35 29]*
Streptococcus UA159 [24 32 24 19] [25 37 30 24] [28 31 26 31]
mutans
TABLE 7B
Base Compositions of Common Respiratory Pathogens for Bioagent Identifying
Amplicons Corresponding to Primer Pair Nos: 349, 360, and 356
Primer 349 Primer 360 Primer 356
Organism Strain [A G C T] [A G C T] [A G C T]
Klebsiella MGH78578 [25 31 25 22] [33 37 25 27] NO DATA
pneumoniae
Yersinia pestis CO-92 Biovar [25 31 27 20] [34 35 25 28] NO DATA
Orientalis [25 32 26 20]*
Yersinia pestis KIM5 P12 (Biovar [25 31 27 20] [34 35 25 28] NO DATA
Mediaevalis) [25 32 26 20]*
Yersinia pestis 91001 [25 31 27 20] [34 35 25 28] NO DATA
Haemophilus KW20 [28 28 25 20] [32 38 25 27] NO DATA
influenzae
Pseudomonas PAO1 [24 31 26 20] [31 36 27 27] NO DATA
aeruginosa [31 36 27 28]*
Pseudomonas Pf0-1 NO DATA [30 37 27 28] NO DATA
fluorescens [30 37 27 28]
Pseudomonas KT2440 [24 31 26 20] [30 37 27 28] NO DATA
putida
Legionella Philadelphia-1 [23 30 25 23] [30 39 29 24] NO DATA
pneumophila
Francisella schu 4 [26 31 25 19] [32 36 27 27] NO DATA
tularensis
Bordetella Tohama I [21 29 24 18] [33 36 26 27] NO DATA
pertussis
Burkholderia J2315 [23 27 22 20] [31 37 28 26] NO DATA
cepacia
Burkholderia K96243 [23 27 22 20] [31 37 28 26] NO DATA
pseudomallei
Neisseria FA 1090, ATCC 700825 [24 27 24 17] [34 37 25 26] NO DATA
gonorrhoeae
Neisseria MC58 (serogroup B) [25 27 22 18] [34 37 25 26] NO DATA
meningitidis
Neisseria serogroup C, FAM18 [25 26 23 18] [34 37 25 26] NO DATA
meningitidis
Neisseria Z2491 (serogroup A) [25 26 23 18] [34 37 25 26] NO DATA
meningitidis
Chlamydophila TW-183 [30 28 27 18] NO DATA NO DATA
pneumoniae
Chlamydophila AR39 [30 28 27 18] NO DATA NO DATA
pneumoniae
Chlamydophila CWL029 [30 28 27 18] NO DATA NO DATA
pneumoniae
Chlamydophila J138 [30 28 27 18] NO DATA NO DATA
pneumoniae
Corynebacterium NCTC13129 NO DATA [29 40 28 25] NO DATA
diphtheriae
Mycobacterium k10 NO DATA [33 35 32 22] NO DATA
avium
Mycobacterium 104 NO DATA [33 35 32 22] NO DATA
avium
Mycobacterium CSU#93 NO DATA [30 36 34 22] NO DATA
tuberculosis
Mycobacterium CDC 1551 NO DATA [30 36 34 22] NO DATA
tuberculosis
Mycobacterium H37Rv (lab strain) NO DATA [30 36 34 22] NO DATA
tuberculosis
Mycoplasma M129 [28 30 24 19] [34 31 29 28] NO DATA
pneumoniae
Staphylococcus MRSA252 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Staphylococcus MSSA476 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Staphylococcus COL [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Staphylococcus Mu50 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Staphylococcus MW2 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Staphylococcus N315 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Staphylococcus NCTC 8325 [26 30 25 20] [31 38 24 29] [33 30 31 27]
aureus
Streptococcus NEM316 [28 31 22 20] [33 37 24 28] [37 30 28 26]
agalactiae
Streptococcus NC_002955 [28 31 23 19] [33 38 24 27] [37 31 28 25]
equi
Streptococcus MGAS8232 [28 31 23 19] [33 37 24 28] [38 31 29 23]
pyogenes
Streptococcus MGAS315 [28 31 23 19] [33 37 24 28] [38 31 29 23]
pyogenes
Streptococcus SSI-1 [28 31 23 19] [33 37 24 28] [38 31 29 23]
pyogenes
Streptococcus MGAS10394 [28 31 23 19] [33 37 24 28] [38 31 29 23]
pyogenes
Streptococcus Manfredo (M5) [28 31 23 19] [33 37 24 28] [38 31 29 23]
pyogenes
Streptococcus SF370 (M1) [28 31 23 19] [33 37 24 28] [38 31 29 23]
pyogenes [28 31 22 20]*
Streptococcus 670 [28 31 22 20] [34 36 24 28] [37 30 29 25]
pneumoniae
Streptococcus R6 [28 31 22 20] [34 36 24 28] [37 30 29 25]
pneumoniae
Streptococcus TIGR4 [28 31 22 20] [34 36 24 28] [37 30 29 25]
pneumoniae
Streptococcus NCTC7868 [28 32 23 20] [34 36 24 28] [36 31 29 25]
gordonii
Streptococcus NCTC 12261 [28 31 22 20] [34 36 24 28] [37 30 29 25]
mitis [29 30 22 20]*
Streptococcus UA159 [26 32 23 22] [34 37 24 27] NO DATA
mutans
TABLE 7C
Base Compositions of Common Respiratory Pathogens for Bioagent Identifying
Amplicons Corresponding to Primer Pair Nos: 449, 354, and 352
Primer 449 Primer 354 Primer 352
Organism Strain [A G C T] [A G C T] [A G C T]
Klebsiella MGH78578 NO DATA [27 33 36 26] NO DATA
pneumoniae
Yersinia pestis CO-92 Biovar NO DATA [29 31 33 29] [32 28 20 25]
Orientalis
Yersinia pestis KIM5 P12 (Biovar NO DATA [29 31 33 29] [32 28 20 25]
Mediaevalis)
Yersinia pestis 91001 NO DATA [29 31 33 29] NO DATA
Haemophilus KW20 NO DATA [30 29 31 32] NO DATA
influenzae
Pseudomonas PAO1 NO DATA [26 33 39 24] NO DATA
aeruginosa
Pseudomonas Pf0-1 NO DATA [26 33 34 29] NO DATA
fluorescens
Pseudomonas KT2440 NO DATA [25 34 36 27] NO DATA
putida
Legionella Philadelphia-1 NO DATA NO DATA NO DATA
pneumophila
Francisella schu 4 NO DATA [33 32 25 32] NO DATA
tularensis
Bordetella Tohama I NO DATA [26 33 39 24] NO DATA
pertussis
Burkholderia J2315 NO DATA [25 37 33 27] NO DATA
cepacia
Burkholderia K96243 NO DATA [25 37 34 26] NO DATA
pseudomallei
Neisseria FA 1090, ATCC 700825 [17 23 22 10] [29 31 32 30] NO DATA
gonorrhoeae
Neisseria MC58 (serogroup B) NO DATA [29 30 32 31] NO DATA
meningitidis
Neisseria serogroup C, FAM18 NO DATA [29 30 32 31] NO DATA
meningitidis
Neisseria Z2491 (serogroup A) NO DATA [29 30 32 31] NO DATA
meningitidis
Chlamydophila TW-183 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila AR39 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila CWL029 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila J138 NO DATA NO DATA NO DATA
pneumoniae
Corynebacterium NCTC13129 NO DATA NO DATA NO DATA
diphtheriae
Mycobacterium k10 NO DATA NO DATA NO DATA
avium
Mycobacterium 104 NO DATA NO DATA NO DATA
avium
Mycobacterium CSU#93 NO DATA NO DATA NO DATA
tuberculosis
Mycobacterium CDC 1551 NO DATA NO DATA NO DATA
tuberculosis
Mycobacterium H37Rv (lab strain) NO DATA NO DATA NO DATA
tuberculosis
Mycoplasma M129 NO DATA NO DATA NO DATA
pneumoniae
Staphylococcus MRSA252 [17 20 21 17] [30 27 30 35] [36 24 19 26]
aureus
Staphylococcus MSSA476 [17 20 21 17] [30 27 30 35] [36 24 19 26]
aureus
Staphylococcus COL [17 20 21 17] [30 27 30 35] [35 24 19 27]
aureus
Staphylococcus Mu50 [17 20 21 17] [30 27 30 35] [36 24 19 26]
aureus
Staphylococcus MW2 [17 20 21 17] [30 27 30 35] [36 24 19 26]
aureus
Staphylococcus N315 [17 20 21 17] [30 27 30 35] [36 24 19 26]
aureus
Staphylococcus NCTC 8325 [17 20 21 17] [30 27 30 35] [35 24 19 27]
aureus
Streptococcus NEM316 [22 20 19 14] [26 31 27 38] [29 26 22 28]
agalactiae
Streptococcus NC_002955 [22 21 19 13] NO DATA NO DATA
equi
Streptococcus MGAS8232 [23 21 19 12] [24 32 30 36] NO DATA
pyogenes
Streptococcus MGAS315 [23 21 19 12] [24 32 30 36] NO DATA
pyogenes
Streptococcus SSI-1 [23 21 19 12] [24 32 30 36] NO DATA
pyogenes
Streptococcus MGAS10394 [23 21 19 12] [24 32 30 36] NO DATA
pyogenes
Streptococcus Manfredo (M5) [23 21 19 12] [24 32 30 36] NO DATA
pyogenes
Streptococcus SF370 (M1) [23 21 19 12] [24 32 30 36] NO DATA
pyogenes
Streptococcus 670 [22 20 19 14] [25 33 29 35] [30 29 21 25]
pneumoniae
Streptococcus R6 [22 20 19 14] [25 33 29 35] [30 29 21 25]
pneumoniae
Streptococcus TIGR4 [22 20 19 14] [25 33 29 35] [30 29 21 25]
pneumoniae
Streptococcus NCTC7868 [21 21 19 14] NO DATA [29 26 22 28]
gordonii
Streptococcus NCTC 12261 [22 20 19 14] [26 30 32 34] NO DATA
mitis
Streptococcus UA159 NO DATA NO DATA NO DATA
mutans
TABLE 7D
Base Compositions of Common Respiratory Pathogens for Bioagent Identifying
Amplicons Corresponding to Primer Pair Nos: 355, 358, and 359
Primer 355 Primer 358 Primer 359
Organism Strain [A G C T] [A G C T] [A G C T]
Klebsiella MGH78578 NO DATA [24 39 33 20] [25 21 24 17]
pneumoniae
Yersinia pestis CO-92 Biovar NO DATA [26 34 35 21] [23 23 19 22]
Orientalis
Yersinia pestis KIM5 P12 (Biovar NO DATA [26 34 35 21] [23 23 19 22]
Mediaevalis)
Yersinia pestis 91001 NO DATA [26 34 35 21] [23 23 19 22]
Haemophilus KW20 NO DATA NO DATA NO DATA
influenzae
Pseudomonas PAO1 NO DATA NO DATA NO DATA
aeruginosa
Pseudomonas Pf0-1 NO DATA NO DATA NO DATA
fluorescens
Pseudomonas KT2440 NO DATA [21 37 37 21] NO DATA
putida
Legionella Philadelphia-1 NO DATA NO DATA NO DATA
pneumophila
Francisella schu 4 NO DATA NO DATA NO DATA
tularensis
Bordetella Tohama I NO DATA NO DATA NO DATA
pertussis
Burkholderia J2315 NO DATA NO DATA NO DATA
cepacia
Burkholderia K96243 NO DATA NO DATA NO DATA
pseudomallei
Neisseria FA 1090, ATCC 700825 NO DATA NO DATA NO DATA
gonorrhoeae
Neisseria MC58 (serogroup B) NO DATA NO DATA NO DATA
meningitidis
Neisseria serogroup C, FAM18 NO DATA NO DATA NO DATA
meningitidis
Neisseria Z2491 (serogroup A) NO DATA NO DATA NO DATA
meningitidis
Chlamydophila TW-183 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila AR39 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila CWL029 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila J138 NO DATA NO DATA NO DATA
pneumoniae
Corynebacterium NCTC13129 NO DATA NO DATA NO DATA
diphtheriae
Mycobacterium k10 NO DATA NO DATA NO DATA
avium
Mycobacterium 104 NO DATA NO DATA NO DATA
avium
Mycobacterium CSU#93 NO DATA NO DATA NO DATA
tuberculosis
Mycobacterium CDC 1551 NO DATA NO DATA NO DATA
tuberculosis
Mycobacterium H37Rv (lab strain) NO DATA NO DATA NO DATA
tuberculosis
Mycoplasma M129 NO DATA NO DATA NO DATA
pneumoniae
Staphylococcus MRSA252 NO DATA NO DATA NO DATA
aureus
Staphylococcus MSSA476 NO DATA NO DATA NO DATA
aureus
Staphylococcus COL NO DATA NO DATA NO DATA
aureus
Staphylococcus Mu50 NO DATA NO DATA NO DATA
aureus
Staphylococcus MW2 NO DATA NO DATA NO DATA
aureus
Staphylococcus N315 NO DATA NO DATA NO DATA
aureus
Staphylococcus NCTC 8325 NO DATA NO DATA NO DATA
aureus
Streptococcus NEM316 NO DATA NO DATA NO DATA
agalactiae
Streptococcus NC_002955 NO DATA NO DATA NO DATA
equi
Streptococcus MGAS8232 NO DATA NO DATA NO DATA
pyogenes
Streptococcus MGAS315 NO DATA NO DATA NO DATA
pyogenes
Streptococcus SSI-1 NO DATA NO DATA NO DATA
pyogenes
Streptococcus MGAS10394 NO DATA NO DATA NO DATA
pyogenes
Streptococcus Manfredo (M5) NO DATA NO DATA NO DATA
pyogenes
Streptococcus SF370 (M1) NO DATA NO DATA NO DATA
pyogenes
Streptococcus 670 NO DATA NO DATA NO DATA
pneumoniae
Streptococcus R6 NO DATA NO DATA NO DATA
pneumoniae
Streptococcus TIGR4 NO DATA NO DATA NO DATA
pneumoniae
Streptococcus NCTC7868 NO DATA NO DATA NO DATA
gordonii
Streptococcus NCTC 12261 NO DATA NO DATA NO DATA
mitis
Streptococcus UA159 NO DATA NO DATA NO DATA
mutans
TABLE 7E
Base Compositions of Common Respiratory Pathogens for Bioagent Identifying
Amplicons Corresponding to Primer Pair Nos: 362, 363, and 367
Primer 362 Primer 363 Primer 367
Organism Strain [A G C T] [A G C T] [A G C T]
Klebsiella MGH78578 [21 33 22 16] [16 34 26 26] NO DATA
pneumoniae
Yersinia pestis CO-92 Biovar [20 34 18 20] NO DATA NO DATA
Orientalis
Yersinia pestis KIM5 P12 (Biovar [20 34 18 20] NO DATA NO DATA
Mediaevalis)
Yersinia pestis 91001 [20 34 18 20] NO DATA NO DATA
Haemophilus KW20 NO DATA NO DATA NO DATA
influenzae
Pseudomonas PAO1 [19 35 21 17] [16 36 28 22] NO DATA
aeruginosa
Pseudomonas Pf0-1 NO DATA [18 35 26 23] NO DATA
fluorescens
Pseudomonas KT2440 NO DATA [16 35 28 23] NO DATA
putida
Legionella Philadelphia-1 NO DATA NO DATA NO DATA
pneumophila
Francisella schu 4 NO DATA NO DATA NO DATA
tularensis
Bordetella Tohama I [20 31 24 17] [15 34 32 21] [26 25 34 19]
pertussis
Burkholderia J2315 [20 33 21 18] [15 36 26 25] [25 27 32 20]
cepacia
Burkholderia K96243 [19 34 19 20] [15 37 28 22] [25 27 32 20]
pseudomallei
Neisseria FA 1090, ATCC 700825 NO DATA NO DATA NO DATA
gonorrhoeae
Neisseria MC58 (serogroup B) NO DATA NO DATA NO DATA
meningitidis
Neisseria serogroup C, FAM18 NO DATA NO DATA NO DATA
meningitidis
Neisseria Z2491 (serogroup A) NO DATA NO DATA NO DATA
meningitidis
Chlamydophila TW-183 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila AR39 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila CWL029 NO DATA NO DATA NO DATA
pneumoniae
Chlamydophila J138 NO DATA NO DATA NO DATA
pneumoniae
Corynebacterium NCTC13129 NO DATA NO DATA NO DATA
diphtheriae
Mycobacterium k10 [19 34 23 16] NO DATA [24 26 35 19]
avium
Mycobacterium 104 [19 34 23 16] NO DATA [24 26 35 19]
avium
Mycobacterium CSU#93 [19 31 25 17] NO DATA [25 25 34 20]
tuberculosis
Mycobacterium CDC 1551 [19 31 24 18] NO DATA [25 25 34 20]
tuberculosis
Mycobacterium H37Rv (lab strain) [19 31 24 18] NO DATA [25 25 34 20]
tuberculosis
Mycoplasma M129 NO DATA NO DATA NO DATA
pneumoniae
Staphylococcus MRSA252 NO DATA NO DATA NO DATA
aureus
Staphylococcus MSSA476 NO DATA NO DATA NO DATA
aureus
Staphylococcus COL NO DATA NO DATA NO DATA
aureus
Staphylococcus Mu50 NO DATA NO DATA NO DATA
aureus
Staphylococcus MW2 NO DATA NO DATA NO DATA
aureus
Staphylococcus N315 NO DATA NO DATA NO DATA
aureus
Staphylococcus NCTC 8325 NO DATA NO DATA NO DATA
aureus
Streptococcus NEM316 NO DATA NO DATA NO DATA
agalactiae
Streptococcus NC_002955 NO DATA NO DATA NO DATA
equi
Streptococcus MGAS8232 NO DATA NO DATA NO DATA
pyogenes
Streptococcus MGAS315 NO DATA NO DATA NO DATA
pyogenes
Streptococcus SSI-1 NO DATA NO DATA NO DATA
pyogenes
Streptococcus MGAS10394 NO DATA NO DATA NO DATA
pyogenes
Streptococcus Manfredo (M5) NO DATA NO DATA NO DATA
pyogenes
Streptococcus SF370 (M1) NO DATA NO DATA NO DATA
pyogenes
Streptococcus 670 NO DATA NO DATA NO DATA
pneumoniae
Streptococcus R6 [20 30 19 23] NO DATA NO DATA
pneumoniae
Streptococcus TIGR4 [20 30 19 23] NO DATA NO DATA
pneumoniae
Streptococcus NCTC7868 NO DATA NO DATA NO DATA
gordonii
Streptococcus NCTC 12261 NO DATA NO DATA NO DATA
mitis
Streptococcus UA159 NO DATA NO DATA NO DATA
mutans
Four sets of throat samples from military recruits at different military facilities taken at different time points were analyzed using the primers of the present invention. The first set was collected at a military training center from November 1 to Dec. 20, 2002 during one of the most severe outbreaks of pneumonia associated with group A Streptococcus in the United States since 1968. During this outbreak, fifty-one throat swabs were taken from both healthy and hospitalized recruits and plated on blood agar for selection of putative group A Streptococcus colonies. A second set of 15 original patient specimens was taken during the height of this group A Streptococcus-associated respiratory disease outbreak. The third set were historical samples, including twenty-seven isolates of group A Streptococcus, from disease outbreaks at this and other military training facilities during previous years. The fourth set of samples was collected from five geographically separated military facilities in the continental U.S. in the winter immediately following the severe November/December 2002 outbreak.
Pure colonies isolated from group A Streptococcus-selective media from all four collection periods were analyzed with the surveillance primer set. All samples showed base compositions that precisely matched the four completely sequenced strains of Streptococcus pyogenes. Shown in FIG. 4 is a 3D diagram of base composition (axes A, G and C) of bioagent identifying amplicons obtained with primer pair number 14 (a precursor of primer pair number 348 which targets 16S rRNA). The diagram indicates that the experimentally determined base compositions of the clinical samples closely match the base compositions expected for Streptococcus pyogenes and are distinct from the expected base compositions of other organisms.
In addition to the identification of Streptococcus pyogenes, other potentially pathogenic organisms were identified concurrently. Mass spectral analysis of a sample whose nucleic acid was amplified by primer pair number 349 (SEQ ID NOs: 401:1156) exhibited signals of bioagent identifying amplicons with molecular masses that were found to correspond to analogous base compositions of bioagent identifying amplicons of Streptococcus pyogenes (A27 G32 C24 T18), Neisseria meningitidis (A25 G27 C22 T18), and Haemophilus influenzae (A28 G28 C25 T20) (see FIG. 5 and Table 7B). These organisms were present in a ratio of 4:5:20 as determined by comparison of peak heights with peak height of an internal PCR calibration standard as described in commonly owned U.S. Patent Application Ser. No. 60/545,425 which is incorporated herein by reference in its entirety.
Since certain division-wide primers that target housekeeping genes are designed to provide coverage of specific divisions of bacteria to increase the confidence level for identification of bacterial species, they are not expected to yield bioagent identifying amplicons for organisms outside of the specific divisions. For example, primer pair number 356 (SEQ ID NOs: 449:1380) primarily amplifies the nucleic acid of members of the classes Bacilli and Clostridia and is not expected to amplify proteobacteria such as Neisseria meningitidis and Haemophilus influenzae. As expected, analysis of the mass spectrum of amplification products obtained with primer pair number 356 does not indicate the presence of Neisseria meningitidis and Haemophilus influenzae but does indicate the presence of Streptococcus pyogenes (FIGS. 3 and 6, Table 7B). Thus, these primers or types of primers can confirm the absence of particular bioagents from a sample.
The 15 throat swabs from military recruits were found to contain a relatively small set of microbes in high abundance. The most common were Haemophilus influenza, Neisseria meningitides, and Streptococcus pyogenes. Staphylococcus epidermidis, Moraxella cattarhalis, Corynebacterium pseudodiphtheriticum, and Staphylococcus aureus were present in fewer samples. An equal number of samples from healthy volunteers from three different geographic locations, were identically analyzed. Results indicated that the healthy volunteers have bacterial flora dominated by multiple, commensal non-beta-hemolytic Streptococcal species, including the viridans group streptococci (S. parasangunis, S. vestibularis, S. mitis, S. oralis and S. pneumoniae; data not shown), and none of the organisms found in the military recruits were found in the healthy controls at concentrations detectable by mass spectrometry. Thus, the military recruits in the midst of a respiratory disease outbreak had a dramatically different microbial population than that experienced by the general population in the absence of epidemic disease.
Example 7 Triangulation Genotyping Analysis for Determination of emm-Type of Streptococcus pyogenes in Epidemic Surveillance As a continuation of the epidemic surveillance investigation of Example 6, determination of sub-species characteristics (genotyping) of Streptococcus pyogenes, was carried out based on a strategy that generates strain-specific signatures according to the rationale of Multi-Locus Sequence Typing (MLST). In classic MLST analysis, internal fragments of several housekeeping genes are amplified and sequenced (Enright et al. Infection and Immunity, 2001, 69, 2416-2427). In classic MLST analysis, internal fragments of several housekeeping genes are amplified and sequenced. In the present investigation, bioagent identifying amplicons from housekeeping genes were produced using drill-down primers and analyzed by mass spectrometry. Since mass spectral analysis results in molecular mass, from which base composition can be determined, the challenge was to determine whether resolution of emm classification of strains of Streptococcus pyogenes could be determined.
For the purpose of development of a triangulation genotyping assay, an alignment was constructed of concatenated alleles of seven MLST housekeeping genes (glucose kinase (gki), glutamine transporter protein (gtr), glutamate racemase (murI), DNA mismatch repair protein (mutS), xanthine phosphoribosyl transferase (xpt), and acetyl-CoA acetyl transferase (yqiL)) from each of the 212 previously emm-typed strains of Streptococcus pyogenes. From this alignment, the number and location of primer pairs that would maximize strain identification via base composition was determined. As a result, 6 primer pairs were chosen as standard drill-down primers for determination of emm-type of Streptococcus pyogenes. These six primer pairs are displayed in Table 8. This drill-down set comprises primers with T modifications (note TMOD designation in primer names) which constitutes a functional improvement with regard to prevention of non-templated adenylation (vide supra) relative to originally selected primers which are displayed below in the same row. TABLE 8
Triangulation Genotyping Analysis Primer Pairs for Group A Streptococcus Drill-Down
Forward
Primer
Primer (SEQ ID Reverse Primer Target
Pair No. Forward Primer Name NO:) Reverse Primer Name (SEQ ID NO:) Gene
442 SP101_SPET11_358_387_TMOD_F 588 SP101_SPET11_448_473_TMOD_R 998 gki
80 SP101_SPET11_358_387_F 126 SP101_SPET11_448_473_TMOD_R 766 gki
443 SP101_SPET11_600_629_TMOD_F 348 SP101_SPET11_686_714_TMOD_R 1018 gtr
81 SP101_SPET11_600_629_F 62 SP101_SPET11_686_714_R 772 gtr
426 SP101_SPET11_1314_1336_TMOD_F 363 SP101_SPET11_1403_1431_TMOD_R 849 murI
86 SP101_SPET11_1314_1336_F 68 SP101_SPET11_1403_1431_R 711 murI
430 SP101_SPET11_1807_1835_TMOD_F 235 SP101_SPET11_1901_1927_TMOD_R 1439 mutS
90 SP101_SPET11_1807_1835_F 33 SP101_SPET11_1901_1927_R 1412 mutS
438 SP101_SPET11_3075_3103_TMOD_F 473 SP101_SPET11_3168_3196_TMOD_R 875 xpt
96 SP101_SPET11_3075_3103_F 108 SP101_SPET11_3168_3196_R 715 xpt
441 SP101_SPET11_3511_3535_TMOD_F 531 SP101_SPET11_3605_3629_TMOD_R 1294 yqiL
98 SP101_SPET11_3511_3535_F 116 SP101_SPET11_3605_3629_R 832 yqiL
The primers of Table 8 were used to produce bioagent identifying amplicons from nucleic acid present in the clinical samples. The bioagent identifying amplicons which were subsequently analyzed by mass spectrometry and base compositions corresponding to the molecular masses were calculated.
Of the 51 samples taken during the peak of the November/December 2002 epidemic (Table 9A-C rows 1-3), all except three samples were found to represent emm3, a Group A Streptococcus genotype previously associated with high respiratory virulence. The three outliers were from samples obtained from healthy individuals and probably represent non-epidemic strains. Archived samples (Tables 9A-C rows 5-13) from historical collections showed a greater heterogeneity of base compositions and emm types as would be expected from different epidemics occurring at different places and dates. The results of the mass spectrometry analysis and emm gene sequencing were found to be concordant for the epidemic and historical samples. TABLE 9A
Base Composition Analysis of Bioagent Identifying Amplicons of Group A Streptococcus
samples from Six Military Installations Obtained with Primer Pair Nos. 426 and 430
emm-type by murI mutS
# of Mass emm-Gene Location (Primer Pair (Primer Pair
Instances Spectrometry Sequencing (sample) Year No. 426) No. 430)
48 3 3 MCRD San 2002 A39 G25 C20 T34 A38 G27 C23 T33
2 6 6 Diego A40 G24 C20 T34 A38 G27 C23 T33
1 28 28 (Cultured) A39 G25 C20 T34 A38 G27 C23 T33
15 3 ND A39 G25 C20 T34 A38 G27 C23 T33
6 3 3 NHRC San 2003 A39 G25 C20 T34 A38 G27 C23 T33
3 5, 58 5 Diego- A40 G24 C20 T34 A38 G27 C23 T33
6 6 6 Archive A40 G24 C20 T34 A38 G27 C23 T33
1 11 11 (Cultured) A39 G25 C20 T34 A38 G27 C23 T33
3 12 12 A40 G24 C20 T34 A38 G26 C24 T33
1 22 22 A39 G25 C20 T34 A38 G27 C23 T33
3 25, 75 75 A39 G25 C20 T34 A38 G27 C23 T33
4 44/61, 82, 9 44/61 A40 G24 C20 T34 A38 G26 C24 T33
2 53, 91 91 A39 G25 C20 T34 A38 G27 C23 T33
1 2 2 Ft. 2003 A39 G25 C20 T34 A38 G27 C24 T32
2 3 3 Leonard A39 G25 C20 T34 A38 G27 C23 T33
1 4 4 Wood A39 G25 C20 T34 A38 G27 C23 T33
1 6 6 (Cultured) A40 G24 C20 T34 A38 G27 C23 T33
11 25 or 75 75 A39 G25 C20 T34 A38 G27 C23 T33
1 25, 75, 33, 75 A39 G25 C20 T34 A38 G27 C23 T33
34, 4, 52, 84
1 44/61 or 82 44/61 A40 G24 C20 T34 A38 G26 C24 T33
or 9
2 5 or 58 5 A40 G24 C20 T34 A38 G27 C23 T33
3 1 1 Ft. Sill 2003 A40 G24 C20 T34 A38 G27 C23 T33
2 3 3 (Cultured) A39 G25 C20 T34 A38 G27 C23 T33
1 4 4 A39 G25 C20 T34 A38 G27 C23 T33
1 28 28 A39 G25 C20 T34 A38 G27 C23 T33
1 3 3 Ft. 2003 A39 G25 C20 T34 A38 G27 C23 T33
1 4 4 Benning A39 G25 C20 T34 A38 G27 C23 T33
3 6 6 (Cultured) A40 G24 C20 T34 A38 G27 C23 T33
1 11 11 A39 G25 C20 T34 A38 G27 C23 T33
1 13 94** A40 G24 C20 T34 A38 G27 C23 T33
1 44/61 or 82 82 A40 G24 C20 T34 A38 G26 C24 T33
or 9
1 5 or 58 58 A40 G24 C20 T34 A38 G27 C23 T33
1 78 or 89 89 A39 G25 C20 T34 A38 G27 C23 T33
2 5 or 58 ND Lackland 2003 A40 G24 C20 T34 A38 G27 C23 T33
1 2 AFB A39 G25 C20 T34 A38 G27 C24 T32
1 81 or 90 (Throat A40 G24 C20 T34 A38 G27 C23 T33
1 78 Swabs) A38 G26 C20 T34 A38 G27 C23 T33
3*** No detection No detection No detection
7 3 ND MCRD San 2002 A39 G25 C20 T34 A38 G27 C23 T33
1 3 ND Diego No detection A38 G27 C23 T33
1 3 ND (Throat No detection No detection
1 3 ND Swabs) No detection No detection
2 3 ND No detection A38 G27 C23 T33
3 No detection ND No detection No detection
TABLE 9B
Base Composition Analysis of Bioagent Identifying Amplicons of Group A Streptococcus
samples from Six Military Installations Obtained with Primer Pair Nos. 438 and 441
emm-type by xpt yqiL
# of Mass emm-Gene Location (Primer Pair (Primer Pair
Instances Spectrometry Sequencing (sample) Year No. 438) No. 441)
48 3 3 MCRD San 2002 A30 G36 C20 T36 A40 G29 C19 T31
2 6 6 Diego A30 G36 C20 T36 A40 G29 C19 T31
1 28 28 (Cultured) A30 G36 C20 T36 A41 G28 C18 T32
15 3 ND A30 G36 C20 T36 A40 G29 C19 T31
6 3 3 NHRC San 2003 A30 G36 C20 T36 A40 G29 C19 T31
3 5, 58 5 Diego- A30 G36 C20 T36 A40 G29 C19 T31
6 6 6 Archive A30 G36 C20 T36 A40 G29 C19 T31
1 11 11 (Cultured) A30 G36 C20 T36 A40 G29 C19 T31
3 12 12 A30 G36 C19 T37 A40 G29 C19 T31
1 22 22 A30 G36 C20 T36 A40 G29 C19 T31
3 25, 75 75 A30 G36 C20 T36 A40 G29 C19 T31
4 44/61, 82, 9 44/61 A30 G36 C20 T36 A41 G28 C19 T31
2 53, 91 91 A30 G36 C19 T37 A40 G29 C19 T31
1 2 2 Ft. 2003 A30 G36 C20 T36 A40 G29 C19 T31
2 3 3 Leonard A30 G36 C20 T36 A40 G29 C19 T31
1 4 4 Wood A30 G36 C19 T37 A41 G28 C19 T31
1 6 6 (Cultured) A30 G36 C20 T36 A40 G29 C19 T31
11 25 or 75 75 A30 G36 C20 T36 A40 G29 C19 T31
1 25, 75, 33, 75 A30 G36 C19 T37 A40 G29 C19 T31
34, 4, 52, 84
1 44/61 or 82 44/61 A30 G36 C20 T36 A41 G28 C19 T31
or 9
2 5 or 58 5 A30 G36 C20 T36 A40 G29 C19 T31
3 1 1 Ft. Sill 2003 A30 G36 C19 T37 A40 G29 C19 T31
2 3 3 (Cultured) A30 G36 C20 T36 A40 G29 C19 T31
1 4 4 A30 G36 C19 T37 A41 G28 C19 T31
1 28 28 A30 G36 C20 T36 A41 G28 C18 T32
1 3 3 Ft. 2003 A30 G36 C20 T36 A40 G29 C19 T31
1 4 4 Benning A30 G36 C19 T37 A41 G28 C19 T31
3 6 6 (Cultured) A30 G36 C20 T36 A40 G29 C19 T31
1 11 11 A30 G36 C20 T36 A40 G29 C19 T31
1 13 94** A30 G36 C20 T36 A41 G28 C19 T31
1 44/61 or 82 82 A30 G36 C20 T36 A41 G28 C19 T31
or 9
1 5 or 58 58 A30 G36 C20 T36 A40 G29 C19 T31
1 78 or 89 89 A30 G36 C20 T36 A41 G28 C19 T31
2 5 or 58 ND Lackland 2003 A30 G36 C20 T36 A40 G29 C19 T31
1 2 AFB A30 G36 C20 T36 A40 G29 C19 T31
1 81 or 90 (Throat A30 G36 C20 T36 A40 G29 C19 T31
1 78 Swabs) A30 G36 C20 T36 A41 G28 C19 T31
3*** No detection No detection No detection
7 3 ND MCRD San 2002 A30 G36 C20 T36 A40 G29 C19 T31
1 3 ND Diego A30 G36 C20 T36 A40 G29 C19 T31
1 3 ND (Throat A30 G36 C20 T36 No detection
1 3 ND Swabs) No detection A40 G29 C19 T31
2 3 ND A30 G36 C20 T36 A40 G29 C19 T31
3 No detection ND No detection No detection
TABLE 9C
Base Composition Analysis of Bioagent Identifying Amplicons of Group A Streptococcus
samples from Six Military Installations Obtained with Primer Pair Nos. 438 and 441
emm-type by gki gtr
# of Mass emm-Gene Location (Primer Pair ((Primer Pair
Instances Spectrometry Sequencing (sample) Year No. 442) No. 443)
48 3 3 MCRD San 2002 A32 G35 C17 T32 A39 G28 C16 T32
2 6 6 Diego A31 G35 C17 T33 A39 G28 C15 T33
1 28 28 (Cultured) A30 G36 C17 T33 A39 G28 C16 T32
15 3 ND A32 G35 C17 T32 A39 G28 C16 T32
6 3 3 NHRC San 2003 A32 G35 C17 T32 A39 G28 C16 T32
3 5, 58 5 Diego- A30 G36 C20 T30 A39 G28 C15 T33
6 6 6 Archive A31 G35 C17 T33 A39 G28 C15 T33
1 11 11 (Cultured) A30 G36 C20 T30 A39 G28 C16 T32
3 12 12 A31 G35 C17 T33 A39 G28 C15 T33
1 22 22 A31 G35 C17 T33 A38 G29 C15 T33
3 25, 75 75 A30 G36 C17 T33 A39 G28 C15 T33
4 44/61, 82, 9 44/61 A30 G36 C18 T32 A39 G28 C15 T33
2 53, 91 91 A32 G35 C17 T32 A39 G28 C16 T32
1 2 2 Ft. 2003 A30 G36 C17 T33 A39 G28 C15 T33
2 3 3 Leonard A32 G35 C17 T32 A39 G28 C16 T32
1 4 4 Wood A31 G35 C17 T33 A39 G28 C15 T33
1 6 6 (Cultured) A31 G35 C17 T33 A39 G28 C15 T33
11 25 or 75 75 A30 G36 C17 T33 A39 G28 C15 T33
1 25, 75, 33, 75 A30 G36 C17 T33 A39 G28 C15 T33
34, 4, 52, 84
1 44/61 or 82 44/61 A30 G36 C18 T32 A39 G28 C15 T33
or 9
2 5 or 58 5 A30 G36 C20 T30 A39 G28 C15 T33
3 1 1 Ft. Sill 2003 A30 G36 C18 T32 A39 G28 C15 T33
2 3 3 (Cultured) A32 G35 C17 T32 A39 G28 C16 T32
1 4 4 A31 G35 C17 T33 A39 G28 C15 T33
1 28 28 A30 G36 C17 T33 A39 G28 C16 T32
1 3 3 Ft. 2003 A32 G35 C17 T32 A39 G28 C16 T32
1 4 4 Benning A31 G35 C17 T33 A39 G28 C15 T33
3 6 6 (Cultured) A31 G35 C17 T33 A39 G28 C15 T33
1 11 11 A30 G36 C20 T30 A39 G28 C16 T32
1 13 94** A30 G36 C19 T31 A39 G28 C15 T33
1 44/61 or 82 82 A30 G36 C18 T32 A39 G28 C15 T33
or 9
1 5 or 58 58 A30 G36 C20 T30 A39 G28 C15 T33
1 78 or 89 89 A30 G36 C18 T32 A39 G28 C15 T33
2 5 or 58 ND Lackland 2003 A30 G36 C20 T30 A39 G28 C15 T33
1 2 AFB A30 G36 C17 T33 A39 G28 C15 T33
1 81 or 90 (Throat A30 G36 C17 T33 A39 G28 C15 T33
1 78 Swabs) A30 G36 C18 T32 A39 G28 C15 T33
3*** No detection No detection No detection
7 3 ND MCRD San 2002 A32 G35 C17 T32 A39 G28 C16 T32
1 3 ND Diego No detection No detection
1 3 ND (Throat A32 G35 C17 T32 A39 G28 C16 T32
1 3 ND Swabs) A32 G35 C17 T32 No detection
2 3 ND A32 G35 C17 T32 No detection
3 No detection ND No detection No detection
Example 8 Design of Calibrant Polynucleotides Based on Bioagent Identifying Amplicons for Identification of Species of Bacteria (Bacterial Bioagent Identifying Amplicons) This example describes the design of 19 calibrant polynucleotides based on bacterial bioagent identifying amplicons corresponding to the primers of the broad surveillance set (Table 5) and the Bacillus anthracis drill-down set (Table 6).
Calibration sequences were designed to simulate bacterial bioagent identifying amplicons produced by the T modified primer pairs shown in Tables 5 and 6 (primer names have the designation “TMOD”). The calibration sequences were chosen as a representative member of the section of bacterial genome from specific bacterial species which would be amplified by a given primer pair. The model bacterial species upon which the calibration sequences are based are also shown in Table 10. For example, the calibration sequence chosen to correspond to an amplicon produced by primer pair no. 361 is SEQ ID NO: 1445. In Table 10, the forward (_F) or reverse (_R) primer name indicates the coordinates of an extraction representing a gene of a standard reference bacterial genome to which the primer hybridizes e.g.: the forward primer name 16S_EC—713—732_TMOD_F indicates that the forward primer hybridizes to residues 713-732 of the gene encoding 16S ribosomal RNA in an E. coli reference sequence (in this case, the reference sequence is an extraction consisting of residues 4033120-4034661 of the genomic sequence of E. coli K12 (GenBank gi number 16127994). Additional gene coordinate reference information is shown in Table 11. The designation “TMOD” in the primer names indicates that the 5′ end of the primer has been modified with a non-matched template T residue which prevents the PCR polymerase from adding non-templated adenosine residues to the 5′ end of the amplification product, an occurrence which may result in miscalculation of base composition from molecular mass data (vide supra).
The 19 calibration sequences described in Tables 10 and 11 were combined into a single calibration polynucleotide sequence (SEQ ID NO: 1464—which is herein designated a “combination calibration polynucleotide”) which was then cloned into a pCR®-Blunt vector (Invitrogen, Carlsbad, Calif.). This combination calibration polynucleotide can be used in conjunction with the primers of Tables 5 or 6 as an internal standard to produce calibration amplicons for use in determination of the quantity of any bacterial bioagent. Thus, for example, when the combination calibration polynucleotide vector is present in an amplification reaction mixture, a calibration amplicon based on primer pair 346 (16S rRNA) will be produced in an amplification reaction with primer pair 346 and a calibration amplicon based on primer pair 363 (rpoC) will be produced with primer pair 363. Coordinates of each of the 19 calibration sequences within the calibration polynucleotide (SEQ ID NO: 1464) are indicated in Table 11. TABLE 10
Bacterial Primer Pairs for Production of Bacterial Bioagent Identifying
Amplicons and Corresponding Representative Calibration Sequences
Forward Reverse Calibration
Primer Primer Calibration Sequence
Primer (SEQ ID (SEQ ID Sequence Model (SEQ ID
Pair No. Forward Primer Name NO:) Reverse Primer Name NO:) Species NO:)
361 16S_EC_1090_1111_2_TMOD_F 697 16S_EC_1175_1196_TMOD_R 1398 Bacillus 1445
anthracis
346 16S_EC_713_732_TMOD_F 202 16S_EC_789_809_TMOD_R 1110 Bacillus 1446
anthracis
347 16S_EC_785_806_TMOD_F 560 16S_EC_880_897_TMOD_R 1278 Bacillus 1447
anthracis
348 16S_EC_960_981_TMOD_F 706 16S_EC_1054_1073_TMOD_R 895 Bacillus 1448
anthracis
349 23S_EC_1826_1843_TMOD_F 401 23S_EC_1906_1924_TMOD_R 1156 Bacillus 1449
anthracis
360 23S_EC_2646_2667_TMOD_F 409 23S_EC_2745_2765_TMOD_R 1434 Bacillus 1450
anthracis
350 CAPC_BA_274_303_TMOD_F 476 CAPC_BA_349_376_TMOD_R 1314 Bacillus 1451
anthracis
351 CYA_BA_1353_1379_TMOD_F 355 CYA_BA_1448_1467_TMOD_R 1423 Bacillus 1452
anthracis
352 INFB_EC_1365_1393_TMOD_F 687 INFB_EC_1439_1467_TMOD_R 1411 Bacillus 1453
anthracis
353 LEF_BA_756_781_TMOD_F 220 LEF_BA_843_872_TMOD_R 1394 Bacillus 1454
anthracis
356 RPLB_EC_650_679_TMOD_F 449 RPLB_EC_739_762_TMOD_R 1380 Clostridium 1455
botulinum
449 RPLB_EC_690_710_F 309 RPLB_EC_737_758_R 1336 Clostridium 1456
botulinum
359 RPOB_EC_1845_1866_TMOD_F 659 RPOB_EC_1909_1929_TMOD_R 1250 Yersinia 1457
Pestis
362 RPOB_EC_3799_3821_TMOD_F 581 RPOB_EC_3862_3888_TMOD_R 1325 Burkholderia 1458
mallei
363 RPOC_EC_2146_2174_TMOD_F 284 RPOC_EC_2227_2245_TMOD_R 898 Burkholderia 1459
mallei
354 RPOC_EC_2218_2241_TMOD_F 405 RPOC_EC_2313_2337_TMOD_R 1072 Bacillus 1460
anthracis
355 SSPE_BA_115_137_TMOD_F 255 SSPE_BA_197_222_TMOD_R 1402 Bacillus 1461
anthracis
367 TUFB_EC_957_979_TMOD_F 308 TUFB_EC_1034_1058_TMOD_R 1276 Burkholderia 1462
mallei
358 VALS_EC_1105_1124_TMOD_F 385 VALS_EC_1195_1218_TMOD_R 1093 Yersinia 1463
Pestis
TABLE 11
Primer Pair Gene Coordinate References and Calibration Polynucleotide Sequence
Coordinates within the Combination Calibration Polynucleotide
Coordinates of
Gene Extraction Calibration Sequence in
Bacterial Coordinates Reference GenBank GI Combination Calibration
Gene and of Genomic or Plasmid No. of Genomic (G) or Primer Polynucleotide (SEQ ID
Species Sequence Plasmid (P) Sequence Pair No. NO: 1464)
16S E. coli 4033120 . . . 4034661 16127994 (G) 346 16 . . . 109
16S E. coli 4033120 . . . 4034661 16127994 (G) 347 83 . . . 190
16S E. coli 4033120 . . . 4034661 16127994 (G) 348 246 . . . 353
16S E. coli 4033120 . . . 4034661 16127994 (G) 361 368 . . . 469
23S E. coli 4166220 . . . 4169123 16127994 (G) 349 743 . . . 837
23S E. coli 4166220 . . . 4169123 16127994 (G) 360 865 . . . 981
rpoB E. coli. 4178823 . . . 4182851 16127994 (G) 359 1591 . . . 1672
(complement strand)
rpos E. coli. 4178823 . . . 4182851 16127994 (G) 362 2081 . . . 2167
(complement strand)
rpoC E. coli 4182928 . . . 4187151 16127994 (G) 354 1810 . . . 1926
rpoC E. coli 4182928 . . . 4187151 16127994 (G) 363 2183 . . . 2279
infB E. coli. 3313655 . . . 3310983 16127994 (G) 352 1692 . . . 1791
(complement strand)
tufB E. coli 4173523 . . . 4174707 16127994 (G) 367 2400 . . . 2498
rplB E. coli 3449001 . . . 3448180 16127994 (G) 356 1945 . . . 2060
rplB E. coli 3449001 . . . 3448180 16127994 (G) 449 1986 . . . 2055
vals E. coli 4481405 . . . 4478550 16127994 (G) 358 1462 . . . 1572
(complement strand)
capC 56074 . . . 55628 6470151 (P) 350 2517 . . . 2616
B. anthracis (complement strand)
cya 156626 . . . 154288 4894216 (P) 351 1338 . . . 1449
B. anthracis (complement strand)
lef 127442 . . . 129921 4894216 (P) 353 1121 . . . 1234
B. anthracis
sspE 226496 . . . 226783 30253828 (G) 355 1007-1104
B. anthracis
Example 9 Use of a Calibration Polynucleotide for Determining the Quantity of Bacillus Anthracis in a Sample Containing a Mixture of Microbes The process described in this example is shown in FIG. 2. The capC gene is a gene involved in capsule synthesis which resides on the pX02 plasmid of Bacillus anthracis. Primer pair number 350 (see Tables 10 and 11) was designed to identify Bacillus anthracis via production of a bacterial bioagent identifying amplicon. Known quantities of the combination calibration polynucleotide vector described in Example 8 were added to amplification mixtures containing bacterial bioagent nucleic acid from a mixture of microbes which included the Ames strain of Bacillus anthracis. Upon amplification of the bacterial bioagent nucleic acid and the combination calibration polynucleotide vector with primer pair no. 350, bacterial bioagent identifying amplicons and calibration amplicons were obtained and characterized by mass spectrometry. A mass spectrum measured for the amplification reaction is shown in FIG. 7. The molecular masses of the bioagent identifying amplicons provided the means for identification of the bioagent from which they were obtained (Ames strain of Bacillus anthracis) and the molecular masses of the calibration amplicons provided the means for their identification as well. The relationship between the abundance (peak height) of the calibration amplicon signals and the bacterial bioagent identifying amplicon signals provides the means of calculation of the copies of the pX02 plasmid of the Ames strain of Bacillus anthracis. Methods of calculating quantities of molecules based on internal calibration procedures are well known to those of ordinary skill in the art.
Averaging the results of 10 repetitions of the experiment described above, enabled a calculation that indicated that the quantity of Ames strain of Bacillus anthracis present in the sample corresponds to approximately 10 copies of pX02 plasmid.
Example 10 Triangulation Genotyping Analysis of Campylobacter Species A series of triangulation genotyping analysis primers were designed as described in Example 1 with the objective of identification of different strains of Campylobacter jejuni. The primers are listed in Table 12 with the designation “CJST_CJ.” Housekeeping genes to which the primers hybridize and produce bioagent identifying amplicons include: tkt (transketolase), glyA (serine hydroxymethyltransferase), gltA (citrate synthase), aspA (aspartate ammonia lyase), glnA (glutamine synthase), pgm (phosphoglycerate mutase), and uncA (ATP synthetase alpha chain). TABLE 12
Campylobacter Genotyping Primer Pairs
Primer
Pair Forward Primer Reverse Primer
No. Forward Primer Name (SEQ ID NO:) Reverse Primer Name (SEQ ID NO:) Target Gene
1053 CJST_CJ_1080_1110_F 681 CJST_CJ_1166_1198_R 1022 gltA
1047 CJST_CJ_584_616_F 315 CJST_CJ_663_692_R 1379 glnA
1048 CJST_CJ_360_394_F 346 CJST_CJ_442_476_R 955 aspA
1049 CJST_CJ_2636_2668_F 504 CJST_CJ_2753_2777_R 1409 tkt
1054 CJST_CJ_2060_2090_F 323 CJST_CJ_2148_2174_R 1068 pgm
1064 CJST_CJ_1680_1713_F 479 CJST_CJ_1795_1822_R 938 glyA
The primers were used to amplify nucleic acid from 50 food product samples provided by the USDA, 25 of which contained Campylobacter jejuni and 25 of which contained Campylobacter coli. Primers used in this study were developed primarily for the discrimination of Campylobacter jejuni clonal complexes and for distinguishing Campylobacter jejuni from Campylobacter coli. Finer discrimination between Campylobacter coli types is also possible by using specific primers targeted to loci where closely-related Campylobacter coli isolates demonstrate polymorphisms between strains. The conclusions of the comparison of base composition analysis with sequence analysis are shown in Tables 13A-C. TABLE 13A
Results of Base Composition Analysis of 50 Campylobacter Samples with Drill-down
MLST Primer Pair Nos: 1048 and 1047
Base Base
Composition of Composition of
MLST type or Bioagent Bioagent
Clonal MLST Type Identifying Identifying
Complex by or Clonal Amplicon Amplicon
Base Complex by Obtained with Obtained with
Isolate Composition Sequence Primer Pair No: Primer Pair
Group Species origin analysis analysis Strain 1048 (aspA) No: 1047 (glnA)
J-1 C. jejuni Goose ST 690/ ST 991 RM3673 A30 G25 C16 T46 A47 G21 C16 T25
692/707/991
J-2 C. jejuni Human Complex ST 356, RM4192 A30 G25 C16 T46 A48 G21 C17 T23
206/48/353 complex
353
J-3 C. jejuni Human Complex ST 436 RM4194 A30 G25 C15 T47 A48 G21 C18 T22
354/179
J-4 C. jejuni Human Complex 257 ST 257, RM4197 A30 G25 C16 T46 A48 G21 C18 T22
complex
257
J-5 C. jejuni Human Complex 52 ST 52, RM4277 A30 G25 C16 T46 A48 G21 C17 T23
complex 52
J-6 C. jejuni Human Complex 443 ST 51, RM4275 A30 G25 C15 T47 A48 G21 C17 T23
complex RM4279 A30 G25 C15 T47 A48 G21 C17 T23
443
J-7 C. jejuni Human Complex 42 ST 604, RM1864 A30 G25 C15 T47 A48 G21 C18 T22
complex 42
J-8 C. jejuni Human Complex ST 362, RM3193 A30 G25 C15 T47 A48 G21 C18 T22
42/49/362 complex
362
J-9 C. jejuni Human Complex ST 147, RM3203 A30 G25 C15 T47 A47 G21 C18 T23
45/283 Complex 45
C. jejuni Human Consistent ST 828 RM4183 A31 G27 C20 T39 A48 G21 C16 T24
C-1 C. coli with 74 ST 832 RM1169 A31 G27 C20 T39 A48 G21 C16 T24
closely ST 1056 RM1857 A31 G27 C20 T39 A48 G21 C16 T24
Poultry related ST 889 RM1166 A31 G27 C20 T39 A48 G21 C16 T24
sequence ST 829 RM1182 A31 G27 C20 T39 A48 G21 C16 T24
types (none ST 1050 RM1518 A31 G27 C20 T39 A48 G21 C16 T24
belong to a ST 1051 RM1521 A31 G27 C20 T39 A48 G21 C16 T24
clonal ST 1053 RM1523 A31 G27 C20 T39 A48 G21 C16 T24
complex) ST 1055 RM1527 A31 G27 C20 T39 A48 G21 C16 T24
ST 1017 RM1529 A31 G27 C20 T39 A48 G21 C16 T24
ST 860 RM1840 A31 G27 C20 T39 A48 G21 C16 T24
ST 1063 RM2219 A31 G27 C20 T39 A48 G21 C16 T24
ST 1066 RM2241 A31 G27 C20 T39 A48 G21 C16 T24
ST 1067 RM2243 A31 G27 C20 T39 A48 G21 C16 T24
ST 1068 RM2439 A31 G27 C20 T39 A48 G21 C16 T24
Swine ST 1016 RM3230 A31 G27 C20 T39 A48 G21 C16 T24
ST 1069 RM3231 A31 G27 C20 T39 A48 G21 C16 T24
ST 1061 RM1904 A31 G27 C20 T39 A48 G21 C16 T24
Unknown ST 825 RM1534 A31 G27 C20 T39 A48 G21 C16 T24
ST 901 RM1505 A31 G27 C20 T39 A48 G21 C16 T24
C-2 C. coli Human ST 895 ST 895 RM1532 A31 G27 C19 T40 A48 G21 C16 T24
C-3 C. coli Poultry Consistent ST 1064 RM2223 A31 G27 C20 T39 A48 G21 C16 T24
with 63 ST 1082 RM1178 A31 G27 C20 T39 A48 G21 C16 T24
closely ST 1054 RM1525 A31 G27 C20 T39 A48 G21 C16 T24
related ST 1049 RM1517 A31 G27 C20 T39 A48 G21 C16 T24
Marmoset sequence ST 891 RM1531 A31 G27 C20 T39 A48 G21 C16 T24
types (none
belong to a
clonal
complex)
TABLE 13B
Results of Base Composition Analysis of 50 Campylobacter Samples with Drill-
down MLST Primer Pair Nos: 1053 and 1064
Base Base
Composition of Composition of
MLST type or Bioagent Bioagent
Clonal MLST Type Identifying Identifying
Complex by or Clonal Amplicon Amplicon
Base Complex by Obtained with Obtained with
Isolate Composition Sequence Primer Pair Primer Pair
Group Species origin analysis analysis Strain No: 1053 (gltA) No: 1064 (glyA)
J-1 C. jejuni Goose ST 690/ ST 991 RM3673 A24 G25 C23 T47 A40 G29 C29 T45
692/707/991
J-2 C. jejuni Human Complex ST 356, RM4192 A24 G25 C23 T47 A40 G29 C29 T45
206/48/353 complex
353
J-3 C. jejuni Human Complex ST 436 RM4194 A24 G25 C23 T47 A40 G29 C29 T45
354/179
J-4 C. jejuni Human Complex 257 ST 257, RM4197 A24 G25 C23 T47 A40 G29 C29 T45
complex
257
J-5 C. jejuni Human Complex 52 ST 52, RM4277 A24 G25 C23 T47 A39 G30 C26 T48
complex 52
J-6 C. jejuni Human Complex 443 ST 51, RM4275 A24 G25 C23 T47 A39 G30 C28 T46
complex RM4279 A24 G25 C23 T47 A39 G30 C28 T46
443
J-7 C. jejuni Human Complex 42 ST 604, RM1864 A24 G25 C23 T47 A39 G30 C26 T48
complex 42
J-8 C. jejuni Human Complex ST 362, RM3193 A24 G25 C23 T47 A38 G31 C28 T46
42/49/362 complex
362
J-9 C. jejuni Human Complex ST 147, RM3203 A24 G25 C23 T47 A38 G31 C28 T46
45/283 Complex 45
C. jejuni Human Consistent ST 828 RM4183 A23 G24 C26 T46 A39 G30 C27 T47
C-1 C. coli with 74 ST 832 RM1169 A23 G24 C26 T46 A39 G30 C27 T47
closely ST 1056 RM1857 A23 G24 C26 T46 A39 G30 C27 T47
Poultry related ST 889 RM1166 A23 G24 C26 T46 A39 G30 C27 T47
sequence ST 829 RM1182 A23 G24 C26 T46 A39 G30 C27 T47
types (none ST 1050 RM1518 A23 G24 C26 T46 A39 G30 C27 T47
belong to a ST 1051 RM1521 A23 G24 C26 T46 A39 G30 C27 T47
clonal ST 1053 RM1523 A23 G24 C26 T46 A39 G30 C27 T47
complex) ST 1055 RM1527 A23 G24 C26 T46 A39 G30 C27 T47
ST 1017 RM1529 A23 G24 C26 T46 A39 G30 C27 T47
ST 860 RM1840 A23 G24 C26 T46 A39 G30 C27 T47
ST 1063 RM2219 A23 G24 C26 T46 A39 G30 C27 T47
ST 1066 RM2241 A23 G24 C26 T46 A39 G30 C27 T47
ST 1067 RM2243 A23 G24 C26 T46 A39 G30 C27 T47
ST 1068 RM2439 A23 G24 C26 T46 A39 G30 C27 T47
Swine ST 1016 RM3230 A23 G24 C26 T46 A39 G30 C27 T47
ST 1069 RM3231 A23 G24 C26 T46 NO DATA
ST 1061 RM1904 A23 G24 C26 T46 A39 G30 C27 T47
Unknown ST 825 RM1534 A23 G24 C26 T46 A39 G30 C27 T47
ST 901 RM1505 A23 G24 C26 T46 A39 G30 C27 T47
C-2 C. coli Human ST 895 ST 895 RM1532 A23 G24 C26 T46 A39 G30 C27 T47
C-3 C. coli Poultry Consistent ST 1064 RM2223 A23 G24 C26 T46 A39 G30 C27 T47
with 63 ST 1082 RM1178 A23 G24 C26 T46 A39 G30 C27 T47
closely ST 1054 RM1525 A23 G24 C25 T47 A39 G30 C27 T47
related ST 1049 RM1517 A23 G24 C26 T46 A39 G30 C27 T47
Marmoset sequence ST 891 RM1531 A23 G24 C26 T46 A39 G30 C27 T47
types (none
belong to a
clonal
complex)
TABLE 13C
Results of Base Composition Analysis of 50 Campylobacter Samples with Drill-
down MLST Primer Pair Nos: 1054 and 1049
Base Base
Composition of Composition of
MLST type or Bioagent Bioagent
Clonal MLST Type Identifying Identifying
Complex by or Clonal Amplicon Amplicon
Base Complex by Obtained with Obtained with
Isolate Composition Sequence Primer Pair No: Primer Pair
Group Species origin analysis analysis Strain 1054 (pgm) No: 1049 (tkt)
J-1 C. jejuni Goose ST 690/ ST 991 RM3673 A26 G33 C18 T38 A41 G28 C35 T38
692/707/991
J-2 C. jejuni Human Complex ST 356, RM4192 A26 G33 C19 T37 A41 G28 C36 T37
206/48/353 complex
353
J-3 C. jejuni Human Complex ST 436 RM4194 A27 G32 C19 T37 A42 G28 C36 T36
354/179
J-4 C. jejuni Human Complex 257 ST 257, RM4197 A27 G32 C19 T37 A41 G29 C35 T37
complex
257
J-5 C. jejuni Human Complex 52 ST 52, RM4277 A26 G33 C18 T38 A41 G28 C36 T37
complex 52
J-6 C. jejuni Human Complex 443 ST 51, RM4275 A27 G31 C19 T38 A41 G28 C36 T37
complex RM4279 A27 G31 C19 T38 A41 G28 C36 T37
443
J-7 C. jejuni Human Complex 42 ST 604, RM1864 A27 G32 C19 T37 A42 G28 C35 T37
complex 42
J-8 C. jejuni Human Complex ST 362, RM3193 A26 G33 C19 T37 A42 G28 C35 T37
42/49/362 complex
362
J-9 C. jejuni Human Complex ST 147, RM3203 A28 G31 C19 T37 A43 G28 C36 T35
45/283 Complex 45
C. jejuni Human Consistent ST 828 RM4183 A27 G30 C19 T39 A46 G28 C32 T36
C-1 C. coli with 74 ST 832 RM1169 A27 G30 C19 T39 A46 G28 C32 T36
closely ST 1056 RM1857 A27 G30 C19 T39 A46 G28 C32 T36
Poultry related ST 889 RM1166 A27 G30 C19 T39 A46 G28 C32 T36
sequence ST 829 RM1182 A27 G30 C19 T39 A46 G28 C32 T36
types (none ST 1050 RM1518 A27 G30 C19 T39 A46 G28 C32 T36
belong to a ST 1051 RM1521 A27 G30 C19 T39 A46 G28 C32 T36
clonal ST 1053 RM1523 A27 G30 C19 T39 A46 G28 C32 T36
complex) ST 1055 RM1527 A27 G30 C19 T39 A46 G28 C32 T36
ST 1017 RM1529 A27 G30 C19 T39 A46 G28 C32 T36
ST 860 RM1840 A27 G30 C19 T39 A46 G28 C32 T36
ST 1063 RM2219 A27 G30 C19 T39 A46 G28 C32 T36
ST 1066 RM2241 A27 G30 C19 T39 A46 G28 C32 T36
ST 1067 RM2243 A27 G30 C19 T39 A46 G28 C32 T36
ST 1068 RM2439 A27 G30 C19 T39 A46 G28 C32 T36
Swine ST 1016 RM3230 A27 G30 C19 T39 A46 G28 C32 T36
ST 1069 RM3231 A27 G30 C19 T39 A46 G28 C32 T36
ST 1061 RM1904 A27 G30 C19 T39 A46 G28 C32 T36
Unknown ST 825 RM1534 A27 G30 C19 T39 A46 G28 C32 T36
ST 901 RM1505 A27 G30 C19 T39 A46 G28 C32 T36
C-2 C. coli Human ST 895 ST 895 RM1532 A27 G30 C19 T39 A45 G29 C32 T36
C-3 C. coli Poultry Consistent ST 1064 RM2223 A27 G30 C19 T39 A45 G29 C32 T36
with 63 ST 1082 RM1178 A27 G30 C19 T39 A45 G29 C32 T36
closely ST 1054 RM1525 A27 G30 C19 T39 A45 G29 C32 T36
related ST 1049 RM1517 A27 G30 C19 T39 A45 G29 C32 T36
Marmoset sequence ST 891 RM1531 A27 G30 C19 T39 A45 G29 C32 T36
types (none
belong to a
clonal
complex)
The base composition analysis method was successful in identification of 12 different strain groups. Campylobacter jejuni and Campylobacter coli are generally differentiated by all loci. Ten clearly differentiated Campylobacter jejuni isolates and 2 major Campylobacter coli groups were identified even though the primers were designed for strain typing of Campylobacter jejuni. One isolate (RM4183) which was designated as Campylobacter jejuni was found to group with Campylobacter coli and also appears to actually be Campylobacter coli by full MLST sequencing.
Example 11 Identification of Acinetobacter baumannii Using Broad Range Survey and Division-Wide Primers in Epidemiological Surveillance To test the capability of the broad range survey and division-wide primer sets of Table 5 in identification of Acinetobacter species, 183 clinical samples were obtained from individuals participating in, or in contact with individuals participating in Operation Iraqi Freedom (including US service personnel, US civilian patients at the Walter Reed Army Institute of Research (WRAIR), medical staff, Iraqi civilians and enemy prisoners. In addition, 34 environmental samples were obtained from hospitals in Iraq, Kuwait, Germany, the United States and the USNS Comfort, a hospital ship.
Upon amplification of nucleic acid obtained from the clinical samples, primer pairs 346-349, 360, 361, 354, 362 and 363 (Table 5) all produced bacterial bioagent amplicons which identified Acinetobacter baumannii in 215 of 217 samples. The organism Klebsiella pneumoniae was identified in the remaining two samples. In addition, 14 different strain types (containing single nucleotide polymorphisms relative to a reference strain of Acinetobacter baumannii) were identified and assigned arbitrary numbers from 1 to 14. Strain type 1 was found in 134 of the sample isolates and strains 3 and 7 were found in 46 and 9 of the isolates respectively.
The epidemiology of strain type 7 of Acinetobacter baumannii was investigated. Strain 7 was found in 4 patients and 5 environmental samples (from field hospitals in Iraq and Kuwait). The index patient infected with strain 7 was a pre-war patient who had a traumatic amputation in March of 2003 and was treated at a Kuwaiti hospital. The patient was subsequently transferred to a hospital in Germany and then to WRAIR. Two other patients from Kuwait infected with strain 7 were found to be non-infectious and were not further monitored. The fourth patient was diagnosed with a strain 7 infection in September of 2003 at WRAIR. Since the fourth patient was not related involved in Operation Iraqi Freedom, it was inferred that the fourth patient was the subject of a nosocomial infection acquired at WRAIR as a result of the spread of strain 7 from the index patient.
The epidemiology of strain type 3 of Acinetobacter baumannii was also investigated. Strain type 3 was found in 46 samples, all of which were from patients (US service members, Iraqi civilians and enemy prisoners) who were treated on the USNS Comfort hospital ship and subsequently returned to Iraq or Kuwait. The occurrence of strain type 3 in a single locale may provide evidence that at least some of the infections at that locale were a result of nosocomial infections.
This example thus illustrates an embodiment of the present invention wherein the methods of analysis of bacterial bioagent identifying amplicons provide the means for epidemiological surveillance.
Example 12 Selection and Use of Triangulation Genotyping Analysis Primer Pairs for Acinetobacter baumanii To combine the power of high-throughput mass spectrometric analysis of bioagent identifying amplicons with the sub-species characteristic resolving power provided by triangulation genotyping analysis, an additional 21 primer pairs were selected based on analysis of housekeeping genes of the genus Acinetobacter. Genes to which the drill-down triangulation genotyping analysis primers hybridize for production of bacterial bioagent identifying amplicons include anthranilate synthase component I (trpE), adenylate kinase (adk), adenine glycosylase (mutY), fumarate hydratase (fumC), and pyrophosphate phospho-hydratase (ppa). These 21 primer pairs are indicated with reference to sequence listings in Table 14. Primer pair numbers 1151-1154 hybridize to and amplify segments of trpE. Primer pair numbers 1155-1157 hybridize to and amplify segments of adk. Primer pair numbers 1158-1164 hybridize to and amplify segments of mutY. Primer pair numbers 1165-1170 hybridize to and amplify segments of fumC. Primer pair number 1171 hybridizes to and amplifies a segment of ppa. Primer pair numbers: 2846-2848 hybridize to and amplify segments of the parC gene of DNA topoisomerase which include a codon known to confer quinolone drug resistance upon sub-types of Acinetobacter baumannii. Primer pair numbers 2852-2854 hybridize to and amplify segments of the gyrA gene of DNA gyrase which include a codon known to confer quinolone drug resistance upon sub-types of Acinetobacter baumannii. Primer pair numbers 2922 and 2972 are speciating primers which are useful for identifying different species members of the genus Acinetobacter. The primer names given in Table 14A (with the exception of primer pair numbers 2846-2848, 2852-2854) indicate the coordinates to which the primers hybridize to a reference sequence which comprises a concatenation of the genes TrpE, efp (elongation factor p), adk, mutT, fumC, and ppa. For example, the forward primer of primer pair 1151 is named AB_MLST-11-OIF007—62—91_F because it hybridizes to the Acinetobacter primer reference sequence of strain type 11 in sample 007 of Operation Iraqi Freedom (OIF) at positions 62 to 91. DNA was sequenced from strain type 11 and from this sequence data and an artificial concatenated sequence of partial gene extractions was assembled for use in design of the triangulation genotyping analysis primers. The stretches of arbitrary residues “N”s in the concatenated sequence were added for the convenience of separation of the partial gene extractions (40N for AB_MLST (SEQ ID NO: 1444)).
The hybridization coordinates of primer pair numbers 2846-2848 are with respect to GenBank Accession number X95819. The hybridization coordinates of primer pair numbers 2852-2854 are with respect to GenBank Accession number AY642140. Sequence residue “I” appearing in the forward and reverse primers of primer pair number 2972 represents inosine. TABLE 14A
Triangulation Genotyping Analysis Primer Pairs for Identification of Sub-species
characteristics (Strain Type) of Members of the Bacterial Genus Acinetobacter
Primer Forward Primer Reverse Primer
Pair No. Forward Primer Name (SEQ ID NO:) Reverse Primer Name (SEQ ID NO:)
1151 AB_MLST-11-OIF007_62_91_F 454 AB_MLST-11-OIF007_169_203_R 1418
1152 AB_MLST-11-OIF007_185_214_F 243 AB_MLST-11-OIF007_291_324_R 969
1153 AB_MLST-11-OIF007_260_289_F 541 AB_MLST-11-OIF007_364_393_R 1400
1154 AB_MLST-11-OIF007_206_239_F 436 AB_MLST-11-OIF007_318_344_R 1036
1155 AB_MLST-11-OIF007_522_552_F 378 AB_MLST-11-OIF007_587_610_R 1392
1156 AB_MLST-11-OIF007_547_571_F 250 AB_MLST-11-OIF007_656_686_R 902
1157 AB_MLST-11-OIF007_601_627_F 256 AB_MLST-11-OIF007_710_736_R 881
1158 AB_MLST-11-OIF007_1202_1225_F 384 AB_MLST-11-OIF007_1266_1296_R 878
1159 AB_MLST-11-OIF007_1202_1225_F 384 AB_MLST-11-OIF007_1299_1316_R 1199
1160 AB_MLST-11-OIF007_1234_1264_F 694 AB_MLST-11-OIF007_1335_1362_R 1215
1161 AB_MLST-11-OIF007_1327_1356_F 225 AB_MLST-11-OIF007_1422_1448_R 1212
1162 AB_MLST-11-OIF007_1345_1369_F 383 AB_MLST-11-OIF007_1470_1494_R 1083
1163 AB_MLST-11-OIF007_1351_1375_F 662 AB_MLST-11-OIF007_1470_1494_R 1083
1164 AB_MLST-11-OIF007_1387_1412_F 422 AB_MLST-11-OIF007_1470_1494_R 1083
1165 AB_MLST-11-OIF007_1542_1569_F 194 AB_MLST-11-OIF007_1656_1680_R 1173
1166 AB_MLST-11-OIF007_1566_1593_F 684 AB_MLST-11-OIF007_1656_1680_R 1173
1167 AB_MLST-11-OIF007_1611_1638_F 375 AB_MLST-11-OIF007_1731_1757_R 890
1168 AB_MLST-11-OIF007_1726_1752_F 182 AB_MLST-11-OIF007_1790_1821_R 1195
1169 AB_MLST-11-OIF007_1792_1826_F 656 AB_MLST-11-OIF007_1876_1909_R 1151
1170 AB_MLST-11-OIF007_1792_1826_F 656 AB_MLST-11-OIF007_1895_1927_R 1224
1171 AB_MLST-11-OIF007_1970_2002_F 618 AB_MLST-11-OIF007_2097_2118_R 1157
2846 PARC_X95819_33_58_F 302 PARC_X95819_121_153_R 852
2847 PARC_X95819_33_58_F 199 PARC_X95819_157_178_R 889
2848 PARC_X95819_33_58_F 596 PARC_X95819_97_128_R 1169
2852 GYRA_AY642140_−1_24_F 150 GYRA_AY642140_71_100_R 1242
2853 GYRA_AY642140_26_54_F 166 GYRA_AY642140_121_146_R 1069
2854 GYRA_AY642140_26_54_F 166 GYRA_AY642140_58_89_R 1168
2922 AB_MLST-11-OIF007_991_1018_F 583 AB_MLST-11-OIF007_1110_1137_R 923
2972 AB_MLST-11-OIF007_1007_1034_F 592 AB_MLST-11-OIF007_1126_1153_R 924
TABLE 14B
Triangulation Genotyping Analysis Primer Pairs for Identification of Sub-species
characteristics (Strain Type) of Members of the Bacterial Genus Acinetobacter
Primer Reverse
Primer Forward Primer
Pair (SEQ ID (SEQ ID
No. NO:) SEQUENCE NO:) SEQUENCE
1151 454 TGAGATTGCTGAACATTTAATGCTGATTGA 1418 TTGTACATTTGAAACAATATGCATGACATGTGAAT
1152 243 TATTGTTTCAAATGTACAAGGTGAAGTGCG 969 TCACAGGTTCTACTTCATCAATAATTTCCATTGC
1153 541 TGGAACGTTATCAGGTGCCCCAAAAATTCG 1400 TTGCAATCGACATATCCATTTCACCATGCC
1154 436 TGAAGTGCGTGATGATATCGATGCACTTGATGTA 1036 TCCGGCAAAAACTCCCCTTTTCACAGG
1155 378 TCGGTTTAGTAAAAGAACGTATTGCTCAACC 1392 TTCTGCTTGAGGAATAGTGCGTGG
1156 250 TCAACCTGACTGCGTGAATGGTTGT 902 TACGTTCTACGATTTCTTCATCAGGTACATC
1157 256 TCAAGCAGAAGCTTTGGAAGAAGAAGG 881 TACAACGTGATAAACACGACCAGAAGC
1158 384 TCGTGCCCGCAATTTGCATAAAGC 878 TAATGCCGGGTAGTGCAATCCATTCTTCTAG
1159 384 TCGTGCCCGCAATTTGCATAAAGC 1199 TGCACCTGCGGTCGAGCG
1160 694 TTGTAGCACAGCAAGGCAAATTTCCTGAAAC 1215 TGCCATCCATAATCACGCCATACTGACG
1161 225 TAGGTTTACGTCAGTATGGCGTGATTATGG 1212 TGCCAGTTTCCACATTTCACGTTCGTG
1162 383 TCGTGATTATGGATGGCAACGTGAA 1083 TCGCTTGAGTGTAGTCATGATTGCG
1163 662 TTATGGATGGCAACGTGAAACGCGT 1083 TCGCTTGAGTGTAGTCATGATTGCG
1164 422 TCTTTGCCATTGAAGATGACTTAAGC 1083 TCGCTTGAGTGTAGTCATGATTGCG
1165 194 TACTAGCGGTAAGCTTAAACAAGATTGC 1173 TGAGTCGGGTTCACTTTACCTGGCA
1166 684 TTGCCAATGATATTCGTTGGTTAGCAAG 1173 TGAGTCGGGTTCACTTTACCTGGCA
1167 375 TCGGCGAAATCCGTATTCCTGAAAATGA 890 TACCGGAAGCACCAGCGACATTAATAG
1168 182 TACCACTATTAATGTCGCTGGTGCTTC 1195 TGCAACTGAATAGATTGCAGTAAGTTATAAGC
1169 656 TTATAACTTACTGCAATCTATTCAGTTGCTTGGTG 1151 TGAATTATGCAAGAAGTGATCAATTTTCTCACGA
1170 656 TTATAACTTACTGCAATCTATTCAGTTGCTTGGTG 1224 TGCCGTAACTAACATAAGAGAATTATGCAAGAA
1171 618 TGGTTATGTACCAAATACTTTGTCTGAAGATGG 1157 TGACGGCATCGATACCACCGTC
2846 302 TCCAAAAAAATCAGCGCGTACAGTGG 852 TAAAGGATAGCGGTAACTAAATGGCTGAGCCAT
2847 199 TACTTGGTAAATACCACCCACATGGTGA 889 TACCCCAGTTCCCCTGACCTTC
2848 596 TGGTAAATACCACCCACATGGTGAC 1169 TGAGCCATGAGTACCATGGCTTCATAACATGC
2852 150 TAAATCTGCCCGTGTCGTTGGTGAC 1242 TGCTAAAGTCTTGAGCCATACGAACAATGG
2853 166 TAATCGGTAAATATCACCCGCATGGTGAC 1069 TCGATCGAACCGAAGTTACCCTGACC
2854 166 TAATCGGTAAATATCACCCGCATGGTGAC 1168 TGAGCCATACGAACAATGGTTTCATAAACAGC
2922 583 TGGGCGATGCTGCGAAATGGTTAAAAGA 923 TAGTATCACCACGTACACCCGGATCAGT
2972 592 TGGGIGATGCTGCIAAATGGTTAAAAGA 924 TAGTATCACCACGTACICCIGGATCAGT
Analysis of bioagent identifying amplicons obtained using the primers of Table 14B for over 200 samples from Operation Iraqi Freedom resulted in the identification of 50 distinct strain type clusters. The largest cluster, designated strain type 11 (ST11) includes 42 sample isolates, all of which were obtained from US service personnel and Iraqi civilians treated at the 28th Combat Support Hospital in Baghdad. Several of these individuals were also treated on the hospital ship USNS Comfort. These observations are indicative of significant epidemiological correlation/linkage.
All of the sample isolates were tested against a broad panel of antibiotics to characterize their antibiotic resistance profiles. As an example of a representative result from antibiotic susceptibility testing, ST11 as found to consist of four different clusters of isolates, each with a varying degree of sensitivity/resistance to the various antibiotics tested which included penicillins, extended spectrum penicillins, cephalosporins, carbepenem, protein synthesis inhibitors, nucleic acid synthesis inhibitors, anti-metabolites, and anti-cell membrane antibiotics. Thus, the genotyping power of bacterial bioagent identifying amplicons, particularly drill-down bacterial bioagent identifying amplicons, has the potential to increase the understanding of the transmission of infections in combat casualties, to identify the source of infection in the environment, to track hospital transmission of nosocomial infections, and to rapidly characterize drug-resistance profiles which enable development of effective infection control measures on a time-scale previously not achievable.
Example 13 Triangulation Genotyping Analysis and Codon Analysis of Acinetobacter baumannii Samples from Two Health Care Facilities In this investigation, 88 clinical samples were obtained from Walter Reed Hospital and 95 clinical samples were obtained from Northwestern Medical Center. All samples from both healthcare facilities were suspected of containing sub-types of Acinetobacter baumannii, at least some of which were expected to be resistant to quinolone drugs. Each of the 183 samples was analyzed by the method of the present invention. DNA was extracted from each of the samples and amplified with eight triangulation genotyping analysis primer pairs represented by primer pair numbers: 1151, 1156, 1158, 1160, 1165, 1167, 1170, and 1171. The DNA was also amplified with speciating primer pair number 2922 and codon analysis primer pair numbers 2846-2848 which interrogate a codon present in the parC gene, and primer pair numbers 2852-2854 which bracket a codon present in the gyrA gene. The parC and gyrA codon mutations are both responsible for causing drug resistance in Acinetobacter baumannii. During evolution of drug resistant strains, the gyrA mutation usually occurs before the parC mutation. Amplification products were measured by ESI-TOF mass spectrometry as indicated in Example 4. The base compositions of the amplification products were calculated from the average molecular masses of the amplification products and are shown in Tables 15-18. The entries in each of the tables are grouped according to strain type number, which is an arbitrary number assigned to Acinetobacter baumannii strains in the order of observance beginning from the triangulation genotyping analysis OIF genotyping study described in Example 12. For example, strain type 11 which appears in samples from the Walter Reed Hospital is the same strain as the strain type 11 mentioned in Example 12. Ibis# refers to the order in which each sample was analyzed. Isolate refers to the original sample isolate numbering system used at the location from which the samples were obtained (either Walter Reed Hospital or Northwestern Medical Center). ST=strain type. ND=not detected. Base compositions highlighted with bold type indicate that the base composition is a unique base composition for the amplification product obtained with the pair of primers indicated. TABLE 15A
Base Compositions of Amplification Products of 88 A. baumannii Samples Obtained from
Walter Reed Hospital and Amplified with Codon Analysis Primer Pairs Targeting the gyrA Gene
PP No: 2852 PP No: 2853 PP No: 2854
Species Ibis# Isolate ST gyrA gyrA gyrA
A. baumannii 20 1082 1 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 13 854 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 22 1162 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 27 1230 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 31 1367 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 37 1459 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 55 1700 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 64 1777 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 73 1861 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 74 1877 10 ND A29G28C21T43 A17G13C13T21
A. baumannii 86 1972 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 3 684 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 6 720 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 7 726 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 19 1079 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 21 1123 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 23 1188 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 33 1417 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 34 1431 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 38 1496 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 40 1523 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 42 1640 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 50 1666 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 51 1668 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 52 1695 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 65 1781 11 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 44 1649 12 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 49A 1658.1 12 A25G23C22T31 A29G28C21T43 A17G13C13T21
A. baumannii 49B 1658.2 12 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 56 1707 12 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 80 1893 12 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 5 693 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 8 749 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 10 839 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 14 865 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 16 888 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 29 1326 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 35 1440 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 41 1524 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 46 1652 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 47 1653 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 48 1657 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 57 1709 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 61 1727 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 63 1762 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 67 1806 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 75 1881 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 77 1886 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 1 649 46 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 2 653 46 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 39 1497 16 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 24 1198 15 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 28 1243 15 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 43 1648 15 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 62 1746 15 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 4 689 15 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 68 1822 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 69 1823A 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 70 1823B 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 71 1826 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 72 1860 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 81 1924 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 82 1929 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 85 1966 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 11 841 3 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 32 1415 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 45 1651 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 54 1697 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 58 1712 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 60 1725 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 66 1802 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 76 1883 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 78 1891 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 79 1892 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 83 1947 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 84 1964 24 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 53 1696 24 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 36 1458 49 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 59 1716 9 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 9 805 30 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 18 967 39 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 30 1322 48 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. baumannii 26 1218 50 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. sp. 13TU 15 875 A1 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. sp. 13TU 17 895 A1 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. sp. 3 12 853 B7 A25G22C22T32 A30G29C22T40 A17G13C14T20
A. johnsonii 25 1202 NEW1 A25G22C22T32 A30G29C22T40 A17G13C14T20
A. sp. 2082 87 2082 NEW2 A25G22C22T32 A31G28C22T40 A17G13C14T20
TABLE 15B
Base Compositions Determined from A. baumannii DNA Samples Obtained from Walter
Reed Hospital and Amplified with Codon Analysis Primer Pairs Targeting the parC Gene
PP No: 2846 PP No: 2847 PP No: 2848
Species Ibis# Isolate ST parC parC parC
A. baumannii 20 1082 1 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 13 854 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 22 1162 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 27 1230 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 31 1367 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 37 1459 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 55 1700 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 64 1777 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 73 1861 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 74 1877 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 86 1972 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 3 684 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 6 720 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 7 726 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 19 1079 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 21 1123 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 23 1188 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 33 1417 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 34 1431 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 38 1496 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 40 1523 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 42 1640 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 50 1666 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 51 1668 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 52 1695 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 65 1781 11 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 44 1649 12 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 49A 1658.1 12 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 49B 1658.2 12 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 56 1707 12 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 80 1893 12 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 5 693 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 8 749 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 10 839 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 14 865 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 16 888 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 29 1326 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 35 1440 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 41 1524 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 46 1652 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 47 1653 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 48 1657 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 57 1709 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 61 1727 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 63 1762 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 67 1806 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 75 1881 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 77 1886 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 1 649 46 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 2 653 46 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 39 1497 16 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 24 1198 15 A33G26C28T34 A29G29C23T33 A16G14C14T16
A. baumannii 28 1243 15 A33G26C28T34 A29G29C23T33 A16G14C14T16
A. baumannii 43 1648 15 A33G26C28T34 A29G29C23T33 A16G14C14T16
A. baumannii 62 1746 15 A33G26C28T34 A29G29C23T33 A16G14C14T16
A. baumannii 4 689 15 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 68 1822 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 69 1823A 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 70 1823B 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 71 1826 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 72 1860 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 81 1924 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 82 1929 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 85 1966 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 11 841 3 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 32 1415 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 45 1651 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 54 1697 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 58 1712 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 60 1725 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 66 1802 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 76 1883 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 78 1891 24 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 79 1892 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 83 1947 24 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 84 1964 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 53 1696 24 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 36 1458 49 A34G26C29T32 A30G28C24T32 A16G14C15T15
A. baumannii 59 1716 9 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 9 805 30 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 18 967 39 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 30 1322 48 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 26 1218 50 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. sp. 13TU 15 875 A1 A32G26C28T35 A28G28C24T34 A16G14C15T15
A. sp. 13TU 17 895 A1 A32G26C28T35 A28G28C24T34 A16G14C15T15
A. sp. 3 12 853 B7 A29G26C27T39 A26G32C21T35 A16G14C15T15
A. johnsonii 25 1202 NEW1 A32G28C26T35 A29G29C22T34 A16G14C15T15
A. sp. 2082 87 2082 NEW2 A33G27C26T35 A31G28C20T35 A16G14C15T15
TABLE 16A
Base Compositions Determined from A. baumannii DNA Samples Obtained from
Northwestern Medical Center and Amplified with Codon Analysis Primer Pairs Targeting
the gyrA Gene
PP No: 2852 PP No: 2853 PP No: 2854
Species Ibis# Isolate ST gyrA gyrA gyrA
A. baumannii 54 536 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 87 665 3 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 8 80 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 9 91 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 10 92 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 11 131 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 12 137 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 21 218 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 26 242 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 94 678 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 1 9 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 2 13 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 3 19 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 4 24 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 5 36 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 6 39 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 13 139 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 15 165 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 16 170 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 17 186 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 20 202 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 22 221 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 24 234 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 25 239 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 33 370 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 34 389 10 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 19 201 14 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 27 257 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 29 301 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 31 354 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 36 422 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 37 424 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 38 434 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 39 473 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 40 482 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 44 512 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 45 516 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 47 522 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 48 526 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 50 528 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 52 531 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 53 533 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 56 542 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 59 550 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 62 556 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 64 557 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 70 588 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 73 603 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 74 605 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 75 606 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 77 611 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 79 622 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 83 643 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 85 653 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 89 669 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 93 674 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 23 228 51 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 32 369 52 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 35 393 52 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 30 339 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 41 485 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 42 493 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 43 502 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 46 520 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 49 527 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 51 529 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 65 562 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 68 579 53 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 57 546 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 58 548 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 60 552 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 61 555 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 63 557 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 66 570 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 67 578 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 69 584 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 71 593 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 72 602 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 76 609 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 78 621 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 80 625 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 81 628 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 82 632 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 84 649 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 86 655 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 88 668 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 90 671 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 91 672 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 92 673 54 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 18 196 55 A25G23C22T31 A29G28C21T43 A17G13C13T21
A. baumannii 55 537 27 A25G23C21T32 A29G28C21T43 A17G13C13T21
A. baumannii 28 263 27 A25G23C22T31 A29G28C22T42 A17G13C14T20
A. sp. 3 14 164 B7 A25G22C22T32 A30G29C22T40 A17G13C14T20
mixture 7 71 — ND ND A17G13C15T19
TABLE 16B
Base Compositions Determined from A. baumannii DNA Samples Obtained from
Northwestern Medical Center and Amplified with Codon Analysis
Primer Pairs Targeting the parC Gene
PP No: 2846 PP No: 2847 PP No: 2848
Species Ibis# Isolate ST parC parC parC
A. baumannii 54 536 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 87 665 3 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 8 80 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 9 91 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 10 92 10 A33G26C28T34 A29G28C25T32 ND
A. baumannii 11 131 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 12 137 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 21 218 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 26 242 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 94 678 10 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 1 9 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 2 13 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 3 19 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 4 24 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 5 36 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 6 39 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 13 139 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 15 165 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 16 170 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 17 186 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 20 202 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 22 221 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 24 234 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 25 239 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 33 370 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 34 389 10 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 19 201 14 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 27 257 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 29 301 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 31 354 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 36 422 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 37 424 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 38 434 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 39 473 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 40 482 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 44 512 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 45 516 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 47 522 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 48 526 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 50 528 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 52 531 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 53 533 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 56 542 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 59 550 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 62 556 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 64 557 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 70 588 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 73 603 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 74 605 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 75 606 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 77 611 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 79 622 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 83 643 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 85 653 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 89 669 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 93 674 51 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 23 228 51 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 32 369 52 A34G25C28T34 A30G27C25T32 A16G14C14T16
A. baumannii 35 393 52 A34G25C28T34 A30G27C25T32 A16G14C14T16
A. baumannii 30 339 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 41 485 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 42 493 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 43 502 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 46 520 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 49 527 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 51 529 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 65 562 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 68 579 53 A34G25C29T33 A30G27C26T31 A16G14C15T15
A. baumannii 57 546 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 58 548 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 60 552 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 61 555 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 63 557 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 66 570 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 67 578 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 69 584 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 71 593 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 72 602 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 76 609 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 78 621 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 80 625 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 81 628 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 82 632 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 84 649 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 86 655 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 88 668 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 90 671 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 91 672 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 92 673 54 A33G26C28T34 A29G28C25T32 A16G14C14T16
A. baumannii 18 196 55 A33G27C28T33 A29G28C25T31 A15G14C15T16
A. baumannii 55 537 27 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. baumannii 28 263 27 A33G26C29T33 A29G28C26T31 A16G14C15T15
A. sp. 3 14 164 B7 A35G25C29T32 A30G28C17T39 A16G14C15T15
mixture 7 71 — ND ND A17G14C15T14
TABLE 17A
Base Compositions Determined from A. baumannii DNA Samples Obtained from Walter
Reed Hospital and Amplified with Speciating Primer Pair No. 2922 and
Triangulation Genotyping Analysis Primer Pair Nos. 1151 and 1156
PP No: 2922 PP No: 1151 PP No: 1156
Species Ibis# Isolate ST efp trpE Adk
A. baumannii 20 1082 1 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 13 854 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 22 1162 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 27 1230 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 31 1367 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 37 1459 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 55 1700 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 64 1777 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 73 1861 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 74 1877 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 86 1972 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 3 684 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 6 720 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 7 726 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 19 1079 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 21 1123 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 23 1188 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 33 1417 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 34 1431 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 38 1496 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 40 1523 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 42 1640 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 50 1666 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 51 1668 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 52 1695 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 65 1781 11 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 44 1649 12 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 49A 1658.1 12 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 49B 1658.2 12 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 56 1707 12 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 80 1893 12 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 5 693 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 8 749 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 10 839 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 14 865 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 16 888 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 29 1326 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 35 1440 14 A44G35C25T43 ND A44G32C27T37
A. baumannii 41 1524 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 46 1652 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 47 1653 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 48 1657 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 57 1709 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 61 1727 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 63 1762 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 67 1806 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 75 1881 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 77 1886 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 1 649 46 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 2 653 46 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 39 1497 16 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 24 1198 15 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 28 1243 15 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 43 1648 15 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 62 1746 15 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 4 689 15 A44G35C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 68 1822 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 69 1823A 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 70 1823B 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 71 1826 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 72 1860 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 81 1924 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 82 1929 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 85 1966 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 11 841 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 32 1415 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 45 1651 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 54 1697 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 58 1712 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 60 1725 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 66 1802 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 76 1883 24 ND A43G36C20T43 A44G32C27T37
A. baumannii 78 1891 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 79 1892 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 83 1947 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 84 1964 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 53 1696 24 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 36 1458 49 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 59 1716 9 A44G35C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 9 805 30 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 18 967 39 A45G34C25T43 A44G35C22T41 A44G32C26T38
A. baumannii 30 1322 48 A44G35C25T43 A43G36C20T43 A44G32C27T37
A. baumannii 26 1218 50 A44G35C25T43 A44G35C21T42 A44G32C26T38
A. sp. 13TU 15 875 A1 A47G33C24T43 A46G32C20T44 A44G33C27T36
A. sp. 13TU 17 895 A1 A47G33C24T43 A46G32C20T44 A44G33C27T36
A. sp. 3 12 853 B7 A46G35C24T42 A42G34C20T46 A43G33C24T40
A. johnsonii 25 1202 NEW1 A46G35C23T43 A42G35C21T44 A43G33C23T41
A. sp. 2082 87 2082 NEW2 A46G36C22T43 A42G32C20T48 A42G34C23T41
TABLE 17B
Base Compositions Determined from A. baumannii DNA Samples Obtained from Walter
Reed Hospital and Amplified with Triangulation Genotyping Analysis
Primer Pair Nos. 1158 and 1160 and 1165
PP No: 1158 PP No: 1160 PP No: 1165
Species Ibis# Isolate ST mutY mutY fumC
A. baumannii 20 1082 1 A27G21C25T22 A32G35C29T33 A40G33C30T36
A. baumannii 13 854 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 22 1162 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 27 1230 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 31 1367 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 37 1459 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 55 1700 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 64 1777 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 73 1861 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 74 1877 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 86 1972 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 3 684 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 6 720 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 7 726 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 19 1079 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 21 1123 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 23 1188 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 33 1417 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 34 1431 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 38 1496 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 40 1523 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 42 1640 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 50 1666 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 51 1668 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 52 1695 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 65 1781 11 A27G21C25T22 A32G34C28T35 A40G33C30T36
A. baumannii 44 1649 12 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 49A 1658.1 12 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 49B 1658.2 12 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 56 1707 12 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 80 1893 12 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 5 693 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 8 749 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 10 839 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 14 865 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 16 888 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 29 1326 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 35 1440 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 41 1524 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 46 1652 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 47 1653 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 48 1657 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 57 1709 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 61 1727 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 63 1762 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 67 1806 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 75 1881 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 77 1886 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 1 649 46 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 2 653 46 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 39 1497 16 A29G19C26T21 A31G35C29T34 A40G34C29T36
A. baumannii 24 1198 15 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 28 1243 15 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 43 1648 15 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 62 1746 15 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 4 689 15 A29G19C26T21 A31G35C29T34 A40G33C29T37
A. baumannii 68 1822 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 69 1823A 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 70 1823B 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 71 1826 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 72 1860 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 81 1924 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 82 1929 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 85 1966 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 11 841 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 32 1415 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 45 1651 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 54 1697 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 58 1712 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 60 1725 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 66 1802 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 76 1883 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 78 1891 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 79 1892 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 83 1947 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 84 1964 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 53 1696 24 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 36 1458 49 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 59 1716 9 A27G21C25T22 A32G35C28T34 A39G33C30T37
A. baumannii 9 805 30 A27G21C25T22 A32G35C28T34 A39G33C30T37
A. baumannii 18 967 39 A27G21C26T21 A32G35C28T34 A39G33C30T37
A. baumannii 30 1322 48 A28G21C24T22 A32G35C29T33 A40G33C30T36
A. baumannii 26 1218 50 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. sp. 13TU 15 875 A1 A27G21C25T22 A30G36C26T37 A41G34C28T36
A. sp. 13TU 17 895 A1 A27G21C25T22 A30G36C26T37 A41G34C28T36
A. sp. 3 12 853 B7 A26G23C23T23 A30G36C27T36 A39G37C26T37
A. johnsonii 25 1202 NEW1 A25G23C24T23 A30G35C30T34 A38G37C26T38
A. sp. 2082 87 2082 NEW2 A26G22C24T23 A31G35C28T35 A42G34C27T36
TABLE 17C
Base Compositions Determined from A. baumannii DNA Samples Obtained from Walter
Reed Hospital and Amplified with Triangulation Genotyping Analysis
Primer Pair Nos. 1167 and 1170 and 1171
PP No: 1167 PP No: 1170 PP No: 1171
Species Ibis# Isolate ST fumC fumC ppa
A. baumannii 20 1082 1 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 13 854 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 22 1162 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 27 1230 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 31 1367 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 37 1459 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 55 1700 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 64 1777 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 73 1861 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 74 1877 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 86 1972 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 3 684 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 6 720 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 7 726 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 19 1079 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 21 1123 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 23 1188 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 33 1417 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 34 1431 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 38 1496 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 40 1523 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 42 1640 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 50 1666 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 51 1668 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 52 1695 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 65 1781 11 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 44 1649 12 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 49A 1658.1 12 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 49B 1658.2 12 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 56 1707 12 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 80 1893 12 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 5 693 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 8 749 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 10 839 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 14 865 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 16 888 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 29 1326 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 35 1440 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 41 1524 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 46 1652 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 47 1653 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 48 1657 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 57 1709 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 61 1727 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 63 1762 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 67 1806 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 75 1881 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 77 1886 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 1 649 46 A41G35C32T39 A37G28C20T51 A35G37C32T45
A. baumannii 2 653 46 A41G35C32T39 A37G28C20T51 A35G37C32T45
A. baumannii 39 1497 16 A41G35C32T39 A37G28C20T51 A35G37C30T47
A. baumannii 24 1198 15 A41G35C32T39 A37G28C20T51 A35G37C30T47
A. baumannii 28 1243 15 A41G35C32T39 A37G28C20T51 A35G37C30T47
A. baumannii 43 1648 15 A41G35C32T39 A37G28C20T51 A35G37C30T47
A. baumannii 62 1746 15 A41G35C32T39 A37G28C20T51 A35G37C30T47
A. baumannii 4 689 15 A41G35C32T39 A37G28C20T51 A35G37C30T47
A. baumannii 68 1822 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 69 1823A 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 70 1823B 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 71 1826 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 72 1860 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 81 1924 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 82 1929 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 85 1966 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 11 841 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 32 1415 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 45 1651 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 54 1697 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 58 1712 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 60 1725 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 66 1802 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 76 1883 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 78 1891 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 79 1892 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 83 1947 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 84 1964 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 53 1696 24 A40G35C34T38 A39G26C22T49 A35G37C33T44
A. baumannii 36 1458 49 A40G35C34T38 A39G26C22T49 A35G37C30T47
A. baumannii 59 1716 9 A40G35C32T40 A38G27C20T51 A36G35C31T47
A. baumannii 9 805 30 A40G35C32T40 A38G27C21T50 A35G36C29T49
A. baumannii 18 967 39 A40G35C33T39 A38G27C20T51 A35G37C30T47
A. baumannii 30 1322 48 A40G35C35T37 A38G27C21T50 A35G37C30T47
A. baumannii 26 1218 50 A40G35C34T38 A38G27C21T50 A35G37C33T44
A. sp. 13TU 15 875 A1 A41G39C31T36 A37G26C24T49 A34G38C31T46
A. sp. 13TU 17 895 A1 A41G39C31T36 A37G26C24T49 A34G38C31T46
A. sp. 3 12 853 B7 A43G37C30T37 A36G27C24T49 A34G37C31T47
A. johnsonii 25 1202 NEW1 A42G38C31T36 A40G27C19T50 A35G37C32T45
A. sp. 2082 87 2082 NEW2 A43G37C32T35 A37G26C21T52 A35G38C31T45
TABLE 18A
Base Compositions Determined from A. baumannii DNA Samples Obtained from
Northwestern Medical Center and Amplified with Speciating Primer Pair No. 2922
and Triangulation Genotyping Analysis Primer Pair Nos. 1151 and 1156
PP No: 2922 PP No: 1151 PP No: 1156
Species Ibis# Isolate ST efp trpE adk
A. baumannii 54 536 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 87 665 3 A44G35C24T44 A44G35C22T41 A44G32C26T38
A. baumannii 8 80 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 9 91 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 10 92 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 11 131 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 12 137 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 21 218 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 26 242 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 94 678 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 1 9 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 2 13 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 3 19 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 4 24 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 5 36 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 6 39 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 13 139 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 15 165 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 16 170 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 17 186 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 20 202 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 22 221 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 24 234 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 25 239 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 33 370 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 34 389 10 A45G34C25T43 A44G35C21T42 A44G32C26T38
A. baumannii 19 201 14 A44G35C25T43 A44G35C22T41 A44G32C27T37
A. baumannii 27 257 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 29 301 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 31 354 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 36 422 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 37 424 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 38 434 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 39 473 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 40 482 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 44 512 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 45 516 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 47 522 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 48 526 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 50 528 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 52 531 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 53 533 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 56 542 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 59 550 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 62 556 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 64 557 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 70 588 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 73 603 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 74 605 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 75 606 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 77 611 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 79 622 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 83 643 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 85 653 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 89 669 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 93 674 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 23 228 51 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 32 369 52 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 35 393 52 A44G35C25T43 A43G36C20T43 A44G32C26T38
A. baumannii 30 339 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 41 485 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 42 493 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 43 502 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 46 520 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 49 527 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 51 529 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 65 562 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 68 579 53 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 57 546 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 58 548 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 60 552 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 61 555 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 63 557 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 66 570 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 67 578 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 69 584 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 71 593 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 72 602 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 76 609 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 78 621 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 80 625 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 81 628 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 82 632 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 84 649 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 86 655 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 88 668 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 90 671 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 91 672 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 92 673 54 A44G35C25T43 A44G35C20T43 A44G32C26T38
A. baumannii 18 196 55 A44G35C25T43 A44G35C20T43 A44G32C27T37
A. baumannii 55 537 27 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. baumannii 28 263 27 A44G35C25T43 A44G35C19T44 A44G32C27T37
A. sp. 3 14 164 B7 A46G35C24T42 A42G34C20T46 A43G33C24T40
mixture 7 71 ? mixture ND ND
TABLE 18B
Base Compositions Determined from A. baumannii DNA Samples Obtained from
Northwestern Medical Center and Amplified with Triangulation Genotyping
Analysis Primer Pair Nos. 1158, 1160 and 1165
PP No: 1158 PP No: 1160 PP No: 1165
Species Ibis# Isolate ST mutY mutY fumC
A. baumannii 54 536 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 87 665 3 A27G20C27T21 A32G35C28T34 A40G33C30T36
A. baumannii 8 80 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 9 91 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 10 92 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 11 131 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 12 137 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 21 218 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 26 242 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 94 678 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 1 9 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 2 13 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 3 19 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 4 24 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 5 36 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 6 39 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 13 139 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 15 165 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 16 170 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 17 186 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 20 202 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 22 221 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 24 234 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 25 239 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 33 370 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 34 389 10 A27G21C26T21 A32G35C28T34 A40G33C30T36
A. baumannii 19 201 14 A27G21C25T22 A31G36C28T34 A40G33C29T37
A. baumannii 27 257 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 29 301 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 31 354 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 36 422 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 37 424 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 38 434 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 39 473 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 40 482 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 44 512 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 45 516 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 47 522 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 48 526 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 50 528 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 52 531 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 53 533 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 56 542 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 59 550 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 62 556 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 64 557 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 70 588 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 73 603 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 74 605 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 75 606 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 77 611 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 79 622 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 83 643 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 85 653 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 89 669 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 93 674 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 23 228 51 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 32 369 52 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 35 393 52 A27G21C25T22 A32G35C28T34 A40G33C29T37
A. baumannii 30 339 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 41 485 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 42 493 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 43 502 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 46 520 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 49 527 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 51 529 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 65 562 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 68 579 53 A28G20C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 57 546 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 58 548 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 60 552 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 61 555 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 63 557 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 66 570 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 67 578 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 69 584 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 71 593 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 72 602 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 76 609 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 78 621 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 80 625 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 81 628 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 82 632 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 84 649 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 86 655 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 88 668 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 90 671 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 91 672 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 92 673 54 A27G21C26T21 A32G34C29T34 A40G33C30T36
A. baumannii 18 196 55 A27G21C25T22 A31G36C27T35 A40G33C29T37
A. baumannii 55 537 27 A27G21C25T22 A32G35C28T34 A40G33C30T36
A. baumannii 28 263 27 A27G21C25T22 A32G35C28T34 A40G33C30T36
A. sp. 3 14 164 B7 A26G23C23T23 A30G36C27T36 A39G37C26T37
mixture 7 71 ? ND ND ND
TABLE 18C
Base Compositions Determined from A. baumannii DNA Samples Obtained from
Northwestern Medical Center and Amplified with Triangulation Genotyping
Analysis Primer Pair Nos. 1167, 1170 and 1171
PP No: 1167 PP No: 1170 PP No: 1171
Species Ibis# Isolate ST fumC fumC ppa
A. baumannii 54 536 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 87 665 3 A41G34C35T37 A38G27C20T51 A35G37C31T46
A. baumannii 8 80 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 9 91 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 10 92 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 11 131 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 12 137 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 21 218 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 26 242 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 94 678 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 1 9 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 2 13 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 3 19 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 4 24 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 5 36 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 6 39 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 13 139 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 15 165 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 16 170 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 17 186 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 20 202 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 22 221 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 24 234 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 25 239 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 33 370 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 34 389 10 A41G34C34T38 A38G27C21T50 A35G37C33T44
A. baumannii 19 201 14 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 27 257 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 29 301 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 31 354 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 36 422 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 37 424 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 38 434 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 39 473 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 40 482 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 44 512 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 45 516 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 47 522 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 48 526 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 50 528 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 52 531 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 53 533 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 56 542 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 59 550 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 62 556 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 64 557 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 70 588 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 73 603 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 74 605 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 75 606 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 77 611 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 79 622 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 83 643 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 85 653 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 89 669 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 93 674 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 23 228 51 A40G35C34T38 A38G27C21T50 A35G37C30T47
A. baumannii 32 369 52 A40G35C34T38 A38G27C21T50 A35G37C31T46
A. baumannii 35 393 52 A40G35C34T38 A38G27C21T50 A35G37C31T46
A. baumannii 30 339 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 41 485 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 42 493 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 43 502 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 46 520 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 49 527 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 51 529 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 65 562 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 68 579 53 A40G35C35T37 A38G27C21T50 A35G37C31T46
A. baumannii 57 546 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 58 548 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 60 552 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 61 555 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 63 557 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 66 570 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 67 578 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 69 584 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 71 593 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 72 602 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 76 609 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 78 621 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 80 625 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 81 628 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 82 632 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 84 649 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 86 655 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 88 668 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 90 671 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 91 672 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 92 673 54 A40G35C34T38 A39G26C22T49 A35G37C31T46
A. baumannii 18 196 55 A42G34C33T38 A38G27C20T51 A35G37C31T46
A. baumannii 55 537 27 A40G35C33T39 A38G27C20T51 A35G37C33T44
A. baumannii 28 263 27 A40G35C33T39 A38G27C20T51 A35G37C33T44
A. sp. 3 14 164 B7 A43G37C30T37 A36G27C24T49 A34G37C31T47
mixture 7 71 — ND ND ND
Base composition analysis of the samples obtained from Walter Reed hospital indicated that a majority of the strain types identified were the same strain types already characterized by the OIF study of Example 12. This is not surprising since at least some patients from which clinical samples were obtained in OIF were transferred to the Walter Reed Hospital (WRAIR). Examples of these common strain types include: ST10, ST11, ST12, ST14, ST15, ST16 and ST46. A strong correlation was noted between these strain types and the presence of mutations in the gyrA and parC which confer quinolone drug resistance.
In contrast, the results of base composition analysis of samples obtained from Northwestern Medical Center indicate the presence of 4 major strain types: ST10, ST51, ST53 and ST54. All of these strain types have the gyrA quinolone resistance mutation and most also have the parC quinolone resistance mutation, with the exception of ST35. This observation is consistent with the current understanding that the gyrA mutation generally appears before the parC mutation and suggests that the acquisition of these drug resistance mutations is rather recent and that resistant isolates are taking over the wild-type isolates. Another interesting observation was that a single isolate of ST3 (isolate 841) displays a triangulation genotyping analysis pattern similar to other isolates of ST3, but the codon analysis amplification product base compositions indicate that this isolate has not yet undergone the quinolone resistance mutations in gyrA and parC.
The six isolates that represent species other than Acinetobacter baumannii in the samples obtained from the Walter Reed Hospital were each found to not carry the drug resistance mutations.
The results described above involved analysis of 183 samples using the methods and compositions of the present invention. Results were provided to collaborators at the Walter Reed hospital and Northwestern Medical center within a week of obtaining samples. This example highlights the rapid throughput characteristics of the analysis platform and the resolving power of triangulation genotyping analysis and codon analysis for identification of and determination of drug resistance in bacteria.
Example 14 Identification of Drug Resistance Genes and Virulence Factors in Staphylococcus aureus An eight primer pair panel was designed for identification of drug resistance genes and virulence factors of Staphylococcus aureus and is shown in Table 19. The primer sequences are found in Table 2 and are cross-referenced by the primer pair numbers, primer pair names or SEQ ID NOs listed in Table 19. TABLE 19
Primer Pairs for Identification of Drug Resistance Genes and Virulence Factors in
Staphylococcus aureus
Forward Reverse
Primer Primer Primer
Pair (SEQ ID (SEQ ID Target
No. Forward Primer Name NO:) Reverse Primer Name NO:) Gene
879 MECA_Y14051_4507_4530_F 288 MECA_Y14051_4555_4581_R 1269 mecA
2056 MECI-R_NC003923-41798- 698 MECI-R_NC003923-41798- 1420 MecI-R
41609_33_60_F 41609_86_113_R
2081 ERMA_NC002952-55890- 217 ERMA_NC002952-55890- 1167 ermA
56621_366_395_F 56621_438_465_R
2086 ERMC_NC005908-2004- 399 ERMC_NC005908-2004- 1041 ermC
2738_85_116_F 2738_173_206_R
2095 PVLUK_NC003923-1529595- 456 PVLUK_NC003923-1529595- 1261 Pv-luk
1531285_688_713_F 1531285_775_804_R
2249 TUFB_NC002758-615038- 430 TUFB_NC002758-615038- 1321 tufB
616222_696_725_F 616222_793_820_R
2256 NUC_NC002758-894288- 174 NUC_NC002758-894288- 853 Nuc
894974_316_345_F 894974_396_421_R
2313 MUPR_X75439_2486_2516_F 172 MUPR_X75439_2548_2574_R 1360 mupR
Primer pair numbers 2256 and 2249 are confirmation primers designed with the aim of high level identification of Staphylococcus aureus. The nuc gene is a Staphylococcus aureus-specific marker gene. The tufB gene is a universal housekeeping gene but the bioagent identifying amplicon defined by primer pair number 2249 provides a unique base composition (A43 G28 C19 T35) which distinguishes Staphylococcus aureus from other members of the genus Staphylococcus.
High level methicillin resistance in a given strain of Staphylococcus aureus is indicated by bioagent identifying amplicons defined by primer pair numbers 879 and 2056. Analyses have indicated that primer pair number 879 is not expected to prime S. sciuri homolog or Enterococcus faecalis/faciem ampicillin-resistant PBP5 homologs.
Macrolide and erythromycin resistance in a given strain of Staphylococcus aureus is indicated by bioagent identifying amplicons defined by primer pair numbers 2081 and 2086.
Resistance to mupriocin in a given strain of Staphylococcus aureus is indicated by bioagent identifying amplicons defined by primer pair number 2313.
Virulence in a given strain of Staphylococcus aureus is indicated by bioagent identifying amplicons defined by primer pair number 2095. This primer pair can simultaneously and identify the pvl (lukS-PV) gene and the lukD gene which encodes a homologous enterotoxin. A bioagent identifying amplicon of the lukD gene has a six nucleobase length difference relative to the lukS-PV gene.
A total of 32 blinded samples of different strains of Staphylococcus aureus were provided by the Center for Disease Control (CDC). Each sample was analyzed by PCR amplification with the eight primer pair panel, followed by purification and measurement of molecular masses of the amplification products by mass spectrometry. Base compositions for the amplification products were calculated. The base compositions provide the information summarized above for each primer pair. The results are shown in Tables 20A and B. One result noted upon un-blinding of the samples is that each of the PVL+ identifications agreed with PVL+ identified in the same samples by standard PCR assays. These results indicate that the panel of eight primer pairs is useful for identification of drug resistance and virulence sub-species characteristics for Staphylococcus aureus. It is expected that a kit comprising one or more of the members of this panel will be a useful embodiment of the present invention. TABLE 20A
Drug Resistance and Virulence Identified in Blinded Samples of
Various Strains of Staphylococcus aureus with Primer Pair
Nos. 2081, 2086, 2095 and 2256
Primer Primer
Pair No. Pair No.
2081 2086 Primer Pair No. Primer Pair No.
Sample Index No. (ermA) (ermC) 2095 (pv-luk) 2256 (nuc)
CDC0010 − − PVL−/lukD+ +
CDC0015 − − PVL+/lukD+ +
CDC0019 − + PVL−/lukD+ +
CDC0026 + − PVL−/lukD+ +
CDC0030 + − PVL−/lukD+ +
CDC004 − − PVL+/lukD+ +
CDC0014 − + PVL+/lukD+ +
CDC008 − − PVL−/lukD+ +
CDC001 + − PVL−/lukD+ +
CDC0022 + − PVL−/lukD+ +
CDC006 + − PVL−/lukD+ +
CDC007 − − PVL−/lukD+ +
CDCVRSA1 + − PVL−/lukD+ +
CDCVRSA2 + + PVL−/lukD+ +
CDC0011 + − PVL−/lukD+ +
CDC0012 − − PVL+/lukD− +
CDC0021 + − PVL−/lukD+ +
CDC0023 + − PVL−/lukD+ +
CDC0025 + − PVL−/lukD+ +
CDC005 − − PVL−/lukD+ +
CDC0018 + − PVL+/lukD− +
CDC002 − − PVL−/lukD+ +
CDC0028 + − PVL−/lukD+ +
CDC003 − − PVL−/lukD+ +
CDC0013 − − PVL+/lukD+ +
CDC0016 − − PVL−/lukD+ +
CDC0027 + − PVL−/lukD+ +
CDC0029 − − PVL+/lukD+ +
CDC0020 − + PVL−/lukD+ +
CDC0024 − − PVL−/lukD+ +
CDC0031 − − PVL−/lukD+ +
TABLE 20B
Drug Resistance and Virulence Identified in Blinded Samples of
Various Strains of Staphylococcus aureus with Primer Pair
Nos. 2249, 879, 2056, and 2313
Primer Primer Primer
Pair No. Pair No. Pair No.
Sample Primer Pair No. 2249 879 2056 2313
Index No. (tufB) (mecA) (mecI-R) (mupR)
CDC0010 Staphylococcus aureus + + −
CDC0015 Staphylococcus aureus − − −
CDC0019 Staphylococcus aureus + + −
CDC0026 Staphylococcus aureus + + −
CDC0030 Staphylococcus aureus + + −
CDC004 Staphylococcus aureus + + −
CDC0014 Staphylococcus aureus + + −
CDC008 Staphylococcus aureus + + −
CDC001 Staphylococcus aureus + + −
CDC0022 Staphylococcus aureus + + −
CDC006 Staphylococcus aureus + + +
CDC007 Staphylococcus aureus + + −
CDCVRSA1 Staphylococcus aureus + + −
CDCVRSA2 Staphylococcus aureus + + −
CDC0011 Staphylococcus aureus − − −
CDC0012 Staphylococcus aureus + + −
CDC0021 Staphylococcus aureus + + −
CDC0023 Staphylococcus aureus + + −
CDC0025 Staphylococcus aureus + + −
CDC005 Staphylococcus aureus + + −
CDC0018 Staphylococcus aureus + + −
CDC002 Staphylococcus aureus + + −
CDC0028 Staphylococcus aureus + + −
CDC003 Staphylococcus aureus + + −
CDC0013 Staphylococcus aureus + + −
CDC0016 Staphylococcus aureus + + −
CDC0027 Staphylococcus aureus + + −
CDC0029 Staphylococcus aureus + + −
CDC0020 Staphylococcus aureus − − −
CDC0024 Staphylococcus aureus + + −
CDC0031 Staphylococcus scleiferi − − −
Example 15 Selection and Use of Triangulation Genotyping Analysis Primer Pairs for Staphylococcus aureus To combine the power of high-throughput mass spectrometric analysis of bioagent identifying amplicons with the sub-species characteristic resolving power provided by triangulation genotyping analysis, a panel of eight triangulation genotyping analysis primer pairs was selected. The primer pairs are designed to produce bioagent identifying amplicons within six different housekeeping genes which are listed in Table 21. The primer sequences are found in Table 2 and are cross-referenced by the primer pair numbers, primer pair names or SEQ ID NOs listed in Table 21. TABLE 21
Primer Pairs for Triangulation Genotyping Analysis of Staphylococcus aureus
Forward Reverse
Primer Primer Primer
Pair (SEQ ID (SEQ ID Target
No. Forward Primer Name NO:) Reverse Primer Name NO:) Gene
2146 ARCC_NC003923-2725050- 437 ARCC_NC003923-2725050- 1137 arcC
2724595_131_161_F 2724595_214_245_R
2149 AROE_NC003923-1674726- 530 AROE_NC003923-1674726- 891 aroE
1674277_30_62_F 1674277_155_181_R
2150 AROE_NC003923-1674726- 474 AROE_NC003923-1674726- 869 aroE
1674277_204_232_F 1674277_308_335_R
2156 GMK_NC003923-1190906- 268 GMK_NC003923-1190906- 1284 gmk
1191334_301_329_F 1191334_403_432_R
2157 PTA_NC003923-628885- 418 PTA_NC003923-628885- 1301 pta
629355_237_263_F 629355_314_345_R
2161 TPI_NC003923-830671- 318 TPI_NC003923-830671- 1300 tpi
831072_1_34_F 831072_97_129_R
2163 YQI_NC003923-378916- 440 YQI_NC003923-378916- 1076 yqi
379431_142_167_F 379431_259_284_R
2166 YQI_NC003923-378916- 219 YQI_NC003923-378916- 1013 yqi
379431_275_300_F 379431_364_396_R
The same samples analyzed for drug resistance and virulence in Example 14 were subjected to triangulation genotyping analysis. The primer pairs of Table 21 were used to produce amplification products by PCR, which were subsequently purified and measured by mass spectrometry. Base compositions were calculated from the molecular masses and are shown in Tables 22A and 22B. TABLE 22A
Triangulation Genotyping Analysis of Blinded Samples of Various Strains of
Staphylococcus aureus with Primer Pair Nos. 2146, 2149, 2150 and 2156
Sample Primer Pair No. Primer Pair No. Primer Pair No. Primer Pair No.
Index No. Strain 2146 (arcC) 2149 (aroE) 2150 (aroE) 2156 (gmk)
CDC0010 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0015 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0019 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0026 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0030 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC004 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0014 COL A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC008 ???? A44 G24 C18 T29 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC001 Mu50 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31
CDC0022 Mu50 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31
CDC006 Mu50 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31
CDC0011 MRSA252 A45 G24 C18 T28 A58 G24 C19 T51 A41 G36 C12 T43 A51 G29 C21 T31
CDC0012 MRSA252 A45 G24 C18 T28 A58 G24 C19 T51 A41 G36 C12 T43 A51 G29 C21 T31
CDC0021 MRSA252 A45 G24 C18 T28 A58 G24 C19 T51 A41 G36 C12 T43 A51 G29 C21 T31
CDC0023 ST: 110 A45 G24 C18 T28 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0025 ST: 110 A45 G24 C18 T28 A59 G24 C18 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC005 ST: 338 A44 G24 C18 T29 A59 G23 C19 T51 A40 G36 C14 T42 A51 G29 C21 T31
CDC0018 ST: 338 A44 G24 C18 T29 A59 G23 C19 T51 A40 G36 C14 T42 A51 G29 C21 T31
CDC002 ST: 108 A46 G23 C20 T26 A58 G24 C19 T51 A42 G36 C12 T42 A51 G29 C20 T32
CDC0028 ST: 108 A46 G23 C20 T26 A58 G24 C19 T51 A42 G36 C12 T42 A51 G29 C20 T32
CDC003 ST: 107 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31
CDC0013 ST: 12 ND A59 G24 C18 T51 A40 G36 C13 T43 A51 G29 C21 T31
CDC0016 ST: 120 A45 G23 C18 T29 A58 G24 C19 T51 A40 G37 C13 T42 A51 G29 C21 T31
CDC0027 ST: 105 A45 G23 C20 T27 A58 G24 C18 T52 A40 G36 C13 T43 A51 G29 C21 T31
CDC0029 MSSA476 A45 G23 C20 T27 A58 G24 C19 T51 A40 G36 C13 T43 A50 G30 C20 T32
CDC0020 ST: 15 A44 G23 C21 T27 A59 G23 C18 T52 A40 G36 C13 T43 A50 G30 C20 T32
CDC0024 ST: 137 A45 G23 C20 T27 A57 G25 C19 T51 A40 G36 C13 T43 A51 G29 C22 T30
CDC0031 *** No product No product No product No product
TABLE 22B
Triangulation Genotyping Analysis of Blinded Samples of Various Strains of
Staphylococcus aureus with Primer Pair Nos. 2146, 2149, 2150 and 2156
Sample Primer Pair No. Primer Pair No. Primer Pair No. Primer Pair No.
Index No. Strain 2157 (pta) 2161 (tpi) 2163 (yqi) 2166 (yqi)
CDC0010 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0015 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0019 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0026 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0030 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC004 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0014 COL A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC008 unknown A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC001 Mu50 A33 G25 C22 T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36
CDC0022 Mu50 A33 G25 C22 T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36
CDC006 Mu50 A33 G25 C22 T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36
CDC0011 MRSA252 A32 G25 C23 T29 A50 G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37
CDC0012 MRSA252 A32 G25 C23 T29 A50 G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37
CDC0021 MRSA252 A32 G25 C23 T29 A50 G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37
CDC0023 ST: 110 A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0025 ST: 110 A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC005 ST: 338 A32 G25 C24 T28 A51 G27 C21 T30 A42 G36 C22 T43 A37 G30 C18 T37
CDC0018 ST: 338 A32 G25 C24 T28 A51 G27 C21 T30 A42 G36 C22 T43 A37 G30 C18 T37
CDC002 ST: 108 A33 G25 C23 T28 A50 G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37
CDC0028 ST: 108 A33 G25 C23 T28 A50 G28 C22 T29 A42 G36 C22 T43 A37 G30 C18 T37
CDC003 ST: 107 A32 G25 C23 T29 A51 G28 C22 T28 A41 G37 C22 T43 A37 G30 C18 T37
CDC0013 ST: 12 A32 G25 C23 T29 A51 G28 C22 T28 A42 G36 C22 T43 A37 G30 C18 T37
CDC0016 ST: 120 A32 G25 C24 T28 A50 G28 C21 T30 A42 G36 C22 T43 A37 G30 C18 T37
CDC0027 ST: 105 A33 G25 C22 T29 A50 G28 C22 T29 A43 G36 C21 T43 A36 G31 C19 T36
CDC0029 MSSA476 A33 G25 C22 T29 A50 G28 C22 T29 A42 G36 C22 T43 A36 G31 C19 T36
CDC0020 ST: 15 A33 G25 C22 T29 A50 G28 C21 T30 A42 G36 C22 T43 A36 G31 C18 T37
CDC0024 ST: 137 A33 G25 C22 T29 A51 G28 C22 T28 A42 G36 C22 T43 A37 G30 C18 T37
CDC0031 *** A34 G25 C25 T25 A51 G27 C24 T27 No product No product
Note:
*** The sample CDC0031 was identified as Staphylococcus scleiferi as indicated in Example 14. Thus, the triangulation genotyping primers designed for Staphylococcus aureus would
# generally not be expected to prime and produce amplification products of this organism. Tables 22A and 22B indicate that amplification products are obtained for this organism only with primer pair numbers 2157 and 2161.
A total of thirteen different genotypes of Staphylococcus aureus were identified according to the unique combinations of base compositions across the eight different bioagent identifying amplicons obtained with the eight primer pairs. These results indicate that this eight primer pair panel is useful for analysis of unknown or newly emerging strains of Staphylococcus aureus. It is expected that a kit comprising one or more of the members of this panel will be a useful embodiment of the present invention.
Example 16 Selection and Use of Triangulation Genotyping Analysis Primer Pairs for Members of the Bacterial Genus Vibrio To combine the power of high-throughput mass spectrometric analysis of bioagent identifying amplicons with the sub-species characteristic resolving power provided by triangulation genotyping analysis, a panel of eight triangulation genotyping analysis primer pairs was selected. The primer pairs are designed to produce bioagent identifying amplicons within seven different housekeeping genes which are listed in Table 23. The primer sequences are found in Table 2 and are cross-referenced by the primer pair numbers, primer pair names or SEQ ID NOs listed in Table 23. TABLE 23
Primer Pairs for Triangulation Genotyping Analysis of Members
of the Bacterial Genus Vibrio
Forward Reverse
Primer Primer Primer
Pair (SEQ ID (SEQ ID Target
No. Forward Primer Name NO:) Reverse Primer Name NO:) Gene
1098 RNASEP_VBC_331_349_F 325 RNASEP_VBC_388_414_R 1163 RNAse P
2000 CTXB_NC002505_46_70_F 278 CTXB_NC002505_132_162_R 1039 ctxB
2001 FUR_NC002505_87_113_F 465 FUR_NC002505_205_228_R 1037 fur
2011 GYRB_NC002505_1161_1190_F 148 GYRB_NC002505_1255_1284_R 1172 gyrB
2012 OMPU_NC002505_85_110_F 190 OMPU_NC002505_154_180_R 1254 ompU
2014 OMPU_NC002505_431_455_F 266 OMPU_NC002505_544_567_R 1094 ompU
2323 CTXA_NC002505-1568114- 508 CTXA_NC002505-1568114- 1297 ctxA
1567341_122_149_F 1567341_186_214_R
2927 GAPA_NC002505_694_721_F 259 GAPA_NC_002505_29_58_R 1060 gapA
A group of 50 bacterial isolates containing multiple strains of both environmental and clinical isolates of Vibrio cholerae, 9 other Vibnio species, and 3 species of Photobacteria were tested using this panel of primer pairs. Base compositions of amplification products obtained with these 8 primer pairs were used to distinguish amongst various species tested, including sub-species differentiation within Vibrio cholerae isolates. For instance, the non-O1/non-O139 isolates were clearly resolved from the O1 and the O139 isolates, as were several of the environmental isolates of Vibrio cholerae from the clinical isolates.
It is expected that a kit comprising one or more of the members of this panel will be a useful embodiment of the present invention.
Example 17 Selection and Use of Triangulation Genotyping Analysis Primer Pairs for Members of the Bacterial Genus Pseudomonas To combine the power of high-throughput mass spectrometric analysis of bioagent identifying amplicons with the sub-species characteristic resolving power provided by triangulation genotyping analysis, a panel of twelve triangulation genotyping analysis primer pairs was selected. The primer pairs are designed to produce bioagent identifying amplicons within seven different housekeeping genes which are listed in Table 24. The primer sequences are found in Table 2 and are cross-referenced by the primer pair numbers, primer pair names or SEQ ID NOs listed in Table 24. TABLE 24
Primer Pairs for Triangulation Genotyping Analysis of Members of the
Bacterial Genus Pseudomonas
Forward Reverse
Primer Primer Primer
Pair (SEQ ID (SEQ ID Target
No. Forward Primer Name NO:) Reverse Primer Name NO:) Gene
2949 ACS_NC002516-970624- 376 ACS_NC002516-970624- 1265 acsA
971013_299_316_F 971013_364_383_R
2950 ARO_NC002516-26883- 267 ARO_NC002516-26883- 1341 aroE
27380_4_26_F 27380_111_128_R
2951 ARO_NC002516-26883- 705 ARO_NC002516-26883- 1056 aroE
27380_356_377_F 27380_459_484_R
2954 GUA_NC002516-4226546- 710 GUA_NC002516-4226546- 1259 guaA
4226174_155_178_F 4226174_265_287_R
2956 GUA_NC002516-4226546- 374 GUA_NC002516-4226546- 1111 guaA
4226174_242_263_F 4226174_355_371_R
2957 MUT_NC002516-5551158- 545 MUT_NC002516-5551158- 978 mutL
5550717_5_26_F 5550717_99_116_R
2959 NUO_NC002516-2984589- 249 NUO_NC002516-2984589- 1095 nuoD
2984954_8_26_F 2984954_97_117_R
2960 NUO_NC002516-2984589- 195 NUO_NC002516-2984589- 1376 nuoD
2984954_218_239_F 2984954_301_326_R
2961 PPS_NC002516-1915014- 311 PPS_NC002516-1915014- 1014 pps
1915383_44_63_F 1915383_140_165_R
2962 PPS_NC002516-1915014- 365 PPS_NC002516-1915014- 1052 pps
1915383_240_258_F 1915383_341_360_R
2963 TRP_NC002516-671831- 527 TRP_NC002516-671831- 1071 trpE
672273_24_42_F 672273_131_150_R
2964 TRP_NC002516-671831- 490 TRP_NC002516-671831- 1182 trpE
672273_261_282_F 672273_362_383_R
It is expected that a kit comprising one or more of the members of this panel will be a useful embodiment of the present invention.
The present invention includes any combination of the various species and subgeneric groupings falling within the generic disclosure. This invention therefore includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
While in accordance with the patent statutes, description of the various embodiments and examples have been provided, the scope of the invention is not to be limited thereto or thereby. Modifications and alterations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention.
Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific examples which have been presented by way of example.
Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, gene bank gi or accession numbers, internet web sites, and the like) cited in the present application is incorporated herein by reference in its entirety.
